<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="d">
		<monograph id="1" status="active">
			<mono_name>dabigatran</mono_name>
			<info>
				<pronunciation>(da-bye-gat′ran)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x210">Pradaxa</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Thrombin inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x31">
				<sec_title>Action:</sec_title>
				<para>Direct thrombin inhibitor that inhibits both free and clot-bound thrombin, prevents thrombin-induced platelet aggregation and thrombus formation by preventing conversion of fibrinogen to fibrin</para>
			</section>
			<section type="uses" id="sidelem4x36">
				<sec_title>Uses:</sec_title>
				<para>Stroke/systemic embolism prophylaxis with nonvalvular atrial fibrillation, DVT, pulmonary embolism in hip replacement</para>
			</section>
			<section type="contra" id="sidelem4x41">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, bleeding, prosthetic heart valves</para>
				<section type="none" id="sidelem4x46">
					<section type="none" id="sidelem4x47">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), labor, obstetric delivery, breastfeeding, children, geriatric patients, abrupt discontinuation, anticoagulant therapy, renal disease, surgery</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x62">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x65">
					<section type="none" id="sidelem4x66">
						<sec_title>Stroke prophylaxis</sec_title>
						<section type="none" id="sidelem4x74">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x74">
									<item>
										<label>•</label>
										<para> 150 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x78">
						<sec_title>For conversion from an alternative anticoagulant to dabigatran</sec_title>
						<para>
							<list id="lidelem4x82">
								<item>
									<label>•</label>
									<para>When converting from warfarin to dabigatran, discontinue warfarin and initiate dabigatran therapy when the INR is &lt;2.0; when converting from a parenteral anticoagulant to dabigatran, initiate dabigatran 0-2 hr before the time of the next scheduled anticoagulant dose or at the time of discontinuation of a continuously administered anticoagulant (e.g., intravenous unfractionated heparin)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x88">
						<sec_title>For conversion from dabigatran to warfarin</sec_title>
						<section type="none" id="sidelem4x96">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x96">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> CCr &gt;50 ml/min, start warfarin 3 days before discontinuing dabigatran; CCr 31-50 ml/min, start warfarin 2 days before discontinuing dabigatran; CCr 15-30 ml/min, start warfarin 1 day before discontinuing dabigatran</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x100">
						<sec_title>For conversion from dabigatran to parenteral anticoagulants</sec_title>
						<section type="none" id="sidelem4x108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x108">
									<item>
										<label>•</label>
										<para> discontinue dabigatran; start parenteral anticoagulant 12 hr (CCr ≥30 ml/min) or 24 hr (CCr &lt;30 ml/min) after the last dabigatran dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x112">
						<sec_title>Deep venous thrombus (DVT)/pulmonary embolism (PE) prophylaxis</sec_title>
						<section type="none" id="sidelem4x120">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x120">
									<item>
										<label>•</label>
										<para> 220 mg or 150 mg/day × 28-35 days, starting with <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> dose 1-4 hr after surgery (knee replacement); 110 on first day 1-4 hr after surgery, hemostasis achieved, then 220 mg qd × 28-35 days; those previously treated 150 mg bid (hip replacement)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x130">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x138">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 15-30 ml/min, 75 mg bid</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x141">
						<sec_title>DVT/PE/treated with a parenteral anticoagulant × 5-10 days</sec_title>
						<section type="none" id="sidelem4x149">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x149">
									<item>
										<label>•</label>
										<para> 150 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x153">
						<sec_title>Available forms:</sec_title>
						<para> Caps 75, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x158">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x162">
								<item>
									<label>•</label>
									<para>Do not crush, break, chew, or empty contents of capsule</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in original package at room temperature until time of use; discard after 30 days; protect from moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x178">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x181">
					<section type="none" id="sidelem4x182">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Intracranial bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x189">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Myocardial infarction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x196">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, dyspepsia, peptic ulcer, esophagitis, GERD, gastritis, <emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x203">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Bleeding (any site), hemorrhagic erosive gastritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x210">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x215">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis (rare)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x222">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 35%, half-life 12-17 hr (extended in renal disease), peak 1 hr, high-fat meal delays peak</para>
			</section>
			<section type="interactions" id="sidelem4x228">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: bleeding risk—amiodarone, other anticoagulants, clopidogrel, ketoconazole, quiNIDine, thrombolytics, verapamil</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dabigatran effect—rifampin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dabigatran effect—P-glycoprotein inducers (carBAMazepine, rifampin, tipranovir</para>
				<section type="none" id="sidelem4x242">
					<section type="none" id="sidelem4x243">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> dabigatran—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x250">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> thrombin time, aPTT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x257">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x260">
					<section type="none" id="sidelem4x261">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x269">
							<label>•</label>
							<sec_title>Bleeding<route> blood in urine or emesis, dark tarry stools, lower back pain; caution with arterial/venous punctures, catheters, NG tubes; monitor vital signs frequently; elderly patients more prone to serious bleeding, monitor aPTT, ecarin clotting time baseline and during treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x275">
							<label>•</label>
							<sec_title>Thrombosis/MI/emboli<route> swelling, pain, redness, difficulty breathing, chest pain, tachypnea, cough, coughing up blood, cyanosis</route></sec_title>
						</section>
						<section type="none" id="sidelem4x281">
							<label>•</label>
							<sec_title>Postthrombotic syndrome<route> pain, heaviness, itching/tingling, swelling, varicose veins, brownish/reddish skin discoloration, ulcers; use of ambulation, compression stockings, adequate anticoagulation can prevent this syndrome</route></sec_title>
						</section>
						<section type="none" id="sidelem4x287">
							<label>•</label>
							<sec_title>Surgery<route> discontinue 24-48 hr before surgery in those with CCr ≥50 ml/min, 72-96 hr in those with CCr &lt;50 ml/min; longer times may be needed in major surgery</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x290">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x294">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased thrombus formation/extension, absence of emboli, postthrombotic effects</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x300">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x305">
								<item>
									<label>•</label>
									<para>About the purpose and expected results of this product; to take at same time of day; not to skip or double doses; if dose is missed, take as soon as remembered if on the same day; do not administer if &lt;6 hr before next dose; store in original container</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x310">
								<item>
									<label>•</label>
									<para>To take without regard to food, swallow cap whole, not to open</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x315">
								<item>
									<label>•</label>
									<para>To notify all providers that this product is being used, check with prescriber about when to discontinue</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x324">
							<label>•</label>
							<sec_title>
								<route>To report any bleeding or bruising including blood in stool, emesis, urine; nosebleeds</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x327">
								<item>
									<label>•</label>
									<para>Not to use any other OTC products, herbs without prescriber approval</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x332">
								<item>
									<label>•</label>
									<para>That lab tests will be required during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x337">
								<item>
									<label>•</label>
									<para>To keep dry, do not use other containers</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>dabrafenib</mono_name>
			<info>
				<pronunciation>(da-braf′e-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3470">Tafinlar</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Signal transduction inhibitor, kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x357">
				<sec_title>Action:</sec_title>
				<para>Inhibits kinase, inhibitor against mutated forms of BRAF kinases in melanoma cells</para>
			</section>
			<section type="uses" id="sidelem4x362">
				<sec_title>Uses:</sec_title>
				<para>Unresectable or metastatic BRAD V600E-mutated malignant melanoma</para>
			</section>
			<section type="contra" id="sidelem4x367">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x372">
					<section type="none" id="sidelem4x373">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, infection, dehydration, diabetes mellitus, fever, G6PD deficiency, hemolytic anemia, hyperglycemia, hypotension, infertility, iritis, renal failure, secondary malignancy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x378">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x386">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x386">
							<item>
								<label>•</label>
								<para> 150 mg q12hr until disease progression; avoid strong CYP3A4/CYP2C8 inhibitors or inducers</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x390">
					<section type="none" id="sidelem4x391">
						<sec_title>Available forms:</sec_title>
						<para> Caps 50, 75 mg</para>
					</section>
					<section type="none" id="sidelem4x396">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x399">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x403">
									<item>
										<label>•</label>
										<para>Swallow whole</para>
									</item>
									<item>
										<label>•</label>
										<para>If dose is missed, take within 6 hr of missed dose; if &gt;6 hr have passed, skip dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Space doses q12hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Take at least 1 hr before or 2 hr after a meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x424">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x427">
					<section type="none" id="sidelem4x428">
						<sec_title>CNS:</sec_title>
						<para> Headache, fever</para>
					</section>
					<section type="none" id="sidelem4x433">
						<sec_title>GI:</sec_title>
						<para> Pancreatitis</para>
					</section>
					<section type="none" id="sidelem4x438">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia</para>
					</section>
					<section type="none" id="sidelem4x443">
						<sec_title>MISC:</sec_title>
						<para> Arthralgia, myalgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x448">
						<sec_title>OTHER:</sec_title>
						<para> Hyperglycemia, hypophosphatemia, hyponatremia, <emphasis style="bold">secondary malignancy,</emphasis> hand/foot syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x456">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 99.7%, half-life 8 hr (dabrafenib), 10 hr, 21-22 hr metabolites, excreted 71% (feces), 23% (urine)</para>
			</section>
			<section type="interactions" id="sidelem4x461">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Altered:</emphasis> dabrafenib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dabrafenib concentrations—CYP3A4 inducers (dexamethasome, phenytoin, carBAMazepine, rifampin, PHENobarbital), antacids, proton-pump inhibitors</para>
				<section type="none" id="sidelem4x472">
					<section type="none" id="sidelem4x473">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> dabrafenib concentrations St. John’s Wort</para>
					</section>
					<section type="none" id="sidelem4x480">
						<sec_title>Drug/Food Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> dabrafenib effect—grapefruit juice; avoid use while taking product</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x487">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x490">
					<section type="none" id="sidelem4x491">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x495">
								<item>
									<label>•</label>
									<para>Toxicity: fever, grade 2, 3</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x501">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x505">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in melanoma progression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x511">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x516">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x521">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x529">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception during treatment and up to 30 days after discontinuing treatment, pregnancy (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name> dacarbazine (Rx)</mono_name>
			<info>
				<pronunciation>(da-kar′ba-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x5391">
						<country code="CAN">DTIC </country>
					</tradename>
					<tradename id="tnidelem4x5390">DTIC-Dome</tradename>
				</tradenames>
				<class type="func"> Antineoplastic alkylating agent</class>
				<class type="chem"> Cytotoxic triazine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x552">
				<sec_title>Action:</sec_title>
				<para>Alkylates DNA, RNA; inhibits DNA, RNA synthesis; also responsible for breakage, cross-linking of DNA strands; activity is not cell-cycle–phase specific</para>
			</section>
			<section type="uses" id="sidelem4x557">
				<sec_title>Uses:</sec_title>
				<para>Hodgkin’s disease, malignant melanoma</para>
				<section type="none" id="sidelem4x562">
					<section type="none" id="sidelem4x563">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Malignant pheochromocytoma in combination with cyclophosphamide and vinCRIStine, metastatic soft-tissue sarcoma in combination with other agents, carcinoma meningitis, neuroblastoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x568">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x573">
					<section type="none" id="sidelem4x574">
						<sec_title>Precautions:</sec_title>
						<para> Renal disease, infection</para>
						<para>
							<bbw>Pregnancy (C) 1st trimester, radiation therapy, hepatic disease, bone marrow suppression, secondary malignancy</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x589">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x592">
					<section type="none" id="sidelem4x593">
						<sec_title>Metastatic malignant melanoma</sec_title>
						<section type="none" id="sidelem4x601">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x601">
									<item>
										<label>•</label>
										<para> 2-4.5 mg/kg/day × 10 days or 100-250 mg/m<emphasis style="sup">2</emphasis>/day × 5 days; repeat q3-4wk depending on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x608">
						<sec_title>Hodgkin’s disease</sec_title>
						<section type="none" id="sidelem4x616">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x616">
									<item>
										<label>•</label>
										<para> 150 mg/m<emphasis style="sup">2</emphasis>/day × 5 days with other agents, repeat q4wk; or 375 mg/m<emphasis style="sup">2</emphasis> on days 1 and 15 when given in combination, repeat q28days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x626">
						<sec_title>Osteogenic sarcoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x634">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x634">
									<item>
										<label>•</label>
										<para> 250 mg/m<emphasis style="sup">2</emphasis>/day as continuous infusion × 4 days in combination with other agents q28days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x641">
						<sec_title>Soft-tissue sarcoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x649">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x649">
									<item>
										<label>•</label>
										<para> 250-300 mg/m<emphasis style="sup">2</emphasis>/day as continuous infusion × 3 days q21-28days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x657">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 100, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x662">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x666">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before giving product to prevent vomiting, nausea; vomiting may subside after several doses, nausea/vomiting may be severe and last several hours</para>
								</item>
								<item>
									<label>•</label>
									<para>Antibiotics for prophylaxis of infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x677">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x681">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling precautions</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x687">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x691">
									<item>
										<label>•</label>
										<para>After diluting 100 mg/9.9 or 200 mg/19.7 ml of sterile water for inj (10 mg/ml), give by direct IV over 2-3 min through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x700">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x704">
									<item>
										<label>•</label>
										<para>May be further diluted in 50-250 ml D<emphasis style="inf">5</emphasis>W or NS for inj, given as an infusion over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Watch for extravasation; stop infusion, apply ice to area</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in light-resistant container in a dry area</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, anidulafungin, atenolol, aztreonam, bivalirudin, bleomycin, caspofungin, DAPTOmycin, dexmedetomidine, DOCEtaxel, DOXOrubicin, ertapenem, etoposide, fenoldopam, filgrastim, fludarabine, gemtuzumab, granisetron, levofloxacin, mechlorethamine, melphalan, nesiritide, octreotide, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, quinupristin-dalfopristin, sargramostim, teniposide, thiotepa, tigecycline, tirofiban, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x733">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x736">
					<section type="none" id="sidelem4x737">
						<sec_title>CNS:</sec_title>
						<para> Facial paresthesia, flushing, fever, malaise; confusion, headache, <emphasis style="bold">seizures, cerebral hemorrhage,</emphasis> blurred vision (high doses)</para>
					</section>
					<section type="none" id="sidelem4x745">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia, vomiting,</emphasis><emphasis style="bold">hepatotoxicity</emphasis> (rare)</para>
					</section>
					<section type="none" id="sidelem4x755">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x763">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> dermatitis, pain at inj site, photosensitivity; severe sun reactions (high doses)</para>
					</section>
					<section type="none" id="sidelem4x771">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms, malaise, fever, myalgia, hypotension</para>
					</section>
					<section type="none" id="sidelem4x776">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x783">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted in urine; terminal half-life 19 min; 5% protein bound</para>
			</section>
			<section type="interactions" id="sidelem4x788">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Toxicity, bone marrow suppression:</emphasis> bone marrow suppressants, radiation, other antineoplastics•Bleeding: salicylates, anticoagulants, NSAIDs</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reaction; decrease antibody reaction—live virus vaccines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—aminoglycosides</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ototoxicity—loop diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dacarbazine effect—phenytoin, PHENobarbital</para>
			</section>
			<section type="considerations" id="sidelem4x825">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x828">
					<section type="none" id="sidelem4x829">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow suppression:</emphasis> CBC, differential, platelet count weekly; notify prescriber of results</bbw>
						</para>
						<para>
							<list id="lidelem4x844">
								<item>
									<label>•</label>
									<para>Monitor temperature; may indicate beginning infection, I&amp;O, for nausea, appetite</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Secondary malignancy: assess for secondary malignancy that may occur with this product</bbw>
						</para>
						<para>
							<list id="lidelem4x860">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae of mucosa or orifices q8hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image, discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hepatic disease:</emphasis> jaundice of skin, sclera; dark urine; clay-colored stools; itchy skin; abdominal pain; fever; diarrhea; hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed or monthly</bbw>
						</para>
						<para>
							<list id="lidelem4x885">
								<item>
									<label>•</label>
									<para>Inflammation of mucosa, breaks in skin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x890">
								<item>
									<label>•</label>
									<para>IV site for irritation, redness, pain; if infiltration occurs, use hot packs at site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x896">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity reactions, anaphylaxis, discontinue product, administer meds for anaphylaxis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x901">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent urate deposits, calculi formation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x906">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x910">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x916">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x921">
								<item>
									<label>•</label>
									<para>That patient should avoid prolonged exposure to sun, wear sunscreen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x926">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make the patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x934">
							<label>•</label>
							<sec_title>To report signs of infection<route> fever, sore throat, flulike symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x940">
							<label>•</label>
							<sec_title>To report signs of anemia<route> fatigue, headache, faintness, SOB, irritability</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x943">
								<item>
									<label>•</label>
									<para>To report bleeding; to avoid use of razors, commercial mouthwash</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x951">
							<label>•</label>
							<sec_title>Pregnancy<route> to notify prescriber if pregnancy is planned or suspected pregnancy (D)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x954">
								<item>
									<label>•</label>
									<para>To avoid aspirin products or ibuprofen
<bbw>To use reliable contraceptives during and for several mo after therapy; not to breastfeed</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>dalbavancin</mono_name>
			<info>
				<pronunciation>(dal-ba-van′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x9730">Dalvance</tradename>
				</tradenames>
				<class type="func"> Antiinfective-glycopeptide</class>
			</info>
			<section type="actions" id="sidelem4x979">
				<sec_title>Action:</sec_title>
				<para> Binds to the bacterial cell walls, inhibiting their synthesis</para>
			</section>
			<section type="uses" id="sidelem4x984">
				<sec_title>Uses:</sec_title>
				<para> Treatment of acute bacterial skin and skin structure infections due to gram-positive organisms (cellulitis, major abscess, wound infections)</para>
			</section>
			<section type="contra" id="sidelem4x989">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<section type="none" id="sidelem4x994">
					<section type="none" id="sidelem4x995">
						<sec_title>Precautions:</sec_title>
						<para> Antimicrobial resistance, breastfeeding, colitis, diarrhea, GI disease, inflammatory bowel disease, infusion-related reactions, pregnancy, pseudomembranous colitis, ulcerative colitis, vancomycin hypersensitivity, viral infection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1000">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1008">
					<label>•</label>
					<sec_title>Adults<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1008">
							<item>
								<label>•</label>
								<para> 1000 mg once, then 500 mg IV 1 wk later</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1012">
					<section type="none" id="sidelem4x1013">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 500 mg</para>
					</section>
					<section type="none" id="sidelem4x1018">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1021">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1026">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1034">
								<label>•</label>
								<sec_title>Reconstitution</sec_title>
								<para>
									<list id="lidelem4x1034">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reconstitution:</emphasis> Reconstitute each 500 mg/25 ml sterile water for injection, to avoid foaming, alternate between gentle swirling and inversion until completely dissolved, do not shake; further dilution is required</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x1041">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x1041">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> Refrigerate or store at room temperature. Do not freeze. The total time from reconstitution to dilution to use should not exceed 48 hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x1048">
								<label>•</label>
								<sec_title>Dilution</sec_title>
								<para>
									<list id="lidelem4x1048">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Dilution:</emphasis> Transfer the dose of reconstituted solution from the vial(s) to an IV bag or bottle containing D<emphasis style="inf">5</emphasis>W (1-5 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x1055">
							<sec_title>Intermittent IV INFUSION</sec_title>
							<para>
								<list id="lidelem4x1059">
									<item>
										<label>•</label>
										<para>Give over 30 min, do not infuse with other medications or electrolytes, saline-based infusion solutions may cause precipitation and should not be used; if a common IV line is being used to administer other drugs, the line should be flushed before and after each dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1065">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1068">
					<section type="none" id="sidelem4x1069">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, flushing</para>
					</section>
					<section type="none" id="sidelem4x1074">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, <emphasis style="bold">pseudomembranous colitis, GI bleeding,</emphasis> abdominal pain, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x1082">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, neutropenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1089">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Red man syndrome, hypersensitivity reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1096">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, <emphasis style="bold">infusion-related reactions,</emphasis> pruritus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1105">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 93%, primarily to albumin, with a protein binding of approximately 93%, excreted in feces and urine, metabolism decreased in renal disease</para>
			</section>
			<section type="interactions" id="sidelem4x1110">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1113">
					<section type="none" id="sidelem4x1114">
						<sec_title>Decrease:</sec_title>
						<para> oral contraceptives may occur with prolonged use</para>
					</section>
					<section type="none" id="sidelem4x1119">
						<sec_title>Drug/lab test</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x1123">
						<sec_title>Increase: </sec_title>
						<para>LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1128">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1131">
					<section type="none" id="sidelem4x1132">
						<sec_title>Assess:</sec_title>
						<para> <emphasis style="bold">BUN/creatinine, lower dose may be required in severe renal disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1139">
						<sec_title>Pseudomembranous colitis:</sec_title>
						<para> <emphasis style="bold">bowel pattern daily, if severe diarrhea occurs, product should be discontinued</emphasis></para>
						<section type="none" id="sidelem4x1146">
							<sec_title>IV site for INFUSION-site reactions</sec_title>
							<para>
								<emphasis alert="lifethreat">Anaphylaxis: rash, urticaria, pruritus, wheezing, may occur a few days after administration</emphasis>
							</para>
							<para>
								<emphasis alert="lifethreat">Red man syndrome: flushing, rash over upper torso and neck, may occur after a few minutes of infusion, may be treated with antihistamines and a slower infusion</emphasis>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1155">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1159">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection, negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1165">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x1173">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, bruising, bleeding, joint pain (blood dyscrasias); diarrhea with mucus, blood (pseudomembranous colitis)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1176">
								<item>
									<label>•</label>
									<para>To use nonhormonal contraceptive if on long-term therapy (controversial)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>dalfampridine (Rx)</mono_name>
			<info>
				<pronunciation>(dal-fam′pri-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x11861">Ampyra</tradename>
					<tradename id="tnidelem4x11860"/>
				</tradenames>
				<class type="func"> Neurological agent—multiple sclerosis</class>
				<class type="chem"> Broad-spectrum potassium channel blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1198">
				<sec_title>Action:</sec_title>
				<para>Mechanism of action is not fully understood; a broad-spectrum potassium channel blocker that inhibits potassium channels and increased action potential conduction in demyelinated axions</para>
			</section>
			<section type="uses" id="sidelem4x1203">
				<sec_title>Uses:</sec_title>
				<para>For improved walking in patients with multiple sclerosis</para>
			</section>
			<section type="contra" id="sidelem4x1208">
				<sec_title>Contraindications:</sec_title>
				<para>Renal failure (CCr &lt;50 ml/min), seizures</para>
				<section type="none" id="sidelem4x1213">
					<section type="none" id="sidelem4x1214">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1219">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1227">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1227">
							<item>
								<label>•</label>
								<para> 10 mg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1231">
					<section type="none" id="sidelem4x1232">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1240">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 51-80 ml/min, no dosage adjustment needed but seizure risk unknown; CCr ≤50 ml/min, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1243">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel tab 10 mg</para>
					</section>
					<section type="none" id="sidelem4x1248">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1252">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew; give without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not give closer together than q12hr; seizures may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not double doses; if a dose is missed, skip it</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1268">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1271">
					<section type="none" id="sidelem4x1272">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> paresthesias, headache, dizziness, asthenia, insomnia</para>
					</section>
					<section type="none" id="sidelem4x1280">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x1285">
						<sec_title>GU:</sec_title>
						<para> Urinary tract infection</para>
					</section>
					<section type="none" id="sidelem4x1290">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1295">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 96%; peak 3-4 hr (fasting), longer if taken with food; largely unbound to plasma proteins; 96% recovered in urine</para>
			</section>
			<section type="interactions" id="sidelem4x1300">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1308">
					<label>•</label>
					<sec_title>
						<route>Do not use with fampridine, other 4-aminopyridine (4-AP)–containing products</route>
					</sec_title>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1311">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1314">
					<section type="none" id="sidelem4x1315">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1323">
							<label>•</label>
							<sec_title>Multiple sclerosis</sec_title>
							<para>
								<list id="lidelem4x1323">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Multiple sclerosis:</emphasis> improved walking, including speed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1331">
							<label>•</label>
							<sec_title>Seizures<route> more common in those with previous seizure disorder</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1334">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1338">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to walk at improved speed in multiple sclerosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1344">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1348">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; not to breastfeed</para>
								</item>
								<item>
									<label>•</label>
									<para>Expected results; side effects, including seizures</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active" ha="yes">
			<mono_name> dalteparin (Rx)</mono_name>
			<info>
				<pronunciation>(dahl′ta-pear-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x13660">Fragmin</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Low–molecular-weight heparin</class>
			</info>
			<section type="actions" id="sidelem4x1376">
				<sec_title>Action:</sec_title>
				<para>Inhibits factor Xa/IIa (thrombin), resulting in anticoagulation</para>
			</section>
			<section type="uses" id="sidelem4x1381">
				<sec_title>Uses:</sec_title>
				<para>Unstable angina/non–Q-wave MI; prevention/treatment of deep venous thrombosis in abdominal surgery, hip replacement, or in those with restricted mobility during acute illness, pulmonary embolism</para>
				<section type="none" id="sidelem4x1386">
					<section type="none" id="sidelem4x1387">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Antiphospholipid antibody, arterial thromboembolism (after heart valve surgery), cerebral thromboembolism, acute MI</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1392">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, heparin, or pork products; active major bleeding, hemophilia, leukemia with bleeding, thrombocytopenic purpura, cerebrovascular hemorrhage, cerebral aneurysm; those undergoing regional anesthesia for unstable angina, non–Q-wave MI, dalteparin-induced thrombocytopenia</para>
				<section type="none" id="sidelem4x1397">
					<section type="none" id="sidelem4x1398">
						<sec_title>Precautions:</sec_title>
						<para> Hypersensitivity to benzyl alcohol, pregnancy (B), breastfeeding, children, recent childbirth, geriatric patients; hepatic disease; severe renal disease; blood dyscrasias; bacterial endocarditis; acute nephritis; uncontrolled hypertension; recent brain, spine, eye surgery; congenital or acquired disorders; severe cardiac disease; peptic ulcer disease; hemorrhagic stroke; history of HIT; pericarditis; pericardial effusion; recent lumbar puncture; vasculitis; other diseases in which bleeding is possible</para>
						<para>
							<bbw>Epidural anesthesia, lumbar puncture</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1413">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1416">
					<section type="none" id="sidelem4x1417">
						<sec_title>DVT/pulmonary embolism</sec_title>
						<section type="none" id="sidelem4x1425">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1425">
									<item>
										<label>•</label>
										<para> 200 international units/kg daily during 1st mo (max single dose 18,000 international units), then 150 international units/kg daily for mo 2-6 (max single dose 18,000 international units), use prefilled syringe that is closest to calculated dose; if platelets are 50,000-100,000/mm<emphasis style="sup">3</emphasis>, reduce dose by 2500 international units until platelets ≥100,000 mm<emphasis style="sup">3</emphasis>; if platelets &lt;50,000/mm<emphasis style="sup">3</emphasis>, discontinue until &gt;50,000/mm<emphasis style="sup">3</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1440">
						<sec_title>Hip replacement surgery/DVT prophylaxis</sec_title>
						<section type="none" id="sidelem4x1448">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1448">
									<item>
										<label>•</label>
										<para> 2500 international units 2 hr before surgery and 2nd dose in the evening on the day of surgery (4-8 hr postop), then 5000 international units  1st postop day and daily × 5-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1455">
						<sec_title>Unstable angina/non–Q-wave MI</sec_title>
						<section type="none" id="sidelem4x1463">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1463">
									<item>
										<label>•</label>
										<para> 120 international units/kg q12hr × 5-8 days, max 10,000 international units q12hr × 5-8 days with concurrent aspirin; continue until stable</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1467">
						<sec_title>DVT, prophylaxis for abdominal surgery</sec_title>
						<section type="none" id="sidelem4x1475">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1475">
									<item>
										<label>•</label>
										<para> 2500 international units 1-2 hr before surgery; repeat daily × 5-10 days; for high-risk patients, &gt;3400 international units should be used</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1479">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1487">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT cancer patient with CCr &lt;30 ml/min, monitor and adjust based on anti-factor Xa during extended treatment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1490">
						<sec_title>APLA (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1498">
							<label>•</label>
							<sec_title>Adult (female)<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1498">
									<item>
										<label>•</label>
										<para> Antepartum 5000 international units/day with aspirin; maintain anti-factor Xa of 0.2-0.6 international units/ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1503">
						<sec_title>Arterial thromboembolism prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1511">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x1511">
									<item>
										<label>•</label>
										<para> LMWH in combination with oral anticoagulants until INR is in therapeutic range × 2 consecutive days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1515">
						<sec_title>Available forms:</sec_title>
						<para> Prefilled syringes, 2500, 5000 international units/0.2 ml; 7500 international units/0.3 ml; 10,000, 12,500, 15,000, 18,000, 25,000 international units/ml</para>
					</section>
					<section type="none" id="sidelem4x1520">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1524">
								<item>
									<label>•</label>
									<para>Cannot be used interchangeably (unit for unit) with unfractionated heparin or other LMWHs</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not give IM or IV product route; approved is SUBCUT only; do not mix with other inj or sol</para>
								</item>
								<item>
									<label>•</label>
									<para>Have patient sit or lie down; SUBCUT inj may be 2 inches from umbilicus in a <emphasis style="sans-serif">U</emphasis>-shape, upper outer side of thigh, around navel, or upper outer quadrangle of the buttocks; rotate inj sites</para>
								</item>
								<item>
									<label>•</label>
									<para>Change inj site daily; use at same time of day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1548">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1551">
					<section type="none" id="sidelem4x1552">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Intracranial bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1559">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1566">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, superficial wound infection, skin necrosis, inj site reaction, alopecia</para>
					</section>
					<section type="none" id="sidelem4x1571">
						<sec_title>SYST:</sec_title>
						<para> Hypersensitivity, <emphasis style="bold">hemorrhage, anaphylaxis</emphasis> possible, <emphasis style="bold">hematoma</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1581">
				<sec_title>Pharmacokinetics</sec_title>
				<para>87% absorbed, excreted by kidneys, elimination half-life 3-5 hr, peak 2-4 hr, onset 1-2 hr, duration &gt;12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1586">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—aspirin, oral anticoagulants, platelet inhibitors, NSAIDs, salicylates, thrombolytics, some cephalosporins</para>
				<section type="none" id="sidelem4x1593">
					<section type="none" id="sidelem4x1594">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—feverfew, garlic, ginger, ginkgo, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x1601">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1608">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1611">
					<section type="none" id="sidelem4x1612">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1620">
							<label>•</label>
							<sec_title>
								<route>Blood studies (Hct/Hgb, CBC, platelets, anti-Xa, stool guaiac) during treatment because bleeding can occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1624">
								<item>
									<para>
										<emphasis alert="nurse">Bleeding: Bleeding gums, petechiae, ecchymosis, black tarry stools, hematuria, epistaxis, decrease in Hct, B/P; may indicate bleeding, possible hemorrhage; notify prescriber immediately, product should be discontinued</emphasis>
<bbw>
											<emphasis alert="lifethreat">Epidural anesthesia:</emphasis> Neurologic impairment frequently in those when neuraxial anesthesia has been used, spinal/epidural hematomas can occur, with paralysis</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1643">
							<label>•</label>
							<sec_title>Hypersensitivity<route> fever, skin rash, urticaria; notify prescriber immediately</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1646">
								<item>
									<label>•</label>
									<para>Needed dosage change q1-2wk; dose may need to be decreased if bleeding occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1651">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1655">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of DVT</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1661">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1666">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations that contain aspirin; other anticoagulants, serious product interaction may occur unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1671">
								<item>
									<label>•</label>
									<para>To use soft-bristle toothbrush to avoid bleeding gums; to avoid contact sports; to use electric razor; to avoid IM inj</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1679">
							<label>•</label>
							<sec_title>
								<route>To report any signs of bleeding (gums, under skin, urine, stools), unusual bruising</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>dantrolene (Rx)</mono_name>
			<info>
				<pronunciation>(dan′troe-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x16921">Dantrium</tradename>
					<tradename id="tnidelem4x16920">Revonto</tradename>
				</tradenames>
				<class type="func"> Skeletal muscle relaxant, direct acting</class>
				<class type="chem"> Hydantoin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1703">
				<para>
					<confusion>
						<tradename id="tnidelem4x17030">Dantrium</tradename>
						<drug type="generic" refid="idelem4x17030">danazol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1707">
				<sec_title>Action:</sec_title>
				<para>Interferes with intracellular release of calcium from the sarcoplasmic reticulum necessary to initiate contraction; slows catabolism in malignant hyperthermia</para>
			</section>
			<section type="uses" id="sidelem4x1712">
				<sec_title>Uses:</sec_title>
				<para>Spasticity in multiple sclerosis, stroke, spinal cord injury, cerebral palsy, malignant hyperthermia</para>
				<section type="none" id="sidelem4x1717">
					<section type="none" id="sidelem4x1718">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Neuroleptic malignant syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1723">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, compromised pulmonary function, impaired myocardial function</para>
				<para>
					<bbw>Active hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x1738">
					<section type="none" id="sidelem4x1739">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, peptic ulcer disease, cardiac/renal/hepatic disease, stroke, seizure disorder, diabetes mellitus, ALS, COPD, MS, mannitol/gelatin hypersensitivity, labor, lactase deficiency, extravasation</para>
						<para>
							<bbw>Females &gt;35 yr, with MS, or taking estrogens</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1754">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1757">
					<section type="none" id="sidelem4x1758">
						<sec_title>Spasticity</sec_title>
						<section type="none" id="sidelem4x1766">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1766">
									<item>
										<label>•</label>
										<para> 25 mg/day; may increase to 25-100 mg bid-qid, max 400 mg/day, may be increased q 7 days as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1773">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1773">
									<item>
										<label>•</label>
										<para> 0.5 mg/kg/day given in divided doses bid, may be increased q 7 days as needed, max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1777">
						<sec_title>Prevention of malignant hyperthermia</sec_title>
						<section type="none" id="sidelem4x1785">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1785">
									<item>
										<label>•</label>
										<para> 4-8 mg/kg/day in 3-4 divided doses × 1-3 days before procedure, give last dose 4 hr preop;  2.5 mg/kg before anesthesia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1792">
						<sec_title>Malignant hyperthermia</sec_title>
						<section type="none" id="sidelem4x1800">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1800">
									<item>
										<label>•</label>
										<para> 1-2.5 mg/kg, may repeat to total dose of 10 mg/kg;  4-8 mg/kg/day in 4 divided doses × 1-3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1807">
						<sec_title>Neuroleptic malignant syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1815">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1815">
									<item>
										<label>•</label>
										<para> 100-300 mg/day in divided doses;  1.25-1.5 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1822">
						<sec_title>Available forms:</sec_title>
						<para> Caps 25, 50, 100 mg; powder for inj 20 mg/vial</para>
					</section>
					<section type="none" id="sidelem4x1827">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1831">
								<item>
									<label>•</label>
									<para>Avoid use with other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1837">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1841">
									<item>
										<label>•</label>
										<para>Do not crush or chew caps</para>
									</item>
									<item>
										<label>•</label>
										<para>Caps may be opened, mixed with juice and swallowed</para>
									</item>
									<item>
										<label>•</label>
										<para>With meals for GI symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1857">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x1861">
									<item>
										<label>•</label>
										<para>IV after diluting 20 mg/60 ml sterile water for inj without bacteriostatic agent (333 mcg/ml); shake until clear; give by rapid IV push through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; follow with prescribed doses immediately; may also give by intermittent infusion over 1 hr before anesthesia</para>
									</item>
									<item>
										<label>•</label>
										<para>Considered incompatible in sol or syringe; compatibility unknown</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container at room temperature; protect diluted sol from light, use reconstituted sol within 6 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1880">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1883">
					<section type="none" id="sidelem4x1884">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, weakness, fatigue, drowsiness,</emphasis> headache, disorientation, insomnia, paresthesias, tremors, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1894">
						<sec_title>CV:</sec_title>
						<para> Hypotension, chest pain, palpitations, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x1899">
						<sec_title>EENT:</sec_title>
						<para> Nasal congestion, blurred vision, mydriasis, excessive lacrimation</para>
					</section>
					<section type="none" id="sidelem4x1904">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hepatic injury,</emphasis><emphasis style="italic">nausea,</emphasis> constipation, vomiting, increased AST, alk phos, abdominal pain, dry mouth, anorexia, hepatitis, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x1914">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, nocturia, impotence, crystalluria, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1921">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Eosinophilia, aplastic anemia, leukopenia, thrombocytopenia/lymphoma</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1928">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, photosensitivity, extravasation (tissue necrosis), phlebitis</para>
					</section>
					<section type="none" id="sidelem4x1933">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pleural effusion, pulmonary edema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1940">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1943">
					<section type="none" id="sidelem4x1944">
						<sec_title>PO:</sec_title>
						<para> Peak 5 hr, highly protein bound, half-life 8 hr, metabolized in liver, excreted in urine (metabolites), absorption poor (35%)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1949">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—verapamil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hepatotoxicity—estrogens, other hepatotoxics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, tricyclics, opiates, barbiturates, sedatives, hypnotics, antihistamines, tramadol</para>
			</section>
			<section type="considerations" id="sidelem4x1965">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1968">
					<section type="none" id="sidelem4x1969">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1977">
							<label>•</label>
							<sec_title>Seizures<route> increased seizure activity, ECG in epilepsy patient; poor seizure control has occurred</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1983">
							<para>
								<list id="lidelem4x1983">
									<item>
										<label>•</label>
										<para>I&amp;O ratio; check for urinary retention, frequency, hesitancy, especially geriatric patients
<bbw>
												<emphasis alert="lifethreat">Active hepatic disease:</emphasis> hepatic function by frequent determination of AST, ALT, bilirubin, alk phos, GGTP; renal function studies, BUN, creatinine, CBC, use lowest dose possible; check for jaundice, dark urine, diarrhea, weakness; product should be discontinued</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1999">
							<label>•</label>
							<sec_title>Allergic reactions<route> rash, fever, respiratory distress</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2005">
							<label>•</label>
							<sec_title>
								<route>Severe weakness, numbness in extremities; prescriber should be notified and product discontinued</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2008">
								<item>
									<label>•</label>
									<para>Tolerance: increased need/more frequent requests for medication, increased pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2013">
								<item>
									<label>•</label>
									<para>CNS depression: dizziness, drowsiness, insomnia, psychiatric symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2019">
								<item>
									<para>
										<emphasis alert="nurse">Signs of hepatotoxicity: jaundice, yellow sclera, pain in abdomen, nausea, fever; prescriber should be notified, product discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2024">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2028">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, spasticity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2034">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2042">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication quickly because hallucinations, spasticity, tachycardia will occur; product should be tapered off over 1-2 wk; to notify prescriber of abdominal pain, jaundiced sclera, clay-colored stools, change in color of urine</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2045">
								<item>
									<label>•</label>
									<para>That if improvement does not occur within 6 wk, prescriber may discontinue product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2050">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsiness, dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2055">
								<item>
									<label>•</label>
									<para>To report severe weakness, seizures, signs of liver insufficiency</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2060">
								<item>
									<label>•</label>
									<para>To avoid using OTC medications: cough preparations, antihistamines, other CNS depressants, alcohol unless directed by prescriber, to take with meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2065">
								<item>
									<label>•</label>
									<para>To use sunscreen or stay out of the sun to prevent burns</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2070">
						<sec_title>Malignant hyperthermia: </sec_title>
						<para>To use a medical ID stating condition, products used</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>dapagliflozin</mono_name>
			<info>
				<pronunciation>(dap′a-gli-floe′zin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x20850">Farxiga</tradename>
				</tradenames>
				<class type="func"> Oral antidiabetic</class>
				<class type="chem"> SGLT 2 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2095">
				<sec_title>Action:</sec_title>
				<para>Blocks reabsorption of glucose by the kidney, increases glucose excretion, lower blood glucose concentrations</para>
			</section>
			<section type="uses" id="sidelem4x2100">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus, with diet and exercise</para>
			</section>
			<section type="contra" id="sidelem4x2105">
				<sec_title>Contraindications:</sec_title>
				<para>Dialysis, renal failure, hypersensitivity, breastfeeding, diabetic ketoacidosis</para>
				<section type="none" id="sidelem4x2110">
					<section type="none" id="sidelem4x2111">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, renal/hepatic disease, hypothyroidism, hyperglycemia, hypotension, bladder cancer, hypercholesterolemia, pituitary insufficiency, type 1 diabetes mellitus, malnutrition, fever, dehydration, adrenal insufficiency, geriatrics, genital fungal infections, hypoglycemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2116">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2124">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2124">
							<item>
								<label>•</label>
								<para> 5 mg in AM; may increase to 10 mg daily if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2129">
					<section type="none" id="sidelem4x2130">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x2138">
							<label>•</label>
							<sec_title>Adult<route> PO eGFR ≥60 ml/min/1.73 m</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2146">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x2151">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2154">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2158">
									<item>
										<label>•</label>
										<para>Once daily in <emphasis style="smallcaps">am</emphasis> without regard to food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2167">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2170">
					<section type="none" id="sidelem4x2171">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x2176">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, <emphasis style="bold">pancreatitis,</emphasis> constipation, nausea</para>
					</section>
					<section type="none" id="sidelem4x2184">
						<sec_title>GU:</sec_title>
						<para> Cystitis, candidiasis, urinary frequency, polydipsia, polyuria, increased serum creatinine; <emphasis style="bold">renal impairment/failure;</emphasis> infections</para>
					</section>
					<section type="none" id="sidelem4x2192">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity, rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x2197">
						<sec_title>META:</sec_title>
						<para> Hypercholesterolemia, lipidemia, hypoglycemia, hyperkalemia, hypomagnesemia, hypo/hyperphosphatemia</para>
					</section>
					<section type="none" id="sidelem4x2202">
						<sec_title>MISC:</sec_title>
						<para> Bone fractures, hypotension; dehydration; orthostatic hypotension; hypersensitivity; new <emphasis style="bold">bladder cancer;</emphasis> increased hematocrit</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2210">
				<sec_title>Pharmacokinetics</sec_title>
				<para>91% protein binding, primary excretion in urine, half-life 12.9 hr; primarily metabolized by O-glucuronidation by UGT1A9; minor CYP3A4; Cmax is less than 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x2215">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2223">
					<label>•</label>
					<sec_title>
						<route>Do not use gatifloxacin</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—sulfonylureas, insulin, MAOIs, salicylates, fibric acid derivatives, bile acid sequestrates, ACE inhibitors, angiotensin II receptor antagonists, beta blockers</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> glycemic control—androgens, lithium, bortezomib, quinolones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect hyperglycemia—digestive enzymes, intestinal absorbents, thiazide diuretics, loop diuretics, corticosteroids, estrogen, progestins, oral contraceptives, sympathomimetics, isoniazid, phenothiazines, protease inhibitors, atypical antipsychotics, carbonic anhydrase inhibitors, cycloSPORINE, tacrolimus, baclofen</para>
				<section type="none" id="sidelem4x2238">
					<section type="none" id="sidelem4x2239">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> HCT, LDL</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2246">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2249">
					<section type="none" id="sidelem4x2250">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2258">
							<label>•</label>
							<sec_title>
								<route>Hypoglycemia</route>
							</sec_title>
							<para>
								<list id="lidelem4x2258">
									<item>
										<label>•</label>
										<para> (weakness, hunger, dizziness, tremors, anxiety, tachycardia, sweating),  even though product does not cause hyperglycemia, if patient is on sulfonylureas or insulin, hypoglycemia may be additive; if hypoglycemia occurs, treat with dextrose, or, if severe, with IV glucagon; HbA1c; lipid panel; renal function tests; volume status; blood pressure</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2265">
								<item>
									<label>•</label>
									<para>Renal function: baseline and periodically, discontinue if renal function is reduced</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2270">
								<item>
									<label>•</label>
									<para>Hypersensitivity: discontinue immediately</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2275">
								<item>
									<label>•</label>
									<para>Hypotension: more frequent in those with poor renal function</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2280">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2284">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved signs/symptoms of diabetes mellitus (decreased polyuria, polydipsia, polyphagia); clear sensorium, absence of dizziness, stable gait; HbA1c WNL</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2290">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2294">
								<item>
									<label>•</label>
									<para>The symptoms of hypo/hyperglycemia, what to do about each</para>
								</item>
								<item>
									<label>•</label>
									<para>That medication must be taken as prescribed; explain consequences of discontinuing medication abruptly; that insulin may need to be used for stress, including trauma, fever, surgery</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications and herbal supplements unless approved by health care provider</para>
								</item>
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that the diet and exercise regimen must be followed; that this product is not a cure</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID and glucose source</para>
								</item>
								<item>
									<label>•</label>
									<para>That blood glucose monitoring is required to assess product effect</para>
								</item>
								<item>
									<label>•</label>
									<para>That GI side effects may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That there is a risk of renal impairment, dehydration, and bladder cancer</para>
								</item>
								<item>
									<label>•</label>
									<para>To report fever, itching, change in urine output, light-headedness or feeling faint</para>
								</item>
								<item>
									<label>•</label>
									<para>To use adequate fluids</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>DAPTOmycin (Rx)</mono_name>
			<info>
				<pronunciation>(dap′toe-mye-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x23510">Cubicin</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Lipopeptides</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x2361">
				<sec_title>Action:</sec_title>
				<para>A new class of antiinfective; it binds to the bacterial membrane and results in a rapid depolarization of the membrane potential, thereby leading to inhibition of DNA, RNA, and protein synthesis</para>
			</section>
			<section type="uses" id="sidelem4x2366">
				<sec_title>Uses:</sec_title>
				<para>Bacteremia, endocarditis, UTI, complicated skin, skin-structure infections caused by <emphasis style="italic">Staphylococcus aureus</emphasis> (MRSA, MSSA) including methicillin-resistant strains, <emphasis style="italic">Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Enterococcus faecalis</emphasis> (vancomycin-susceptible strains), <emphasis style="italic">Streptococcus pyogenes</emphasis> (group A beta hemolytic), <emphasis style="italic">Staphylococcus aureus, Staphylococcus epidermidis, Corynebacterium jeikeium, Staphylococcus haemolyticus</emphasis></para>
				<section type="none" id="sidelem4x2382">
					<section type="none" id="sidelem4x2383">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Vancomycin-resistant enterococci (VRE), bone, joint infection, infectious arthritis, orthopedic device-related infection, osteomyelitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2388">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2393">
					<section type="none" id="sidelem4x2394">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, GI/renal disease, myopathy, ulcerative/pseudomembranous colitis, rhabdomyolysis, eosinophilic pneumonia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2399">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2407">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x2407">
							<item>
								<label>•</label>
								<para> 4 mg/kg over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr diluted in 0.9% NaCl, give q24hr × 7-14 days; some indications may use up to 6 mg/kg</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2420">
					<label>•</label>
					<sec_title>Adolescent/child/infant ≥5 mo (unlabeled)<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x2420">
							<item>
								<label>•</label>
								<para> 4-6 mg/kg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2424">
					<section type="none" id="sidelem4x2425">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">Staphylococcus aureus bacteremia,</emphasis>
							</emphasis> including right-sided infective endocarditis</sec_title>
						<section type="none" id="sidelem4x2436">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x2436">
									<item>
										<label>•</label>
										<para> 6 mg/kg daily × 2-6 wk, up to 8-10 mg/kg daily; treatment failures should use another agent</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2440">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2448">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION CCr &lt;30 ml/min, hemodialysis, CAPD 4 mg/kg q48hr, 6 mg/kg q48hr (bacteremia)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2451">
						<sec_title>Bacteremia, endocarditis, UTI (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2459">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2459">
									<item>
										<label>•</label>
										<para> 6 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2463">
						<sec_title>VRE (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2471">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2471">
									<item>
										<label>•</label>
										<para> 4 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2475">
						<sec_title>Available forms:</sec_title>
						<para> Lyophilized powder for inj 500 mg</para>
					</section>
					<section type="none" id="sidelem4x2480">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2483">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x2487">
									<item>
										<label>•</label>
										<para>After reconstitution with 10 ml 0.9% NaCl (500 mg/10 ml); further dilution is needed with 0.9 NaCl; infuse over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr or give reconstituted sol (50 mg/ml) by IV inj over 2 min; do not use dextrose-containing solutions</para>
									</item>
									<item>
										<label>•</label>
										<para>Refrigerate vials, for single use only, discard unused portion; prepared solutions are stable for 12 hr at room temperature or 48 hr refrigerated</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B liposome, ampicillin, ampicillin-sulbactam, argatroban, arsenic trioxide, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, dacarbazine, DACTINomycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, diazepam, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lepirudin, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, midazolam, milrinone, mitoXANtrone, mivacurium, morphine, moxifloxacin, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, niCARdipine, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, PHENobarbital, phenylephrine, piperacillin-tazobactam, polymyxin B, potassium acetate/chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, rocuronium, sodium acetate/bicarbonate/citrate/phosphates, succinylcholine, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trimethobenzamide, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> 0.9% NaCl, LR</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2514">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2517">
					<section type="none" id="sidelem4x2518">
						<sec_title>CNS:</sec_title>
						<para> Headache, insomnia, dizziness, confusion, anxiety, fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x2523">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, <emphasis style="bold">heart failure</emphasis>, chest pain</para>
					</section>
					<section type="none" id="sidelem4x2531">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, diarrhea, vomiting, dyspepsia, <emphasis style="bold">pseudomembranous colitis,</emphasis> abdominal pain, stomatitis, xerostomia, anorexia</para>
					</section>
					<section type="none" id="sidelem4x2539">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2546">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukocytosis, anemia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2553">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x2558">
						<sec_title>META:</sec_title>
						<para> Electrolyte imbalances</para>
					</section>
					<section type="none" id="sidelem4x2563">
						<sec_title>MISC:</sec_title>
						<para> Fungal infections, UTI, anemia, hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x2568">
						<sec_title>MS:</sec_title>
						<para> Muscle pain or weakness, arthralgia, pain, myopathy, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2575">
						<sec_title>RESP:</sec_title>
						<para> Cough, <emphasis style="bold">eosinophilic pneumonia,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x2583">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, DRESS, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2590">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Site of metabolism unknown, protein binding 92%, terminal half-life 8-9 hr, 78% excreted unchanged (urine), breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x2595">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> tobramycin levels</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> daptomycin action-tobramycin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy—HMG-CoA reductase inhibitors</para>
				<section type="none" id="sidelem4x2610">
					<section type="none" id="sidelem4x2611">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK, AST, ALT, BUN, creatinine, albumin, LDH</para>
						<para>
							<emphasis style="bold">Increase/Decrease:</emphasis> glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> alkaline phosphatase, magnesium, phosphate, bicarbonate</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2626">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2629">
					<section type="none" id="sidelem4x2630">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2638">
							<label>•</label>
							<sec_title>Eosinophilic pneumonia<route> dyspnea, fever, cough, shortness of breath; if left untreated, can lead to respiratory failure and death</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2642">
							<sec_title>Nephrotoxicity</sec_title>
							<para>
								<list id="lidelem4x2642">
									<item>
										<para>
											<emphasis alert="nurse">Nephrotoxicity:</emphasis> any patient with compromised renal system, toxicity may occur; BUN, creatinine</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2652">
							<label>•</label>
							<sec_title>Rhabdomyolysis<route> Check for myopathy CPK &gt; 1000 U/L (5 × ULN), discontinue product, muscle pain, weakness</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2658">
							<label>•</label>
							<sec_title>Bowel function<route> diarrhea, fever, abdominal pain report to prescriber; pseudomembranous colitis may occur</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2661">
								<item>
									<label>•</label>
									<para>I&amp;O ratio: report hematuria, oliguria, nephrotoxicity may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2666">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, CPK</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2671">
								<item>
									<label>•</label>
									<para>C&amp;S; product may be given as soon as culture taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2676">
								<item>
									<label>•</label>
									<para>B/P during administration; hypo/hypertension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2681">
								<item>
									<label>•</label>
									<para>Signs of infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2686">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction of each medication</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2691">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2695">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative culture</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2701">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2706">
								<item>
									<label>•</label>
									<para>About allergies before treatment, reaction to each medication</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2714">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, fever, fatigue; could indicate superinfection; diarrhea; muscle weakness, pain, shortness of breath</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2717">
								<item>
									<label>•</label>
									<para>Avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active" ha="yes">
			<mono_name> darbepoetin (Rx)</mono_name>
			<info>
				<pronunciation>(dar′bee-poh′eh-tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x27290">Aranesp</tradename>
				</tradenames>
				<class type="func"> Hematopoietic agent</class>
				<class type="chem"> Recombinant human erythropoietin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2739">
				<sec_title>Action:</sec_title>
				<para>Stimulates erythropoiesis by the same mechanism as endogenous erythropoietin; in response to hypoxia, erythropoietin is produced in the kidney and released into the bloodstream, where it interacts with progenitor stem cells to increase red-cell production</para>
			</section>
			<section type="uses" id="sidelem4x2744">
				<sec_title>Uses:</sec_title>
				<para>Anemia associated with chronic renal failure, in patients on and not on dialysis, and anemia in nonmyeloid malignancies for patients receiving coadministered chemotherapy</para>
			</section>
			<section type="contra" id="sidelem4x2749">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to hamster protein products, human albumin, polysorbate 80; uncontrolled hypertension; red-cell aplasia</para>
				<section type="none" id="sidelem4x2754">
					<section type="none" id="sidelem4x2755">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, seizure disorder, porphyria, hypertension, sickle cell disease; vit B<emphasis style="inf">12</emphasis>, folate deficiency; chronic renal failure, dialysis; latex hypersensitivity, CABG, angina, anemia</para>
						<para>
							<bbw>Hgb &gt;11 g/dl, neoplastic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2773">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2776">
					<section type="none" id="sidelem4x2777">
						<sec_title>Correction of anemia in chronic renal failure</sec_title>
						<section type="none" id="sidelem4x2785">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x2785">
									<item>
										<label>•</label>
										<para> 0.45 mcg/kg as a single inj; every wk, titrate max target Hgb of 11 g/dl</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2789">
						<sec_title>Chemotherapy treatment</sec_title>
						<section type="none" id="sidelem4x2797">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2797">
									<item>
										<label>•</label>
										<para> 2.25 mcg/kg/wk or 500 mcg q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2801">
						<sec_title>Epoetin alfa to darbepoetin conversion</sec_title>
						<section type="none" id="sidelem4x2809">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x2809">
									<item>
										<label>•</label>
										<para> (epoetin alfa &lt;2500 units/wk) 6.25 mcg/wk; (epoetin alfa 2500-4999 units/wk) 12.5 mcg/wk; (epoetin alfa 5000-10,999 units/wk) 25 mcg/wk; (epoetin alfa 11,000-17,999 units/wk) 40 mcg/wk; (epoetin alfa 18,000-33,999 units/wk) 60 mcg/wk; (epoetin alfa 34,000-89,999 units/wk) 100 mcg/wk; (epoetin alfa &gt;90,000 units/wk) 200 mcg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2813">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 25, 40, 60, 100, 150, 200, 300, 500 mcg/ml</para>
					</section>
					<section type="none" id="sidelem4x2818">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2822">
								<item>
									<label>•</label>
									<para>Transfusions may still be required for anemia, use iron supplements with this product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2828">
							<sec_title>SUBCUT/IV route</sec_title>
							<para>
								<list id="lidelem4x2832">
									<item>
										<label>•</label>
										<para>Without shaking; check for discoloration, particulate matter, do not use if present; do not dilute, do not mix with other products or sol, discard unused portion, do not pool unused portions</para>
									</item>
									<item>
										<label>•</label>
										<para>Subcut typically used for those not requiring dialysis</para>
									</item>
									<item>
										<label>•</label>
										<para>IV given direct undiluted or bolus into IV tubing or venous line after completion of dialysis; watch for clotting of line</para>
									</item>
									<item>
										<label>•</label>
										<para>Adjust dosage every mo or more</para>
									</item>
									<item>
										<label>•</label>
										<para>Store refrigerated, do not freeze; protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2859">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2862">
					<section type="none" id="sidelem4x2863">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> sweating, headache, dizziness, <emphasis style="bold">stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2873">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypo/hypertension,</emphasis><emphasis style="bold">cardiac arrest,</emphasis><emphasis style="italic">angina pectoris,</emphasis><emphasis style="bold">thrombosis, CHF, acute MI, dysrhythmias,</emphasis> chest pain, transient ischemic attacks, edema</para>
					</section>
					<section type="none" id="sidelem4x2887">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, vomiting, nausea, abdominal pain, constipation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2894">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Red-cell aplasia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2901">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Infection, fatigue, fever,</emphasis><emphasis style="bold">death,</emphasis><emphasis style="italic">fluid overload,</emphasis><emphasis style="bold">vascular access hemorrhage,</emphasis> dehydration, <emphasis style="bold">sepsis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2917">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Bone pain, myalgia, limb pain, back pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2924">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">URI, dyspnea, cough, bronchitis,</emphasis><emphasis style="bold">PE</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2933">
						<sec_title>SYST:</sec_title>
						<para> Allergic reactions, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2940">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2943">
					<section type="none" id="sidelem4x2944">
						<sec_title>IV:</sec_title>
						<para> Onset of increased reticulocyte count 2-6 wk; distributed to vascular space; absorption slow and rate limiting; terminal half-life 49 hr (SUBCUT), 21 hr (IV); peak concentrations at 34 hr; increased Hgb levels not generally observed until 2-6 wk after treatment initiated</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2949">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use epoetin alfa with product</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> darbepoetin-alfa effect—androgens</para>
				<section type="none" id="sidelem4x2961">
					<section type="none" id="sidelem4x2962">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> WBC, platelets, Hgb</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> bleeding time</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2973">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2976">
					<section type="none" id="sidelem4x2977">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2982">
								<item>
									<label>•</label>
									<para>Symptoms of anemia: fatigue, dyspnea, pallor</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2988">
								<item>
									<para>
										<emphasis alert="nurse">Serious allergic reactions: rash, urticaria; if anaphylaxis occurs, stop product, administer emergency treatment (rare)</emphasis>
<bbw>Renal studies: urinalysis, protein, blood, BUN, creatinine; monitor dialysis shunts; during dialysis, heparin may need to be increased, those with renal dysfunction may be at greater risk of death</bbw>

<bbw>Blood studies: ferritin, transferrin monthly; transferrin saturation ≥20%, ferritin ≥100 ng/ml; Hgb 2×/wk until stabilized in target range (30%-33%), then at regular intervals; those with endogenous erythropoietin levels of &lt;500 units/L respond to this agent; iron stores should be corrected before beginning therapy; if there is lack of response, obtain folic acid, iron, B12 levels</bbw>

<bbw>Neoplastic disease: breast, non–small-cell lung, head and neck, lymphoid, or cervical cancers, increased tumor progression; use lowest dose to avoid RBC transfusion</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3027">
							<para>
								<list id="lidelem4x3027">
									<item>
										<label>•</label>
										<para>B/P: check for rising B/P as Hgb rises; antihypertensives may be needed
<bbw>CV status: hypertension may occur rapidly, leading to <emphasis alert="lifethreat">hypertensive encephalopathy</emphasis>; Hgb &gt;11 g/dl may lead to death, do not administer</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3044">
							<para>
								<list id="lidelem4x3044">
									<item>
										<label>•</label>
										<para>I&amp;O; report drop in output to &lt;50 ml/hr
<bbw>
												<emphasis alert="lifethreat">Seizures:</emphasis> if Hgb is increased by 4 pts within 2 wk, institute seizure precautions</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3058">
								<item>
									<label>•</label>
									<para>CNS symptoms: sweating, pain in long bones</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3066">
							<label>•</label>
							<sec_title>Dialysis patients</sec_title>
							<para>
								<list id="lidelem4x3066">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Dialysis patients:</emphasis> thrill, bruit of shunts, monitor for circulation impairment
<bbw>Facility must be enrolled in the ESA APPRISE oncology program 1-866-284-8089 to use this product in cancer</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3080">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3084">
								<item>
									<label>•</label>
									<para>Therapeutic response: increase in reticulocyte count, Hgb/Hct; increased appetite, enhanced sense of well-being</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3090">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3095">
								<item>
									<label>•</label>
									<para>To avoid driving or hazardous activity during beginning of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3101">
								<item>
									<label>•</label>
									<para>To monitor B/P, Hgb, max Hgb 11 g/dl</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3106">
								<item>
									<label>•</label>
									<para>To take iron supplements, vit B<emphasis style="inf">12</emphasis>, folic acid as directed
<bbw>To report chest pain, SOB, swelling/pain in legs, confusion in ability to speak to prescriber; to comply with treatment regimen</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3124">
								<item>
									<label>•</label>
									<para>That menses and fertility may return; to use contraception</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3132">
							<para>
								<list id="lidelem4x3132">
									<item>
										<label>•</label>
										<para>About home administration procedures, if appropriate
<bbw>
												<emphasis alert="lifethreat">Seizures:</emphasis> discuss injury prevention in those who are prone to seizures</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>darifenacin</mono_name>
			<info>
				<pronunciation>(da-ree-fen′ah-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31510">Enablex</tradename>
				</tradenames>
				<class type="func"> Antispasmodic/Guanticholinergic</class>
			</info>
			<section type="actions" id="sidelem4x3157">
				<sec_title>Action:</sec_title>
				<para>Bladder smooth muscle relaxation by decreasing the action of muscarinic receptors, thereby relieving overactive bladder</para>
			</section>
			<section type="uses" id="sidelem4x3162">
				<sec_title>Uses:</sec_title>
				<para>Urge incontinence, frequency, urgency in overactive bladder</para>
			</section>
			<section type="contra" id="sidelem4x3167">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, urinary retention, narrow-angle glaucoma (uncontrolled)</para>
				<section type="none" id="sidelem4x3172">
					<section type="none" id="sidelem4x3173">
						<sec_title>Precautions:</sec_title>
						<para> Severe hepatic disease (Child-Pugh C), GI/GU obstruction, controlled narrow-angle glaucoma, ulcerative colitis, myasthenia gravis, moderate hepatic disease (Child-Pugh B), elderly</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3178">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3186">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3186">
							<item>
								<label>•</label>
								<para> 7.5 mg/day, initially; may increase to 15 mg/day after 14 days if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3190">
					<section type="none" id="sidelem4x3191">
						<sec_title>With CYP3A4 inhibitor</sec_title>
						<section type="none" id="sidelem4x3199">
							<label>•</label>
							<sec_title>Adult<route> PO max 7.5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3202">
						<sec_title>Hepatic dosage</sec_title>
						<section type="none" id="sidelem4x3210">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh B) max 7.5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3213">
						<sec_title>Available forms:</sec_title>
						<para> Tabs, ext rel 7.5, 15 mg</para>
					</section>
					<section type="none" id="sidelem4x3218">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3222">
								<item>
									<label>•</label>
									<para>Without regard to meals, do not crush, break, chew extended-release tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3233">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3236">
					<section type="none" id="sidelem4x3237">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x3242">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, drying eyes, sinusitis, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x3247">
						<sec_title>GI:</sec_title>
						<para> Constipation, dry mouth, abdominal pain, nausea, vomiting, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x3252">
						<sec_title>GU:</sec_title>
						<para> UTI, urine retention, vaginosis</para>
					</section>
					<section type="none" id="sidelem4x3257">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, skin drying</para>
					</section>
					<section type="none" id="sidelem4x3262">
						<sec_title>MISC:</sec_title>
						<para> Bronchitis, flulike symptoms</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3267">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 7 hr, half-life 12-19 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3272">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effect—anticholinergics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> darifenacin level—CYP3A4 and CYP2D6 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of—drugs metabolized by CYP2D6</para>
			</section>
			<section type="considerations" id="sidelem4x3291">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3294">
					<section type="none" id="sidelem4x3295">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3299">
								<item>
									<label>•</label>
									<para>Urinary function: urgency, frequency, retention in bladder-outflow obstruction</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3305">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3309">
								<item>
									<label>•</label>
									<para>Decreasing urgency, frequency of urination</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3315">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3319">
								<item>
									<label>•</label>
									<para>To take without regard to meals; do not crush, break, chew extended-release tabs, not to use other products unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To store at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding; to notify prescriber if pregnancy (C) is planned or suspected</para>
								</item>
								<item>
									<label>•</label>
									<para>About anticholinergic symptoms (dry mouth, constipation, dry eyes, heat prostration); not to become overheated</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until reaction is known; dizziness, blurred vision can occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>darunavir (Rx)</mono_name>
			<info>
				<pronunciation>(dar-ue′na-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x33510">Prezista</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3361">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV-1) protease; this prevents maturation of the virus</para>
			</section>
			<section type="uses" id="sidelem4x3366">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with ritonavir and other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x3371">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3376">
					<section type="none" id="sidelem4x3377">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal/hepatic disease, history of renal stones, diabetes, hypercholesterolemia, sulfonamide hypersensitivity, antimicrobial resistance, bleeding, immune reconstitution syndrome, pancreatitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3382">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3385">
					<section type="none" id="sidelem4x3386">
						<sec_title>Treatment-naive patients</sec_title>
						<section type="none" id="sidelem4x3394">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3394">
									<item>
										<label>•</label>
										<para> 800 mg with ritonavir 100 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3401">
							<label>•</label>
							<sec_title>Child/Adolescent ≥ 40 kg and ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3401">
									<item>
										<label>•</label>
										<para> 800 mg with ritonavir 100 mg q day, avoid once daily darunavir dosing in those &lt;12 yr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3408">
							<label>•</label>
							<sec_title>Child/Adolescent 30 to 39 kg and ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3408">
									<item>
										<label>•</label>
										<para> 675 mg with ritonavir 100 mg q day, avoid once daily darunavir dosing in those &lt;12 yr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3415">
							<label>•</label>
							<sec_title>Children ≥3 yr, 15 to 29 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3415">
									<item>
										<label>•</label>
										<para> 600 mg with ritonavir 100 mg q day, avoid once daily darunavir dosing in those &lt;12 yr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3422">
							<label>•</label>
							<sec_title>Children ≥3 yr, &lt;14 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3422">
									<item>
										<label>•</label>
										<para> 490 mg with ritonavir 96 mg qd; <emphasis style="bold">13 kg:</emphasis> 455 mg with ritonavir 80 mg q day; <emphasis style="bold">12 kg:</emphasis> 420 mg with ritonavir 80 mg q day; <emphasis style="bold">11 kg:</emphasis> 385 mg with ritonavir 64 mg q day; <emphasis style="bold">10 kg:</emphasis> 350 mg with ritonavir 64 mg q day, avoid once daily dosing in those &lt;12 yrs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3438">
						<sec_title>Treatment-experienced patients with at least one darunavir resistance-associated substitution</sec_title>
						<section type="none" id="sidelem4x3446">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3446">
									<item>
										<label>•</label>
										<para> 600 mg bid; with ritonavir 100 mg bid with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3453">
							<label>•</label>
							<sec_title>Adolescent ≥30 kg, &lt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3453">
									<item>
										<label>•</label>
										<para> 450 mg bid with ritonavir 60 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3460">
							<label>•</label>
							<sec_title>Adolescent ≥15 kg, &lt;30 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3460">
									<item>
										<label>•</label>
										<para> 375 mg bid with ritonavir 50 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3467">
							<label>•</label>
							<sec_title>Child 3 to &lt;6 yr (14 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3467">
									<item>
										<label>•</label>
										<para> 280 mg (with ritonavir 48 mg) bid with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3474">
							<label>•</label>
							<sec_title>Child 3 to &lt;6 yr (13 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3474">
									<item>
										<label>•</label>
										<para> 260 mg (with ritonavir 40 mg) bid with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3481">
							<label>•</label>
							<sec_title>Child 3 to &lt;6 yr (12 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3481">
									<item>
										<label>•</label>
										<para> 240 mg (with ritonavir 40 mg) bid with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3488">
							<label>•</label>
							<sec_title>Child 3 to &lt;6 yr (11 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3488">
									<item>
										<label>•</label>
										<para> 220 mg (with ritonavir 32 mg) bid with food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3495">
							<label>•</label>
							<sec_title>Child 3 to &lt;6 yr (10 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3495">
									<item>
										<label>•</label>
										<para> 200 mg (with ritonavir 32 mg) bid with food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3499">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 75, 150, 400, 600, 800 mg; oral susp 100 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x3504">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3508">
								<item>
									<label>•</label>
									<para>With food and ritonavir</para>
								</item>
								<item>
									<label>•</label>
									<para>Tab should be swallowed whole</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3519">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3522">
					<section type="none" id="sidelem4x3523">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia,</emphasis> dizziness, somnolence</para>
					</section>
					<section type="none" id="sidelem4x3531">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, abdominal pain, nausea, vomiting,</emphasis> anorexia, dry mouth, <emphasis style="bold">hepatitis, hepatotoxicity, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3541">
						<sec_title>GU:</sec_title>
						<para> Nephrolithiasis</para>
					</section>
					<section type="none" id="sidelem4x3546">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, exanthematous pustulosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3553">
						<sec_title>MS:</sec_title>
						<para> Pain</para>
					</section>
					<section type="none" id="sidelem4x3558">
						<sec_title>OTHER:</sec_title>
						<para> Asthenia, <emphasis style="bold">insulin-resistant hyperglycemia,</emphasis> hyperlipidemia, <emphasis style="bold">ketoacidosis,</emphasis> lipodystrophy</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3569">
				<sec_title>Pharmacokinetics</sec_title>
				<para>95% protein binding; metabolized by CYP3A; peak 2.5-4 hr; terminal half-life 15 hr; excreted in feces 79.5%, urine 13.9%</para>
			</section>
			<section type="interactions" id="sidelem4x3575">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Life-threatening dysrhythmias: ergots, midazolam, rifampin, pimozide, triazolam; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis—HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> darunavir levels—CYP3A4 inhibitors (ketoconazole, itraconazole)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of both products—clarithromycin, zidovudine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of telapravir, rilpivarine, monitor for adverse reactions</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—(CYP3A4 substrate) artemether/lumefantrine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> darunavir levels—CYP3A4 inducers (carBAMazepine, phenytoin, fosphenytoin, PHENobarbital), rifamycins, fluconazole, nevirapine, efavirenz</para>
				<para>
					<emphasis alert="lifethreat">Decrease: levels of oral contraceptives</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of both products—tenofovir, avoid concurrent use</para>
				<section type="none" id="sidelem4x3613">
					<section type="none" id="sidelem4x3614">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> darunavir levels—St. John’s wort; avoid concurrent use</para>
						<para>
							<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis risk—red yeast rice</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x3624">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> darunavir absorption</para>
					</section>
					<section type="none" id="sidelem4x3631">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bilirubin, uric acid, amylase, lipase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, neutrophils, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3642">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3645">
					<section type="none" id="sidelem4x3646">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3651">
								<item>
									<label>•</label>
									<para>Complaints of lower back, flank pain; indicates kidney stones</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3656">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia, the presence of other sexually transmitted diseases</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3664">
							<label>•</label>
							<sec_title>Serious skin reactions<route> angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis; discontinue immediately, notify prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3670">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> hepatic studies (ALT, AST, bilirubin, amylase); all may be elevated in those with underlying liver disease; product should be discontinued in those with increased LFTs</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x3673">
								<item>
									<label>•</label>
									<para>Viral load, CD4, HIV RNA during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3678">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3686">
							<label>•</label>
							<sec_title>Hyperlipidemia</sec_title>
							<para>
								<list id="lidelem4x3686">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperlipidemia:</emphasis> cholesterol, triglycerides, LDL may be elevated; monitor serum cholesterol, lipid panel throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3690">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3694">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased viral load, increased CD4 count</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3700">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3705">
								<item>
									<label>•</label>
									<para>To use nonhormonal birth control; not to breastfeed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3710">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3715">
								<item>
									<label>•</label>
									<para>That product must be taken at same time of day to maintain blood levels for duration of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3721">
								<item>
									<para>
										<emphasis alert="nurse">That hyperglycemia may occur; to watch for increased thirst, weight loss, hunger, dry, itchy skin; to notify prescriber if these occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3726">
								<item>
									<label>•</label>
									<para>To increase fluids to prevent kidney stones; that if stone formation occurs, treatment may need to be interrupted</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3731">
								<item>
									<label>•</label>
									<para>That product does not cure AIDS, only controls symptoms; not to donate blood; not to share medication; to notify all health care providers of use; not to use with any other products without prescriber’s approval</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>dasatinib (Rx)</mono_name>
			<info>
				<pronunciation>(da-si′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x37410">Sprycel</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Protein-tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x3751">
				<sec_title>Action:</sec_title>
				<para>Inhibits a tyrosine kinase enzyme, thereby reducing cell growth in leukemia, inhibitor of BCR-ABL and imatinib-resistant mutations of BCR-ABL</para>
			</section>
			<section type="uses" id="sidelem4x3756">
				<sec_title>Uses:</sec_title>
				<para>Treatment of accelerated, chronic blast phase CML or acute lymphoblastic leukemia (ALL); chronic phase CML with resistance or intolerance to prior therapy; Philadelphia chromosome–positive CML in chronic phase</para>
			</section>
			<section type="contra" id="sidelem4x3762">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<section type="none" id="sidelem4x3767">
					<section type="none" id="sidelem4x3768">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, QT prolongation, infection, thrombocytopenia, accidental exposure, edema, infertility, lactase deficiency, neutropenia, anemia, autoimmune disease with immune reconstitution syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3773">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3776">
					<section type="none" id="sidelem4x3777">
						<sec_title>Accelerated or myeloid/lymphoid blast phase CML with resistance/intolerance to prior therapy</sec_title>
						<section type="none" id="sidelem4x3785">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3785">
									<item>
										<label>•</label>
										<para> 140 mg daily titrated up to 180 mg daily in those resistant to therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3789">
						<sec_title>Chronic phase CML with resistance/intolerance to prior therapy</sec_title>
						<section type="none" id="sidelem4x3797">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3797">
									<item>
										<label>•</label>
										<para> 100 mg daily either <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3806">
						<sec_title>Dosage reduction for those taking a strong CYP3A4 inhibitor</sec_title>
						<section type="none" id="sidelem4x3814">
							<label>•</label>
							<sec_title>Adult<route> PO 20-40 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3817">
						<sec_title>Available forms:</sec_title>
						<para>Tabs 20, 50, 70, 80, 100, 140 mg</para>
					</section>
					<section type="none" id="sidelem4x3822">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3826">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew tab</para>
								</item>
								<item>
									<label>•</label>
									<para>After meal and with large glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Separate from antacids by 2 hr before and 2 hr after; do not use with H2 blockers and PPIs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3842">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3845">
					<section type="none" id="sidelem4x3846">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">CNS hemorrhage,</emphasis> headache, dizziness, insomnia, neuropathy, asthenia</para>
					</section>
					<section type="none" id="sidelem4x3854">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias,</emphasis> chest pain, <emphasis style="bold">CHF, pericardial effusion, congestive cardiomyopathy, decreased injection fraction, QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3864">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis><emphasis style="bold">vomiting,</emphasis><emphasis style="italic">anorexia, abdominal pain,</emphasis> constipation, diarrhea, GI bleeding, muscositis, stomatitis, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3878">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3885">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> alopecia</para>
					</section>
					<section type="none" id="sidelem4x3893">
						<sec_title>META:</sec_title>
						<para> Fluid retention, edema, hypocalcemia, hypophosphatemia</para>
					</section>
					<section type="none" id="sidelem4x3898">
						<sec_title>MISC:</sec_title>
						<para> Increased/decreased weight, infection, fatigue</para>
					</section>
					<section type="none" id="sidelem4x3903">
						<sec_title>MS:</sec_title>
						<para> Pain, arthralgia, myalgia</para>
					</section>
					<section type="none" id="sidelem4x3908">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, pulmonary edema/hypertension, pneumonia, upper respiratory tract infection, <emphasis style="bold">pleural effusion</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3915">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by CYP3A4; 96% protein bound; peak 0.5-6 hr; excreted in feces (85%), small amount in urine (4%); terminal half-life 3-5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3920">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x3924">
						<item>
							<label>•</label>
							<para>Altered action of CYP3A4 substrates: alfentanil, cycloSPORINE, ergots, fentaNYL, pimozide, quiNIDine, sirolimus, tacrolimus</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dasatinib concentrations—CYP3A4 inhibitors: ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, protease inhibitors, telithromycin</para>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis-HMG-CoA reductase inhibitors (rare)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antidysrhythmics and other products that increase QT prolongation</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dasatinib concentrations—CYP3A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital), H<emphasis style="inf">2</emphasis> blockers (famotidine), proton pump inhibitors (omeprazole)</para>
				<section type="none" id="sidelem4x3951">
					<section type="none" id="sidelem4x3952">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x3956">
								<item>
									<label>•</label>
									<para>Grapefruit: do not use</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3962">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> dasatinib concentrations—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3970">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3973">
					<section type="none" id="sidelem4x3974">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3982">
							<label>•</label>
							<sec_title>Myelosuppression<route> ANC, platelets; in chronic phase, if ANC &lt;1 × 109/L and/or platelets &lt;50 × 109/L, stop until ANC &gt;1.5 × 109/L and platelets &gt;75 × 109/L; in accelerated phase/blast crisis, if ANC &lt;0.5 × 109/L and/or platelets &lt;10 × 109/L, determine whether cytopenia is related to biopsy/aspirate, if not, reduce dose by 200 mg, if cytopenia continues, reduce dose by another 100 mg; if cytopenia continues for 4 wk, stop product until ANC ≥1 × 109/L, monitor CBC weekly × 8 wk, then monthly</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4009">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> monitor LFTs before treatment and monthly; if liver transaminases &gt;5 × IULN, withhold until transaminase levels return to &lt;2.5 × IULN</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4015">
							<label>•</label>
							<sec_title>Signs of fluid retention, edema</sec_title>
							<para>
								<list id="lidelem4x4015">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Signs of fluid retention, edema:</emphasis> weigh, monitor lung sounds, assess for edema; some fluid retention is dose dependent, may result in CHF, congestive cardiomyopathy, decreased injection failure</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4022">
							<label>•</label>
							<sec_title>QT Prolongation<route> more common in those with hypokalemia, hypomagnesemia, congenital long QT syndrome, those taking products that prolong QT; correct electrolyte imbalances before use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4025">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4029">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in leukemic cells or size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4035">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4043">
							<label>•</label>
							<sec_title>To report adverse reactions immediately<route> SOB, swelling of extremities, bleeding, bruising</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4046">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4054">
							<label>•</label>
							<sec_title>
								<route>To use contraception (pregnancy [D]); to avoid breastfeeding; men should use condoms</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4057">
								<item>
									<label>•</label>
									<para>To take at same time of day; not to crush or chew; not to use grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active" ha="yes">
			<mono_name> DAUNOrubicin (Rx)</mono_name>
			<info>
				<pronunciation>(daw-noe-roo′bi-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x40690">Cerubidine</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="15" status="active">
			<mono_name>DAUNOrubicin citrate liposomal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x40740"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="16" status="active">
			<mono_name>DaunoXome</mono_name>
			<info>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="chem"> Anthracycline glycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4086">
				<para>
					<confusion>
						<tradename id="tnidelem4x40860">DAUNOrubicin</tradename>
						<drug type="generic" refid="idelem4x40860">DOXOrubicin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4090">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA synthesis, primarily; derived from <emphasis style="italic">Streptomyces coerulorubidus;</emphasis> replication is decreased by binding to DNA, binds DNA causing confirmational changes; a vesicant</para>
			</section>
			<section type="uses" id="sidelem4x4098">
				<sec_title>Uses:</sec_title>
				<para>Acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML); <emphasis style="italic">liposomal:</emphasis> Kaposi’s sarcoma</para>
				<section type="none" id="sidelem4x4106">
					<section type="none" id="sidelem4x4107">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Liposomal:</emphasis> AML, non-Hodgkin’s lymphoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4115">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, systemic infections, cardiac disease, bone marrow depression</para>
				<para>
					<bbw>IM/SUBCUT use</bbw>
				</para>
				<section type="none" id="sidelem4x4130">
					<section type="none" id="sidelem4x4131">
						<sec_title>Precautions:</sec_title>
						<para> Tumor lysis syndrome, MI, infection, thrombocytopenia, renal/hepatic disease; gout</para>
						<para>
							<bbw>Bone marrow suppression, cardiac disease, extravasation, renal failure, hepatic disease; requires a specialized care setting and an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4146">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis alert="lifethreat">Use decreased dose for those &gt;60 yr</emphasis>
				</para>
				<section type="none" id="sidelem4x4152">
					<section type="none" id="sidelem4x4153">
						<sec_title>DAUNOrubicin</sec_title>
						<section type="none" id="sidelem4x4161">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4161">
									<item>
										<label>•</label>
										<para> 45-60 mg/m<emphasis style="sup">2</emphasis>/day × 3 days, then 2 days of subsequent courses in combination, max 400-600 mg/m<emphasis style="sup">2</emphasis> total cumulative dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4174">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4174">
									<item>
										<label>•</label>
										<para> 30-40 mg/m<emphasis style="sup">2</emphasis>/day depending on cycle (AML); ≤2 yr or &lt;0.5 m<emphasis style="sup">2</emphasis>: 1 mg/kg on day 1 weekly in combination with vinCRIStine and predniSONE, base dose on body weight not surface area (ALL); &gt;2 yr or 0.5 m<emphasis style="sup">2</emphasis>: 25 mg/m<emphasis style="sup">2</emphasis> day 1 weekly in combination with vinCRIStine and predniSONE (ALL)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4190">
						<sec_title>DAUNOrubicin citrate liposomal</sec_title>
						<section type="none" id="sidelem4x4198">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4198">
									<item>
										<label>•</label>
										<para> 40 mg/m<emphasis style="sup">2</emphasis> q2wk (Kaposi’s sarcoma);  100-140 mg/m<emphasis style="sup">2</emphasis> q3wk (non-Hodgkin’s lymphoma, unlabeled); IV escalating doses of 75, 100, 125, 135, 150 mg/m<emphasis style="sup">2</emphasis>/day × 3 days (AML, unlabeled)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4215">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4223">
							<label>•</label>
							<sec_title>Adult<route> IV serum CCr &gt;3 mg/dl, reduce dose by 50%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4226">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x4234">
							<label>•</label>
							<sec_title>Adult<route> IV serum bilirubin 1.2-3 mg/dl, reduce dose by 50%; bilirubin &gt;3 mg/dl, reduce dose by 75%; bilirubin &gt;5 mg/dl, omit dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4237">
						<sec_title>Available forms:</sec_title>
						<para> Inj 20 mg powder/vial, <emphasis style="italic">liposomal:</emphasis> solution for inj 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4245">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4249">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before giving product to prevent vomiting</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To be used in a care setting with emergency equipment available</bbw>
						</para>
						<para>
							<bbw>To be used by a clinician knowledgeable in cytotoxic therapy</bbw>
						</para>
						<para>
							<bbw>Do not give by IM/subcut injection</bbw>
						</para>
						<section type="none" id="sidelem4x4283">
							<sec_title>IV route (Cerubidine)</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x4287">
							<sec_title>Do not confuse with liposome</sec_title>
							<para>
								<list id="lidelem4x4291">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling precautions</para>
									</item>
									<item>
										<label>•</label>
										<para>After diluting 20 mg/4 ml sterile water for inj (5 mg/ml), rotate, further dilute in 10-15 ml 0.9% NaCl; give over 3-5 min by direct IV through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock of infusion of D<emphasis style="inf">5</emphasis>W or 0.9% NaCl; or dilute in 50 ml 0.9% NaCl and give over 10-15 min; or dilute in 100 ml and give over 30 min, may use premix vial 5 mg/ml</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply ice compress after stopping infusion for extravasation</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">3.3</emphasis>%/0.3% NaCl, D<emphasis style="inf">5</emphasis>W, Normosol R, LR, 0.9% NaCl</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, anidulafungin, atenolol, bivalirudin, bleomycin, CARBOplatin, caspofungin, CISplatin, codeine, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, etoposide, fenoldopam, filgrastim, gemcitabine, gemtuzumab, granisetron, melphalan, meperidine, methotrexate, nesiritide, octreotide, ondansetron, oxaliplatin, PACLitaxel, palonosetron, quinupristin-dalfopristin, riTUXimab, sodium acetate/bicarbonate, teniposide, thiotepa, tigecycline, trastuzumab, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
						<section type="none" id="sidelem4x4327">
							<sec_title>IV route (DaunoXome)</sec_title>
							<para>
								<list id="lidelem4x4331">
									<item>
										<label>•</label>
										<para>Dilute with D<emphasis style="inf">5</emphasis>W to (1 mg/ml), give over 1-2 hr, do not use in-line filter, reconstituted sol may be stored ≤6 hr refrigerated; do not admix</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">IV compatibilities:</emphasis> Anidulafungin, bivalirudin, meperidine, octreotide, sodium acetate, tirofiban, trastuzumab</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4344">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4347">
					<section type="none" id="sidelem4x4348">
						<sec_title>DAUNOrubicin</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x4352">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills</para>
					</section>
					<section type="none" id="sidelem4x4357">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">CHF, pericarditis, myocarditis,</emphasis> peripheral edema, <emphasis style="bold">fatal myocarditis, left ventricular failure, QT prolongation, ST-T wave changes, QRS voltage changes, tachycardia, SVT, PVCs</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4367">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, mucositis,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4376">
						<sec_title>GU:</sec_title>
						<para> Impotence, sterility, amenorrhea, gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x4381">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4388">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">extravasation,</emphasis> dermatitis, reversible alopecia, cellulitis, thrombophlebitis at inj site</para>
					</section>
					<section type="none" id="sidelem4x4398">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, tumor lysis syndrome, secondary malignancies</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4405">
						<sec_title>DAUNOrubicin citrate liposomal</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x4409">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fatigue, headache,</emphasis> depression, insomnia, dizziness, <emphasis style="italic">malaise, neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4419">
						<sec_title>CV:</sec_title>
						<para> Chest pain, edema</para>
					</section>
					<section type="none" id="sidelem4x4424">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, stomatitis, <emphasis style="italic">nausea, vomiting, diarrhea,</emphasis> constipation</para>
					</section>
					<section type="none" id="sidelem4x4432">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia, pruritus,</emphasis> sweating</para>
					</section>
					<section type="none" id="sidelem4x4440">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Allergic reactions, chest pain, fever,</emphasis> edema, flulike symptoms</para>
					</section>
					<section type="none" id="sidelem4x4448">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Rigors,</emphasis> arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x4456">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, dyspnea, rhinitis, sinusitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4463">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 18<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, liposome 55<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; metabolized by liver; crosses placenta; excreted in breast milk, urine, bile</para>
			</section>
			<section type="interactions" id="sidelem4x4481">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation, torsades de pointes—arsenic trioxide, chloroquine, clarithromycin, class IA, class III antidysrhythmics, dasatinib, dolasetron, droperidol, erythromycin, flecainide, haloperidol, methadone, ondansetron, palonosetron, pentamidine, some phenothiazines, propafenone, risperiDONE, sparfloxacin; tricyclic antidepressants (high doses); vorinostat, ziprasidone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, salicylates, anticoagulants, platelet inhibitors, thrombolytics</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—other antineoplastics, radiation, cyclophosphamide</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> DAUNOrubicin effects—hematopoietic progenitor cells given within 24 hr</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody reaction—live virus vaccines</para>
				<section type="none" id="sidelem4x4502">
					<section type="none" id="sidelem4x4503">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4510">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4513">
					<section type="none" id="sidelem4x4514">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow suppression:</emphasis> CBC, differential, platelet count weekly, leukocyte nadir within 2 wk after administration, recovery within 3 wk; do not administer if absolute granulocyte count is &lt;750/mm3 (liposome)</bbw>
						</para>
						<section type="none" id="sidelem4x4536">
							<label>•</label>
							<sec_title>Acute renal failure, uric acid nephropathy<route> renal studies</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4539">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr; fever may indicate beginning infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4547">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> monitor hepatic studies baseline before each dose</route></sec_title>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Cardiac toxicity:</emphasis> chest x-ray, echocardiography, radionuclide angiography, MUGA, ECG; watch for ST-T wave changes, low QRS and QT prolongation, possible dysrhythmias (sinus tachycardia, heart block, PVCs); watch for CHF (jugular vein distention, weight gain, edema, crackles), may occur after 2-6 mo of treatment, cumulative dose (400-550 mg/m2), 450 mg/m2 if used in combination with radiation, cyclophosphamide</bbw>
						</para>
						<para>
							<list id="lidelem4x4570">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac stools, bruising, petechiae, mucosa, or orifices q8hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4575">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4580">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia, rinse mouth tid-qid with water, club soda; brush teeth bid-qid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4588">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia</route></sec_title>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Extravasation:</emphasis> swelling, pain, decreased blood return; if extravasation occurs, stop infusion, remove tubing, attempt to aspirate the drug before removing the needle, elevate area, treat with ice pack</bbw>
						</para>
						<para>
							<list id="lidelem4x4603">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
								<item>
									<label>•</label>
									<para>Increase fluid intake to 2-3 L/day to prevent urate and calculi formation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4614">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4618">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4624">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x4632">
							<label>•</label>
							<sec_title>
								<route>To report signs of infection, bleeding, bruising, SOB, swelling, change in heart rate</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4635">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4643">
							<label>•</label>
							<sec_title>
								<route>To avoid pregnancy (D) while taking product and for 4 mo thereafter; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4646">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot, or rough texture if stomatitis is present</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4651">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4656">
								<item>
									<label>•</label>
									<para>That urine and other body fluids may be red-orange for 48 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4661">
								<item>
									<label>•</label>
									<para>To avoid vaccines, alcohol, aspirin, NSAIDs while taking this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4666">
								<item>
									<label>•</label>
									<para>To avoid crowds, those with known infections</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active" ru="yes">
			<mono_name> deferasirox (Rx)</mono_name>
			<info>
				<pronunciation>(def-a′sir-ox)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x46790">Exjade</tradename>
				</tradenames>
				<class type="func"> Heavy-metal chelating agent</class>
			</info>
			<section type="uses" id="sidelem4x4685">
				<sec_title>Uses:</sec_title>
				<para>Chronic iron overload, transfusion hemosiderosis</para>
			</section>
			<section type="contra" id="sidelem4x4690">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity, severe renal/hepatic disease, GI hemorrhage</para>
			</section>
			<section type="doses" id="sidelem4x4695">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4703">
					<label>•</label>
					<sec_title>Adult and child &gt;2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4703">
							<item>
								<label>•</label>
								<para> 20-30 mg/kg/day; oral dispersion tablet is dissolved in water &lt;1 g in 3.5 oz; &gt;1 g in 7 oz or more; give on empty stomach at least 30 min before meals</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active">
			<mono_name>degarelix</mono_name>
			<info>
				<pronunciation>(day-gah-rel′iks)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x47120">Firmagon</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> GnRH-receptor antagonist</class>
			</info>
			<section type="actions" id="sidelem4x4722">
				<sec_title>Action:</sec_title>
				<para>Reduces gonadotropins release and testicular steroidogenesis by reversibly binding to GnRH receptors</para>
			</section>
			<section type="uses" id="sidelem4x4727">
				<sec_title>Uses:</sec_title>
				<para>Advanced prostate cancer</para>
			</section>
			<section type="contra" id="sidelem4x4732">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, QT prolongation, osteoporosis, severe hepatic/renal disease, pregnancy (X), breastfeeding<list id="lidelem4x4737">
						<item>
							<label>•</label>
							<para>Precautions: CV disease, electrolyte abnormalities, geriatric patients</para>
						</item>
					</list></para>
			</section>
			<section type="doses" id="sidelem4x4743">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4751">
					<label>•</label>
					<sec_title>Adult (male)<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x4751">
							<item>
								<label>•</label>
								<para> 240 mg given as two 120-mg injections; (40 mg/ml concentrations) maintenance 80 mg (20 mg/ml concentrations) every 28 days, starting 28 days after first dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4755">
					<section type="none" id="sidelem4x4756">
						<sec_title>Available forms:</sec_title>
						<para> Injection 80, 120 mg vial</para>
					</section>
					<section type="none" id="sidelem4x4761">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4765">
								<item>
									<label>•</label>
									<para>Do not give IV, subcut only</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4771">
							<sec_title>General reconstitution information:</sec_title>
							<para>
								<list id="lidelem4x4775">
									<item>
										<label>•</label>
										<para>Use gloves, aseptic technique during preparation and administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep vials vertical at all times; do <emphasis style="italic">not</emphasis> shake the vials; give reconstituted drug within 1 hr after addition of sterile water for injection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4789">
							<sec_title>Reconstitution of 120-mg vial (240-mg dose <emphasis style="bold">
									<emphasis style="italic">only</emphasis>
								</emphasis>):</sec_title>
							<para>
								<list id="lidelem4x4797">
									<item>
										<label>•</label>
										<para>For a 240-mg dose, use two 120-mg vials; repeat for each 120-mg vial: draw up 3 ml of sterile water for injection with a 2-inch, 21-G needle; do not use bacteriostatic water for injection; inject the sterile water slowly into vial containing 120 mg; to maintain sterility, do not remove the syringe or the needle from the vial; keep the vial in an upright position and swirl gently; avoid shaking; reconstitution can take up to 15 min; tilt the vial slightly and withdraw 3 ml (40 mg/ml); avoid turning the vial upside down; repeat with a new vial, needle, and syringe for the second 120-mg dose (total dose = 240 mg)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4803">
							<sec_title>Reconstitution of 80-mg vial:</sec_title>
							<para>
								<list id="lidelem4x4807">
									<item>
										<label>•</label>
										<para>Draw up 4.2 ml of sterile water for injection with a 2-inch, 21-G needle; do not use bacteriostatic water for injection; inject the sterile water slowly into vial containing 80 mg; do not remove the syringe or the needle from the vial; keep the vial upright, swirl gently; avoid shaking; reconstitution can take up to 15 min; tilt vial slightly and withdraw 4 ml (20 mg/ml); avoid turning upside down during withdrawal</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4813">
							<sec_title>Subcut injection:</sec_title>
							<para>
								<list id="lidelem4x4817">
									<item>
										<label>•</label>
										<para>Exchange the reconstitution needle with a 1.25-inch, 27-G needle; remove air bubbles; give in the abdominal region; rotate injection site periodically; use area not exposed to pressure; grasp the skin of abdomen, elevate the subcutaneous tissue, and insert the needle deeply at an angle ≥45 degrees; aspirate before injection; inject the dose subcut; when giving the loading dose of two 120-mg doses, the second dose should be injected at a different site</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4825">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4828">
					<section type="none" id="sidelem4x4829">
						<sec_title>CNS:</sec_title>
						<para> Chills, dizziness, fatigue, fever, headache, insomnia</para>
					</section>
					<section type="none" id="sidelem4x4834">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Increased QT prolongation,</emphasis> hypotension, hot flashes, hypertension</para>
					</section>
					<section type="none" id="sidelem4x4842">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, constipation, nausea</para>
					</section>
					<section type="none" id="sidelem4x4847">
						<sec_title>GU:</sec_title>
						<para> ED, UTI, gynecomastia, testicular atrophy</para>
					</section>
					<section type="none" id="sidelem4x4852">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Injection site reactions,</emphasis> pain at site, redness, swelling</para>
					</section>
					<section type="none" id="sidelem4x4860">
						<sec_title>MS:</sec_title>
						<para> Back pain, decreased bone density</para>
					</section>
					<section type="none" id="sidelem4x4865">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Hypersensitivity, anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4872">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2 days, duration 50 days, half-life 53 days</para>
			</section>
			<section type="interactions" id="sidelem4x4877">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—Class IA/III antidysrhythmics, methyldopa, metoclopramide, reserpine</emphasis>
				</para>
				<section type="none" id="sidelem4x4883">
					<section type="none" id="sidelem4x4884">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PSA, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> bone density test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4895">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4898">
					<section type="none" id="sidelem4x4899">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="lifethreat">QT prolongation: More common in those taking Class IA/III antidysrhythmics, heart failure, congenital long QT syndrome; monitor cardiac status at baseline and often thereafter</emphasis>
						</para>
						<para>
							<emphasis alert="lifethreat">Anaphylaxis angioedema (rash, trouble breathing): Discontinue treatment and do not restart in serious reactions</emphasis>
							<list id="lidelem4x4908">
								<item>
									<label>•</label>
									<para>Liver function studies, PSA, GGT that may be elevated; bone density that may be decreased; electrolytes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4914">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4918">
								<item>
									<label>•</label>
									<para>Decreasing spread, size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4924">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4929">
								<item>
									<label>•</label>
									<para>To notify all prescribers of cardiac disease or use of all cardiac products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4934">
								<item>
									<label>•</label>
									<para>Injection technique if patient/family will be giving product (provide patient information)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4942">
							<label>•</label>
							<sec_title>Pregnancy<route> Notify prescriber if pregnancy is planned or suspected, pregnancy (X), do not breastfeed</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>delavirdine (Rx)</mono_name>
			<info>
				<pronunciation>(de-la-veer′deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x49500">Rescriptor</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nonnucleoside reverse transcriptase inhibitor (NNRTI)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4960">
				<sec_title>Action:</sec_title>
				<para>Binds directly to reverse transcriptase; blocks RNA-, DNA-dependent polymerase activities, causing a disruption of the enzyme’s site</para>
			</section>
			<section type="uses" id="sidelem4x4965">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with at least 2 other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x4970">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x4975">
					<section type="none" id="sidelem4x4976">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hepatic disease, achlorhydria, antimicrobial resistance, exfoliative dermatitis, hepatitis, immune reconstitution syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4981">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4989">
					<label>•</label>
					<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4989">
							<item>
								<label>•</label>
								<para> 400 mg tid, max 1200 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4993">
					<section type="none" id="sidelem4x4994">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x4999">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5003">
								<item>
									<label>•</label>
									<para>100-mg tab: dispersion by adding 4 tab/3-4 oz water, let stand, stir, swallow, rinse glass, swallow; use only 100-mg tabs for dispersion; 200-mg tab take as intact tab</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not give within 1 hr of antacids or didanosine</para>
								</item>
								<item>
									<label>•</label>
									<para>Always use as combination therapy; this product is not recommended for initial treatment; due to inferior, virologic effect, it is no longer listed as part of any preferred regimens</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5020">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5023">
					<section type="none" id="sidelem4x5024">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue, anxiety, insomnia, fever</para>
					</section>
					<section type="none" id="sidelem4x5029">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, abdominal pain, nausea, anorexia, vomiting, dyspepsia, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5036">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5043">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, thrombocytopenia, anemia, granulocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5050">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x5055">
						<sec_title>MISC:</sec_title>
						<para> Cough</para>
					</section>
					<section type="none" id="sidelem4x5060">
						<sec_title>MS:</sec_title>
						<para> Pain, myalgia, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5067">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome; immune reconstitution syndrome (combination therapy)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5074">
				<sec_title>Pharmocokinetics</sec_title>
				<para>98% protein bound, half-life 5.8 hr, peak 1 hr, duration 8 hr, extensively metabolized by CYP3A4, excreted in urine, feces</para>
			</section>
			<section type="interactions" id="sidelem4x5079">
				<sec_title>Interactions</sec_title>
				<para>Do not coadminister with nevirapine, efavirenz, rilpivirine, combined use not beneficial</para>
				<para>
					<emphasis alert="nurse">Serious life-threatening adverse reaction: amphetamines, ergots, benzodiazepines, calcium channel blockers, sedative/hypnotics, antidysrhythmics, sildenafil, pimozide, ALPRAZolam, astemizole, midazolam, opiates, triazolam</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of ALPRAZolam, clarithromycin, dapsone, ergots, felodipine, midazolam, NIFEdipine, indinavir, saquinavir, lovastatin, simvastatin, atorvastatin, other CYP3A4, 2D6 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> delavirdine levels—FLUoxetine, ketoconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of both products—quiNIDine, warfarin, clarithromycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> delavirdine levels—antacids, anticonvulsants, rifamycins, protease inhibitors, didanosine, H2 blockers, PPIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of oral contraceptives, didanosine</para>
				<section type="none" id="sidelem4x5109">
					<section type="none" id="sidelem4x5110">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> delavirdine level—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5117">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5120">
					<section type="none" id="sidelem4x5121">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5129">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x5129">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> obtain hepatitis B virus (HBV) screening to ensure proper treatment, if coinfected, a fully suppressive antiretroviral regimen with products against both; CBC, blood chemistry, plasma HIV RNA, absolute CD41/CD81/cell counts/%, serum β<emphasis style="inf">2</emphasis> microglobulin, serum ICD124 antigen levels</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5139">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> when treated with combination therapy; development of opportunistic infections (</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5149">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5154">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST; renal studies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5159">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5164">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction to each medication; place allergies on chart</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5169">
								<item>
									<label>•</label>
									<para>Plasma delavirdine concentrations (trough 10 micromolar)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5177">
							<label>•</label>
							<sec_title>Toxicity<route> severe nausea/vomiting, maculopapular rash</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5183">
							<label>•</label>
							<sec_title>Serious skin reactions<route> Stevens-Johnson syndrome; rash may occur within 1-3 wk of beginning treatment; if rash is not severe, manage with diphenhydrAMINE, hydrOXYzine, topical corticosteroids</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5186">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5190">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CD4 cell count, decreased viral load, improvement in symptoms of HIV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5196">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5201">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose, do not take antacids concurrently, separate by 1 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5206">
								<item>
									<label>•</label>
									<para>That tabs may be dissolved in <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> cup of water (100 mg only); to stir; when dissolved, drink right away; to rinse cup with water and drink to get all medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5217">
								<item>
									<label>•</label>
									<para>To make sure health care provider knows about all medications being taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5223">
								<item>
									<label>•</label>
									<para>That if severe rash, mouth sores, swelling, aching muscles/joints, or eye redness occur, to notify health care provider</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5231">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed if taking this product</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5234">
								<item>
									<label>•</label>
									<para>That this product is not a cure, only controls symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>denosumab (Rx)</mono_name>
			<info>
				<pronunciation>(den-oh′sue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x52441">Prolia</tradename>
					<tradename id="tnidelem4x52440">Xgeva</tradename>
				</tradenames>
				<class type="func"> Bone resorption inhibitor</class>
				<class type="chem"> Monoclonal antibody, bone resorption</class>
			</info>
			<section type="actions" id="sidelem4x5254">
				<sec_title>Action:</sec_title>
				<para>Neutralizes activity of receptor activator nuclear factor kappa-B ligand (RANKL) by binding to it and blocking its interaction with cell-surface receptors; use of a RANKL inhibitor may reduce bone turnover and decrease tumor burden</para>
			</section>
			<section type="uses" id="sidelem4x5259">
				<sec_title>Uses:</sec_title>
				<para>Osteoporosis in postmenopausal women or men at high risk for fractures; increase bone mass in men who are receiving androgen deprivation therapy for prostate cancer and women receiving aromastase inhibitor therapy for breast cancer at high risk for fractures; prevention of skeletal-related events in bone metastases from solid tumors (Xgeva), giant cell tumor of bone</para>
			</section>
			<section type="contra" id="sidelem4x5264">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypocalcemia, pregnancy (Xgeva) D; (Prolina) X</para>
				<section type="none" id="sidelem4x5269">
					<section type="none" id="sidelem4x5270">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, child/infant/neonate, anemia, coagulopathy, diabetes mellitus, dialysis, eczema, hypoparathyroidism, immunosuppression, latex hypersensitivity, malabsorption syndrome, neoplastic disease, pancreatitis, parathyroid disease, dental/renal/thyroid disease, TB, vit D deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5275">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5278">
					<section type="none" id="sidelem4x5279">
						<sec_title>Postmenopausal osteoporosis (Prolia)</sec_title>
						<section type="none" id="sidelem4x5287">
							<label>•</label>
							<sec_title>Adult female<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5287">
									<item>
										<label>•</label>
										<para> 60 mg q6mo with 1000 mg calcium and 400 international units vit D, max 60 mg q6mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5291">
						<sec_title>Bone metastases from solid tumors (Xgeva)</sec_title>
						<section type="none" id="sidelem4x5299">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5299">
									<item>
										<label>•</label>
										<para> 120 mg q4wk, max 120 mg q4wk; administer with calcium and vit D as necessary to prevent hypocalcemia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5303">
						<sec_title>Giant cell tumor (bone) (Xgeva)</sec_title>
						<section type="none" id="sidelem4x5311">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5311">
									<item>
										<label>•</label>
										<para> 120 mg, then 120 mg q 4 wk on day 1, 8, 15, use calcium, vit D as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5315">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 60 mg/ml (Prolia); 120 mg/1.7 ml (Xgeva)</para>
					</section>
					<section type="none" id="sidelem4x5320">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5323">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x5328">
									<item>
										<label>•</label>
										<para>Give acetaminophen before and for 72 hr after to decrease pain</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5333">
									<item>
										<label>•</label>
										<para>Do not use if particulate matter or discoloration is present; sol is clear and colorless to slightly yellow with small white/opalescent particles; remove from refrigerator and allow to warm to room temperature (15-30 min)</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5341">
								<label>•</label>
								<sec_title>Use of prefilled syringe with needle safety guard</sec_title>
								<para>
									<list id="lidelem4x5341">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Use of prefilled syringe with needle safety guard:</emphasis> leave green guard in original position until after administration; remove and discard needle cap immediately before inj; give by subcut inj in upper arm/thigh or abdomen; after inj, point needle away from people and slide green guard over needle</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5348">
								<label>•</label>
								<sec_title>Use of single-use vials</sec_title>
								<para>
									<list id="lidelem4x5348">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Use of single-use vials:</emphasis> use 27-G needle; give in upper arm/thigh or abdomen; do not reinsert needle in vial; discard supplies as appropriate</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5352">
									<item>
										<label>•</label>
										<para>Store and use out of direct sunlight/heat; do not freeze; use within 14 days after removal from refrigerator; store unopened containers in refrigerator</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5357">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5360">
					<section type="none" id="sidelem4x5361">
						<sec_title>CNS:</sec_title>
						<para> Chills, fever, flushing, headache, vertigo, neuropathic pain</para>
					</section>
					<section type="none" id="sidelem4x5366">
						<sec_title>CV:</sec_title>
						<para> Angina, <emphasis style="bold">atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5373">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, constipation, <emphasis style="italic">diarrhea,</emphasis> flatulence, GERD, <emphasis style="italic">vomiting, nausea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5384">
						<sec_title>GU:</sec_title>
						<para> Cystitis, lactation suppression</para>
					</section>
					<section type="none" id="sidelem4x5389">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5396">
						<sec_title>INTEG:</sec_title>
						<para> Atopic dermatitis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x5401">
						<sec_title>META:</sec_title>
						<para> Hypercholesterolemia, hypocalcemia, hypophosphatemia</para>
					</section>
					<section type="none" id="sidelem4x5406">
						<sec_title>MS:</sec_title>
						<para> Back, bone pain; MS pain, myalgia, <emphasis style="bold">osteonecrosis of the jaw,</emphasis> atypical low trauma femoral fractures</para>
					</section>
					<section type="none" id="sidelem4x5414">
						<sec_title>RESP:</sec_title>
						<para> Cough, <emphasis style="italic">dyspnea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5421">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Infection, secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5428">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 25.4 days, bioavailability 62%, max serum concentrations 3-21 days, steady state 6 mo</para>
			</section>
			<section type="interactions" id="sidelem4x5433">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> infection, possible—immunosupressives, corticosteroids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> osteonecrosis of the jaw, possible—antineoplastics, corticosteroids</para>
			</section>
			<section type="considerations" id="sidelem4x5444">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5447">
					<section type="none" id="sidelem4x5448">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5456">
							<label>•</label>
							<sec_title>Acute phase reaction<route> fever, myalgia, headache, flulike symptoms for 72 hr after inj; usually resolves after 72 hr</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5462">
							<label>•</label>
							<sec_title>Blood tests</sec_title>
							<para>
								<list id="lidelem4x5462">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood tests:</emphasis> serum calcium, creatitine, BUN, magnesium, phosphate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5469">
							<label>•</label>
							<sec_title>Hypocalcemia (may be fatal)<route> paresthesia, twitching, laryngospasm, Chvostek’s and Trouseau’s signs; preexisting hypocalcemia should be corrected before treatment; patient with vit D deficiency may require higher doses of vit D</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5475">
							<label>•</label>
							<sec_title>Hypercalcemia</sec_title>
							<para>
								<list id="lidelem4x5475">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercalcemia:</emphasis> nausea, vomiting, anorexia, weakness, thirst, constipation, dysrhythmias</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5482">
							<label>•</label>
							<sec_title>Dental status<route> correct dental complications before product use; good oral hygiene should be maintained; if dental work is to be performed, antiinfectives should be given to prevent osteonecrosis of the jaw</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5488">
							<label>•</label>
							<sec_title>Infection<route> do not start treatment in patients with active infections; infections should be resolved first</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5491">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5495">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased/maintained bone density, decreased calcium levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5501">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5506">
								<item>
									<label>•</label>
									<para>To report hypercalcemic relapse: nausea, vomiting, bone pain, thirst</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5511">
								<item>
									<label>•</label>
									<para>To continue with dietary recommendations, including additional Ca 1000 mg/day and vit D ≥400 units (Prolia product labeling)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5519">
							<label>•</label>
							<sec_title>
								<route>To avoid use during pregnancy and breastfeeding; to notify prescriber if pregnancy is planned, suspected</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5522">
								<item>
									<label>•</label>
									<para>To use acetaminophen before and for 72 hr after inj to lessen bone pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5527">
								<item>
									<label>•</label>
									<para>About the purpose of this product and its expected results</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5532">
								<item>
									<label>•</label>
									<para>To avoid OTC, Rx medications and herbs and supplements unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5537">
								<item>
									<label>•</label>
									<para>To exercise regularly, stop smoking, and avoid alcohol to maintain bone health</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5542">
								<item>
									<label>•</label>
									<para>To inform all health care providers of product use; to avoid dental procedures/surgery if possible; to practice good oral hygiene</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5547">
								<item>
									<label>•</label>
									<para>That lab tests and follow-up exams will be required</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>desipramine (Rx)</mono_name>
			<info>
				<pronunciation>(dess-ip′ra-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x55570">Norpramin</tradename>
				</tradenames>
				<class type="func"> Antidepressant, tricyclic</class>
				<class type="chem"> Dibenzazepine, secondary amine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5567">
				<sec_title>Action:</sec_title>
				<para>Blocks reuptake of norepinephrine, serotonin into nerve endings, thereby increasing action of norepinephrine, serotonin in nerve cells</para>
			</section>
			<section type="uses" id="sidelem4x5572">
				<sec_title>Uses:</sec_title>
				<para>Depression</para>
				<section type="none" id="sidelem4x5577">
					<section type="none" id="sidelem4x5578">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Chronic pain, postherpetic neuralgia, ADHD, bulimia, diabetic neuropathy, panic disorder, social phobia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5583">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to tricyclics, carBAMazepine, closed-angle glaucoma, acute MI, MAOIs</para>
				<section type="none" id="sidelem4x5588">
					<section type="none" id="sidelem4x5589">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, severe depression, increased intraocular pressure, seizure disorder, CV disease, urinary retention, cardiac dysrhythmias, cardiac conduction disturbances, family history of sudden death, prostatic hypertrophy, thyroid disease</para>
						<para>
							<bbw>Children &lt;18 yr, suicidal patients</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5605">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5608">
					<section type="none" id="sidelem4x5609">
						<sec_title>Major depression</sec_title>
						<section type="none" id="sidelem4x5617">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5617">
									<item>
										<label>•</label>
										<para> 50-75 mg/day in 1-4 divided doses; titrate by 25-50 mg weekly up to 300 mg/day in single or divided doses (inpatient), 200 mg/day (outpatient)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5624">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5624">
									<item>
										<label>•</label>
										<para> 25 mg/day at bedtime, titrate weekly; may increase to 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5631">
							<label>•</label>
							<sec_title>Adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5631">
									<item>
										<label>•</label>
										<para> 25-50 mg/day in divided doses; max 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5638">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5638">
									<item>
										<label>•</label>
										<para> 1-3 mg/kg/day in divided doses; give &gt;3 mg/kg/day with close medical monitoring; max 5 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5642">
						<sec_title>Bulimia nervosa (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5650">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5650">
									<item>
										<label>•</label>
										<para> 25 mg tid; may titrate to 200 mg/day by 25-50 mg/day at weekly intervals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5654">
						<sec_title>ADHD (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5662">
							<label>•</label>
							<sec_title>Child ≥5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5662">
									<item>
										<label>•</label>
										<para> up to 3.5 mg/kg/day divided bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5666">
						<sec_title>Neuropathic pain/postherpetic neuralgia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5674">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5674">
									<item>
										<label>•</label>
										<para> 10-25 mg at bedtime, titrate to relief</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5678">
						<sec_title>Diabetic neuropathy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5686">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5686">
									<item>
										<label>•</label>
										<para> 75-150 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5690">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25, 50, 75, 100, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x5695">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5699">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation, especially in geriatric patients; with food or milk for GI symptoms; crushed if patient is unable to swallow medication whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Dosage at bedtime if oversedation occurs during day; may take entire dose at bedtime; geriatric patients may not tolerate once-daily dosing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5710">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5713">
					<section type="none" id="sidelem4x5714">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, EPS (geriatric patients), increased psychiatric symptoms, paresthenia, <emphasis style="bold">suicidal ideation,</emphasis> impaired memory, <emphasis style="bold">seizures, serotonin syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5727">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes,</emphasis><emphasis style="italic">tachycardia, hypertension,</emphasis> palpitations</para>
					</section>
					<section type="none" id="sidelem4x5739">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis, ophthalmoplegia</para>
					</section>
					<section type="none" id="sidelem4x5747">
						<sec_title>ENDO:</sec_title>
						<para> SIADH</para>
					</section>
					<section type="none" id="sidelem4x5752">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea</emphasis>, <emphasis style="italic">dry mouth,</emphasis> nausea, vomiting, <emphasis style="bold">paralytic ileus,</emphasis> increased appetite, cramps, epigastric distress, jaundice, <emphasis style="bold">hepatitis,</emphasis> stomatitis, constipation, weight gain</para>
					</section>
					<section type="none" id="sidelem4x5769">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Retention,</emphasis><emphasis style="bold">acute renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5778">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5785">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5790">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, widely distributed, protein binding 92%, extensively metabolized in the liver to active metabolite of imipramine, half-life 7-60 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5795">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs, serotonin-receptor agonists, other tricyclic antidepressants</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, barbiturates, opioids, CNS depressants, skeletal muscle relaxants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> desipramine level—cimetidine, diltiazem, fluvoxaMINE, FLUoxetine, PARoxetine, sertraline, verapamil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> life-threatening B/P elevations; do not use concurrently—cloNIDine</para>
				<para>
					<emphasis alert="lifethreat">Increase: hypertension—EPINEPHrine, norepinephrine</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hyperpyrexia, seizures, excitation; do not use within 14 days of MAOIs</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT interval—tricyclics, SUNItinib, vorinostat, ziprasidone, gatifloxacin, levofloxacin, moxifloxacin, sparfloxacin, class IA/III antidysrhythmics</emphasis>
				</para>
				<section type="none" id="sidelem4x5823">
					<section type="none" id="sidelem4x5824">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Increase: serotonin syndrome, avoid concurrent use—St. John’s wort</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x5834">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5845">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5848">
					<section type="none" id="sidelem4x5849">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5854">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take VS q4hr in patients with cardiovascular disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5859">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin; thyroid function studies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5864">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5872">
							<label>•</label>
							<sec_title>
								<route>ECG for flattening</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5883">
							<label>•</label>
							<sec_title>
								<route>EPS</route>
							</sec_title>
							<para>
								<list id="lidelem4x5883">
									<item>
										<label>•</label>
										<para> primarily in geriatric patients: rigidity, dystonia, akathisia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5890">
							<label>•</label>
							<sec_title>
								<route>Seizure activity in those with a history of seizures</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5905">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation most likely in children</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5913">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x5913">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not usual unless product discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5917">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if consumed, hold dose until morning</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5922">
								<item>
									<label>•</label>
									<para>Check to confirm that PO medication is swallowed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5927">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5931">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5937">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5941">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-3 wk
<bbw>That suicidal thoughts/behaviors may occur; to notify prescriber immediately</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue medication abruptly after long-term use because this may cause nausea, headache, malaise</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat because photosensitivity occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>desirudin</mono_name>
			<info>
				<pronunciation>(deh-sihr′uh-din)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x59860">Iprivask</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Thrombin inhibitor</class>
			</info>
			<section type="actions" id="sidelem4x5996">
				<sec_title>Action:</sec_title>
				<para>Selectively inhibits free and clot-bound thrombin, prevents activation of clotting factors</para>
			</section>
			<section type="uses" id="sidelem4x6001">
				<sec_title>Uses:</sec_title>
				<para>Prevents DVT in hip-replacement surgery</para>
				<section type="none" id="sidelem4x6006">
					<section type="none" id="sidelem4x6007">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute MI, PTCA, unstable angina</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6012">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, mannitol (diluent), hirudin, active bleeding, coagulation disorders</para>
				<section type="none" id="sidelem4x6017">
					<section type="none" id="sidelem4x6018">
						<sec_title>Precautions:</sec_title>
						<para> Renal disease (CCr &lt;60 ml/min), hepatic disease, GI/respiratory bleeding ≤3 mo, severe uncontrolled hypertension, spinal/epidural anesthesia, bacterial endocarditis, children, geriatric patients, inflammatory bowel disease, labor, organ biopsy, trauma, pregnancy (C)</para>
						<para>
							<bbw>Epidural anesthesia, lumbar puncture</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6034">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6042">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x6042">
							<item>
								<label>•</label>
								<para> 15 mg every 12 hr × 9-12 days; give first dose 5-15 min before surgery and after induction if a regional block is used</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6046">
					<section type="none" id="sidelem4x6047">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6055">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT CCr 31-60 ml/min 5 mg q12hr; CCr &lt; 31 ml/min 1.7 mg q12hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6058">
						<sec_title>Available forms:</sec_title>
						<para> Inj 15 mg and mannitol 3% in water</para>
					</section>
					<section type="none" id="sidelem4x6063">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6067">
								<item>
									<label>•</label>
									<para>Visually inspect particulate matter and discoloration before use; do not use sols that are cloudy or contain particles</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use IM</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6078">
							<sec_title>Subcut route</sec_title>
							<para>
								<list id="lidelem4x6083">
									<item>
										<label>•</label>
										<para>Do not mix with other injections, solvents, or parenteral fluids</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6091">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x6091">
										<item>
											<label>•</label>
											<para> each vial with 0.5 ml of provided diluent; shake gently until the drug is fully reconstituted; the injection should be clear, colorless; once reconstituted, each 0.5 ml contains 15.75 mg desirudin; use immediately; however, it remains stable ≤24 hr at room temperature and protected from light; discard any unused solution</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6098">
								<label>•</label>
								<sec_title>Subcut injection</sec_title>
								<para>
									<list id="lidelem4x6098">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Subcut injection:</emphasis> have patient sit or lie down; using a syringe with a 26- or 27-G needle, which is approximately 0.5 inch long, withdraw the entire reconstituted sol into the syringe; inject total volume subcut (unless renal dose); alternate between the left and right anterolateral and left and right posterolateral thigh or abdominal wall; insert whole length of the needle in a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection; to minimize bruising, do not rub the site, rotate sites</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6102">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6105">
					<section type="none" id="sidelem4x6106">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fever</para>
					</section>
					<section type="none" id="sidelem4x6111">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Thrombosis, thrombophlebitis,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x6119">
						<sec_title>EENT:</sec_title>
						<para> Nosebleeds, ocular bleeding</para>
					</section>
					<section type="none" id="sidelem4x6124">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hematemesis,</emphasis> nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x6132">
						<sec_title>GU:</sec_title>
						<para> Hematuria</para>
					</section>
					<section type="none" id="sidelem4x6137">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemorrhage,</emphasis> anemia</para>
					</section>
					<section type="none" id="sidelem4x6145">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> impaired healing, edema, inj site reaction</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6153">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr, 1-1<emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr, half-life 2 hr (12 hr in severe renal disease)</para>
			</section>
			<section type="interactions" id="sidelem4x6170">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—other anticoagulants, salicylates, NSAIDs, thrombolytics, glycoprotein IIb/IIIa antagonists, corticosteroids, dextran 40</para>
				<section type="none" id="sidelem4x6177">
					<section type="none" id="sidelem4x6178">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—feverfew, garlic, ginger, ginkgo, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x6185">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hct/Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6192">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6195">
					<section type="none" id="sidelem4x6196">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6199">
							<sec_title>Bleeding:</sec_title>
							<para>
								<list id="lidelem4x6203">
									<item>
										<label>•</label>
										<para>Gums, black tarry stools, hematuria, epistaxis, decreased Hct/Hgb, guiac-positive stools, bleeding from hip-replacement site, notify prescriber if these occur; observe for thrombosis, ecchymosis</para>
									</item>
									<item>
										<label>•</label>
										<para>Monitor aPTT daily in those with bleeding risk, CCr &lt;60 ml/min, aPTT should not be &gt;2× control
<bbw>Epidural/spinal anesthesia sites for hematomas; can result in irreversible paralysis</bbw>
</para>
									</item>
									<item>
										<label>•</label>
										<para>CCr baseline and daily if CCr &gt;60 ml/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6228">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6232">
								<item>
									<label>•</label>
									<para>Decreased occurrence of DVT in hip-replacement surgery</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6238">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6242">
								<item>
									<label>•</label>
									<para>To report any signs of bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>To use a soft-bristle toothbrush to avoid bleeding gums, to use an electric razor</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>desloratadine (Rx)</mono_name>
			<info>
				<pronunciation>(des′lor-at′ah-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x62591">Clarinex</tradename>
					<tradename id="tnidelem4x62590">Clarinex RediTabs</tradename>
				</tradenames>
				<class type="func"> Antihistamine, 2nd generation</class>
				<class type="chem"> Selective histamine (H)-receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6272">
				<sec_title>Action:</sec_title>
				<para>Binds to peripheral histamine receptors, thus providing antihistamine action without sedation</para>
			</section>
			<section type="uses" id="sidelem4x6277">
				<sec_title>Uses:</sec_title>
				<para>Seasonal/perennial allergic rhinitis, chronic idiopathic urticaria, pruritus</para>
			</section>
			<section type="contra" id="sidelem4x6282">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, infants/neonates</para>
				<section type="none" id="sidelem4x6287">
					<section type="none" id="sidelem4x6288">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, child, asthma, renal/hepatic impairment, phenylketonuria</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6293">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6301">
					<label>•</label>
					<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6301">
							<item>
								<label>•</label>
								<para> 5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6308">
					<label>•</label>
					<sec_title>Child 6-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6308">
							<item>
								<label>•</label>
								<para> 2.5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6315">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6315">
							<item>
								<label>•</label>
								<para> 1.25 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6322">
					<label>•</label>
					<sec_title>Child 6-11 mo<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6322">
							<item>
								<label>•</label>
								<para> 1 mg/day (urticaria, only)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6326">
					<section type="none" id="sidelem4x6327">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x6335">
							<label>•</label>
							<sec_title>Adult<route> PO 5 mg every other day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6338">
						<sec_title>Available form:</sec_title>
						<para> Tabs 5 mg; orally disintegrating tabs 2.5, 5 mg (RediTabs); syr 0.5 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x6343">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6347">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not remove RediTabs from blister until ready to use</para>
								</item>
								<item>
									<label>•</label>
									<para>RediTabs directly on tongue; may take with or without water</para>
								</item>
								<item>
									<label>•</label>
									<para>Use calibrated device for syrup</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6368">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6371">
					<section type="none" id="sidelem4x6372">
						<sec_title>CNS:</sec_title>
						<para> Sedation (more common with increased doses), headache, psychomotor hyperactivity, <emphasis style="bold">seizures,</emphasis> fatigue, dizziness</para>
					</section>
					<section type="none" id="sidelem4x6380">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Hepatitis,</emphasis> nausea, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x6388">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms, pharyngitis, myalgias</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6393">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset antihistamine effect 1 hr, peak 1½ hr, elimination half-life 8½-28 hr, metabolized in liver to active metabolites, excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x6398">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x6401">
					<section type="none" id="sidelem4x6402">
						<sec_title>Increase:</sec_title>
						<para> CNS depression (rare)—alcohol, opiates, sedative/hypnotics, H<emphasis style="inf">1</emphasis> blockers, antipsychotics, tricyclic antidepressants, anxiolytics</para>
					</section>
					<section type="none" id="sidelem4x6410">
						<sec_title>Increase:</sec_title>
						<para> desloratadine—nilotinib, etravirine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6415">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6418">
					<section type="none" id="sidelem4x6419">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6427">
							<label>•</label>
							<sec_title>Allergy</sec_title>
							<para>
								<list id="lidelem4x6427">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergy:</emphasis> hives, rash, rhinitis; monitor respiratory status; stop product 4 days before antigen skin test</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6431">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6435">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running or congested nose, other allergy symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6441">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6445">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if drowsiness occurs; to use caution until product’s effects are known</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause photosensitivity; to use sunscreen or stay out of the sun to prevent burns</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to exceed max dose, take without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>To use RediTab by removing from pack and allow to dissolve on tongue, without regard to water</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>desmopressin (Rx)</mono_name>
			<info>
				<pronunciation>(des-moe-press′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64723">DDAVP</tradename>
					<tradename id="tnidelem4x64722">Minirin</tradename>
					<tradename id="tnidelem4x64721">
						<country code="CAN">Octostim </country>
					</tradename>
					<tradename id="tnidelem4x64720">Stimate</tradename>
				</tradenames>
				<class type="func"> Pituitary hormone</class>
				<class type="chem"> Synthetic antidiuretic hormone</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x6485">
				<sec_title>Action:</sec_title>
				<para>Promotes reabsorption of water by action on renal tubular epithelium; causes smooth muscle constriction, increase in plasma factor VIII levels, which increases platelet aggregation, thereby resulting in vasopressor effect; similar to vasopressin</para>
			</section>
			<section type="uses" id="sidelem4x6490">
				<sec_title>Uses:</sec_title>
				<para>Hemophilia A, von Willebrand’s disease type 1, nonnephrogenic diabetes insipidus, symptoms of polyuria/polydipsia caused by pituitary dysfunction, nocturnal enuresis</para>
				<section type="none" id="sidelem4x6495">
					<section type="none" id="sidelem4x6496">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cardiopulmonary bypass, sickle cell disease, uremic bleeding, primary nocturnal enuresis (intranasal)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6501">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, nephrogenic diabetes insipidus, severe renal disease, hyponatremia</para>
				<section type="none" id="sidelem4x6506">
					<section type="none" id="sidelem4x6507">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, coronary artery disease, hypertension, cystic fibrosis, thrombus, electrolyte imbalances, male infertility</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6512">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6515">
					<section type="none" id="sidelem4x6516">
						<sec_title>Primary nocturnal enuresis</sec_title>
						<section type="none" id="sidelem4x6524">
							<label>•</label>
							<sec_title>Adult and child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6524">
									<item>
										<label>•</label>
										<para> 20 mcg at bedtime, max 0.6 mg at bedtime;  0.2 ml at bedtime, half in each nostril (unlabeled)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6531">
						<sec_title>Diabetes insipidus</sec_title>
						<section type="none" id="sidelem4x6539">
							<label>•</label>
							<sec_title>Adult<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x6539">
									<item>
										<label>•</label>
										<para> 10-40 mcg in divided doses (1-4 sprays with pump);  Initially 0.05 mg bid, adjust based on diurnal pattern of response; usual range (0.1-1.2 mg)/day in 2-3 divided doses IV/SUBCUT 2-4 mcg/day or SUBCUT in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6549">
							<label>•</label>
							<sec_title>Child 3 mo to 12 yr<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x6549">
									<item>
										<label>•</label>
										<para> 5-30 mcg in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6553">
						<sec_title>Hemophilia/von Willebrand’s disease</sec_title>
						<section type="none" id="sidelem4x6561">
							<label>•</label>
							<sec_title>Adult and child &gt;3 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6561">
									<item>
										<label>•</label>
										<para> 0.3 mcg/kg in 0.9% NaCl over 15-30 min; may repeat if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6565">
						<sec_title>Antihemorrhagic</sec_title>
						<section type="none" id="sidelem4x6573">
							<label>•</label>
							<sec_title>Adult and child &gt;3 mo<route> IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x6573">
									<item>
										<label>•</label>
										<para> 0.2-0.4 mcg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6580">
							<label>•</label>
							<sec_title>Adult and child &lt;50 kg<route> INTRANASAL</route></sec_title>
							<para>
								<list id="lidelem4x6580">
									<item>
										<label>•</label>
										<para> 1 spray in 1 nostril</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6587">
							<label>•</label>
							<sec_title>Adult and child &gt;50 kg</sec_title>
							<para>
								<list id="lidelem4x6587">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult and child &gt;50 kg:</emphasis> 1 spray in each nostril</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6591">
						<sec_title>Cardiopulmonary bypass (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6599">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6599">
									<item>
										<label>•</label>
										<para> 0.3 mcg/kg with aminocaproic acid given as a single postop dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6603">
						<sec_title>Sickle cell disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6611">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x6611">
									<item>
										<label>•</label>
										<para> 0.3 mcg/kg with a high fluid intake</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6615">
						<sec_title>Uremic bleeding (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6623">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x6623">
									<item>
										<label>•</label>
										<para> 0.3-0.4 mcg/kg as a single inj</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6627">
						<sec_title>Available forms:</sec_title>
						<para> Inj 4 mcg/ml, rhinal tube delivery 2.5 mg/vial (0.1 mg/ml); tabs 0.1, 0.2 mg; nasal spray pump (DDAVP) 10 mcg/spray (0.1 mg/ml); nasal spray (Stimate) 1.5 mg/ml (150 mcg/dose)</para>
					</section>
					<section type="none" id="sidelem4x6632">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6635">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6639">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6645">
							<sec_title>Nasal route</sec_title>
							<para>
								<list id="lidelem4x6649">
									<item>
										<label>•</label>
										<para>DDAVP and Stimate are not interchangeable</para>
									</item>
									<item>
										<label>•</label>
										<para>Prime before 1st dose (press down 4 times), pump stays primed for 1 wk, to reprime, press down 1 time</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6660">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x6664">
									<item>
										<label>•</label>
										<para>Undiluted over 1 min for diabetes insipidus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6670">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6674">
									<item>
										<label>•</label>
										<para>Diluted single dose/50 ml of 0.9% NaCl (adult and child &gt;10 kg), single dose/10 ml as IV infusion over 15-30 min for von Willebrand’s disease or hemophilia A</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6685">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6688">
					<section type="none" id="sidelem4x6689">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, headache, lethargy, flushing, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6697">
						<sec_title>CV:</sec_title>
						<para> Increased B/P, palpitations, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x6702">
						<sec_title>EENT:</sec_title>
						<para> Nasal irritation, congestion, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x6707">
						<sec_title>GI:</sec_title>
						<para> Nausea, heartburn, cramps</para>
					</section>
					<section type="none" id="sidelem4x6712">
						<sec_title>GU:</sec_title>
						<para> Vulval pain</para>
					</section>
					<section type="none" id="sidelem4x6717">
						<sec_title>META:</sec_title>
						<para> Hyponatremia, hyponatremia-induced seizures</para>
					</section>
					<section type="none" id="sidelem4x6722">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis (IV)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6729">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6732">
					<section type="none" id="sidelem4x6733">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, peak 4-7 hr</para>
					</section>
					<section type="none" id="sidelem4x6738">
						<sec_title>INTRANASAL:</sec_title>
						<para> Onset 1 hr; peak 1-4 hr; duration 8-20 hr</para>
					</section>
					<section type="none" id="sidelem4x6743">
						<sec_title>IV:</sec_title>
						<para> Onset 1 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration &gt;3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6754">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> antidiuretic action—carBAMazepine, chlorproPAMIDE, clofibrate, SSRIs, lamotrigine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pressor effect—pressor products</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antidiuretic action—lithium, alcohol, demeclocycline, heparin, large doses of EPINEPHrine</para>
			</section>
			<section type="considerations" id="sidelem4x6769">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6772">
					<section type="none" id="sidelem4x6773">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6778">
								<item>
									<label>•</label>
									<para>Pulse, B/P when giving IV or SUBCUT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6783">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, weight daily; check for edema in extremities; if water retention severe, diuretic may be prescribed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6791">
							<label>•</label>
							<sec_title>Water intoxication<route> lethargy, behavioral changes, disorientation, neuromuscular excitability</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6797">
							<label>•</label>
							<sec_title>Intranasal use</sec_title>
							<para>
								<list id="lidelem4x6797">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Intranasal use:</emphasis> nausea, congestion, cramps, headache; usually decreased with decreased dose; for nasal mucosa changes: congestion, edema, discharge, scarring (nasal route)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6802">
								<item>
									<para>
										<emphasis alert="nurse">For severe allergic reaction, including anaphylaxis (IV route), notify prescriber, discontinue use</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6810">
							<label>•</label>
							<sec_title>Nocturnal enuresis</sec_title>
							<para>
								<list id="lidelem4x6810">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nocturnal enuresis:</emphasis> identify how often enuresis is occurring, avoid use in those prone to water intoxication or sodium depletion</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6814">
								<item>
									<label>•</label>
									<para>Urine volume/osmolality and plasma osmolality (diabetes insipidus)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6819">
								<item>
									<label>•</label>
									<para>Factor VIII coagulant activity, bleeding time before using for hemostasis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6827">
							<label>•</label>
							<sec_title>Nocturnal enuresis</sec_title>
							<para>
								<list id="lidelem4x6827">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nocturnal enuresis:</emphasis> frequency of enuresis before and during treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6831">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6835">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of severe thirst, decreased urine output, decreased osmolality</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6841">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6845">
								<item>
									<label>•</label>
									<para>About the proper technique for nasal instillation: to insert tube into nostril to instill product, clear nasal passage before use</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products (cough, hay fever) because these preparations may contain EPINEPHrine, decrease product response; not to use with alcohol because adverse reactions may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear emergency ID specifying therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>That, if dose is missed, to take when remembered up to 1 hr before next dose; not to double dose; to avoid fluids from 1 hr to up to 8 hr after PO dose</para>
								</item>
								<item>
									<label>•</label>
									<para>To report upper respiratory infection, nasal congestion to prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>How to use subcut, rotate sites</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>desonide topical</mono_name>
			<section type="none" id="sidelem4x6879">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>desoximetasone</mono_name>
			<info>
				<pronunciation>(dess-ox′ee-met′ah-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x68881">Topicort</tradename>
					<tradename id="tnidelem4x68880">Topicort Spray</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, topical</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6894">
				<sec_title>Action:</sec_title>
				<para>Crosses cell membrane to attach to receptors to decrease inflammation, itching; inhibits multiple inflammatory cytokines</para>
			</section>
			<section type="uses" id="sidelem4x6899">
				<sec_title>Uses:</sec_title>
				<para>Inflammation/itching of corticosteroid-responsive dermatoses on the skin; spray-plaque psoriasis</para>
			</section>
			<section type="contra" id="sidelem4x6904">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, use of some preparations on face, axilla, groin, intertriginous areas; monotherapy in primary bacterial infection, TB</para>
				<section type="none" id="sidelem4x6911">
					<section type="none" id="sidelem4x6912">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, skin infections, Cushing syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6917">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6920">
					<section type="none" id="sidelem4x6921">
						<section type="none" id="sidelem4x6922">
							<sec_title>Adult/child &gt;10 yr:</sec_title>
							<para>
								<list id="lidelem4x6926">
									<item>
										<label>•</label>
										<para>Apply to affected areas 2 times/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6932">
						<sec_title>Available forms:</sec_title>
						<para> Cream 0.05%, 0.25%; ointment 0.05%, 0.25%; gel 0.05%; spray 0.25%</para>
					</section>
					<section type="none" id="sidelem4x6937">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6940">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x6946">
									<item>
										<para>
											<emphasis alert="nurse">Do not use with occlusive dressings</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6954">
								<label>•</label>
								<sec_title>Cream/ointment/lotion</sec_title>
								<para>
									<list id="lidelem4x6954">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/ointment/lotion:</emphasis> apply sparingly in a thin film and rub gently into the cleansed, affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6961">
								<label>•</label>
								<sec_title>Gel</sec_title>
								<para>
									<list id="lidelem4x6961">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gel:</emphasis> apply sparingly in a thin film and rub gently into the cleansed, affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6968">
								<label>•</label>
								<sec_title>Spray</sec_title>
								<para>
									<list id="lidelem4x6968">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Spray:</emphasis> discard after 30 days; keep away from heat/flame; store at room temperature</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6972">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6975">
					<section type="none" id="sidelem4x6976">
						<sec_title>INTEG:</sec_title>
						<para> Burning, folliculitis, pruritus, dermatitis, maceration</para>
					</section>
					<section type="none" id="sidelem4x6981">
						<sec_title>MISC:</sec_title>
						<para> Hyperglycemia, glycosuria, systemic absorption, hypothalamic-pituitary-adrenal (HPA) axis suppression, <emphasis style="bold">Cushing syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6988">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6991">
					<section type="none" id="sidelem4x6992">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6997">
								<item>
									<label>•</label>
									<para>Skin reactions: burning pruritus, folliculitis, dermatitis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7005">
							<label>•</label>
							<sec_title>Systemic absorption<route> HPA suppression and possible adrenocortical insufficiency after stopping treatment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7008">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7012">
								<item>
									<label>•</label>
									<para>Decreasing itching, inflammation on the skin</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7018">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7021">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x7027">
									<item>
										<para>
											<emphasis alert="nurse">Not to use with occlusive dressings</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7035">
								<label>•</label>
								<sec_title>Cream/ointment/lotion</sec_title>
								<para>
									<list id="lidelem4x7035">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/ointment/lotion:</emphasis> apply sparingly in a thin film and rub gently into the cleansed, affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x7042">
								<label>•</label>
								<sec_title>Gel</sec_title>
								<para>
									<list id="lidelem4x7042">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gel:</emphasis> apply sparingly in a thin film and rub gently into the cleansed, affected area</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x7049">
								<label>•</label>
								<sec_title>Spray</sec_title>
								<para>
									<list id="lidelem4x7049">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Spray:</emphasis> discard after 30 days; keep away from heat/flame; store at room temperature</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>desvenlafaxine</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x70561">Khedezla</tradename>
					<tradename id="tnidelem4x70560">Pristiq</tradename>
				</tradenames>
				<class type="func"> Antidepressant, serotonin-receptor norepinephrine reuptake inhibitor (SNRI)</class>
			</info>
			<section type="actions" id="sidelem4x7062">
				<sec_title>Action:</sec_title>
				<para>May work by blocking the central presynaptic reuptake of 5-HT and NE, resulting in an increased sustained level of these neurotransmitters</para>
			</section>
			<section type="uses" id="sidelem4x7067">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder</para>
				<section type="none" id="sidelem4x7072">
					<section type="none" id="sidelem4x7073">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Vasomotor symptoms (hot flashes) associated with menopause</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7078">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or venlafaxine, MAOI therapy</para>
				<section type="none" id="sidelem4x7083">
					<section type="none" id="sidelem4x7084">
						<sec_title>Precautions:</sec_title>
						<para> CNS depression, abrupt discontinuation, hypertension, hepatic/renal disease, hyponatremia, geriatric patients, pregnancy (C), labor and delivery, breastfeeding, angina, bleeding, cardiac dysrhythmias, MI, stroke, mania, hypovolemia, dehydration, increased intraocular pressure</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7099">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7107">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7107">
							<item>
								<label>•</label>
								<para> Initially, 50 mg/day; max 400 mg/day with adjustments as needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7111">
					<section type="none" id="sidelem4x7112">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7120">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-50 ml/min 50 mg daily; CCr &lt; 30 ml/min or end stage renal disease 50 mg q other day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7123">
						<sec_title>Available forms:</sec_title>
						<para>Extended release tabs 50, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x7129">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7133">
								<item>
									<label>•</label>
									<para>Without regard to food; food may minimize GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Extended release tab: do not crush, break, or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7149">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7152">
					<section type="none" id="sidelem4x7153">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> drowsiness, <emphasis style="italic">headache</emphasis>, tremor, paresthesias, asthenia, <emphasis style="bold">suicidal thoughts/behaviors, seizures,</emphasis> fatigue, chills, yawning, hot flashes, flushing, <emphasis style="italic">irritability</emphasis>, <emphasis style="italic">insomnia</emphasis>, <emphasis style="italic">anxiety, abnormal dreams, fatigue</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7175">
						<sec_title>CV:</sec_title>
						<para> Palpitations, sinus tachycardia, increased blood pressure, orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x7180">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, mydriasis, tinnitus, bruxism</para>
					</section>
					<section type="none" id="sidelem4x7185">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> xerostomia, <emphasis style="italic">diarrhea</emphasis>, constipation, vomiting, anorexia, weight loss, dysgeusia, hypercholesterolemia, hypertriglyceridemia</para>
					</section>
					<section type="none" id="sidelem4x7196">
						<sec_title>GU:</sec_title>
						<para> Urinary retention/hesitancy, orgasm dysfunction, decreased libido, impotence, proteinuria</para>
					</section>
					<section type="none" id="sidelem4x7201">
						<sec_title>HEMA:</sec_title>
						<para> Impaired platelet aggregation</para>
					</section>
					<section type="none" id="sidelem4x7206">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity, hyperhidrosis, diaphoresis, rash</para>
					</section>
					<section type="none" id="sidelem4x7211">
						<sec_title>SYST:</sec_title>
						<para>
							<emphasis alert="lifethreat"> Serotonin syndrome, neuroleptic malignant syndrome–like symptoms, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, angioedema; neonatal abstinence syndrome (fetal exposure)</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7217">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 30%, elimination half-life 11 hr; elimination half-life is increased (hepatic/renal disease)</para>
			</section>
			<section type="interactions" id="sidelem4x7222">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome–like reactions—SSRIs, other SNRIs, serotonin receptor agonists (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, SUMAtriptan, ZOLMitriptan), tricyclics, traZODone, sibutramine, SUMAtriptan, ergots, lithium, nefazodone, meperidine, phentermine, MAOIs, dextromethorphan, linezolid, promethazine, methylphenidate, dexmethylphenidate, mirtazapine, pentazocine, tryptophan, methylene blue IV; do not administer concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—salicylates, thrombolytics, NSAIDs, platelet inhibitors, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, opioids, antihistamines, sedatives/hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hallucinations, delusions, disorientation—zolpidem</para>
				<section type="none" id="sidelem4x7240">
					<section type="none" id="sidelem4x7241">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> desvenlafaxine action—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x7248">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> sodium, cholesterol, triglycerides</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> amphetamine, phencyclidine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7259">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7262">
					<section type="none" id="sidelem4x7263">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Suicidal thoughts/behaviors: mental status and mood; identify suicidal ideation</bbw>
						</para>
						<section type="none" id="sidelem4x7280">
							<label>•</label>
							<sec_title>Serotonin syndrome, neuroleptic malignant syndrome–like symptoms<route> assess for nausea/vomiting, sedation, dizziness, diaphoresis (sweating), facial flush, hallucinations, mental status changes, myoclonia, restlessness, shivering, elevated blood pressure, hyperthermia, muscle rigidity, autonomic instability, mental status changes; if serotonin syndrome occurs, discontinue desvenlafaxine and any other serotonergic agents</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7283">
								<item>
									<label>•</label>
									<para>Monitor B/P baseline and periodically during treatment, lipid levels, signs of glaucoma</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7288">
								<item>
									<label>•</label>
									<para>Appetite and nutritional intake, weight loss is common, change diet as need to support weight</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7293">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7297">
								<item>
									<label>•</label>
									<para>Decreased depression, increased sense of well-being, renewed interest in activities</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7304">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7309">
								<item>
									<label>•</label>
									<para>To take as directed, not to double or skip doses; if a dose is missed, take as soon as remembered unless close to next dose; do not discontinue abruptly, decrease gradually
<bbw>To report immediately suicidal thoughts/behaviors; have family members look for symptoms of suicidal ideation</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7323">
								<item>
									<label>•</label>
									<para>Not to operate machinery or engage in hazardous activities until reaction is known, may cause dizziness, drowsiness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7328">
								<item>
									<label>•</label>
									<para>To avoid all other products unless approval by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7333">
								<item>
									<label>•</label>
									<para>To report if pregnancy is planned or suspected (pregnancy [C]) or if breastfeeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7341">
							<label>•</label>
							<sec_title>
								<route>To report immediately allergic reactions, including rash, hives, difficulty breathing, or swelling of face, lips</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7344">
								<item>
									<label>•</label>
									<para>That continuing follow-up exams will be needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>dexamethasone (Rx)</mono_name>
			<info>
				<pronunciation>(dex-ah-meth′a-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x73540">
						<country code="CAN">Dexasone </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="29" status="active">
			<mono_name>dexamethasone sodium phosphate (Rx)</mono_name>
			<info>
				<class type="func"> Corticosteroid, synthetic</class>
				<class type="chem"> Glucocorticoid, long acting</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7369">
				<para>
					<confusion>
						<tradename id="tnidelem4x73690">Decadron</tradename>
						<drug type="generic" refid="idelem4x73690">Percodan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7373">
				<sec_title>Action:</sec_title>
				<para>Decreases inflammation by suppression of migration of polymorphonuclear leukocytes, fibroblasts, reversal of increased capillary permeability and lysosomal stabilization, suppresses normal immune response, no mineralocorticoid effects</para>
			</section>
			<section type="uses" id="sidelem4x7378">
				<sec_title>Uses:</sec_title>
				<para>Inflammation, allergies, neoplasms, cerebral edema, septic shock, collagen disorders, dexamethasone suppression test for Cushing syndrome, adrenocortical insufficiency, TB, meningitis, acute exacerbations of MS</para>
			</section>
			<section type="contra" id="sidelem4x7383">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to corticosteroids, sulfites, or benzyl alcohol; fungal infections, abrupt discontinuation, coagulopathy, ulcerative colitis, seizure disorders</para>
				<section type="none" id="sidelem4x7388">
					<section type="none" id="sidelem4x7389">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, diabetes mellitus, osteoporosis, seizure disorders, ulcerative colitis, CHF, myasthenia gravis, renal disease, peptic ulcer, esophagitis, recent MI, hypertension, TB, active hepatitis, psychosis, sulfite hypersensitivity, thromboembolic disorders</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7394">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7397">
					<section type="none" id="sidelem4x7398">
						<sec_title>Inflammation</sec_title>
						<section type="none" id="sidelem4x7406">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7406">
									<item>
										<label>•</label>
										<para> 0.75-9 mg/day in divided doses q6-12hr or phosphate  0.5-9 mg/day divided q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7416">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7416">
									<item>
										<label>•</label>
										<para> 0.024-0.34 mg/kg/day in divided doses q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7420">
						<sec_title>Anaphylactic shock</sec_title>
						<section type="none" id="sidelem4x7428">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7428">
									<item>
										<label>•</label>
										<para> (phosphate) single dose 1-6 mg/kg or  40 mg q2-6hr as needed up to 72 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7435">
						<sec_title>Cerebral edema</sec_title>
						<section type="none" id="sidelem4x7443">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7443">
									<item>
										<label>•</label>
										<para> (phosphate) 10 mg, then 4-6 mg  q6hr × 2-4 days, then taper over 1 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7453">
							<label>•</label>
							<sec_title>Child</sec_title>
							<para>
								<list id="lidelem4x7453">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child:</emphasis> loading dose 1-2 mg/kg , then 1-1.5 mg/kg/day, max 16 mg/day divided q4-6hr for 2-4 days, then taper down weekly</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7460">
						<sec_title>Adrenocortical insufficiency</sec_title>
						<section type="none" id="sidelem4x7468">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7468">
									<item>
										<label>•</label>
										<para> 0.75-9 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7475">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7475">
									<item>
										<label>•</label>
										<para> 0.03-0.3 mg/kg/day in 2-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7479">
						<sec_title>Suppression test</sec_title>
						<section type="none" id="sidelem4x7487">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7487">
									<item>
										<label>•</label>
										<para> 1 mg at 11 <emphasis style="smallcaps">pm</emphasis> or 0.5 mg q6hr × 48 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7494">
						<sec_title>ARDS (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7502">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7502">
									<item>
										<label>•</label>
										<para> (phosphate) 0.5-9 mg/day in 2-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7509">
							<label>•</label>
							<sec_title>Child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x7509">
									<item>
										<label>•</label>
										<para> 0.06-0.3 mg/kg/day or 1.2-10 mg/m<emphasis style="sup">2</emphasis> in divided doses q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7517">
						<sec_title>Bone pain (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7525">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x7525">
									<item>
										<label>•</label>
										<para> 12-20 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7529">
						<sec_title>Pediatric bacterial meningitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7537">
							<label>•</label>
							<sec_title>Child and infant &gt;2 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7537">
									<item>
										<label>•</label>
										<para> 0.15 mg/kg qid × first 2 days of antibiotics</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7541">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Dexamethasone:</emphasis> tabs 0.5, 0.75, 1, 1.5, 2, 4, 6 mg; elix 0.5 mg/5 ml; oral sol 0.5 mg/5 ml, 1 mg/1 ml; <emphasis style="bold">sodium phosphate:</emphasis> 4, 10 mg/ml; ophth implant 0.7 mg; ophth susp drops/solution 0.1%</para>
					</section>
					<section type="none" id="sidelem4x7552">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7555">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7559">
									<item>
										<label>•</label>
										<para>Titrated dose; use lowest effective dose</para>
									</item>
									<item>
										<label>•</label>
										<para>With food or milk to decrease GI symptoms, give once daily in <emphasis style="smallcaps">am</emphasis> for less toxicity, fewer adverse reactions</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7573">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x7577">
									<item>
										<label>•</label>
										<para>IM inj deeply in large muscle mass; rotate sites; avoid deltoid; use 21-G needle</para>
									</item>
									<item>
										<label>•</label>
										<para>In 1 dose in <emphasis style="smallcaps">am</emphasis> to prevent adrenal suppression; avoid SUBCUT administration, may damage tissue</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7591">
							<sec_title>Direct IV route (sodium phosphate)</sec_title>
							<para>
								<list id="lidelem4x7595">
									<item>
										<label>•</label>
										<para>Undiluted direct over ≤1 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7601">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7605">
									<item>
										<label>•</label>
										<para>Diluted with 0.9% NaCl or D<emphasis style="inf">5</emphasis>W, give as IV infusion at prescribed rate</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7614">
						<sec_title>Dexamethasone sodium phosphate</sec_title>
						<para>
							<emphasis style="bold">Syringe compatibilities:</emphasis> Acetaminophen, caffeine, dimenhydrAMINE, furosemide, granisetron, hyaluronidase, ketamine, metoclopramide, octreotide, oxyCODONE, palonosetron, ranitidine, salbutamol, SUFentanil, traMADol</para>
						<para>
							<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome, amsacrine, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, caffeine, CARBOplatin, carmustine, ceFAZolin, cefepime, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefpirome, ceftaroline, cefTAZidime, ceftizoxime, cefTRIAXone, chloramphenicol, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexmedetomidine, digoxin, diltiazem, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, eptifibatide, ertapenem, etoposide, etoposide phosphate, famotidine, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, fosaprepitant, foscarnet, furosemide, ganciclovir, gatifloxacin, gemcitabine, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, lansoprazole, leucovorin, levofloxacin, lidocaine, linezolid, liposome, LORazepam, LR, mannitol, mechlorethamine, melphalan, meropenem, metaraminol, methadone, methicillin, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, milrinone, morphine, multiple vitamins injection, nafcillin, nalbuphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxyCODONE, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, penicillin G potassium/sodium, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, potassium chloride, procainamide, propofol, propranolol, pyridoxine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, telavancin, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tolazoline, topotecan, trastuzumab, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zidovudine, zoledronic acid</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7627">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7630">
					<section type="none" id="sidelem4x7631">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Depression, flushing, sweating,</emphasis> headache, mood changes, euphoria, psychosis, <emphasis style="bold">seizures,</emphasis> insomnia, <emphasis style="bold">pseudotumor cerebri</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7644">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension,</emphasis><emphasis style="bold">circulatory collapse,</emphasis> tachycardia, edema, cardiomyopathy, <emphasis style="bold">thromboembolism, heart failure, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7656">
						<sec_title>EENT:</sec_title>
						<para> Fungal infections, increased intraocular pressure, blurred vision, cataracts, glaucoma</para>
					</section>
					<section type="none" id="sidelem4x7661">
						<sec_title>ENDO:</sec_title>
						<para> HPA suppression, hyperglycemia, sodium, fluid retention</para>
					</section>
					<section type="none" id="sidelem4x7666">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, abdominal distention,</emphasis><emphasis style="bold">GI hemorrhage,</emphasis><emphasis style="italic">increased appetite,</emphasis><emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7679">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia,</emphasis> transient leukocytosis, <emphasis style="bold">thromboembolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7689">
						<sec_title>INTEG:</sec_title>
						<para> Acne, poor wound healing, ecchymosis, petechiae, hirsutism, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7696">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x7701">
						<sec_title>MS:</sec_title>
						<para> Fractures, osteoporosis, weakness, arthralgia, myopathy</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7706">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1-2 days</para>
				<section type="none" id="sidelem4x7711">
					<section type="none" id="sidelem4x7712">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, peak 1-2 hr, duration 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> days</para>
					</section>
					<section type="none" id="sidelem4x7723">
						<sec_title>IM:</sec_title>
						<para> Duration 2 days-3 wk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7728">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—cycloSPORINE</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—alcohol, salicylates, amphotericin B, digoxin, cycloSPORINE, diuretics, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dexamethasone action—salicylates, estrogens, indomethacin, hormonal contraceptives, ketoconazole, macrolide antiinfectives, NSAIDs</para>
				<para>
					<emphasis alert="lifethreat">Increase: tendinitis, tendon rupture risk—quinolones</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—antidiabetics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dexamethasone action—cholestyramine, colestipol, barbiturates, rifampin, ePHEDrine, phenytoin, theophylline, antacids, bosentan, carBAMazepine, ethotoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> anticoagulant effect—anticonvulsants, antidiabetics, ambenonium, neostigmine, isoniazid, toxoids, vaccines, anticholinesterases, salicylates, somatrem</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> potassium levels—thiazide/loop diuretics, amphotericin B</para>
				<section type="none" id="sidelem4x7761">
					<section type="none" id="sidelem4x7762">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, sodium, blood glucose, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, potassium, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, thyroid <emphasis style="sup">131</emphasis>I uptake test, urine 17-OHCS, 17-KS, PBI</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7786">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7789">
					<section type="none" id="sidelem4x7790">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7795">
								<item>
									<label>•</label>
									<para>Potassium, blood, urine glucose while receiving long-term therapy; hypo/hyperglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7800">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly gain &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7805">
								<item>
									<label>•</label>
									<para>B/P, pulse; notify prescriber of chest pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7810">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7818">
							<label>•</label>
							<sec_title>Epidural injections (unlabeled)<route> may cause rare events (vision loss, paralysis, stroke, death)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7824">
							<label>•</label>
							<sec_title>Cushingoid symptoms<route> assess for buffalo hump, moon face, increased B/P; monitor; plasma cortisol levels during long-term therapy (normal</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7834">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x7834">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> fever, WBC even after withdrawal of medication; product masks infection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7841">
							<label>•</label>
							<sec_title>Potassium depletion</sec_title>
							<para>
								<list id="lidelem4x7841">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Potassium depletion:</emphasis> paresthesias, fatigue, nausea, vomiting, depression, polyuria, dysrhythmias, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7845">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7853">
							<label>•</label>
							<sec_title>Mental status</sec_title>
							<para>
								<list id="lidelem4x7853">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Mental status:</emphasis> affect, mood, behavioral changes, aggression</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7861">
							<label>•</label>
							<sec_title>Abrupt withdrawal<route> acute adrenal insufficiency and death may occur following abrupt discontinuation of systemic therapy; withdraw gradually</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7864">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7868">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7874">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7879">
								<item>
									<label>•</label>
									<para>That ID as corticosteroid user should be carried</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7887">
							<label>•</label>
							<sec_title>
								<route>To contact prescriber if surgery, trauma, stress occurs because dose may need to be adjusted</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7890">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases because dosage adjustment may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7895">
								<item>
									<label>•</label>
									<para>To take with food or milk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7900">
								<item>
									<label>•</label>
									<para>That bruising may occur easily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7905">
								<item>
									<label>•</label>
									<para>That if on long-term therapy, a high-protein diet may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7911">
								<item>
									<para>
										<emphasis alert="nurse">Not to discontinue abruptly because adrenal crisis can result</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7919">
							<label>•</label>
							<sec_title>About symptoms of adrenal insufficiency<route> nausea, anorexia, fatigue, dizziness, dyspnea, weakness, joint pain</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7922">
								<item>
									<label>•</label>
									<para>To avoid OTC products: salicylates, alcohol in cough products, cold preparations unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7927">
								<item>
									<label>•</label>
									<para>About all aspects of product usage, including cushingoid symptoms; to notify health care provider of infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7932">
								<item>
									<label>•</label>
									<para>To avoid exposure to chickenpox or measles, persons with infection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>dexamethasone (ophthalmic)</mono_name>
			<info>
				<pronunciation>(dex-a-meth′a-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79420">Maxidex</tradename>
				</tradenames>
				<class type="func"> Ophthalmic antiinflammatory</class>
				<class type="chem"> Corticosteroid</class>
			</info>
			<section type="confusion" id="sidelem4x7952">
				<para>
					<confusion>
						<tradename id="tnidelem4x79520">dexamethasone</tradename>
						<drug type="generic" refid="idelem4x79520">desoximetasone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7956">
				<sec_title>Action:</sec_title>
				<para>Exact mechanism of antiinflammatory action unknown; inhibits multiple inflammatory cytokines; decreases inflammation, collagen deposits, capillary dilation, edema</para>
			</section>
			<section type="uses" id="sidelem4x7961">
				<sec_title>Uses:</sec_title>
				<para>Treatment of corticosteroid-responsive ophthalmic disorders</para>
			</section>
			<section type="contra" id="sidelem4x7966">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or sulfites, ocular TB, acute herpes simplex (superficial), fungal/viral infections of the eye, posterior lens capsule rupture</para>
				<section type="none" id="sidelem4x7971">
					<section type="none" id="sidelem4x7972">
						<sec_title>Precautions:</sec_title>
						<para> Corneal infected abrasions, glaucoma, pregnancy (C), breastfeeding, migration of intravitreal implant risk, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7977">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7980">
					<section type="none" id="sidelem4x7981">
						<sec_title>Corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, cyclitis, Graves’ ophthalmopathy, giant papillary conjunctivitis (GPC), ophthalmic herpes zoster (herpes zoster ophthalmicus, herpes zoster keratitis), iritis, keratitis, superficial punctate keratitis, postoperative ocular inflammation, optic neuritis, diffuse choroiditis, sympathetic ophthalmia, vernal keratoconjunctivitis, corneal injury (corneal abrasion):</sec_title>
						<section type="none" id="sidelem4x7989">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x7989">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> Instill 1 or 2 drops of 0.1% ophthalmic sol or susp every hr during the day and every 2 hr at night; reduce application to every 4 hr after response occurs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7993">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution, suspension 0.1%</para>
					</section>
					<section type="none" id="sidelem4x7998">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8002">
								<item>
									<label>•</label>
									<para>For ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Instruct patient on proper instillation of eye ointment or solution; do not touch the tip of the dropper to the eye, fingertips, or other surface; wait ≥15 min before inserting soft contact lens</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8013">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8016">
					<section type="none" id="sidelem4x8017">
						<sec_title>EENT:</sec_title>
						<para> Burning, stinging, poor vision, corneal ulcerations, increased IOP, optic nerve damage</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8023">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8026">
					<section type="none" id="sidelem4x8027">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8035">
							<label>•</label>
							<sec_title>Corneal effects</sec_title>
							<para>
								<list id="lidelem4x8035">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Corneal effects:</emphasis> ulcerations, infections can worsen with this product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8039">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8043">
								<item>
									<label>•</label>
									<para>Decreased corneal inflammation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8049">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8054">
								<item>
									<label>•</label>
									<para>How to use products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8059">
								<item>
									<label>•</label>
									<para>Not to share with others or use for other conditions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8067">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately if vision changes or if condition worsens</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8070">
								<item>
									<label>•</label>
									<para>To take as prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>dexlansoprazole (Rx)</mono_name>
			<info>
				<pronunciation>(dex-lan-so-prey′zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x80800">Dexilant</tradename>
				</tradenames>
				<class type="func"> Antiulcer, proton-pump inhibitor</class>
				<class type="chem"> Benzimidazole</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x8090">
				<sec_title>Action:</sec_title>
				<para>Suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in gastric parietal cell; characterized as gastric acid pump inhibitor because it blocks final step of acid production</para>
			</section>
			<section type="uses" id="sidelem4x8095">
				<sec_title>Uses:</sec_title>
				<para>Gastroesophageal reflux disease (GERD), severe erosive esophagitis, heartburn</para>
			</section>
			<section type="contra" id="sidelem4x8100">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x8105">
					<section type="none" id="sidelem4x8106">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, proton-pump hypersensitivity, gastric cancer, hepatic disease, vit B<emphasis style="inf">12</emphasis> deficiency, colitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8114">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8117">
					<section type="none" id="sidelem4x8118">
						<sec_title>Erosive esophagitis</sec_title>
						<section type="none" id="sidelem4x8126">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8126">
									<item>
										<label>•</label>
										<para> 60 mg daily for up to 8 wk; maintenance:  30 mg daily for up to 6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8133">
						<sec_title>GERD</sec_title>
						<section type="none" id="sidelem4x8141">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8141">
									<item>
										<label>•</label>
										<para> 30 mg daily × 4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8145">
						<sec_title>Hepatic disease</sec_title>
						<section type="none" id="sidelem4x8153">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh B)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8156">
						<sec_title>Available forms:</sec_title>
						<para> Del rel caps 30, 60 mg</para>
					</section>
					<section type="none" id="sidelem4x8161">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8165">
								<item>
									<label>•</label>
									<para>Swallow caps whole; do not crush, chew caps; caps may be opened, contents sprinkled on food, use immediately; do not chew contents of capsule; give without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8171">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8174">
					<section type="none" id="sidelem4x8175">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, confusion, agitation, amnesia, depression, <emphasis style="bold">anxiety, seizures,</emphasis> insomnia, migraine</para>
					</section>
					<section type="none" id="sidelem4x8183">
						<sec_title>CV:</sec_title>
						<para> Chest pain, angina, bradycardia, palpitations, <emphasis style="bold">CVA,</emphasis> hypertension, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8193">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus</para>
					</section>
					<section type="none" id="sidelem4x8198">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, abdominal pain, vomiting, nausea, constipation, flatulence, colitis, dysgeusia, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8205">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">neutropenia, thrombocytopenia, pernicious anemia, thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8212">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus</para>
					</section>
					<section type="none" id="sidelem4x8217">
						<sec_title>META:</sec_title>
						<para> Gout</para>
					</section>
					<section type="none" id="sidelem4x8222">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, mylagia</para>
					</section>
					<section type="none" id="sidelem4x8227">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory infections, cough, epistaxis, dyspnea, <emphasis style="bold">pneumonia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8234">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8241">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption 57%-64%; plasma half-life 1-2 hr; protein binding 96.1%-98.8%; extensively metabolized in liver; excreted in urine, feces; clearance decreased in geriatric patients, renal/hepatic impairment; peak dual 1-2 hr, 4-5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8246">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> dexlansoprazole effect—CYP2C19, 3A4 inhibitors (fluvoxaMINE, voriconazole)<list id="lidelem4x8253">
						<item>
							<label>•</label>
							<para>Dexlansoprazole absorption: sucralfate</para>
						</item>
					</list></para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of ketoconazole, itraconazole, iron, delavirdine, ampicillin, calcium carbonate</para>
				<section type="none" id="sidelem4x8264">
					<section type="none" id="sidelem4x8265">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, bilirubin, creatinine, glucose, lipids</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8276">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8279">
					<section type="none" id="sidelem4x8280">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8288">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> diarrhea, abdominal cramps, fever, report to prescriber promptly</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8294">
							<label>•</label>
							<sec_title>Hepatotoxicity (rare)<route> hepatitis, jaundice, monitor hepatic studies (AST, ALT, alk phos) if hepatic adverse reactions occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8300">
							<label>•</label>
							<sec_title>Hypomagnesemia</sec_title>
							<para>
								<list id="lidelem4x8300">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypomagnesemia:</emphasis> usually 3 mo to 1 yr after beginning therapy; monitor magnesium level, assess for irregular heartbeats, muscle spasms; in children, fatigue, upset stomach, dizziness; magnesium supplement may be used</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8307">
							<label>•</label>
							<sec_title>Anaphylaxis (rare), serious skin disorders<route> require emergency intervention</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8310">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8314">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of epigastric pain, swelling, fullness; healing of erosive esophagitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8320">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8328">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> report to prescriber at once abdominal cramps, bloody diarrhea, fever</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8331">
								<item>
									<label>•</label>
									<para>That diabetic patient should know that hypoglycemia may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8336">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8341">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, ibuprofen; may cause GI irritation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8346">
								<item>
									<label>•</label>
									<para>To report allergic reactions, symptoms of low magnesium levels</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8354">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8357">
								<item>
									<label>•</label>
									<para>To swallow cap whole, not to chew, crush, to report all products being used to prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active">
			<mono_name>dexmethylphenidate (Rx)</mono_name>
			<info>
				<pronunciation>(dex′meth-ul-fen′ih-dayt)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x83671">Focalin</tradename>
					<tradename id="tnidelem4x83670">Focalin XR</tradename>
				</tradenames>
				<class type="func"> Central nervous system (CNS) stimulant, psychostimulant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x8375">
				<para>
					<confusion>
						<tradename id="tnidelem4x83750">dexmethylphenidate</tradename>
						<drug type="generic" refid="idelem4x83750">methylphenidate</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8379">
				<sec_title>Action:</sec_title>
				<para>Increases release of norepinephrine and DOPamine into the extraneuronal space; also blocks the reuptake of norepinephrine and DOPamine into the presynaptic neuron; mode of action for treating attention-deficit/hyperactivity disorder (ADHD) is unknown</para>
			</section>
			<section type="uses" id="sidelem4x8384">
				<sec_title>Uses:</sec_title>
				<para>ADHD</para>
			</section>
			<section type="contra" id="sidelem4x8389">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to methylphenidate, anxiety, history of Gilles de la Tourette’s syndrome, tics, glaucoma, concurrent treatment with MAOIs or within 14 days of discontinuing treatment with MAOIs</para>
				<section type="none" id="sidelem4x8394">
					<section type="none" id="sidelem4x8395">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), hypertension, depression, seizures, CV disorders, breastfeeding, child &lt;6 yr, geriatric patients, psychosis, thyrotoxicosis</para>
						<para>
							<bbw>Substance abuse, alcoholism</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8410">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8418">
					<label>•</label>
					<sec_title>Adult/adolescent/child &gt;6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8418">
							<item>
								<label>•</label>
								<para> 2.5 mg bid with doses at least 4 hr apart, gradually increase to a maximum of 20 mg/day (10 mg bid); for those taking methylphenidate, use <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> of methylphenidate dose initially, then increase as needed to a max of 20 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8431">
					<label>•</label>
					<sec_title>Adolescent and child ≥6 yr<route> EXT REL</route></sec_title>
					<para>
						<list id="lidelem4x8431">
							<item>
								<label>•</label>
								<para> 5 mg/day, may adjust to 20 mg/day in 5-mg increments, max 30 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8439">
					<label>•</label>
					<sec_title>Adult<route> PO EXT REL</route></sec_title>
					<para>
						<list id="lidelem4x8439">
							<item>
								<label>•</label>
								<para> 10 mg/day, may adjust to 20 mg/day in 10-mg increments, max 40 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8443">
					<section type="none" id="sidelem4x8444">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10 mg; ext rel caps 5, 10, 15, 20, 25, 30, 35, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x8449">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8453">
								<item>
									<label>•</label>
									<para>Twice daily at least 4 hr apart; ext rel once a day; in the morning, ext rel cap may be opened and contents sprinkled onto applesauce and consumed without chewing</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel product</para>
								</item>
								<item>
									<label>•</label>
									<para>Med guide should be provided by dispenser</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8474">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8477">
					<section type="none" id="sidelem4x8478">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, drowsiness, nervousness, insomnia, <emphasis style="bold">toxic psychosis, neuroleptic malignant syndrome (rare),</emphasis> Tourette’s syndrome</para>
					</section>
					<section type="none" id="sidelem4x8486">
						<sec_title>CV:</sec_title>
						<para> Palpitations, B/P changes, angina, <emphasis style="bold">dysrhythmias, tachycardia, MI, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8493">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia</emphasis>, abnormal hepatic function, <emphasis style="bold">hepatic coma,</emphasis><emphasis style="italic">abdominal pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8505">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, anemia, thrombocytopenic purpura</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8512">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Exfoliative dermatitis,</emphasis> urticaria, rash, erythema multiforme</para>
					</section>
					<section type="none" id="sidelem4x8520">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Fever</emphasis>, arthralgia, scalp hair loss, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8530">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Readily absorbed, elimination half-life 2.2 hr, metabolized by liver, excreted by kidneys</para>
				<section type="none" id="sidelem4x8535">
					<section type="none" id="sidelem4x8536">
						<sec_title>PO:</sec_title>
						<para> Peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
					</section>
					<section type="none" id="sidelem4x8553">
						<sec_title>PO-ER:</sec_title>
						<para> Onset unknown, peak 4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8558">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: hypertensive crisis—MAOIs or within 14 days of MAOIs, vasopressors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sympathomimetic effect—decongestants, vasoconstrictors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of anticonvulsants, tricyclics, SSRIs, coumarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of antihypertensives</para>
				<section type="none" id="sidelem4x8578">
					<section type="none" id="sidelem4x8579">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x8583">
								<item>
									<label>•</label>
									<para>Synergistic effect: melatonin</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8589">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8592">
					<section type="none" id="sidelem4x8593">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Substance abuse, past or current; psychotic episodes may occur, especially with parental abuse</bbw>
						</para>
						<section type="none" id="sidelem4x8610">
							<label>•</label>
							<sec_title>Toxicity<route> rhabdomyolysis, headache, flushing, vomiting, agitation, tachycardia, tremor, euphoria, hallucinations, hyperreflexia</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8613">
								<item>
									<label>•</label>
									<para>VS, B/P; may reverse antihypertensives; check patients with cardiac disease more often for increased B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8618">
								<item>
									<label>•</label>
									<para>CBC, differential platelet counts during long-term therapy, urinalysis; with diabetes: blood glucose, urine glucose; insulin changes may have to be made because eating will decrease; platelets</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8623">
								<item>
									<label>•</label>
									<para>Height, growth rate q3mo in children; growth rate may be decreased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8628">
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, stimulation, insomnia, aggressiveness, hostility</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8634">
								<item>
									<para>
										<emphasis alert="nurse">Withdrawal symptoms: headache, nausea, vomiting, muscle pain, weakness</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8639">
								<item>
									<label>•</label>
									<para>Appetite, sleep, speech patterns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8644">
								<item>
									<label>•</label>
									<para>For attention span, decreased hyperactivity in persons with ADHD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8649">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8653">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased hyperactivity or ability to stay awake</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8659">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8664">
								<item>
									<label>•</label>
									<para>To decrease caffeine consumption (coffee, tea, cola, chocolate); may increase irritability, stimulation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8669">
								<item>
									<label>•</label>
									<para>To take early in day to prevent insomnia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8674">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber; to avoid alcohol ingestion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8679">
								<item>
									<label>•</label>
									<para>To taper off product over several wk to avoid depression, increased sleeping, lethargy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8684">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8689">
								<item>
									<label>•</label>
									<para>To get needed rest; patients will feel more tired at end of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8695">
								<item>
									<label>•</label>
									<para>To notify all health care workers, including school nurse, of medication and schedule</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8700">
								<item>
									<label>•</label>
									<para>About information, instructions provided in patient information section</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8705">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; to avoid breastfeeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8713">
							<label>•</label>
							<sec_title>To report toxicity immediately<route> vomiting, agitation, tremor, hyperreflexia, euphoria, confusion, hallucinations, flushing, headache, tachycardia, rhabdomyolysis</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>dextroamphetamine (Rx)</mono_name>
			<info>
				<pronunciation>(dex-troe-am-fet′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x87261">Dexedrine</tradename>
					<tradename id="tnidelem4x87260">ProCentra</tradename>
				</tradenames>
				<class type="func"> Cerebral stimulant</class>
				<class type="chem"> Amphetamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="actions" id="sidelem4x8738">
				<sec_title>Action:</sec_title>
				<para>Increases release of norepinephrine, DOPamine in cerebral cortex to reticular activating system</para>
			</section>
			<section type="uses" id="sidelem4x8743">
				<sec_title>Uses:</sec_title>
				<para>Narcolepsy, attention-deficit/hyperactivity disorder (ADHD)</para>
				<section type="none" id="sidelem4x8748">
					<section type="none" id="sidelem4x8749">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Obesity</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8754">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetic amines, hyperthyroidism, glaucoma, severe arteriosclerosis</para>
				<para>
					<bbw>Symptomatic CV disease, substance abuse</bbw>
				</para>
				<section type="none" id="sidelem4x8769">
					<section type="none" id="sidelem4x8770">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;3 yr, depression, Gilles de la Tourette’s disorder, cardiomyopathy, bipolar disorder, abrupt discontinuation, acute MI; benzyl alcohol, salicylate hypersensitivity; hypercortisolism, obesity, psychosis, seizure disorder, hypertension, anxiety, anorexia nervosa, tartrazine dye hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8775">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8778">
					<section type="none" id="sidelem4x8779">
						<sec_title>Narcolepsy</sec_title>
						<section type="none" id="sidelem4x8787">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8787">
									<item>
										<label>•</label>
										<para> 5 mg bid, titrate daily dose by no more than 10 mg/wk, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8794">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8794">
									<item>
										<label>•</label>
										<para> 5 mg/day, titrate daily dose by no more than 5 mg/day at weekly intervals, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8798">
						<sec_title>ADHD</sec_title>
						<section type="none" id="sidelem4x8806">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8806">
									<item>
										<label>•</label>
										<para> 5-60 mg/day daily or divided bid, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8813">
							<label>•</label>
							<sec_title>Child 3-5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8813">
									<item>
										<label>•</label>
										<para> 2.5 mg/day increasing by 2.5 mg/day at weekly intervals, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8820">
							<label>•</label>
							<sec_title>Child &gt;6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8820">
									<item>
										<label>•</label>
										<para> 5 mg daily-bid increasing by 5 mg/day at weekly intervals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8824">
						<sec_title>Obesity, exogenous (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8832">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8832">
									<item>
										<label>•</label>
										<para> 5-30 mg/dose given 30-60 min before meals, use for 3-6 wk only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8836">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg; oral sol 5 mg/5 ml; caps: ext rel 5, 10, 15 mg</para>
					</section>
					<section type="none" id="sidelem4x8841">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8845">
								<item>
									<label>•</label>
									<para>At least 6 hr before bedtime to avoid sleeplessness</para>
								</item>
								<item>
									<label>•</label>
									<para>Use calibrated measuring device for oral sol</para>
								</item>
								<item>
									<label>•</label>
									<para>Store all forms at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8861">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8864">
					<section type="none" id="sidelem4x8865">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Hyperactivity, insomnia, restlessness, talkativeness,</emphasis> dizziness, headache, chills, stimulation, dysphoria, irritability, aggressiveness, tremor, dependence, addiction</para>
					</section>
					<section type="none" id="sidelem4x8873">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, tachycardia,</emphasis> hypertension, decrease in heart rate, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8883">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Anorexia,</emphasis> dry mouth, diarrhea, constipation, weight loss, metallic taste</para>
					</section>
					<section type="none" id="sidelem4x8891">
						<sec_title>GU:</sec_title>
						<para> Impotence, change in libido</para>
					</section>
					<section type="none" id="sidelem4x8896">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria</para>
					</section>
					<section type="none" id="sidelem4x8902">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8909">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 1 hr; peak 2 hr; ext rel onset 1 hr, peak 2 hr, duration 8 hr; metabolized by liver; urine excretion pH dependent; crosses placenta, breast milk; half-life 6-8 hr (child), 10-12 hr (adult)</para>
			</section>
			<section type="interactions" id="sidelem4x8914">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hypertensive crisis: MAOIs or within 14 days of MAOIs</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome: SSRIs, SNRIs, serotonin-receptor agonists; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dextroamphetamine effect—acetaZOLAMIDE, antacids, sodium bicarbonate</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS effect—haloperidol, tricyclics, phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of barbiturates, phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dextroamphetamine effect—ascorbic acid, ammonium chloride</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of adrenergic blockers, antidiabetics, antihypertensives, antihistamines</para>
				<section type="none" id="sidelem4x8945">
					<section type="none" id="sidelem4x8946">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x8954">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> St. John’s wort</route></sec_title>
						</section>
						<para>
							<emphasis style="bold">Decrease:</emphasis> stimulant effect—eucalyptus</para>
					</section>
					<section type="none" id="sidelem4x8961">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amine effect—caffeine (cola, coffee, tea [green/black])</para>
					</section>
					<section type="none" id="sidelem4x8968">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> plasma corticosteroids, urinary steroids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8975">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8978">
					<section type="none" id="sidelem4x8979">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Cardiac disease:</emphasis> VS, B/P; product may reverse antihypertensives; check patients with cardiac disease often</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Substance abuse:</emphasis> use for prolonged periods may lead to dependence; sudden death or serious CV events can occur from misuse; chronic intoxication (insomnia, irritability, personality changes)</bbw>
						</para>
						<para>
							<list id="lidelem4x9007">
								<item>
									<label>•</label>
									<para>CBC, urinalysis; with diabetes: blood glucose, urine glucose; insulin changes may be required because eating will decrease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9012">
								<item>
									<label>•</label>
									<para>Height, growth rate in children; growth rate may be decreased, weight</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9020">
							<label>•</label>
							<sec_title>Toxicity<route> Symptoms may vary in children; anxiety, headache, flushing, vomiting, rhabdomyolysis, tremor, hyperreflexia, confusion, euphoria, tachycardia</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9023">
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, stimulation, insomnia, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9028">
								<item>
									<label>•</label>
									<para>Tolerance or dependency: increased amount may be used to get same effect; will develop after long-term use</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9033">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9037">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CNS stimulation, decreased drowsiness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9043">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9047">
								<item>
									<label>•</label>
									<para>To take before meals (obesity)</para>
								</item>
								<item>
									<label>•</label>
									<para>To decrease caffeine consumption (coffee, tea, cola, chocolate); may increase irritability, stimulation</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber, to avoid alcohol ingestion</para>
								</item>
								<item>
									<label>•</label>
									<para>To taper product over several wk; depression, increased sleeping, lethargy may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To get needed rest; patient will feel more tired at end of day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>dextromethorphan (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(dex-troe-meth-or′fan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x909211">
						<country code="CAN">Balminil </country>
					</tradename>
					<tradename id="tnidelem4x909210">Buckley’s Mixture</tradename>
					<tradename id="tnidelem4x90929">Delsym 12-Hour</tradename>
					<tradename id="tnidelem4x90928">ElixSure Cough</tradename>
					<tradename id="tnidelem4x90927">
						<country code="CAN">Koffex </country>
					</tradename>
					<tradename id="tnidelem4x90926">Robitussin</tradename>
					<tradename id="tnidelem4x90925">Robitussin Cough with honey</tradename>
					<tradename id="tnidelem4x90924">Robitussin Long Acting Strength</tradename>
					<tradename id="tnidelem4x90923">Scot-Tussin Diabetes CF</tradename>
					<tradename id="tnidelem4x90922">Triaminic Long Acting Cough</tradename>
					<tradename id="tnidelem4x90921">Vicks Formula 44</tradename>
					<tradename id="tnidelem4x90920">Wal-Tussin</tradename>
				</tradenames>
				<class type="func"> Antitussive, nonopioid</class>
				<class type="chem"> Levorphanol derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9108">
				<sec_title>Action:</sec_title>
				<para>Depresses cough center in medulla by direct effect</para>
			</section>
			<section type="uses" id="sidelem4x9113">
				<sec_title>Uses:</sec_title>
				<para>Nonproductive cough caused by colds or inhaled irritants</para>
			</section>
			<section type="contra" id="sidelem4x9118">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x9123">
					<section type="none" id="sidelem4x9124">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), fever, hepatic disease, asthma/emphysema, chronic cough</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9129">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9137">
					<label>•</label>
					<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9137">
							<item>
								<label>•</label>
								<para> 10-20 mg q4hr or 30 mg q6-8hr, max 120 mg/day;  60 mg q12hr, max 120 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9147">
					<label>•</label>
					<sec_title>Child 6-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9147">
							<item>
								<label>•</label>
								<para> 5-10 mg q4hr;  30 mg bid,  5-10 mg q1-4hr; max 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9160">
					<label>•</label>
					<sec_title>Child 4-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9160">
							<item>
								<label>•</label>
								<para> 2.5-7.5 mg q4-8hr, max 30 mg/day;  15 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9167">
					<section type="none" id="sidelem4x9168">
						<sec_title>Available forms:</sec_title>
						<para> Liq 7.5, 15 mg/5 ml; syr 10 mg/5 ml, 15 mg/5 ml, 30 mg/15 ml; gel caps 15 mg; caps 15 mg; ext rel susp: 30 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x9173">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9181">
							<label>•</label>
							<sec_title>Chew tabs</sec_title>
							<para>
								<list id="lidelem4x9181">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Chew tabs:</emphasis> chew well; <emphasis style="bold">syrup:</emphasis> use calibrated measuring device; <emphasis style="bold">ext rel susp:</emphasis> shake well, use calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9191">
								<item>
									<label>•</label>
									<para>Decreased dose for geriatric patients; metabolism may be slowed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9196">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9199">
					<section type="none" id="sidelem4x9200">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> sedation, confusion, ataxia, fatigue</para>
					</section>
					<section type="none" id="sidelem4x9208">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9215">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9218">
					<section type="none" id="sidelem4x9219">
						<sec_title>PO:</sec_title>
						<para> Onset 15-30 min, duration 3-6 hr</para>
					</section>
					<section type="none" id="sidelem4x9224">
						<sec_title>SUS:</sec_title>
						<para> Duration 12 hr, terminal half-life 11 hr, metabolized by the liver, excreted via kidneys</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9229">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x9237">
					<label>•</label>
					<sec_title>
						<route>Do not give with MAOIs or within 2 wk of MAOIs; avoid furazolidone, linezolid, procarbazine (MAOI activity)</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, antidepressants, antihistamines, opioids, sedative/hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—amiodarone, quiNIDine, serotonin receptor agonist, sibutramine, SSRI</para>
			</section>
			<section type="considerations" id="sidelem4x9248">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9251">
					<section type="none" id="sidelem4x9252">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9260">
							<label>•</label>
							<sec_title>Cough</sec_title>
							<para>
								<list id="lidelem4x9260">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cough:</emphasis> type, frequency, character, including sputum</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9264">
								<item>
									<label>•</label>
									<para>Increase fluids to liquify secretions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9269">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9273">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of cough</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9279">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9283">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until stabilized on medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled rooms, perfumes, dust, environmental pollutants, cleaners that increase cough</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if cough persists over a few days</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active" ru="yes">
			<mono_name> dextrose (<emphasis style="smallcaps">d</emphasis>-glucose) (Rx)</mono_name>
			<info>
				<class type="func"> Caloric, parenteral solution</class>
			</info>
			<section type="uses" id="sidelem4x9316">
				<sec_title>Uses:</sec_title>
				<para>Increases intake of calories; increases fluids in patients unable to take adequate fluids, calories orally; acute hypoglycemia</para>
			</section>
			<section type="contra" id="sidelem4x9323">
				<sec_title>Contraindications:</sec_title>
				<para>Hyperglycemia, delirium tremens, hemorrhage (cranial/spinal), CHF, anuria, allergy to corn products (concentrated products)</para>
			</section>
			<section type="doses" id="sidelem4x9328">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9331">
					<section type="none" id="sidelem4x9332">
						<sec_title>Hypoglycemia</sec_title>
						<section type="none" id="sidelem4x9340">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x9340">
									<item>
										<label>•</label>
										<para> 10-25 mg g/dose (20-50 ml of a 50% sol), may need subsequent continuous IV infusion of 10% dextrose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9344">
						<sec_title>Acute symptomatic hypoglycemia (infants/neonates)</sec_title>
						<section type="none" id="sidelem4x9352">
							<label>•</label>
							<sec_title>Neonate/infant<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9352">
									<item>
										<label>•</label>
										<para> 250-500 mg/kg/dose (25% sol)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>diazepam (Rx)</mono_name>
			<info>
				<pronunciation>(dye-az′-e-pam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x93612">
						<country code="CAN">Diazemuls </country>
					</tradename>
					<tradename id="tnidelem4x93611">Diastat</tradename>
					<tradename id="tnidelem4x93610">Valium</tradename>
				</tradenames>
				<class type="func"> Antianxiety, anticonvulsant, skeletal muscle relaxant, central acting</class>
				<class type="chem"> Benzodiazepine, long-acting</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x9376">
				<para>
					<confusion>
						<tradename id="tnidelem4x93760">diazepam</tradename>
						<drug type="generic" refid="idelem4x93760">Ditropan/LORazepam</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9380">
				<sec_title>Action:</sec_title>
				<para>Potentiates the actions of GABA, especially in the limbic system, reticular formation; enhances presympathetic inhibition, inhibits spinal polysynaptic afferent paths</para>
			</section>
			<section type="uses" id="sidelem4x9385">
				<sec_title>Uses:</sec_title>
				<para>Anxiety, acute alcohol withdrawal, adjunct for seizure disorders; preoperatively as a relaxant for skeletal muscle relaxation; rectally for acute repetitive seizures</para>
				<section type="none" id="sidelem4x9390">
					<section type="none" id="sidelem4x9391">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Agitation, benzodiazepine withdrawal, chloroquine overdose, insomnia, seizure prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9396">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to benzodiazepines, closed-angle glaucoma, coma, myasthenia gravis, ethanol intoxication, hepatic disease, sleep apnea</para>
				<section type="none" id="sidelem4x9401">
					<section type="none" id="sidelem4x9402">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children &lt;6 mo, geriatric patients, debilitation, renal disease, asthma, bipolar disorder, COPD, CNS depression, labor, Parkinson’s disease, neutropenia, psychosis, seizures, substance abuse, smoking</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9407">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9410">
					<section type="none" id="sidelem4x9411">
						<sec_title>Anxiety/seizure disorders</sec_title>
						<section type="none" id="sidelem4x9419">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9419">
									<item>
										<label>•</label>
										<para> 2-10 mg bid-qid;  2-5 mg q3-4hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9429">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9429">
									<item>
										<label>•</label>
										<para> 2-2.5 mg daily-bid, increase slowly as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9436">
							<label>•</label>
							<sec_title>Child &gt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9436">
									<item>
										<label>•</label>
										<para> 1-2.5 mg tid/qid;  0.04-0.3 mg/kg/dose q2-4hr, max 0.6 mg/kg in an 8-hr period</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9443">
						<sec_title>Precardioversion</sec_title>
						<section type="none" id="sidelem4x9451">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9451">
									<item>
										<label>•</label>
										<para> 5-15 mg 5-10 min precardioversion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9455">
						<sec_title>Preendoscopy</sec_title>
						<section type="none" id="sidelem4x9463">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9463">
									<item>
										<label>•</label>
										<para> 2.5-20 mg;  5-10 mg <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr preendoscopy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9476">
						<sec_title>Muscle relaxation</sec_title>
						<section type="none" id="sidelem4x9484">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9484">
									<item>
										<label>•</label>
										<para> 2-10 mg tid-qid or  15-30 mg/day;  5-10 mg, repeat in 2-4 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9494">
						<sec_title>Tetanic muscle spasms</sec_title>
						<section type="none" id="sidelem4x9502">
							<label>•</label>
							<sec_title>Child &gt;5 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x9502">
									<item>
										<label>•</label>
										<para> 5-10 mg q3-4hr prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9509">
							<label>•</label>
							<sec_title>Infant &gt;30 days<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x9509">
									<item>
										<label>•</label>
										<para> 1-2 mg q3-4hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9513">
						<sec_title>Status epilepticus</sec_title>
						<section type="none" id="sidelem4x9521">
							<label>•</label>
							<sec_title>Adult<route> IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x9521">
									<item>
										<label>•</label>
										<para> 5-10 mg, 2 mg/min, may repeat q10-15min, max 30 mg; may repeat in 2-4 hr if seizures reappear</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9528">
							<label>•</label>
							<sec_title>Child &gt;5 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x9528">
									<item>
										<label>•</label>
										<para> 1 mg q2-5min;  1 mg slowly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9538">
							<label>•</label>
							<sec_title>Child 1 mo-5 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9538">
									<item>
										<label>•</label>
										<para> 0.2-0.5 mg slowly;  0.2-0.5 mg slowly q2-5min up to 5 mg, may repeat in 2-4 hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9545">
						<sec_title>Seizures other than status epilepticus</sec_title>
						<section type="none" id="sidelem4x9553">
							<label>•</label>
							<sec_title>Adult<route> RECT</route></sec_title>
							<para>
								<list id="lidelem4x9553">
									<item>
										<label>•</label>
										<para> 0.2 mg/kg, may repeat in 4-12 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9560">
							<label>•</label>
							<sec_title>Child 6-11 yr<route> RECT</route></sec_title>
							<para>
								<list id="lidelem4x9560">
									<item>
										<label>•</label>
										<para> 0.3 mg/kg, may repeat in 4-12 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9567">
							<label>•</label>
							<sec_title>Child 2-5 yr<route> RECT</route></sec_title>
							<para>
								<list id="lidelem4x9567">
									<item>
										<label>•</label>
										<para> 0.5 mg/kg, may repeat in 4-12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9572">
						<sec_title>Alcohol withdrawal</sec_title>
						<section type="none" id="sidelem4x9580">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9580">
									<item>
										<label>•</label>
										<para> 10 mg initially, then 5-10 mg q3-4hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9584">
						<sec_title>Benzodiazepine withdrawal (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9592">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9592">
									<item>
										<label>•</label>
										<para> Taper 0.5-2 mg over 4-16 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9596">
						<sec_title>Febrile seizure prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9604">
							<label>•</label>
							<sec_title>Child 6 mo-5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9604">
									<item>
										<label>•</label>
										<para> 0.33 mg/kg q8hr until afebrile for ≥24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9608">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2, 5, 10 mg; inj 5 mg/ml; oral sol 5 mg/5 ml, rectal 2.5 (pediatric), 10, 20 mg, twin packs; ext rel cap 15 mg, rectal gel</para>
					</section>
					<section type="none" id="sidelem4x9613">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9618">
								<item>
									<label>•</label>
									<para>With food or milk for GI symptoms; crushed if patient is unable to swallow medication whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9623">
								<item>
									<label>•</label>
									<para>Reduced opioid dose by <emphasis style="sup">1</emphasis>/<emphasis style="inf">3</emphasis> if given concomitantly with diazepam</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9637">
							<label>•</label>
							<sec_title>Concentrate</sec_title>
							<para>
								<list id="lidelem4x9637">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Concentrate:</emphasis> use calibrated dropper only; mix with water, juice, pudding, applesauce; to be consumed immediately</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9641">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x9645">
									<item>
										<label>•</label>
										<para>Do not use more than 5×/mo or for an episode q5days (Diastat)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9651">
							<sec_title>Direct IV route</sec_title>
							<section type="none" id="sidelem4x9659">
								<label>•</label>
								<sec_title>
									<route>do not dilute or mix with other products</route>
								</sec_title>
								<para>
									<list id="lidelem4x9659">
										<item>
											<label>•</label>
											<para>Into large vein; give IV 5 mg or less/1 min or total dose over 3 min or more (children, infants); continuous infusion is not recommended; inject as close to vein insertion as possible; </para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9663">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9666">
					<section type="none" id="sidelem4x9667">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, fatigue, depression, insomnia, hallucinations, ataxia, fatigue</para>
					</section>
					<section type="none" id="sidelem4x9675">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes, tachycardia,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x9685">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis, nystagmus</para>
					</section>
					<section type="none" id="sidelem4x9693">
						<sec_title>GI:</sec_title>
						<para> Constipation, dry mouth, nausea, vomiting, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x9698">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9705">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, itching</para>
					</section>
					<section type="none" id="sidelem4x9710">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9717">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver via CYP2C19, CYP3A4; excreted by kidneys; crosses placenta; excreted in breast milk; crosses the blood-brain barrier; half-life 1-12 days; more reliable by mouth; 99% protein binding</para>
				<section type="none" id="sidelem4x9722">
					<section type="none" id="sidelem4x9723">
						<sec_title>PO:</sec_title>
						<para> Rapidly absorbed, onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 2 hr, duration up to 24 hr</para>
					</section>
					<section type="none" id="sidelem4x9734">
						<sec_title>IM:</sec_title>
						<para> Onset 15-30 min, duration 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, absorption slow and erratic</para>
					</section>
					<section type="none" id="sidelem4x9745">
						<sec_title>RECT:</sec_title>
						<para> Peak 1.5 hr</para>
					</section>
					<section type="none" id="sidelem4x9750">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, duration 15 min-1 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9755">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> diazepam effect—amiodarone, protease inhibitors, diltiazem, cimetidine, clarithromycin, dalfopristin-quinupristin, delavirdine, disulfiram, efavirenz, erythromycin, fluconazole, fluvoxaMINE, imatinib, itraconazole, ketoconazole, IV miconazole, nefazodone, niCARdipine, ranolazine, troleandomycin, valproic acid, verapamil, voriconazole, zafirlukast, zileuton</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—barbiturates, SSRIs, cimetidine, CNS depressants, valproic acid, CYP3A4 inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants, alcohol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> diazepam metabolism—oral contraceptives, valproic acid, disulfiram, isoniazid, propranolol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> diazepam effect—CYP3A4 inducers (rifampin, barbiturates, carBAMazepine, ethotoin, phenytoin, fosphenytoin), smoking</para>
				<section type="none" id="sidelem4x9777">
					<section type="none" id="sidelem4x9778">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, serum bilirubin, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9785">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9788">
					<section type="none" id="sidelem4x9789">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9794">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse; respiratory rate; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; respirations q5-15min if given IV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9799">
								<item>
									<label>•</label>
									<para>Blood studies: CBC during long-term therapy; blood dyscrasias (rare); hepatic studies: AST, ALT, bilirubin, creatinine, LDH, alk phos</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9808">
							<label>•</label>
							<sec_title>
								<route>Degree of anxiety;</route>
							</sec_title>
							<para>
								<list id="lidelem4x9808">
									<item>
										<label>•</label>
										<para> what precipitates anxiety and whether product controls symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9815">
							<label>•</label>
							<sec_title>
								<route>Alcohol withdrawal symptoms,</route>
							</sec_title>
							<para>
								<list id="lidelem4x9815">
									<item>
										<label>•</label>
										<para> including hallucinations (visual, auditory), delirium, irritability, agitation, fine to coarse tremors</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9822">
							<label>•</label>
							<sec_title>
								<route>Seizure control and type, duration, intensity of seizures</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9825">
								<item>
									<label>•</label>
									<para>For muscle spasms; pain relief</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9833">
							<label>•</label>
							<sec_title>
								<route>IV site for thrombosis or phlebitis, which may occur rapidly</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9836">
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, sleeping pattern, drowsiness, dizziness, suicidal tendencies</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9844">
							<label>•</label>
							<sec_title>Physical dependency, withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x9844">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Physical dependency, withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness after long-term use</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9848">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9852">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, restlessness, insomnia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9858">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9863">
								<item>
									<label>•</label>
									<para>That product may be taken with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9868">
								<item>
									<label>•</label>
									<para>That product not to be used for everyday stress or for &gt;4 mo unless directed by prescriber; to take no more than prescribed amount; that product may be habit forming</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9873">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9878">
								<item>
									<label>•</label>
									<para>To avoid driving, activities that require alertness; drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9883">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other psychotropic medications unless directed by prescriber; that smoking may decrease diazepam effect by increasing diazepam metabolism</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9891">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication abruptly after long-term use; to gradually taper</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9894">
								<item>
									<label>•</label>
									<para>To rise slowly or fainting may occur, especially in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9899">
								<item>
									<label>•</label>
									<para>That drowsiness may worsen at beginning of treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9907">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected (D), avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>dibucaine topical</mono_name>
			<section type="none" id="sidelem4x9918">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>diclofenac epolamine (Rx)</mono_name>
			<info>
				<pronunciation>(dye-kloe′fen-ak)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x99270">Flector</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="39" status="active">
			<mono_name>diclofenac potassium (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x99323">Cambia</tradename>
					<tradename id="tnidelem4x99322">Cataflam</tradename>
					<tradename id="tnidelem4x99321">
						<country code="CAN">Rapide </country>
					</tradename>
					<tradename id="tnidelem4x99320">Zipsor</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="40" status="active">
			<mono_name>diclofenac sodium (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x99408">
						<country code="CAN">Apo-Diclo </country>
					</tradename>
					<tradename id="tnidelem4x99407">
						<country code="CAN">Novo-Difenac </country>
					</tradename>
					<tradename id="tnidelem4x99406">
						<country code="CAN">Nu-Diclo </country>
					</tradename>
					<tradename id="tnidelem4x99405">PENNSAID</tradename>
					<tradename id="tnidelem4x99404">
						<country code="CAN">Sandoz Diclofenac </country>
					</tradename>
					<tradename id="tnidelem4x99403">Solaraze Topical Gel</tradename>
					<tradename id="tnidelem4x99402">Voltaren</tradename>
					<tradename id="tnidelem4x99401">Voltaren Topical Gel</tradename>
					<tradename id="tnidelem4x99400">Voltaren XR</tradename>
				</tradenames>
				<class type="func"> Nonsteroidal antiinflammatory products (NSAIDs), nonopioid analgesic</class>
				<class type="chem"> Phenylacetic acid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9962">
				<para>
					<confusion>
						<tradename id="tnidelem4x99620">Cataflam</tradename>
						<drug type="generic" refid="idelem4x99620">Catapres</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9966">
				<sec_title>Action:</sec_title>
				<para>Inhibits COX-1, COX-2 by blocking arachidonate resulting in analgesic, antiinflammatory, antipyretic effects</para>
			</section>
			<section type="uses" id="sidelem4x9971">
				<sec_title>Uses:</sec_title>
				<para>Acute, chronic RA; osteoarthritis; ankylosing spondylitis; analgesia; primary dysmenorrhea; patch: mild to moderate pain</para>
				<section type="none" id="sidelem4x9976">
					<section type="none" id="sidelem4x9977">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Arthralgia, headache, migraine, bone pain, myalgia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9982">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to aspirin, iodides, other NSAIDs, bovine protein, asthma, serious CV disease; eczema, exfoliative dermatitis, skin abrasions (gel, patch)</para>
				<para>
					<bbw>Treatment of perioperative pain (CABG), surgery</bbw>
				</para>
				<section type="none" id="sidelem4x9998">
					<section type="none" id="sidelem4x9999">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (tabs, del rel tab, ext rel tab, top gel), (ophthalmic sol); pregnancy (<preg cat="B">B</preg>) (top gel)(solaraze); top patch, top sol, cap, powder for oral sol (C &lt;30 wk, D &gt;30 wk); breastfeeding, children, bleeding disorders, GI disorders, cardiac disorders, hypersensitivity to other antiinflammatory agents, CCr &lt;30 ml/min, accidental exposure, acute bronchospasm, hypersensitivity to benzyl alcohol</para>
						<para>
							<bbw>GI bleeding, MI, stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10014">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10017">
					<section type="none" id="sidelem4x10018">
						<sec_title>Osteoarthritis</sec_title>
						<section type="none" id="sidelem4x10026">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10026">
									<item>
										<label>•</label>
										<para> (Cataflam) 50 mg bid-tid, max 150 mg/day;  (Voltaren) 50 mg bid-tid or 75 mg bid, max 150 mg/day;  (Voltaren-XR) 100 mg daily, max 150 mg/day;  1% (Voltaren gel) 4 g for each of lower extremities qid, max 16 g/day; 2 g for each of upper extremities qid, max 8 g/day;  (Pennsaid) apply 40 drops to each affected knee qid; apply 10 drops at a time, spread over entire knee</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10042">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x10050">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10050">
									<item>
										<label>•</label>
										<para> (Cataflam) 50 mg tid-qid, max 200 mg/day;  (Voltaren) 50 mg tid-qid or 75 mg bid, max 200 mg/day;  (Voltaren-XR) 100 mg daily, may increase to 200 mg/day, max 200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10060">
						<sec_title>Ankylosing spondylitis</sec_title>
						<section type="none" id="sidelem4x10068">
							<label>•</label>
							<sec_title>Adult<route> PO DEL REL</route></sec_title>
							<para>
								<list id="lidelem4x10068">
									<item>
										<label>•</label>
										<para> (Voltaren) 25 mg qid and 25 mg at bedtime, max 125 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10072">
						<sec_title>Acute migraine with/without aura</sec_title>
						<section type="none" id="sidelem4x10080">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10080">
									<item>
										<label>•</label>
										<para> (powder for oral sol) (Cambia) 50 mg as a single dose, mix contents of packet in 1-2 oz water</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10084">
						<sec_title>Mild to moderate pain</sec_title>
						<section type="none" id="sidelem4x10092">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10092">
									<item>
										<label>•</label>
										<para> (Zipsor) 25 mg qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10096">
						<sec_title>Dysmenorrhea or nonrheumatic inflammatory conditions</sec_title>
						<section type="none" id="sidelem4x10104">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10104">
									<item>
										<label>•</label>
										<para> (Cataflam) 50 mg tid or 100 mg initially, then 50 mg tid, max 200 mg 1st day, then 150 mg/day, immediate release only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10108">
						<sec_title>Pain of strains/sprains</sec_title>
						<section type="none" id="sidelem4x10116">
							<label>•</label>
							<sec_title>Adult<route> TOP PATCH</route></sec_title>
							<para>
								<list id="lidelem4x10116">
									<item>
										<label>•</label>
										<para> (Flector) apply patch to area bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10120">
						<sec_title>Actinic keratosis</sec_title>
						<section type="none" id="sidelem4x10128">
							<label>•</label>
							<sec_title>Adult<route> TOP GEL</route></sec_title>
							<para>
								<list id="lidelem4x10128">
									<item>
										<label>•</label>
										<para> (Solaraze) apply to area bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10132">
						<sec_title>Prevention of heterotropic ossification (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10140">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10140">
									<item>
										<label>•</label>
										<para> 50 mg tid × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10144">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x10152">
							<label>•</label>
							<sec_title>Avoid</sec_title>
							<para>
								<list id="lidelem4x10152">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Avoid:</emphasis> Use of topical gel, patch, sol, potassium oral tab for advanced renal disease</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10156">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Epolamine:</emphasis> topical patch 1.3%; <emphasis style="bold">potassium:</emphasis> tabs 50 mg; tabs liquid filled 25 mg; oral powder for sol 50 mg; <emphasis style="bold">sodium:</emphasis> delayed rel tabs (enteric-coated) 25, 50, 75 mg; Pennsaid: ext rel tabs, 100 mg</para>
					</section>
					<section type="none" id="sidelem4x10170">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10173">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10177">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew enteric products</para>
									</item>
									<item>
										<label>•</label>
										<para>Take with a full glass of water to enhance absorption, remain upright for <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; if dose missed, take as soon as remembered within 2 hr if taking 1-2×/day; do not double doses</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10199">
							<sec_title>Topical patch route (Flector)</sec_title>
							<para>
								<list id="lidelem4x10203">
									<item>
										<label>•</label>
										<para>Wash hands before handling patch</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove and release liner before administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Use only on normal, intact skin</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove before bath, shower, swimming, do not use heat or occlusive dressings</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard removed patch in trash away from children, pets</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10234">
							<sec_title>Topical gel route</sec_title>
							<para>
								<list id="lidelem4x10238">
									<item>
										<label>•</label>
										<para>Apply to intact skin, do not use heat or occlusive dressings</para>
									</item>
									<item>
										<label>•</label>
										<para>Use only for osteoarthritis, mild to moderate pain</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature, avoid heat, do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10254">
							<sec_title>Topical solution route</sec_title>
							<para>
								<list id="lidelem4x10258">
									<item>
										<label>•</label>
										<para>Apply to clean, dry skin</para>
									</item>
									<item>
										<label>•</label>
										<para>Wait until dry before applying clothing, other creams/lotions</para>
									</item>
									<item>
										<label>•</label>
										<para>Wait ≥30 min after use before bathing, swimming</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10280">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10283">
					<section type="none" id="sidelem4x10284">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> drowsiness, fatigue, tremors, confusion, insomnia, anxiety, depression, nervousness, paresthesia, muscle weakness</para>
					</section>
					<section type="none" id="sidelem4x10292">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">CHF,</emphasis> tachycardia, peripheral edema, palpitations, <emphasis style="bold">dysrhythmias,</emphasis> hypo/hypertension, fluid retention, <emphasis style="bold">MI, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10305">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision, <emphasis style="bold">laryngeal edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10312">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, vomiting, diarrhea, <emphasis style="bold">jaundice, cholestatic hepatitis,</emphasis> constipation, flatulence, cramps, dry mouth, peptic ulcer, <emphasis style="bold">GI bleeding, hepatotoxicity,</emphasis> hematemesis</para>
					</section>
					<section type="none" id="sidelem4x10323">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity: dysuria, hematuria, oliguria, azotemia, cystitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10330">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias,</emphasis> epistaxis, anemia</para>
					</section>
					<section type="none" id="sidelem4x10338">
						<sec_title>INTEG:</sec_title>
						<para> Purpura, rash, pruritus, sweating, erythema, petechiae, photosensitivity, alopecia</para>
					</section>
					<section type="none" id="sidelem4x10343">
						<sec_title>META:</sec_title>
						<para> <emphasis style="bold">Hyperglycemia, hypoglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10350">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10357">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10364">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10367">
					<section type="none" id="sidelem4x10368">
						<sec_title>PO:</sec_title>
						<para> Peak 2-3 hr; <emphasis style="bold">TOP Patch:</emphasis> peak 12 hr; elimination half-life 1-2 hr, patch 12 hr, 99% bound to plasma proteins, metabolized in liver to metabolite, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10376">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x10380">
						<item>
							<label>•</label>
							<para>Need for dosage adjustment: antidiabetics</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effect—anticoagulants, NSAIDs, platelet inhibitors, salicylates, thrombolytics, SSRIs</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—phenytoin, lithium, cycloSPORINE, methotrexate, digoxin, lithium, cidofovir</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI side effects—aspirin, other NSAIDs, bisphosphonates, corticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—β-blockers, diuretics, ACE inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of diuretics</para>
				<section type="none" id="sidelem4x10409">
					<section type="none" id="sidelem4x10410">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—garlic, ginger, ginkgo; monitor for bleeding</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10417">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10420">
					<section type="none" id="sidelem4x10421">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">CABG:</emphasis> do not use oral, top, gel, patch, in perioperative pain in coronary artery bypass graft surgery for 10-14 days</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Stroke/MI:</emphasis> may increase CHF and hypertension, increased CV thrombotic events that may be fatal; those with CV disease may be at greater risk</bbw>
						</para>
						<section type="none" id="sidelem4x10452">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x10452">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, character, aggravating/alleviating factors, ROM before and 1 hr after dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10456">
								<item>
									<label>•</label>
									<para>Patients with asthma, aspirin hypersensitivity, nasal polyps; may develop hypersensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10461">
								<item>
									<label>•</label>
									<para>LFTs (may be elevated), uric acid (may be decreased—serum; increased—urine) periodically; also BUN, creatinine, electrolytes (may be elevated)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10467">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias (thrombocytopenia): bruising, fatigue, bleeding, poor healing; blood counts during therapy; watch for decreasing platelets; if low, therapy may need to be discontinued, restarted after hematologic recovery; stool guaiac</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10472">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10476">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation in joints, after cataract surgery</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10482">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10487">
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective; to contact prescriber before surgery regarding when to discontinue this product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10495">
							<label>•</label>
							<sec_title>
								<route>To report bleeding, bruising, fatigue, malaise; blood dyscrasias do occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10498">
								<item>
									<label>•</label>
									<para>To avoid aspirin, alcoholic beverages, NSAIDs, or other OTC medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10504">
								<item>
									<label>•</label>
									<para>To take with food, milk, or antacids to avoid GI upset; to swallow whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10509">
								<item>
									<label>•</label>
									<para>To use caution when driving; drowsiness, dizziness may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10517">
							<label>•</label>
							<sec_title>To report hepatotoxicity<route> flulike symptoms, nausea, vomiting, jaundice, pruritus, lethargy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10520">
								<item>
									<label>•</label>
									<para>To use sunscreen to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10525">
								<item>
									<label>•</label>
									<para>To notify all providers of product use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10533">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected (C, tabs) (C, &lt;30 wk, D, &gt;30 wk caps, topical patch/solution, powder for oral solution)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>diclofenac ophthalmic</mono_name>
			<section type="none" id="sidelem4x10539">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="42" status="active" ru="yes">
			<mono_name> dicyclomine (Rx)</mono_name>
			<info>
				<pronunciation>(dye-sye′kloe-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x105503">Bentyl</tradename>
					<tradename id="tnidelem4x105502">
						<country code="CAN">Bentylol </country>
					</tradename>
					<tradename id="tnidelem4x105501">
						<country code="CAN">Formulex </country>
					</tradename>
					<tradename id="tnidelem4x105500">
						<country code="CAN">Lomine </country>
					</tradename>
				</tradenames>
				<class type="func"> Gastrointestinal anticholinergic</class>
			</info>
			<section type="uses" id="sidelem4x10564">
				<sec_title>Uses:</sec_title>
				<para>IBS</para>
			</section>
			<section type="contra" id="sidelem4x10569">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to anticholinergics, closed-angle glaucoma, GI obstruction, myasthenia gravis, paralytic ileus, GI atony, toxic megacolon, dementia</para>
			</section>
			<section type="doses" id="sidelem4x10574">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10582">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10582">
							<item>
								<label>•</label>
								<para> 10-20 mg tid-qid;  20 mg q4-6hr; max 160 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10592">
					<label>•</label>
					<sec_title>Child &gt;2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10592">
							<item>
								<label>•</label>
								<para> 10 mg tid-qid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10599">
					<label>•</label>
					<sec_title>Child 6 mo-2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10599">
							<item>
								<label>•</label>
								<para> 5 mg tid-qid</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="43" status="active">
			<mono_name>didanosine (Rx)</mono_name>
			<info>
				<pronunciation>(dye-dan′oh-seen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x106082">ddl</tradename>
					<tradename id="tnidelem4x106081">Videx Pediatric Powder</tradename>
					<tradename id="tnidelem4x106080">Videx EC</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x10618">
				<sec_title>Action:</sec_title>
				<para>Nucleoside analog incorporating into cellular DNA by viral reverse transcriptase, thereby terminating the cellular DNA chain</para>
			</section>
			<section type="uses" id="sidelem4x10623">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 infection in combination with at least 2 other antiretrovirals</para>
				<section type="none" id="sidelem4x10628">
					<section type="none" id="sidelem4x10629">
						<sec_title>Unlabeled uses:</sec_title>
						<para> HIV prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10634">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, lactic acidosis, pancreatitis, phenylketonuria</para>
				<section type="none" id="sidelem4x10639">
					<section type="none" id="sidelem4x10640">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, renal disease, sodium-restricted diets, elevated amylase, preexisting peripheral neuropathy, hyperuricemia, gout, CHF, noncirrhotic portal hypertension</para>
						<para>
							<bbw>Hepatic disease, lactic acidosis, pancreatitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10655">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10663">
					<label>•</label>
					<sec_title>Adult/adolescent/child ≥6 yr and ≥60 kg<route> PO EXT REL CAP</route></sec_title>
					<para>
						<list id="lidelem4x10663">
							<item>
								<label>•</label>
								<para> 400 mg/day; if used with tenofovir, reduce to 250 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10670">
					<label>•</label>
					<sec_title>Adult/adolescent/child ≥6 yr and 25 kg to &lt;60 kg<route> PO EXT REL CAP</route></sec_title>
					<para>
						<list id="lidelem4x10670">
							<item>
								<label>•</label>
								<para> 250 mg/day; if used with tenofovir, reduce to 200 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10677">
					<label>•</label>
					<sec_title>Adolescent 20 kg to &lt;25 kg<route> PO EXT REL CAP</route></sec_title>
					<para>
						<list id="lidelem4x10677">
							<item>
								<label>•</label>
								<para> 200 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10684">
					<label>•</label>
					<sec_title>Adult ≥60 kg<route> PO ORAL SOL</route></sec_title>
					<para>
						<list id="lidelem4x10684">
							<item>
								<label>•</label>
								<para> 200 mg bid or 400 mg/day; if used with tenofovir, reduce to 250 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10691">
					<label>•</label>
					<sec_title>Adult &lt;60 kg<route> PO ORAL SOL</route></sec_title>
					<para>
						<list id="lidelem4x10691">
							<item>
								<label>•</label>
								<para> 125 mg bid or 250 mg/day; if used with tenofovir, reduce to 200 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10699">
					<label>•</label>
					<sec_title>Adolescent/child/infant &gt;8 mo<route> PO ORAL SOL</route></sec_title>
					<para>
						<list id="lidelem4x10699">
							<item>
								<label>•</label>
								<para> 120 mg/m<emphasis style="sup">2</emphasis> every 12 hr, max adult dosing</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10709">
					<label>•</label>
					<sec_title>Infant &lt;8 mo/neonate ≥2 wk<route> PO ORAL SOL</route></sec_title>
					<para>
						<list id="lidelem4x10709">
							<item>
								<label>•</label>
								<para> 100 mg/m<emphasis style="sup">2</emphasis> every 12 hr for up to 3 months</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10716">
					<section type="none" id="sidelem4x10717">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x10725">
							<label>•</label>
							<sec_title>Adult<route> PO CrCl ≥60 ml/min</route></sec_title>
						</section>
						<section type="none" id="sidelem4x10731">
							<label>•</label>
							<sec_title>Adult/adolescent ≥60 kg<route> PO CCr 30-59 ml/min</route></sec_title>
						</section>
						<section type="none" id="sidelem4x10737">
							<label>•</label>
							<sec_title>Adult/adolescent &lt;60 kg<route> PO CCr 30-59 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10740">
						<sec_title>Intermittent hemodialysis/continuous ambulatory peritoneal dialysis</sec_title>
						<section type="none" id="sidelem4x10748">
							<label>•</label>
							<sec_title>Adult/adolescent &gt;60 kg</sec_title>
							<para>
								<list id="lidelem4x10748">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent &gt;60 kg:</emphasis> Give 100 mg oral sol or 125 mg EXT-REL CAPS every 24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10755">
							<label>•</label>
							<sec_title>Adult/adolescent &lt;60 kg</sec_title>
							<para>
								<list id="lidelem4x10755">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent &lt;60 kg:</emphasis> Give 75 mg oral sol every 24 hr, EXT-REL CAPS are not recommended</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10759">
						<sec_title>Available forms:</sec_title>
						<para> Powder for oral sol 10 mg/ml; del rel caps 125, 200, 250, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x10764">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10768">
								<item>
									<label>•</label>
									<para>Pediatric powder for oral sol after preparation by pharmacist; dilution required using purified USP water, then antacid (10 mg/ml), refrigerate, shake before use</para>
								</item>
								<item>
									<label>•</label>
									<para>On an empty stomach ≥30 min before or 2 hr after meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Adjust dose with renal impairment</para>
								</item>
								<item>
									<label>•</label>
									<para>Store tabs, caps in tightly closed bottle at room temperature; store oral sol after dissolving at room temperature ≤4 hr</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10789">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10792">
					<section type="none" id="sidelem4x10793">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Peripheral neuropathy, seizures,</emphasis> confusion, <emphasis style="italic">anxiety,</emphasis> hypertonia, abnormal thinking, asthenia, <emphasis style="italic">insomnia,</emphasis><emphasis style="bold">CNS depression,</emphasis> pain, dizziness, chills, fever</para>
					</section>
					<section type="none" id="sidelem4x10809">
						<sec_title>CV:</sec_title>
						<para> Hypertension, vasodilation, dysrhythmia, syncope, <emphasis style="bold">CHF,</emphasis> palpitation</para>
					</section>
					<section type="none" id="sidelem4x10817">
						<sec_title>EENT:</sec_title>
						<para> Ear pain, otitis, photophobia, visual impairment, retinal depigmentation, optic neuritis</para>
					</section>
					<section type="none" id="sidelem4x10822">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Pancreatitis,</emphasis><emphasis style="italic">diarrhea, nausea,</emphasis> vomiting, <emphasis style="italic">abdominal pain,</emphasis> constipation, stomatitis, dyspepsia, liver abnormalities, flatulence, taste perversion, dry mouth, oral thrush, melena, increased ALT/AST, alk phos, amylase, <emphasis style="bold">hepatic failure,</emphasis> noncirrhotic portal hypertension</para>
					</section>
					<section type="none" id="sidelem4x10838">
						<sec_title>GU:</sec_title>
						<para> Increased bilirubin, uric acid</para>
					</section>
					<section type="none" id="sidelem4x10843">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, granulocytopenia, thrombocytopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10850">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> alopecia, ecchymosis, hemorrhage, petechiae, sweating</para>
					</section>
					<section type="none" id="sidelem4x10858">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthritis, myopathy, muscular atrophy</para>
					</section>
					<section type="none" id="sidelem4x10863">
						<sec_title>RESP:</sec_title>
						<para> Cough, pneumonia, dyspnea, asthma, epistaxis, hypoventilation, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x10868">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10875">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10878">
					<section type="none" id="sidelem4x10879">
						<sec_title>PO:</sec_title>
						<para> Peak 0.67 hr, del rel 2 hr; elimination half-life 48 min; extensive metabolism; administration within 5 min of food will decrease absorption (50%); excreted urine, feces</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10884">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> didanosine level—allopurinol, tenofovir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects from magnesium, aluminum antacids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pancreatitis risk—stavudine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—ketoconazole, dapsone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> concentrations of fluoroquinolones, other antiretrovirals, itraconazole, tetracyclines</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> fatal lactic acidosis—stavudine, tenofovir, other antiretrovirals</bbw>
				</para>
				<section type="none" id="sidelem4x10924">
					<label>•</label>
					<sec_title>Do not use with these products PO<route> gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin</route></sec_title>
				</section>
				<section type="none" id="sidelem4x10927">
					<section type="none" id="sidelem4x10928">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x10932">
								<item>
									<label>•</label>
									<para>Any food decreases rate of absorption 50%, do not use with food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use with acidic juices</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10943">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10946">
					<section type="none" id="sidelem4x10947">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Pancreatitis:</emphasis> do not use in those with symptoms of pancreatitis; may be dose related in advanced HIV, alcoholism, history of pancreatitis</bbw>
						</para>
						<section type="none" id="sidelem4x10966">
							<label>•</label>
							<sec_title>Peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x10966">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Peripheral neuropathy:</emphasis> tingling or pain in hands and feet, distal numbness; onset usually occurs 2-6 mo after beginning treatment, may persist if product not discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Lactic acidosis, severe hepatomegaly, pancreatitis:</emphasis> abdominal pain, nausea, vomiting, elevated hepatic enzymes; product should be discontinued because condition can be fatal</bbw>
						</para>
						<para>
							<list id="lidelem4x10982">
								<item>
									<label>•</label>
									<para>Children by dilated retinal exam q6mo to rule out retinal depigmentation</para>
								</item>
								<item>
									<label>•</label>
									<para>CBC, differential, platelet count monthly; notify prescriber of results; alk phos, monitor amylase; viral load, CD4 count</para>
								</item>
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr before, during therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Temperature may indicate beginning infection</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT) as needed, monthly</para>
								</item>
								<item>
									<label>•</label>
									<para>Clean up of powdered products; use wet mop or damp sponge</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11013">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11017">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of infection; symptoms of HIV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11023">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11028">
								<item>
									<label>•</label>
									<para>To avoid use with alcohol; not to take with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11033">
								<item>
									<label>•</label>
									<para>To report numbness/tingling in extremities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11038">
								<item>
									<label>•</label>
									<para>To take on an empty stomach; not to take dapsone at same time as ddI; not to mix powder with fruit juice; chew tab or crush and dissolve in water; to drink powder immediately after mixing</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11046">
							<label>•</label>
							<sec_title>infection</sec_title>
							<para>
								<list id="lidelem4x11046">
									<item>
										<label>•</label>
										<para>To report signs of <emphasis style="bold">infection:</emphasis> increased temperature, sore throat, flulike symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11054">
							<label>•</label>
							<sec_title>anemia</sec_title>
							<para>
								<list id="lidelem4x11054">
									<item>
										<label>•</label>
										<para>To report signs of <emphasis style="bold">anemia:</emphasis> fatigue, headache, faintness, SOB, irritability</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11062">
							<label>•</label>
							<sec_title>
								<route>bleeding;</route>
							</sec_title>
							<para>
								<list id="lidelem4x11062">
									<item>
										<label>•</label>
										<para>To report  to avoid use of razors, commercial mouthwash</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11067">
								<item>
									<label>•</label>
									<para>That hair may be lost during therapy (rare); that a wig or hairpiece may make patient feel better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11072">
								<item>
									<label>•</label>
									<para>That product does not cure, only controls symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="44" status="active">
			<mono_name>difluprednate (ophthalmic)</mono_name>
			<info>
				<pronunciation>(die-flu′pred-nate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x110820">Durezol</tradename>
				</tradenames>
				<class type="func"> Ophthalmic antiinflammatory</class>
				<class type="chem"> Corticosteroid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11092">
				<sec_title>Action:</sec_title>
				<para>Exact mechanism of antiinflammatory action unknown; inhibits multiple inflammatory cytokines; decreases release of arachidonic acid, which increases in inflammation</para>
			</section>
			<section type="uses" id="sidelem4x11097">
				<sec_title>Uses:</sec_title>
				<para>For the treatment of postoperative ocular pain and postoperative ocular inflammation; for the treatment of endogenous anterior uveitis</para>
			</section>
			<section type="contra" id="sidelem4x11102">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, glycerin, polysorbate, ocular TB, acute herpes simplex (superficial), fungal/viral infections of the eye</para>
				<section type="none" id="sidelem4x11107">
					<section type="none" id="sidelem4x11108">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, corneal infected abrasions, glaucoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11114">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11117">
					<section type="none" id="sidelem4x11118">
						<sec_title>Postoperative ocular pain, postoperative ocular inflammation</sec_title>
						<section type="none" id="sidelem4x11126">
							<label>•</label>
							<sec_title>Adult/geriatric/adolescents/children/infants<route> OPHTH</route></sec_title>
							<para>
								<list id="lidelem4x11126">
									<item>
										<label>•</label>
										<para> Instill 1 drop into the conjunctival sac of the affected eye(s) qid beginning 24 hr after surgery; continue giving 4 ×/day for the first 2 wk of the postoperative period, then administer bid × 1 wk; at the end of the third wk, taper dosage based on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11130">
						<sec_title>Endogenous anterior uveitis</sec_title>
						<section type="none" id="sidelem4x11138">
							<label>•</label>
							<sec_title>Adult<route> OPHTH</route></sec_title>
							<para>
								<list id="lidelem4x11138">
									<item>
										<label>•</label>
										<para> Instill 1 drop into the conjunctival sac of the affected eye(s) qid × 14 days, followed by tapering based on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11142">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic emulsion 0.05%</para>
					</section>
					<section type="none" id="sidelem4x11147">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11151">
								<item>
									<label>•</label>
									<para>Apply topically to the eye, shake well before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
								</item>
								<item>
									<label>•</label>
									<para>Instruct patient on proper instillation of eye sol</para>
								</item>
								<item>
									<label>•</label>
									<para>When using this product, the patient should not wear contact lenses</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11172">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11175">
					<section type="none" id="sidelem4x11176">
						<sec_title>EENT:</sec_title>
						<para> Burning, stinging, poor vision, corneal ulcerations, increased IOP, optic nerve damage</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11181">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11184">
					<section type="none" id="sidelem4x11185">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11193">
							<label>•</label>
							<sec_title>Corneal effects</sec_title>
							<para>
								<list id="lidelem4x11193">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Corneal effects:</emphasis> ulcerations, infections can worsen with this product, monitor IOP used IO over 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11197">
						<sec_title>Evaluate:</sec_title>
						<section type="none" id="sidelem4x11205">
							<label>•</label>
							<sec_title>Therapeutic response</sec_title>
							<para>
								<list id="lidelem4x11205">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Therapeutic response:</emphasis> Decreased corneal inflammation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11209">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11214">
								<item>
									<label>•</label>
									<para>How to use product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11219">
								<item>
									<label>•</label>
									<para>Not to share with others or use for other conditions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11227">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately if vision changes or if condition worsens</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11230">
								<item>
									<label>•</label>
									<para>To take as prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active" ha="yes">
			<mono_name> digoxin (Rx)</mono_name>
			<info>
				<pronunciation>(di-jox′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x112421">
						<country code="CAN">APO-Digoxin </country>
					</tradename>
					<tradename id="tnidelem4x112420">Lanoxin</tradename>
				</tradenames>
				<class type="func"> Cardiac glycoside, inotropic, antidysrhythmic</class>
				<class type="chem"> Digoxin preparation</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11255">
				<para>
					<confusion>
						<tradename id="tnidelem4x112550">Lanoxin</tradename>
						<drug type="generic" refid="idelem4x112550">Lasix/Lonox/Lomotil/Xanax/Levoxine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11259">
				<sec_title>Action:</sec_title>
				<para>Inhibits the sodium-potassium ATPase pump, which makes more calcium available for contractile proteins, thereby resulting in increased cardiac output (positive inotropic effect); increases force of contractions; decreases heart rate (negative chronotropic effect); decreases AV conduction speed</para>
			</section>
			<section type="uses" id="sidelem4x11264">
				<sec_title>Uses:</sec_title>
				<para>Heart failure, atrial fibrillation</para>
				<section type="none" id="sidelem4x11269">
					<section type="none" id="sidelem4x11270">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Atrial flutter, paroxysmal supraventricular tachycardia (PSVT) treatment/prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11275">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to digoxin, ventricular fibrillation, ventricular tachycardia</para>
				<section type="none" id="sidelem4x11280">
					<section type="none" id="sidelem4x11281">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal disease, acute MI, AV block, severe respiratory disease, hypothyroidism, sinus nodal disease, hypokalemia, carotid sinus syndrome, 2nd- or 3rd-degree heart block, electrolyte disturbances, hypertension, cor pulmonale, Wolff-Parkinson-White syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11286">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11289">
					<section type="none" id="sidelem4x11290">
						<sec_title>Loading dose, IV route</sec_title>
						<section type="none" id="sidelem4x11298">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;10 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11298">
									<item>
										<label>•</label>
										<para> 8-12 mcg/kg, divided into ≥3 doses, with the first dose equaling one-half the total, give subsequent doses every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11306">
							<label>•</label>
							<sec_title>Child 5-10 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11306">
									<item>
										<label>•</label>
										<para> 15-30 mcg/kg divided into ≥3 doses, with the first dose equaling one-half the total, give subsequent doses every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11313">
							<label>•</label>
							<sec_title>Child 2-4 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11313">
									<item>
										<label>•</label>
										<para> 25-35 mcg/kg, divided into ≥3 doses, with the first dose equaling one-half the total, give subsequent doses every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11320">
							<label>•</label>
							<sec_title>Infant/child &lt;2 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11320">
									<item>
										<label>•</label>
										<para> 30-50 mcg/kg, divided into ≥3 doses, with the first dose equaling one-half the total, give subsequent doses every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11327">
							<label>•</label>
							<sec_title>Full-term neonate<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11327">
									<item>
										<label>•</label>
										<para> 20-30 mcg/kg, divided into ≥3 doses, with the first dose equaling one-half the total, give subsequent doses every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11334">
							<label>•</label>
							<sec_title>Premature neonate<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11334">
									<item>
										<label>•</label>
										<para> 15-25 mcg/kg, divided into ≥3 doses, with the first dose equaling one-half the total, give subsequent doses every 6-8 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11338">
						<sec_title>Loading dose, PO (tablets):</sec_title>
						<section type="none" id="sidelem4x11347">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11347">
									<item>
										<label>•</label>
										<para> Total dosage of 10-15 mcg/kg in 3 divided doses, give one-half the total loading dose initially, then one-fourth the loading dose every 4-8 hr × 2 doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11354">
							<label>•</label>
							<sec_title>Child 5-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11354">
									<item>
										<label>•</label>
										<para> Total dosage of 20-45 mcg/kg in 3 divided doses, give one-half the total loading dose initially, then one-fourth the loading dose every 4-8 hr × 2 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11358">
						<sec_title>Loading dose, PO (elixir):</sec_title>
						<section type="none" id="sidelem4x11367">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11367">
									<item>
										<label>•</label>
										<para> Total dosage of 10-15 mcg/kg, give one-half the total loading dose initially, then additional fractions of the planned total dose at 4-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11374">
							<label>•</label>
							<sec_title>Child 5-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11374">
									<item>
										<label>•</label>
										<para> Total dosage of 20-35 mcg/kg, give one-half the total loading dose initially, then additional fractions of the planned total dose at 4-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11381">
							<label>•</label>
							<sec_title>Child 2-4 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11381">
									<item>
										<label>•</label>
										<para> Total dosage of 30-45 mcg/kg, give one-half the total loading dose initially, then additional fractions of the planned total dose at 4-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11388">
							<label>•</label>
							<sec_title>Infant/child &lt;2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11388">
									<item>
										<label>•</label>
										<para> Total dosage of 35-60 mcg/kg, give one-half the total loading dose initially, then additional fractions of the planned total dose at 4-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11395">
							<label>•</label>
							<sec_title>Full-term neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11395">
									<item>
										<label>•</label>
										<para> Total dosage of 25-35 mcg/kg, give one-half the total loading dose initially, then additional fractions of the planned total dose at 4-8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11402">
							<label>•</label>
							<sec_title>Premature neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11402">
									<item>
										<label>•</label>
										<para> Total dosage of 20-30 mcg/kg, give one-half the total loading dose initially, then additional fractions of the planned total dose at 4-8 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11406">
						<sec_title>Maintenance dose, IV</sec_title>
						<section type="none" id="sidelem4x11414">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11414">
									<item>
										<label>•</label>
										<para> 125-350 mcg/day, depending on CrCl, usual daily maintenance dosage for CHF based on corrected CrCl (ml/min/70 kg) and lean body weight (LBW) are listed below</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11418">
								<item>
									<label>•</label>
									<para>LBW 50-59 kg: CrCl ≥100 ml/min: 175 mcg/day; CrCl 70-99 ml/min: 150 mcg/day; CrCl 60-69 ml/min: 125 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11423">
								<item>
									<label>•</label>
									<para>LBW 60-69 kg: CrCl ≥90 ml/min: 200 mcg/day; CrCl 70-89 ml/min: 175 mcg/day; CrCl 60-69 ml/min: 150 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11428">
								<item>
									<label>•</label>
									<para>LBW 70-79 kg: CrCl ≥100 ml/min: 250 mcg/day; CrCl 90-99 ml/min: 225 mcg/day; CrCl 70-89 ml/min: 200 mcg/day; CrCl 60-69 ml/min: 175 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11433">
								<item>
									<label>•</label>
									<para>LBW 80-89 kg: CrCl ≥100 ml/min: 275 mcg/day; CrCl 80-99 ml/min: 250 mcg/day; CrCl 70-79 ml/min: 225 mcg/day; CrCl 60-69 ml/min: 200 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11438">
								<item>
									<label>•</label>
									<para>LBW 90-99 kg: CrCl ≥90 ml/min: 300 mcg/day; CrCl 80-89 ml/min: 275 mcg/day; CrCl 70-79 ml/min: 250 mcg/day; CrCl 60-69 ml/min: 225 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11443">
								<item>
									<label>•</label>
									<para>LBW ≥100 kg: CrCl ≥100 ml/min: 350 mcg/day; CrCl 90-99 ml/min: 325 mcg IV/day; CrCl 80-89 ml/min: 300 mcg/day; CrCl 70-79 ml/min: 275 mcg IV/day; CrCl 60-69 ml/min: 250 mcg/day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11451">
							<label>•</label>
							<sec_title>Full-term neonate to child &gt;10 yr</sec_title>
							<para>
								<list id="lidelem4x11451">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Full-term neonate to child &gt;10 yr:</emphasis> 25%-35% of the IV digitalizing dose bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11455">
						<sec_title>Maintenance dose, PO (tablets)</sec_title>
						<section type="none" id="sidelem4x11463">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11463">
									<item>
										<label>•</label>
										<para> 3.4-5.1 mcg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11467">
								<item>
									<label>•</label>
									<para>LBW 40-49 kg: CrCl ≥70 ml/min: 187.5 mcg/day; CrCl ≥60-69 ml/min: 125 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11473">
								<item>
									<label>•</label>
									<para>LBW 50-59 kg: CrCl ≥90 ml/min: 250 mcg/day; CrCl 60-89 ml/min: 187.5 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11478">
								<item>
									<label>•</label>
									<para>LBW 60-69 kg: CrCl ≥100 ml/min: 312.5 mcg/day; CrCl 60-99 ml/min: 250 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11483">
								<item>
									<label>•</label>
									<para>LBW 70-79 kg: CrCl ≥80 ml/min: 312.5 mcg/day; CrCl 60-79 ml/min: 250 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11488">
								<item>
									<label>•</label>
									<para>LBW 80-89 kg: CrCl ≥90 ml/min: 375 mcg/day; CrCl 60-89 ml/min: 312.5 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11493">
								<item>
									<label>•</label>
									<para>LBW 90-99 kg: CrCl ≥90 ml/min: 437.5 mcg/day; CrCl 70-89 ml/min: 375 mcg/day; CrCl 60-69 ml/min: 312.5 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11498">
								<item>
									<label>•</label>
									<para>LBW ≥100 kg: CrCl ≥100 ml/min: 500 mcg/day; CrCl 80-99 ml/min: 437.5 mcg/day; CrCl 60-79 ml/min: 375 mcg/day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11506">
							<label>•</label>
							<sec_title>Child 5-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11506">
									<item>
										<label>•</label>
										<para> 6.4-12.9 mcg/kg/day in 2 divided doses is recommended starting maintenance dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11510">
						<sec_title>Maintenance dose, PO (elixir)</sec_title>
						<section type="none" id="sidelem4x11518">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11518">
									<item>
										<label>•</label>
										<para> 3-4.5 mcg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11522">
								<item>
									<label>•</label>
									<para>LBW 40-49 kg: CrCl ≥100 ml/min: 170 mcg/day; CrCl 90-99 ml/min: 160 mcg/day; CrCl 80-89 ml/min: 150 mcg/day; CrCl 70-79 ml/min: 140 mcg/day; CrCl 60-69 ml/min: 130 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11527">
								<item>
									<label>•</label>
									<para>LBW 50-59 kg: CrCl ≥100 ml/min: 213 mcg/day; CrCl 90-99 ml/min: 200 mcg/day; CrCl 80-89 ml/min: 188 mcg/day; CrCl 70-79 ml/min: 175 mcg/day; CrCl 60-69 ml/min: 163 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11532">
								<item>
									<label>•</label>
									<para>LBW 60-69 kg: CrCl ≥100 ml/min: 255 mcg/day; CrCl 90-99 ml/min: 240 mcg/day; CrCl 80-89 ml/min: 225 mcg/day; CrCl 70-79 ml/min: 210 mcg/day; CrCl 60-69 ml/min: 195 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11537">
								<item>
									<label>•</label>
									<para>LBW 70-79 kg: CrCl ≥100 ml/min: 298 mcg/day; CrCl 90-99 ml/min: 280 mcg/day; CrCl 80-89 ml/min: 263 mcg/day; CrCl 70-79 ml/min: 245 mcg/day; CrCl 60-69 ml/min: 228 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11542">
								<item>
									<label>•</label>
									<para>LBW 80-89 kg: CrCl ≥100 ml/min: 340 mcg/day; CrCl 90-99 ml/min: 320 mcg/day; CrCl 80-89 ml/min: 300 mcg/day; CrCl 70-79 ml/min: 280 mcg/day; CrCl 60-69 ml/min: 260 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11547">
								<item>
									<label>•</label>
									<para>LBW 90-99 kg: CrCl ≥100 ml/min: 383 mcg/day; CrCl 90-99 ml/min: 360 mcg/day; CrCl 80-89 ml/min: 338 mcg/day; CrCl 70-79 ml/min: 315 mcg/day; CrCl 60-69 ml/min: 293 mcg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11552">
								<item>
									<label>•</label>
									<para>LBW ≥100 kg: CrCl ≥100 ml/min: 425 mcg/day; CrCl 90-99 ml/min: 400 mcg/day; CrCl 80-89 ml/min: 375 mcg/day; CrCl 70-79 ml/min: 350 mcg/day; CrCl 60-69 ml/min: 325 mcg/day</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11560">
							<label>•</label>
							<sec_title>Child 5-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11560">
									<item>
										<label>•</label>
										<para> 5.6-11.3 mcg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11567">
							<label>•</label>
							<sec_title>Child 2-4 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11567">
									<item>
										<label>•</label>
										<para> 9.4-13.1 mcg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11574">
							<label>•</label>
							<sec_title>Infant/child &lt;2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11574">
									<item>
										<label>•</label>
										<para> 11.3-18.8 mcg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11581">
							<label>•</label>
							<sec_title>Full-term neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11581">
									<item>
										<label>•</label>
										<para> 7.5-11.3 mcg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11588">
							<label>•</label>
							<sec_title>Preterm neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11588">
									<item>
										<label>•</label>
										<para> 4.7-7.8 mcg/kg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11593">
						<sec_title>Renal dose, IV route</sec_title>
						<section type="none" id="sidelem4x11601">
							<label>•</label>
							<sec_title>CrCl 50-59 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11607">
							<label>•</label>
							<sec_title>CrCl 40-49 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11613">
							<label>•</label>
							<sec_title>CrCl 30-39 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11619">
							<label>•</label>
							<sec_title>CrCl 20-29 ml/min<route> LBW 50-69 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11625">
							<label>•</label>
							<sec_title>CrCl 10-19 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11631">
							<label>•</label>
							<sec_title>CrCl &lt;10 ml/min LBW 50-69 kg<route> 75 mcg 1× daily; LBW 70-89 kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11634">
						<sec_title>Renal dose, PO (tablets)</sec_title>
						<section type="none" id="sidelem4x11642">
							<label>•</label>
							<sec_title>CrCl 40-59 ml/min<route> LBW 50-69 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11648">
							<label>•</label>
							<sec_title>CrCl 30-39 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11654">
							<label>•</label>
							<sec_title>CrCl 20-29 ml/min<route> LBW 50-69 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11660">
							<label>•</label>
							<sec_title>CrCl &lt;20 ml/min<route> LBW 50-69 kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11663">
						<sec_title>Renal dose, PO (elixir)</sec_title>
						<section type="none" id="sidelem4x11671">
							<label>•</label>
							<sec_title>CrCl 50-59 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11677">
							<label>•</label>
							<sec_title>CrCl 40-49 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11683">
							<label>•</label>
							<sec_title>CrCl 30-39 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11689">
							<label>•</label>
							<sec_title>CrCl 20-29 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11695">
							<label>•</label>
							<sec_title>CrCl &lt;20 ml/min<route> LBW 50-59 kg</route></sec_title>
						</section>
						<para>
							<emphasis alert="lifethreat">The daily maintenance dose can also be estimated using patient CrCl and loading dose (LD) according to the method of Jelliffe and Brooker: Daily % loss = 14 + CrCl/5</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x11701">
						<sec_title>Available forms:</sec_title>
						<para> Elix 0.05 mg/ml; tabs 0.0625, 0.125, 0.1875, 0.25, 0.5 mg; inj 0.5 <country code="CAN">FIX_STRUCTURE Elix 0.05 mg/ml; tabs 0.0625, 0.125, 0.1875, 0.25, 0.5 mg; inj 0.5 </country>, 0.25 mg/ml; pediatric inj 0.1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11709">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11712">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11718">
									<item>
										<para>
											<emphasis alert="nurse">Bioavailability varies among different oral dosage forms of digoxin and among different brands of the same dosage form; changing from one preparation to another might require dosage adjustments</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11726">
								<label>•</label>
								<sec_title>All dosage forms</sec_title>
								<para>
									<list id="lidelem4x11726">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">All dosage forms:</emphasis> may be administered without regard to meals</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11733">
								<label>•</label>
								<sec_title>Tab</sec_title>
								<para>
									<list id="lidelem4x11733">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Tab:</emphasis> may be crushed and administered with food or fluids</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11740">
								<label>•</label>
								<sec_title>Pediatric elixir</sec_title>
								<para>
									<list id="lidelem4x11740">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Pediatric elixir:</emphasis> administer using a calibrated measuring device</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x11744">
							<sec_title>Injectable</sec_title>
							<para>
								<list id="lidelem4x11748">
									<item>
										<label>•</label>
										<para>When changing from PO to IM/IV use 20%-25% less</para>
									</item>
									<item>
										<label>•</label>
										<para>IV is preferred over IM because it is less painful and more rapid action</para>
									</item>
									<item>
										<label>•</label>
										<para>PO should replace parenteral therapy as soon as possible</para>
									</item>
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11769">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x11773">
									<item>
										<label>•</label>
										<para>Do not administer &gt;2 ml at any one IM injection site</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject deeply into gluteal muscle, then massage area</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11784">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x11788">
									<item>
										<label>•</label>
										<para>May be given undiluted or each 1 ml may be diluted in 4 ml of sterile water for injection, NS, D<emphasis style="inf">5</emphasis>W, or LR; diluent volumes &lt;4 ml will cause precipitation; use diluted solutions immediately</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject over ≥5 min via <emphasis style="sans-serif">Y</emphasis>-site or 3-way stopcock; in patients with pulmonary edema, administer over 10-15 min; to avoid inadvertent overdosage, do not flush the syringe following administration</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Cimetidine, furosemide, lidocaine, potassium chloride, ranitidine, verapamil</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Heparin, milrinone</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, ceFAZolin, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, indomethacin, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, meperidine, meropenem, methicillin, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, morphine, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, nesiritide, metilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11818">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11821">
					<section type="none" id="sidelem4x11822">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> drowsiness, apathy, confusion, disorientation, fatigue, depression, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x11830">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias,</emphasis><emphasis style="italic">hypotension,</emphasis> bradycardia, <emphasis style="bold">AV block</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11842">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, yellow-green halos, photophobia, diplopia</para>
					</section>
					<section type="none" id="sidelem4x11847">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, abdominal pain, diarrhea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11852">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 30-40 hr, excreted in urine, protein binding 20%-30%</para>
				<section type="none" id="sidelem4x11857">
					<section type="none" id="sidelem4x11858">
						<sec_title>PO:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, peak 2-6 hr, duration 3-4 days</para>
					</section>
					<section type="none" id="sidelem4x11869">
						<sec_title>IV:</sec_title>
						<para> Onset 5-30 min, peak 1-4 hr, duration variable</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11874">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—azole antifungals, macrolides, tetracyclines, ritonavir</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hypercalcemia, hypomagnesemia, digoxin toxicity—thiazides, parenteral calcium</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hypokalemia, digoxin toxicity—diuretics, amphotericin B, carbenicillin, ticarcillin, corticosteroids</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin levels—propantheline, quiNIDine, verapamil, amiodarone, anticholinergics, diltiazem, NIFEdipine, indomethacin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia—β-adrenergic blockers, antidysrythmics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiac dysrhythmia risk—sympathomimetics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> digoxin absorption—antacids, kaolin/pectin, cholestyramine, metoclopramide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> digoxin level—thyroid agents, cholestyramine, colestipol, metoclopramide, aMILoride</para>
				<section type="none" id="sidelem4x11907">
					<section type="none" id="sidelem4x11908">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> digoxin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> GI absorption—flaxseed, psyllium</para>
					</section>
					<section type="none" id="sidelem4x11919">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> product effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x11926">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11933">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11936">
					<section type="none" id="sidelem4x11937">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11941">
								<item>
									<label>•</label>
									<para>Apical pulse for 1 min before giving product; if pulse &lt;60 in adult or &lt;90 in infant, take again in 1 hr; if &lt;60 in adult, call prescriber; note rate, rhythm, character; monitor ECG continuously during parenteral loading dose</para>
								</item>
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride, magnesium, calcium; renal function studies: BUN, creatinine; blood studies: ALT, AST, bilirubin, Hct, Hgb before initiating treatment and periodically thereafter</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor product levels; therapeutic level 0.5-2 ng/ml, draw ≥6-8 hr after last dose, optimally 12-24 hr after a dose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11957">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11961">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased weight, edema, pulse, respiration, crackles; increased urine output; serum digoxin level (0.5-2 ng/ml)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11967">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11972">
								<item>
									<label>•</label>
									<para>Not to stop product abruptly; about all aspects of product; to take exactly as ordered; how to monitor heart rate</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11977">
								<item>
									<label>•</label>
									<para>To avoid OTC medications, herbal remedies because many adverse product interactions may occur; not to take antacid at same time</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11985">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of loss of appetite, lower stomach pain, diarrhea, weakness, drowsiness, headache, blurred or yellow vision, rash, depression, toxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11988">
								<item>
									<label>•</label>
									<para>About the toxic symptoms of this product; when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11993">
								<item>
									<label>•</label>
									<para>To maintain a sodium-restricted diet as ordered</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11998">
								<item>
									<label>•</label>
									<para>To use one brand consistently</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active" ru="yes">
			<mono_name> digoxin immune FAB (ovine) (Rx)</mono_name>
			<info>
				<pronunciation>(di-jox′in im-myoon′ FAB)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x120150">DigiFab</tradename>
				</tradenames>
				<class type="func"> Antidote—digoxin specific</class>
			</info>
			<section type="uses" id="sidelem4x12021">
				<sec_title>Uses:</sec_title>
				<para>Life-threatening digoxin toxicity</para>
			</section>
			<section type="contra" id="sidelem4x12026">
				<sec_title>Contraindications:</sec_title>
				<para>Mild digoxin toxicity, hypersensitivity to this product, papain or ovine protein</para>
			</section>
			<section type="doses" id="sidelem4x12031">
				<sec_title>Dosage and routes</sec_title>
				<para>1 (40 mg) DigiFab binds 0.5 mg digoxin</para>
				<section type="none" id="sidelem4x12036">
					<section type="none" id="sidelem4x12037">
						<sec_title>Digoxin toxicity (known amount) (tabs, oral sol, IM)</sec_title>
						<section type="none" id="sidelem4x12045">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12045">
									<item>
										<label>•</label>
										<para> dose (mg) = dose ingested (mg) × 0.8/1000 × 38- or 40-mg vial</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12049">
						<sec_title>Toxicity (known amount) (cap, IV)</sec_title>
						<section type="none" id="sidelem4x12057">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12057">
									<item>
										<label>•</label>
										<para> dose = dose ingested (mg)/0.5 × 38- or 40-mg vial</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12061">
						<sec_title>Toxicity (known amount) by serum digoxin concentrations (SDCs)</sec_title>
						<section type="none" id="sidelem4x12069">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12069">
									<item>
										<label>•</label>
										<para> SDC (ng/ml) × kg of weight/100 × 38- or 40-mg vial</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12073">
						<sec_title>Digoxin toxicity (unknown amount)</sec_title>
						<section type="none" id="sidelem4x12081">
							<label>•</label>
							<sec_title>Adult and child &gt;20 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12081">
									<item>
										<label>•</label>
										<para> 228 mg (6 vials)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12088">
							<label>•</label>
							<sec_title>Infant and child &lt;20 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12088">
									<item>
										<label>•</label>
										<para> 38 mg (1 vial)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12092">
						<sec_title>Acute ingestion</sec_title>
						<section type="none" id="sidelem4x12100">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12100">
									<item>
										<label>•</label>
										<para> 380 mg (10 vials)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12104">
						<sec_title>Life-threatening ingestion</sec_title>
						<section type="none" id="sidelem4x12112">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12112">
									<item>
										<label>•</label>
										<para> 760 mg (20 vials)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12117">
						<sec_title>Skin test</sec_title>
						<section type="none" id="sidelem4x12125">
							<label>•</label>
							<sec_title>Adult<route> ID</route></sec_title>
							<para>
								<list id="lidelem4x12125">
									<item>
										<label>•</label>
										<para> 0.1 ml of 1:100 dilution check after 20 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="47" status="active" ha="yes">
			<mono_name> diltiazem (Rx)</mono_name>
			<info>
				<pronunciation>(dil-tye′a-zem)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x1213611">
						<country code="CAN">Apo-Diltiaz </country>
					</tradename>
					<tradename id="tnidelem4x1213610">Cardizem</tradename>
					<tradename id="tnidelem4x121369">Cardizem CD</tradename>
					<tradename id="tnidelem4x121368">Cardizem LA</tradename>
					<tradename id="tnidelem4x121367">Cartia XT</tradename>
					<tradename id="tnidelem4x121366">Dilacor-XR</tradename>
					<tradename id="tnidelem4x121365">Dilt-CD</tradename>
					<tradename id="tnidelem4x121364">Diltia XR</tradename>
					<tradename id="tnidelem4x121363">Diltia XT</tradename>
					<tradename id="tnidelem4x121362">Diltzac</tradename>
					<tradename id="tnidelem4x121361">Taztia XT</tradename>
					<tradename id="tnidelem4x121360">Tiazac</tradename>
				</tradenames>
				<class type="func"> Calcium channel blocker, antiarrhythmic class IV, antihypertensive</class>
				<class type="chem"> Benzothiazepine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12149">
				<para>
					<confusion>
						<tradename id="tnidelem4x121490">Cardizem</tradename>
						<drug type="generic" refid="idelem4x121490">Cardene</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12153">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle, dilates coronary arteries, slows SA/AV node conduction times, dilates peripheral arteries</para>
			</section>
			<section type="uses" id="sidelem4x12158">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">PO</emphasis> angina pectoris due to coronary artery spasm, hypertension, <emphasis style="bold">IV</emphasis> atrial fibrillation, flutter, paroxysmal supraventricular tachycardia</para>
				<section type="none" id="sidelem4x12168">
					<section type="none" id="sidelem4x12169">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Unstable angina, proteinuria, cardiomyopathy, diabetic neuropathy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12174">
				<sec_title>Contraindications:</sec_title>
				<para>Sick sinus syndrome, AV heart block, hypotension &lt;90 mm Hg systolic, acute MI, pulmonary congestion, cardiogenic shock</para>
				<section type="none" id="sidelem4x12179">
					<section type="none" id="sidelem4x12180">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, aortic stenosis, bradycardia, GERD, hepatic disease, hiatal hernia, ventricular dysfunction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12185">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12188">
					<section type="none" id="sidelem4x12189">
						<sec_title>Prinzmetal’s or variant angina, chronic stable angina</sec_title>
						<section type="none" id="sidelem4x12197">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12197">
									<item>
										<label>•</label>
										<para> 30 mg qid, increasing dose gradually to 180-360 mg/day in divided doses or  (LA, CD, XT, XR products) 180-360 mg, max 480-540 mg/day, depending on brand</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12204">
						<sec_title>Atrial fibrillation/flutter, paroxysmal supraventricular tachycardia</sec_title>
						<section type="none" id="sidelem4x12212">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x12212">
									<item>
										<label>•</label>
										<para> 0.25 mg/kg over 2 min initially, then 0.35 mg/kg may be given after 15 min; if no response, may give  5-15 mg/hr for up to 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12219">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x12227">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12227">
									<item>
										<label>•</label>
										<para> 30 mg TID, increase to max 480 mg/day;  120-240 mg q day, max 540 mg/day;  60 mg bid, max 360 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12237">
						<sec_title>Rapid ventricular rate secondary to dysrhythmias (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12245">
							<label>•</label>
							<sec_title>Adolescent/child/infant &gt;7 mo<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x12245">
									<item>
										<label>•</label>
										<para> 0.25 mg/kg over 5 min, then  0.11 mg/kg/hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12252">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 30, 60, 90, 120 mg; ext rel tabs 120, 180, 240, 300, 360, 420 mg; ext rel caps 60, 90, 120, 180, 240, 300, 360, 420 mg; inj 5 mg/ml (5, 10 ml); powder for inj 100 mg</para>
					</section>
					<section type="none" id="sidelem4x12257">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x12260">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x12268">
								<label>•</label>
								<sec_title>
									<route>Not all products are interchangeable</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x12271">
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x12279">
								<label>•</label>
								<sec_title>
									<route>Cardiazem LA</route>
								</sec_title>
								<para>
									<list id="lidelem4x12279">
										<item>
											<label>•</label>
											<para> ext rel tab 24 hr: give daily, either <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis>, without regard to meals</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12292">
								<label>•</label>
								<sec_title>
									<route>Dilacor XR/Diltia XT</route>
								</sec_title>
								<para>
									<list id="lidelem4x12292">
										<item>
											<label>•</label>
											<para> ext rel cap 24 hr: give daily; take on empty stomach; swallow whole; do not cut, crush, chew, open</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12299">
								<label>•</label>
								<sec_title>Tiazac, Tiztia XT</sec_title>
								<para>
									<list id="lidelem4x12299">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Tiazac, Tiztia XT:</emphasis> give daily without regard to meals</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12306">
								<label>•</label>
								<sec_title>Conventional regular-rel tab</sec_title>
								<para>
									<list id="lidelem4x12306">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Conventional regular-rel tab:</emphasis> give before meals, at bedtime</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x12313">
								<label>•</label>
								<sec_title>Cardizem CD or equivalent (Cartia XT)</sec_title>
								<para>
									<list id="lidelem4x12313">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cardizem CD or equivalent (Cartia XT):</emphasis> generic ext rel cap 24 hr: give daily, without regard to meals</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x12317">
									<item>
										<label>•</label>
										<para>May crush, sprinkle regular tab on applesauce for administration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12323">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x12327">
									<item>
										<label>•</label>
										<para>IV undiluted over 2 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12333">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x12337">
									<item>
										<label>•</label>
										<para>Diluted 125 mg/100 ml, 250 mg/250 ml of D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, D<emphasis style="inf">5</emphasis>/0.45% NaCl, give 10 mg/hr, may increase by 5 mg/hr to 15 mg/hr, continue infusion up to 24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Albumin, amikacin, amphotericin B, aztreonam, bumetanide, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, cefTRIAXone, cefuroxime, cimetidine, ciprofloxacin, clindamycin, digoxin, DOBUTamine, DOPamine, doxycycline, EPINEPHrine, erythromycin, esmolol, fentaNYL, fluconazole, gentamicin, hetastarch, HYDROmorphone, imipenem-cilastatin, labetalol, lidocaine, LORazepam, meperidine, metoclopramide, metroNIDAZOLE, midazolam, milrinone, morphine, multivitamins, niCARdipine, nitroglycerin, norepinephrine, oxacillin, penicillin G potassium, pentamidine, piperacillin, potassium chloride, potassium phosphates, ranitidine, sodium nitroprusside, theophylline, ticarcillin, ticarcillin/clavulanate, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vecuronium</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12353">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12356">
					<section type="none" id="sidelem4x12357">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fatigue, drowsiness,</emphasis> dizziness, depression, weakness, insomnia, tremor, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x12365">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmia,</emphasis><emphasis style="italic">edema,</emphasis><emphasis style="bold">CHF,</emphasis> bradycardia, hypotension, palpitations, <emphasis style="bold">heart block</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12379">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, gastric upset, <emphasis style="italic">constipation</emphasis>, increased LFTs</para>
					</section>
					<section type="none" id="sidelem4x12390">
						<sec_title>GU:</sec_title>
						<para> Nocturia, polyuria, <emphasis style="bold">acute renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12397">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> flushing, photosensitivity, burning, pruritus at inj site</para>
					</section>
					<section type="none" id="sidelem4x12405">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, dyspnea, pharyngitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12410">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 30-60 min; peak 2-3 hr immediate rel, 10-14 hr ext rel, 11-18 hr sus rel; half-life 3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-9 hr; metabolized by liver; excreted in urine (96% as metabolites)</para>
			</section>
			<section type="interactions" id="sidelem4x12421">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect, toxicity—theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of β-blockers, digoxin, lithium, carBAMazepine, cycloSPORINE, anesthetics, HMG-CoA reductase inhibitors, benzodiazepines, lovastatin, methylPREDNISolone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of diltiazem—cimetidine</para>
			</section>
			<section type="considerations" id="sidelem4x12436">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12439">
					<section type="none" id="sidelem4x12440">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12448">
							<label>•</label>
							<sec_title>CHF<route> dyspnea, weight gain, edema, jugular venous distention, rales; monitor I&amp;O ratios daily, weight</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12454">
							<label>•</label>
							<sec_title>Angina</sec_title>
							<para>
								<list id="lidelem4x12454">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Angina:</emphasis> location, duration, alleviating factors, activity when pain starts</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12461">
							<label>•</label>
							<sec_title>Dysrhythmias<route> cardiac status</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12464">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12468">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anginal pain, decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12474">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12479">
								<item>
									<label>•</label>
									<para>How to take pulse, B/P before taking product; that a record or graph should be kept</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12484">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness is no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12489">
								<item>
									<label>•</label>
									<para>To limit caffeine consumption; to avoid grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12494">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12499">
								<item>
									<label>•</label>
									<para>About the importance of complying with all areas of medical regimen: diet, exercise, stress reduction, product therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12504">
								<item>
									<label>•</label>
									<para>To change position slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12510">
								<item>
									<para>
										<emphasis alert="nurse">To report dizziness, SOB, palpitations</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12518">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue abruptly</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="48" status="active">
			<mono_name>dimenhyDRINATE (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(dye-men-hye′dri-nate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x125353">
						<country code="CAN">Apo-DimenhyDRINATE </country>
					</tradename>
					<tradename id="tnidelem4x125352">Dramamine</tradename>
					<tradename id="tnidelem4x125351">Driminate</tradename>
					<tradename id="tnidelem4x125350">
						<country code="CAN">Gravol </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="2" status="active">
			<mono_name>Motion Sickness</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x125451">TripTone</tradename>
					<tradename id="tnidelem4x125450">Wal-Dram</tradename>
				</tradenames>
				<class type="func"> Antiemetic, anti-histamine, anticholinergic</class>
				<class type="chem"> H-receptor antagonist, ethanolamine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12558">
				<para>
					<confusion>
						<tradename id="tnidelem4x125580">dimenhyDRINATE</tradename>
						<drug type="generic" refid="idelem4x125580">diphenhydrAMINE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12563">
				<sec_title>Action:</sec_title>
				<para>Competes with histamine for H<emphasis style="inf">1</emphasis> receptors in GI tract, blood vessels, respiratory tract; central anticholinergic activity, which results in decreased vestibular stimulation and blockade of chemoreceptor trigger zone</para>
			</section>
			<section type="uses" id="sidelem4x12571">
				<sec_title>Uses:</sec_title>
				<para>Motion sickness, nausea, vomiting, vertigo</para>
				<section type="none" id="sidelem4x12576">
					<section type="none" id="sidelem4x12577">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hyperemesis gravidarum, Ménière’s syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12582">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, infants, neonates, tartrazine dye hypersensitivity</para>
				<section type="none" id="sidelem4x12587">
					<section type="none" id="sidelem4x12588">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, cardiac dysrhythmias, asthma, prostatic hypertrophy, bladder-neck obstruction, closed-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12593">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12601">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12601">
							<item>
								<label>•</label>
								<para> 50-100 mg q4hr;  50 mg q4hr as needed (Canada only)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12611">
					<label>•</label>
					<sec_title>Child 6-12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12611">
							<item>
								<label>•</label>
								<para> 25-50 mg q6-8hr prn, max 150 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12618">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12618">
							<item>
								<label>•</label>
								<para> 12.5-25 mg q6-8hr, max 75 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12622">
					<section type="none" id="sidelem4x12623">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg; inj 50 mg/ml <country code="CAN">FIX_STRUCTURE Tabs 50 mg; inj 50 mg/ml </country>; elixir 15 mg/5 ml <country code="CAN">FIX_STRUCTURE; elixir 15 mg/5 ml </country>; chew tabs 50 mg</para>
					</section>
					<section type="none" id="sidelem4x12634">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12638">
								<item>
									<label>•</label>
									<para>IM inj in large muscle mass; aspirate to avoid IV administration (Canada only)</para>
								</item>
								<item>
									<label>•</label>
									<para>Tablets may be swallowed whole, chewed, or allowed to dissolve</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12649">
							<sec_title>IV route (Canada only)</sec_title>
							<para>
								<list id="lidelem4x12653">
									<item>
										<label>•</label>
										<para>After diluting 50 mg/10 ml of NaCl inj, give ≤50 mg over 2 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12659">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12662">
					<section type="none" id="sidelem4x12663">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness,</emphasis> restlessness, headache, dizziness, insomnia, confusion, nervousness, tingling, vertigo</para>
					</section>
					<section type="none" id="sidelem4x12671">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="italic">hypotension</emphasis>, palpitation</para>
					</section>
					<section type="none" id="sidelem4x12679">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Dry mouth,</emphasis> blurred vision, diplopia, nasal congestion, photosensitivity, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x12687">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, vomiting, <emphasis style="italic">constipation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12694">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, fever, chills, flushing</para>
					</section>
					<section type="none" id="sidelem4x12699">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12706">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x12709">
					<section type="none" id="sidelem4x12710">
						<sec_title>PO/IM:</sec_title>
						<para> Onset 15-30 min, duration 4-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12715">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect—alcohol, anticholinergic, tricyclics, MAOIs, opiates, sedative/hypnotics, other CNS depressants</para>
				<section type="none" id="sidelem4x12722">
					<section type="none" id="sidelem4x12723">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> Allergy skin testing</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12730">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12733">
					<section type="none" id="sidelem4x12734">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12739">
								<item>
									<label>•</label>
									<para>VS, B/P; check patients with cardiac disease more often</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12747">
							<label>•</label>
							<sec_title>Signs of toxicity of other products or masking of symptoms of disease<route> brain tumor, intestinal obstruction</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12750">
								<item>
									<label>•</label>
									<para>Observe for drowsiness, dizziness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12755">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12759">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting, or vertigo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12766">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12770">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities, activities requiring alertness because dizziness may occur; to request assistance with ambulation</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="1" status="active">
			<mono_name>dimethyl fumarate (Rx)</mono_name>
			<info>
				<pronunciation>(dahy-meth’ul fyoo’ muh-reyt)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x127870">Tecfidera</tradename>
				</tradenames>
				<class type="func"> Immunomodulator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x12793">
				<sec_title>Action:</sec_title>
				<para>Has beneficial effects on inflammation and oxidative stress. Induces an antioxidant effect–related neuronal death, and damage to myelin in the CNS may also improve mitochondrial function.</para>
			</section>
			<section type="uses" id="sidelem4x12798">
				<sec_title>Uses:</sec_title>
				<para>Relapsing multiple sclerosis</para>
			</section>
			<section type="contra" id="sidelem4x12803">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x12808">
					<section type="none" id="sidelem4x12809">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, immunosuppression, infertility, male-mediated teratogenicity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12814">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12822">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12822">
							<item>
								<label>•</label>
								<para> 120 mg bid × 7 days, may increase to 240 mg bid for maintenance</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12826">
					<section type="none" id="sidelem4x12827">
						<sec_title>Available forms: </sec_title>
						<para>Caps, del rel 120, 240 mg</para>
					</section>
					<section type="none" id="sidelem4x12832">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12836">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew, do not open cap; give without regard to meals, use with food may decrease flushing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12842">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12845">
					<section type="none" id="sidelem4x12846">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Flushing</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x12852">
						<sec_title>GI: </sec_title>
						<para>Nausea, dyspepsia, abdominal pain, diarrhea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x12857">
						<sec_title>GU: </sec_title>
						<para>Albuminuria</para>
					</section>
					<section type="none" id="sidelem4x12862">
						<sec_title>INTEG: </sec_title>
						<para>Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x12867">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Lymphopenia, leukopenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x12873">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Anaphylaxis</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12879">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1 hr, peak 2<emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr</para>
			</section>
			<section type="interactions" id="sidelem4x12890">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">None known</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x12896">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12899">
					<section type="none" id="sidelem4x12900">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12908">
							<label>•</label>
							<sec_title>Multiple sclerosis</sec_title>
							<para>
								<list id="lidelem4x12908">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Multiple sclerosis:</emphasis> monitor for improved number and severity of spasms, chronic pain, fatigue and weakness, balance and dizziness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12912">
								<item>
									<label>•</label>
									<para>CBC with differential baseline and every 6 months thereafter; leukopenia and lymphopenia may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12920">
							<label>•</label>
							<sec_title>Anaphylaxis<route> usually during first dose, but may occur any time during treatment; monitor for difficulty breathing, urticaria, and swelling of the throat and tongue</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12926">
							<label>•</label>
							<sec_title>Pregnancy<route> Identify if pregnancy is planned or suspected, pregnancy (C), or if breastfeeding</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12929">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12933">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved symptoms of multiple sclerosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12939">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x12947">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12950">
								<item>
									<label>•</label>
									<para>Expected results; side effects</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12958">
							<label>•</label>
							<sec_title>Anaphylaxis<route> discontinue the drug and seek immediate medical treatment if patient experiences difficulty breathing, urticaria, and swelling of the throat/tongue</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>dinoprostone (Rx)</mono_name>
			<info>
				<pronunciation>(dye-noe-prost′one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x129662">Cervidil</tradename>
					<tradename id="tnidelem4x129661">Prepidil</tradename>
					<tradename id="tnidelem4x129660">Prostin E-2</tradename>
				</tradenames>
				<class type="func"> Oxytocic, abortifacient</class>
				<class type="chem"> Prostaglandin E</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12978">
				<para>
					<confusion>
						<tradename id="tnidelem4x129780">Prepidil</tradename>
						<drug type="generic" refid="idelem4x129780">bepridil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12982">
				<sec_title>Action:</sec_title>
				<para>Stimulates uterine contractions, causing abortion; acts within 30 hr for complete abortion</para>
			</section>
			<section type="uses" id="sidelem4x12987">
				<sec_title>Uses:</sec_title>
				<para>Abortion during 2nd trimester, benign hydatidiform mole, expulsion of uterine contents in fetal deaths to 28 wk, missed abortion, to efface and dilate the cervix in pregnancy at term</para>
			</section>
			<section type="contra" id="sidelem4x12993">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, C-section, surgery, fetal distress, multiparity, vaginal bleeding, cephalopelvic disproportion</para>
				<section type="none" id="sidelem4x12998">
					<section type="none" id="sidelem4x12999">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), cardiac disease, asthma, anemia, jaundice, diabetes mellitus, seizure disorders, hypertension, glaucoma, uterine fibrosis, cervical stenosis, pelvic surgery, pelvic inflammatory disease, respiratory disease</para>
						<para>
							<bbw>Requires a specialized setting and an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13014">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13017">
					<section type="none" id="sidelem4x13018">
						<sec_title>Abortifacient/2nd trimester/missed abortion/benign hydatidiform mole/intrauterine fetal death</sec_title>
						<section type="none" id="sidelem4x13026">
							<label>•</label>
							<sec_title>Adult<route> VAG SUPP</route></sec_title>
							<para>
								<list id="lidelem4x13026">
									<item>
										<label>•</label>
										<para> 20 mg, repeat q3-5hr until abortion occurs, max dose is 240 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13030">
						<sec_title>Cervical ripening</sec_title>
						<section type="none" id="sidelem4x13038">
							<label>•</label>
							<sec_title>Adult<route> GEL</route></sec_title>
							<para>
								<list id="lidelem4x13038">
									<item>
										<label>•</label>
										<para> 0.5 mg vag gel placed in cervical canal, may repeat after 6 hr, max 1.5 mg/24 hr; vag insert 10 mg high in vagina, remove at onset of active labor or within 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13042">
						<sec_title>Available forms:</sec_title>
						<para> VAG SUPP 20 mg; gel 0.5 mg/3 g (prefilled syringe); vag insert 10 mg</para>
					</section>
					<section type="none" id="sidelem4x13047">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x13055">
							<label>•</label>
							<sec_title>By gel</sec_title>
							<para>
								<list id="lidelem4x13055">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">By gel:</emphasis> after warming to room temperature, remove seal from end of syringe, remove protective end cap and insert into plunger stopper assembly; make sure patient is in dorsal position; <emphasis style="bold">insert:</emphasis> must be kept frozen until use, warm to room temperature before use</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13062">
								<item>
									<label>•</label>
									<para>Antiemetic/antidiarrheal before administration of this product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13067">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13070">
					<section type="none" id="sidelem4x13071">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, chills, fever, flushing</para>
					</section>
					<section type="none" id="sidelem4x13079">
						<sec_title>CV:</sec_title>
						<para> Hypotension, <emphasis style="bold">dysrhythmias, DIC</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13086">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x13091">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylactoid syndrome of pregnancy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13098">
						<sec_title>
							<emphasis style="bold">FETAL:</emphasis>
						</sec_title>
						<para>
							<emphasis alert="lifethreat"> Bradycardia (i.e., deceleration)</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x13105">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13112">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, vaginal pain, vulvitis, vaginismus</para>
					</section>
					<section type="none" id="sidelem4x13117">
						<sec_title>INTEG:</sec_title>
						<para> Rash, skin color changes</para>
					</section>
					<section type="none" id="sidelem4x13122">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Leg cramps, joint swelling,</emphasis> weakness</para>
					</section>
					<section type="none" id="sidelem4x13130">
						<sec_title>GEL:</sec_title>
						<para> Uterine contractile abnormality, GI side effects, back pain, fever</para>
					</section>
					<section type="none" id="sidelem4x13135">
						<sec_title>INSERT:</sec_title>
						<para> Uterine hyperstimulation, fever, nausea, vomiting, diarrhea, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x13140">
						<sec_title>SUPPOSITORY:</sec_title>
						<para> <emphasis style="bold">Uterine rupture, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13147">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect—other oxytocics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> oxytocic effect—alcohol</para>
			</section>
			<section type="kinetics" id="sidelem4x13158">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in spleen, kidney, lungs; excreted in urine</para>
				<section type="none" id="sidelem4x13163">
					<section type="none" id="sidelem4x13164">
						<sec_title>GEL:</sec_title>
						<para> Onset 10 min, peak 30-45 min</para>
					</section>
					<section type="none" id="sidelem4x13169">
						<sec_title>SUPP:</sec_title>
						<para> Onset 10 min, duration 2-3 hr</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13174">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13177">
					<section type="none" id="sidelem4x13178">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Specialized setting, specialized clinician: use only with emergency equipment nearby, by a clinician experienced when used in pregnancy termination; complete abortion should result within 17 hr</bbw>
						</para>
						<section type="none" id="sidelem4x13195">
							<label>•</label>
							<sec_title>Cervical ripening</sec_title>
							<para>
								<list id="lidelem4x13195">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cervical ripening:</emphasis> dilation, effacement of cervix and uterine contraction, fetal heart tones, check for contractions over 1 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13202">
							<label>•</label>
							<sec_title>
								<route>For fever that occurs</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13215">
								<item>
									<label>•</label>
									<para>Respiratory rate, rhythm, depth; notify prescriber of abnormalities, pulse, B/P, temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13223">
							<label>•</label>
							<sec_title>Vaginal discharge</sec_title>
							<para>
								<list id="lidelem4x13223">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Vaginal discharge:</emphasis> check for itching, irritation; indicates vaginal infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13227">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13231">
								<item>
									<label>•</label>
									<para>Therapeutic response: expulsion of fetus</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13237">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13242">
								<item>
									<label>•</label>
									<para>To remain supine for 10-15 min after insertion of supp, 2 hr after insert, 15-30 min after gel</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13251">
							<label>•</label>
							<sec_title>
								<route>To report excessive cramping, bleeding, chills, fever</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13254">
								<item>
									<label>•</label>
									<para>About some methods of pain, comfort control</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13259">
								<item>
									<label>•</label>
									<para>To avoid intercourse, tub baths, douches, tampon use for at least 2 wk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>diphenhydrAMINE (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(dye-fen-hye′dra-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x1327237">
						<country code="CAN">Allerdryl </country>
					</tradename>
					<tradename id="tnidelem4x1327236">
						<country code="CAN">AllerMax </country>
					</tradename>
					<tradename id="tnidelem4x1327235">Altaryl</tradename>
					<tradename id="tnidelem4x1327234">Banophen</tradename>
					<tradename id="tnidelem4x1327233">Benadryl</tradename>
					<tradename id="tnidelem4x1327232">Benadryl Allergy</tradename>
					<tradename id="tnidelem4x1327231">Benadryl Allergy Dye Free</tradename>
					<tradename id="tnidelem4x1327230">Benadryl Children’s Allergy</tradename>
					<tradename id="tnidelem4x1327229">Buckley’s Bedtime</tradename>
					<tradename id="tnidelem4x1327228">Diphedryl</tradename>
					<tradename id="tnidelem4x1327227">Diphenhist</tradename>
					<tradename id="tnidelem4x1327226">Dytan</tradename>
					<tradename id="tnidelem4x1327225">ElixSure Allergy</tradename>
					<tradename id="tnidelem4x1327224">Equaline Allergy</tradename>
					<tradename id="tnidelem4x1327223">Equaline Children’s Allergy</tradename>
					<tradename id="tnidelem4x1327222">Equate Allergy</tradename>
					<tradename id="tnidelem4x1327221">Equate Children’s Allergy</tradename>
					<tradename id="tnidelem4x1327220">Genahist</tradename>
					<tradename id="tnidelem4x1327219">Good Sense Children’s Allergy Relief</tradename>
					<tradename id="tnidelem4x1327218">Good Sense Diphedryl</tradename>
					<tradename id="tnidelem4x1327217">Leader Complete Allergy</tradename>
					<tradename id="tnidelem4x1327216">Nytol</tradename>
					<tradename id="tnidelem4x1327215">PediaCare Children’s Allergy</tradename>
					<tradename id="tnidelem4x1327214">PediaCare Nighttime Cough</tradename>
					<tradename id="tnidelem4x1327213">Q-Dryl Allergy</tradename>
					<tradename id="tnidelem4x1327212">Select Brand Allergy</tradename>
					<tradename id="tnidelem4x1327211">Siladryl</tradename>
					<tradename id="tnidelem4x1327210">Silphen</tradename>
					<tradename id="tnidelem4x132729">Simply Sleep</tradename>
					<tradename id="tnidelem4x132728">Sleepinal</tradename>
					<tradename id="tnidelem4x132727">Sleep Tabs</tradename>
					<tradename id="tnidelem4x132726">Sominex</tradename>
					<tradename id="tnidelem4x132725">
						<country code="CAN">Unisom </country>
					</tradename>
					<tradename id="tnidelem4x132724">Valu-Dryl</tradename>
					<tradename id="tnidelem4x132723">Wal-dryl Allergy</tradename>
					<tradename id="tnidelem4x132722">Wal-dryl Allergy Dye Free</tradename>
					<tradename id="tnidelem4x132721">Wal-dryl Children’s Allergy</tradename>
					<tradename id="tnidelem4x132720">ZzzQuil</tradename>
				</tradenames>
				<class type="func"> Antihistamine (1st generation, nonselective)</class>
				<class type="chem"> Ethanolamine derivative, H-receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13294">
				<para>
					<confusion>
						<tradename id="tnidelem4x132940">diphenhydrAMINE</tradename>
						<drug type="generic" refid="idelem4x132940">dicyclomine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13301">
				<sec_title>Action:</sec_title>
				<para>Acts on blood vessels, GI, respiratory system by competing with histamine for H<emphasis style="inf">1</emphasis>-receptor site; decreases allergic response by blocking histamine</para>
			</section>
			<section type="uses" id="sidelem4x13309">
				<sec_title>Uses:</sec_title>
				<para>Allergy symptoms, rhinitis, motion sickness, antiparkinsonism, nighttime sedation, infant colic, nonproductive cough, insomnia in children</para>
				<section type="none" id="sidelem4x13314">
					<section type="none" id="sidelem4x13315">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Nystagmus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13320">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to H<emphasis style="inf">1</emphasis>-receptor antagonist, neonates</para>
				<section type="none" id="sidelem4x13328">
					<section type="none" id="sidelem4x13329">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;2 yr, increased intraocular pressure, cardiac/renal disease, hypertension, bronchial asthma, seizure disorder, stenosed peptic ulcers, hyperthyroidism, prostatic hypertrophy, bladder neck obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13334">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13342">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13342">
							<item>
								<label>•</label>
								<para> 25-50 mg q4-6hr, max 300 mg/day;  10-50 mg, max 300 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13352">
					<label>•</label>
					<sec_title>Child 6-12 yr<route> PO/IM/IV</route></sec_title>
					<para>
						<list id="lidelem4x13352">
							<item>
								<label>•</label>
								<para> 5 mg/kg/day in 4 divided doses, max 300 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13356">
					<section type="none" id="sidelem4x13357">
						<sec_title>Nighttime sleep aid</sec_title>
						<section type="none" id="sidelem4x13365">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13365">
									<item>
										<label>•</label>
										<para> 25-50 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13369">
						<sec_title>Antitussive (syrup only)</sec_title>
						<section type="none" id="sidelem4x13377">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13377">
									<item>
										<label>•</label>
										<para> 25 mg q4hr, max 150 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13384">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13384">
									<item>
										<label>•</label>
										<para> 12.5 mg q4hr, max 75 mg/24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13388">
						<sec_title>Peripheral vestibular nystagmus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13396">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13396">
									<item>
										<label>•</label>
										<para> 25-50 mg q4-6hr up to 48 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13400">
						<sec_title>Available forms:</sec_title>
						<para> Caps 25, 50 mg; tabs 25, 50 mg; chew tabs 12.5, 25 mg; elix 12.5 mg/5 ml; syr 12.5 mg/5 ml; inj 50 mg/ml; orally disintegrating tabs 12.5, mg; orally disintegrating strips 12.5, 25 mg</para>
					</section>
					<section type="none" id="sidelem4x13405">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13411">
								<item>
									<para>
										<emphasis alert="nurse">Avoid use in children &lt;2 yr; death has occurred; overdose has occurred with topical gel taken orally (adult/child)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13416">
								<item>
									<label>•</label>
									<para>With meals for GI symptoms; absorption rate may slightly decrease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13421">
								<item>
									<label>•</label>
									<para>At bedtime only if using for sleep aid</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13426">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x13430">
									<item>
										<label>•</label>
										<para>Deep IM in large muscle; rotate site</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13437">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x13441">
									<item>
										<label>•</label>
										<para>Undiluted; give 25 mg/min or less</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13447">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x13451">
									<item>
										<label>•</label>
										<para>Dilute with 0.9% NaCl, 0.45% NaCl, D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, D<emphasis style="inf">10</emphasis>W, LR, Ringer’s</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, aldesleukin, alfentanil hydrochloride, amifostine, amikacin sulfate, aminocaproic acid, amphotericin B lipid complex (Abelcet), amphotericin B liposome (AmBisome), amsacrine, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium besylate, atropine sulfate, azithromycin, benztropine mesylate, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefTAZidime, ceftizoxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, digoxin, diltiazem, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, folic acid, gallium, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, metaraminol, methadone, methicillin, methotrexate, methoxamine, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, minocycline, mitoXANtrone, morphine, multiple vitamins injection, mycophenolate, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13467">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13470">
					<section type="none" id="sidelem4x13471">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> poor coordination, fatigue, anxiety, euphoria, confusion, paresthesia, neuritis, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13481">
						<sec_title>CV:</sec_title>
						<para> Hypotension, palpitations</para>
					</section>
					<section type="none" id="sidelem4x13486">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, dilated pupils, tinnitus, nasal stuffiness, dry nose, throat, mouth</para>
					</section>
					<section type="none" id="sidelem4x13491">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x13496">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Retention,</emphasis> dysuria, frequency</para>
					</section>
					<section type="none" id="sidelem4x13504">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13511">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x13516">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13523">
						<sec_title>RESP:</sec_title>
						<para> Increased thick secretions, wheezing, chest tightness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13528">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted by kidneys, crosses placenta, excreted in breast milk, half-life 2-4 hr</para>
				<section type="none" id="sidelem4x13533">
					<section type="none" id="sidelem4x13534">
						<sec_title>PO:</sec_title>
						<para> Peak 2-4 hr, duration 4-8 hr</para>
					</section>
					<section type="none" id="sidelem4x13539">
						<sec_title>IM:</sec_title>
						<para> Onset <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, peak 2-4 hr, duration 4-8 hr</para>
					</section>
					<section type="none" id="sidelem4x13550">
						<sec_title>IV:</sec_title>
						<para> Onset immediate, duration 4-8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13555">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—barbiturates, opiates, hypnotics, tricyclics, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> diphenhydrAMINE effect—MAOIs</para>
				<section type="none" id="sidelem4x13566">
					<section type="none" id="sidelem4x13567">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13575">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13578">
					<section type="none" id="sidelem4x13579">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13583">
								<item>
									<label>•</label>
									<para>Urinary retention, frequency, dysuria; product should be discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>CBC during long-term therapy; blood dyscrasias may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, increase in bronchial secretions, wheezing, chest tightness</para>
								</item>
								<item>
									<label>•</label>
									<para>Product should be discontinued 4 days before skin allergy tests</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13609">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13613">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running or congested nose or rashes, improved sleep</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13619">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13624">
								<item>
									<label>•</label>
									<para>About all aspects of product use; to notify prescriber of confusion, sedation, hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13629">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activity if drowsiness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13634">
								<item>
									<label>•</label>
									<para>That photosensitivity may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13639">
								<item>
									<label>•</label>
									<para>To avoid concurrent use of alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13647">
							<label>•</label>
							<sec_title>
								<route>not to breastfeed (injectable)</route>
							</sec_title>
							<para>
								<list id="lidelem4x13647">
									<item>
										<label>•</label>
										<para>To avoid breastfeeding; </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13651">
								<item>
									<label>•</label>
									<para>To use hard candy, gum, frequent rinsing of mouth for dryness</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>diphenoxylate/atropine (Rx)</mono_name>
			<info>
				<pronunciation>(dye-fen-ox′ee-late/a′troe-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x136661">Lomotil</tradename>
					<tradename id="tnidelem4x136660">Lonox</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="5" status="active">
			<mono_name>difenoxin/atropine (Rx)</mono_name>
			<info>
				<pronunciation>(dye-fen-ox′in/a′troe-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x136730">Motofen</tradename>
				</tradenames>
				<class type="func"> Antidiarrheal</class>
				<class type="chem"> Phenylpiperidine derivative opiate agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="5">V</schedule></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x13693">
				<para>
					<confusion>
						<tradename id="tnidelem4x136930">Lomotil</tradename>
						<drug type="generic" refid="idelem4x136930">LaMICtal/LamISIL/Lanoxin/Lasix/Ludomil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13697">
				<sec_title>Action:</sec_title>
				<para>Inhibits gastric motility by acting on mucosal receptors responsible for peristalsis</para>
			</section>
			<section type="uses" id="sidelem4x13702">
				<sec_title>Uses:</sec_title>
				<para>Acute nonspecific and acute exacerbations of chronic functional diarrhea</para>
			</section>
			<section type="contra" id="sidelem4x13707">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;2 yr, hypersensitivity, pseudomembranous colitis, severe electrolyte imbalances, diarrhea associated with organisms that penetrate intestinal mucosa</para>
				<section type="none" id="sidelem4x13712">
					<section type="none" id="sidelem4x13713">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, hepatic disease, ulcerative colitis, severe hepatic disease, substance abuse, dehydration</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13718">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13721">
					<section type="none" id="sidelem4x13722">
						<sec_title>Diphenoxylate/atropine</sec_title>
						<section type="none" id="sidelem4x13730">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13730">
									<item>
										<label>•</label>
										<para> 5 mg qid titrated to patient response needed, max 8 tabs/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13737">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13737">
									<item>
										<label>•</label>
										<para> (liquid only) 0.3-0.4 mg/kg/day in 4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13741">
						<sec_title>Difenoxin/atropine</sec_title>
						<section type="none" id="sidelem4x13749">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13749">
									<item>
										<label>•</label>
										<para> 2 tabs, then 1 tab after each loose stool or q3-4hr prn, max 8 tabs/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13754">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Diphenoxylate/atropine:</emphasis> tabs 2.5 mg with atropine 0.025 mg; liquid 2.5 mg with atropine 0.025 mg/5 ml; <emphasis style="bold">difenoxin/atropine:</emphasis> tabs 1 mg difenoxin/0.025 atropine</para>
					</section>
					<section type="none" id="sidelem4x13765">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13769">
								<item>
									<label>•</label>
									<para>For 48 hr only; if no response, product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13775">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13778">
					<section type="none" id="sidelem4x13779">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness, light-headedness, headache,</emphasis> fatigue, nervousness, insomnia, confusion</para>
					</section>
					<section type="none" id="sidelem4x13787">
						<sec_title>EENT:</sec_title>
						<para> Burning eyes, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x13792">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, dry mouth, epigastric distress,</emphasis> constipation, <emphasis style="bold">paralytic ileus, toxic megacolon</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13802">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13809">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13816">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13819">
					<section type="none" id="sidelem4x13820">
						<sec_title>PO:</sec_title>
						<para> Onset 40-60 min, peak 3 hr, duration 3-4 hr, terminal half-life 12-14 hr, metabolized in liver to active metabolite; excreted in urine and feces</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13825">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x13833">
					<label>•</label>
					<sec_title>
						<route>Do not use with MAOIs; hypertensive crisis may occur</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of alcohol, opioids, barbiturates, other CNS depressants, anticholinergics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> GI motility, possible toxic megacolon—amantadine, antimuscarinics, amoxapine, diphenhydrAMINE, cloZAPine, clemastine, cyclobenzaprine, loperamide, maprotiline, phenothiazines, tricyclics, disopyramide, OLANZapine</para>
			</section>
			<section type="considerations" id="sidelem4x13844">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13847">
					<section type="none" id="sidelem4x13848">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13853">
								<item>
									<label>•</label>
									<para>Electrolytes (potassium, sodium, chlorine) if receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13858">
								<item>
									<label>•</label>
									<para>Bowel pattern before; for rebound constipation after termination of medication; bowel sounds</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13863">
								<item>
									<label>•</label>
									<para>Response after 48 hr; if none, product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13871">
							<label>•</label>
							<sec_title>
								<route>Abdominal distention, toxic megacolon; may occur in ulcerative colitis</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13874">
								<item>
									<label>•</label>
									<para>Hepatic studies if receiving long-term therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13879">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13883">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased diarrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13889">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13894">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber (may contain alcohol); not to use alcohol or CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13899">
								<item>
									<label>•</label>
									<para>Not to exceed recommended dose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13907">
							<label>•</label>
							<sec_title>
								<route>That product may be habit forming</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13910">
								<item>
									<label>•</label>
									<para>Not to engage in hazardous activities; that drowsiness may occur; not to use for longer than 48 hr for acute diarrhea</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>dipyridamole (Rx)</mono_name>
			<info>
				<pronunciation>(dye-peer-id′a-mole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x139200">Persantine</tradename>
				</tradenames>
				<class type="func"> Coronary vasodilator, antiplatelet agent</class>
				<class type="chem"> Nonnitrate</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x13930">
				<sec_title>Action:</sec_title>
				<para>Inhibits adenosine uptake, which produces coronary vasodilation; increases oxygen saturation in coronary tissues, coronary blood flow; acts on small resistance vessels with little effect on vascular resistance; may increase development of collateral circulation; decreases platelet aggregation by the inhibition of phosphodiesterase (an enzyme)</para>
			</section>
			<section type="uses" id="sidelem4x13935">
				<sec_title>Uses:</sec_title>
				<para>Prevention of transient ischemic attacks, inhibition of platelet adhesion to prevent myocardial reinfarction, thromboembolism, with warfarin in prosthetic heart valves, prevention of coronary bypass graft occlusion with aspirin; IV form used to evaluate CAD; used as alternative to exercise with thallium myocardial perfusion imaging to evaluate CAD</para>
				<section type="none" id="sidelem4x13940">
					<section type="none" id="sidelem4x13941">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cardiomyopathy, MI prophylaxis, proteinuria, TIA, valvular heart disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13947">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x13952">
					<section type="none" id="sidelem4x13953">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, hypotension, unstable angina, asthma, hepatic disease, labor</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13958">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13961">
					<section type="none" id="sidelem4x13962">
						<sec_title>Inhibition of platelet adhesion</sec_title>
						<section type="none" id="sidelem4x13970">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13970">
									<item>
										<label>•</label>
										<para> 75-100 mg qid in combination with warfarin, 75 mg qid with aspirin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13974">
						<sec_title>Thallium myocardial perfusion imaging</sec_title>
						<section type="none" id="sidelem4x13982">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x13982">
									<item>
										<label>•</label>
										<para> 570 mcg/kg, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13986">
						<sec_title>TIA with aspirin (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13994">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13994">
									<item>
										<label>•</label>
										<para> 225-400 mg/day max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13998">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 75 mg; inj 10 mg/2 ml</para>
					</section>
					<section type="none" id="sidelem4x14003">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x14006">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x14010">
									<item>
										<label>•</label>
										<para>On empty stomach: 1 hr before meals or 2 hr after; give with 8 oz water for better absorption</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14021">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x14025">
									<item>
										<label>•</label>
										<para>IV after diluting to at least 1:2 ratio using D<emphasis style="inf">5</emphasis>W, 0.45% NaCl, or 0.9% NaCl to a total vol of 20-50 ml; give over 4 min; do not give undiluted</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject thallium 201 within 5 min after product infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14044">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14047">
					<section type="none" id="sidelem4x14048">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, weakness, fainting, syncope;</emphasis> IV: transient cerebral ischemia, weakness</para>
					</section>
					<section type="none" id="sidelem4x14056">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Postural hypotension;</emphasis> IV: <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14066">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x14074">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> flushing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14082">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x14085">
					<section type="none" id="sidelem4x14086">
						<sec_title>PO:</sec_title>
						<para> Peak 75 min; <emphasis style="bold">IV</emphasis> peak 2 min, therapeutic response may take several mo, metabolized in liver, excreted in bile, undergoes enterohepatic recirculation, protein binding 91%-99%, terminal half-life 12 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14094">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x14098">
						<item>
							<label>•</label>
							<para>Prevention of coronary vasodilation: theophylline</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin effect—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, cefoTEtan, valproic acid, salicylates, sulfinpyrazole, anticoagulants, thrombolytics</para>
			</section>
			<section type="considerations" id="sidelem4x14112">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14115">
					<section type="none" id="sidelem4x14116">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14120">
								<item>
									<label>•</label>
									<para>B/P, pulse during treatment until stable; take B/P lying, standing; orthostatic hypotension is common</para>
								</item>
								<item>
									<label>•</label>
									<para>Cardiac status: chest pain; what aggravates, ameliorates condition</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14131">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14135">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased platelet adhesion</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14141">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14145">
								<item>
									<label>•</label>
									<para>That medication is not a cure; may have to be taken continuously in evenly spaced doses only as directed</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication; dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly from sitting or lying to prevent orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use alcohol or OTC medications unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active" ha="yes">
			<mono_name> DOBUTamine (Rx)</mono_name>
			<info>
				<pronunciation>(doe-byoo′ta-meen)</pronunciation>
				<class type="func"> Adrenergic direct-acting β-agonist, cardiac stimulant</class>
				<class type="chem"> Catecholamine</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x14184">
				<para>
					<confusion>
						<tradename id="tnidelem4x141840">DOBUTamine</tradename>
						<drug type="generic" refid="idelem4x141840">DOPamine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x14188">
				<sec_title>Action:</sec_title>
				<para>Causes increased contractility, increased cardiac output without marked increase in heart rate by acting on β<emphasis style="inf">1</emphasis>-receptors in heart; minor α and β<emphasis style="inf">2</emphasis> effects</para>
			</section>
			<section type="uses" id="sidelem4x14199">
				<sec_title>Uses:</sec_title>
				<para>Cardiac decompensation due to organic heart disease or cardiac surgery</para>
				<section type="none" id="sidelem4x14204">
					<section type="none" id="sidelem4x14205">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Cardiogenic shock in children; congenital heart disease in children undergoing cardiac catheterization</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14211">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, idiopathic hypertrophic subaortic stenosis</para>
				<section type="none" id="sidelem4x14216">
					<section type="none" id="sidelem4x14217">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, hypertension, CAD, MI, hypovolemia, dysrhythmias, sulfite hypersensitivity, renal failure, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14222">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14230">
					<label>•</label>
					<sec_title>Adult and child<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x14230">
							<item>
								<label>•</label>
								<para> 0.5-1 mcg/kg/min; titrate to 2-20 mcg/kg/min may increase to 40 mcg/kg/min if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14234">
					<section type="none" id="sidelem4x14235">
						<sec_title>Available forms:</sec_title>
						<para> Inj 12.5 mg/ml, 250 mg/20 ml</para>
					</section>
					<section type="none" id="sidelem4x14240">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x14243">
							<sec_title>Injectable</sec_title>
							<para>
								<list id="lidelem4x14247">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before administration whenever solution and container permit</para>
									</item>
									<item>
										<label>•</label>
										<para>Store reconstituted sol for 24 hr if refrigerated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14258">
							<sec_title>IV route</sec_title>
							<para>
								<emphasis style="italic">Note:</emphasis> Infusions ≤72 hr have been given without development of tolerance; however, beta-receptor desensitization can occur with prolonged infusion of any beta-adrenergic agonist, including DOBUTamine, or as a consequence of sympathetic compensatory mechanisms associated with advanced congestive heart failure, resulting in alterations in DOBUTamine pharmacodynamics; experience with intravenous DOBUTamine in controlled trials does not extend beyond 48 hr of repeated boluses and/or continuous infusion<list id="lidelem4x14265">
									<item>
										<label>•</label>
										<para>Must be diluted before administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse into a large vein</para>
									</item>
								</list></para>
						</section>
						<section type="none" id="sidelem4x14276">
							<sec_title>Dilution</sec_title>
							<para>
								<list id="lidelem4x14280">
									<item>
										<label>•</label>
										<para>Concentrate for injection must be diluted with ≥50 ml of a compatible IV solution (strongly alkaline [e.g., sodium bicarbonate] solutions are incompatible); a common dilution is 500 mg (40 ml) in 210 ml D<emphasis style="inf">5</emphasis>W or NS (withdraw 40 ml from a 250-ml bag) to produce a final concentration of 2000 mcg/ml; or 1000 mg (80 ml) in 170 ml D<emphasis style="inf">5</emphasis>W or NS (withdraw 80 ml from a 250 ml bag) to produce a final concentration of 4000 mcg/ml; maximum concentrations should not exceed 5000 mcg/ml and should be adjusted according to the patient’s fluid requirements</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14292">
							<sec_title>Infusion</sec_title>
							<para>
								<list id="lidelem4x14296">
									<item>
										<label>•</label>
										<para>Administer diluted solution by IV infusion using a controlled-infusion device</para>
									</item>
									<item>
										<label>•</label>
										<para>Premixed bags of DOBUTamine in D<emphasis style="inf">5</emphasis>W solutions can exhibit a pink color that increases with time; this color change is due to slight oxidation of the drug, but there is no significant loss of potency</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not administer DOBUTamine simultaneously with solutions containing sodium bicarbonate or strong alkaline solutions (incompatible)</para>
									</item>
									<item>
										<label>•</label>
										<para>Infusion of DOBUTamine should be started at a low rate and titrated frequently to reach the optimal dosage (see Dosage and Routes); dosage titration is guided by the patient’s response, including systemic blood pressure, urine flow, frequency of ectopic activity, heart rate, and (whenever possible) measurements of cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, alprostadil, amifostine, amikacin, aminocaproic acid, amiodarone, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clarithromycin, cloNIDine, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, irinotecan, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, meperidine, meropenem, metaraminol, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, milrinone, minocycline, mitoXANtrone, morphine, multiple vitamins injection, mycophenolate mofetil, nafcillin, nalbuphine, naloxone, netilmicin, niCARdipine, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, pentamidine, pentazocine, phenylephrine, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sodium acetate, succinylcholine, SUFentanil, tacrolimus, temocillin, teniposide, theophylline, thiamine, thiotepa, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14326">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14329">
					<section type="none" id="sidelem4x14330">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety,</emphasis> headache, dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x14338">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="bold">tachycardia,</emphasis> hypo/hypertension, PVCs, angina</para>
					</section>
					<section type="none" id="sidelem4x14346">
						<sec_title>ENDO:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x14351">
						<sec_title>GI:</sec_title>
						<para> Heartburn, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x14356">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps (leg)</para>
					</section>
					<section type="none" id="sidelem4x14361">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14366">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x14369">
					<section type="none" id="sidelem4x14370">
						<sec_title>IV:</sec_title>
						<para> Onset 1-2 min, peak 10 min, half-life 2 min, metabolized in liver (inactive metabolites), excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14375">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: severe hypertension—guanethidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—general anesthetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pressor effect, dysrhythmias—atomoxetine, COMT inhibitors, tricyclics, MAOIs, oxytocics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> DOBUTamine action—other β-blockers</para>
			</section>
			<section type="considerations" id="sidelem4x14393">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14396">
					<section type="none" id="sidelem4x14397">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x14405">
							<label>•</label>
							<sec_title>
								<route>Hypovolemia; if present, correct first; administer cardiac glycoside before DOBUTamine</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x14411">
							<label>•</label>
							<sec_title>Oxygenation/perfusion deficit<route> check B/P, chest pain, dizziness, loss of consciousness</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14417">
							<label>•</label>
							<sec_title>Heart failure<route> S</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14428">
							<label>•</label>
							<sec_title>
								<route>ECG during administration continuously; if B/P increases, product is decreased; CVP or PCWP, cardiac output during infusion; report changes</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x14434">
							<label>•</label>
							<sec_title>
								<route>Serum electrolytes, urine output</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14438">
								<item>
									<para>
										<emphasis alert="nurse">Sulfite sensitivity, which may be life threatening</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14443">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14447">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased B/P with stabilization, increased urine output</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14453">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x14461">
							<label>•</label>
							<sec_title>
								<route>to report dyspnea, chest pain, numbness of extremities, headache, IV site discomfort</route>
							</sec_title>
							<para>
								<list id="lidelem4x14461">
									<item>
										<label>•</label>
										<para>About the reason for product administration; </para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active" ha="yes">
			<mono_name> DOCEtaxel (Rx)</mono_name>
			<info>
				<pronunciation>(doe-se-tax′el)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x144811">Docefrez</tradename>
					<tradename id="tnidelem4x144810">Taxotere</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Taxane</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x14491">
				<para>
					<confusion>
						<tradename id="tnidelem4x144910">Taxotere</tradename>
						<drug type="generic" refid="idelem4x144910">Taxol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x14495">
				<sec_title>Action:</sec_title>
				<para>Inhibits reorganization of microtubule network needed for interphase and mitotic cellular functions; also causes abnormal bundles of microtubules during cell cycle and multiple esters of microtubules during mitosis</para>
			</section>
			<section type="uses" id="sidelem4x14500">
				<sec_title>Uses:</sec_title>
				<para>Locally advanced or metastatic breast cancer, non–small-cell lung cancer, androgen-independent metastatic prostate cancer, postsurgery operable node-positive breast cancer, induction treatment of locally advanced squamous cell of the head and neck, gastric adenocarcinoma</para>
				<section type="none" id="sidelem4x14505">
					<section type="none" id="sidelem4x14506">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Malignant melanoma, ovarian cancer, front-line use with bevacizumab for metastatic breast cancer, adjuvant treatment of breast cancer with CARBOplatin and trastuzumab</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14511">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity to this product, bilirubin exceeding upper normal limit</para>
				<para>
					<bbw>Other products with polysorbate 80, neutropenia of &lt;1500/mm3</bbw>
				</para>
				<section type="none" id="sidelem4x14528">
					<section type="none" id="sidelem4x14529">
						<sec_title>Precautions:</sec_title>
						<para> Children, cardiovascular disease, pulmonary disorders, bone marrow depression, herpes zoster, pleural effusion</para>
						<para>
							<bbw>Edema, hepatic disease, lung cancer, taxane hypersensitivity</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14544">
				<sec_title>Dosage and routes:</sec_title>
				<para>
					<list id="lidelem4x14548">
						<item>
							<label>•</label>
							<para>Other regimens are used</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x14554">
					<section type="none" id="sidelem4x14555">
						<sec_title>Locally advanced or metastatic breast cancer after failure of other chemotherapy</sec_title>
						<section type="none" id="sidelem4x14563">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14563">
									<item>
										<label>•</label>
										<para> 60-100 mg/m<emphasis style="sup">2</emphasis> given over 1 hr q3wk; if neutrophil count is &lt;500 cells/mm<emphasis style="sup">3</emphasis> for &gt;1 wk, reduce dose by 25%</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14573">
						<sec_title>Operable node-positive breast cancer, adjuvant postsurgery treatment of operable node-positive breast cancer</sec_title>
						<section type="none" id="sidelem4x14581">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14581">
									<item>
										<label>•</label>
										<para> (TAC regimen) 75 mg/m<emphasis style="sup">2</emphasis> 1 hr after DOXOrubicin 50 mg/m<emphasis style="sup">2</emphasis> and cyclophosphamide 500 mg/m<emphasis style="sup">2</emphasis> q3wk × 6 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14594">
						<sec_title>Adjuvant treatment of operable stage I-III invasive breast cancer in combination with cyclophosphamide</sec_title>
						<section type="none" id="sidelem4x14602">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14602">
									<item>
										<label>•</label>
										<para> (TC regimen) DOCEtaxel 75 mg/m<emphasis style="sup">2</emphasis> with cyclophosphamide 600 mg/m<emphasis style="sup">2</emphasis> q21days × 4 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14612">
						<sec_title>Locally advanced or metastatic non–small-cell lung cancer after failure of CISplatin chemotherapy</sec_title>
						<section type="none" id="sidelem4x14620">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14620">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis> over 1 hr q3wk; if neutrophil count is &lt;500 cells/mm<emphasis style="sup">3</emphasis> for &gt;1 wk, reduce dose to 55 mg/m<emphasis style="sup">2</emphasis>; if patient develops grade 3 peripheral neuropathy, stop product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14633">
						<sec_title>Unreactable, locally advanced, or metastatic non–small-cell lung cancer previously treated with chemotherapy</sec_title>
						<section type="none" id="sidelem4x14641">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14641">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis> over 1 hr, then CISplatin 75 mg/m<emphasis style="sup">2</emphasis> given over 30-60 min q3wk; reduce dose to 65 mg/m<emphasis style="sup">2</emphasis> in those with hematologic or non-hematologic toxicities</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14656">
						<sec_title>Androgen-independent metastatic prostate cancer</sec_title>
						<section type="none" id="sidelem4x14664">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14664">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis> given over 1 hr q3wk with 5 mg predniSONE  bid continuously; give dexamethasone 8 mg  at 12 hr, 3 hr, and 1 hr prior to DOCEtaxel; if neutrophil count is &lt;500 cells/mm<emphasis style="sup">3</emphasis> for more than 1 wk or other toxicities occur, reduce dose to 60 mg/m<emphasis style="sup">2</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14683">
						<sec_title>Squamous cell of head and neck</sec_title>
						<section type="none" id="sidelem4x14691">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14691">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis> over 1 hr, then CISplatin 100 mg/m<emphasis style="sup">2</emphasis> over 1 hr on day 1, then 5FU 1000 mg/m<emphasis style="sup">2</emphasis>/day  × 5 days, repeat cycle q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14707">
						<sec_title>Gastric adenocarcinoma</sec_title>
						<section type="none" id="sidelem4x14715">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14715">
									<item>
										<label>•</label>
										<para> 75 mg/m<emphasis style="sup">2</emphasis> q3wk, given with CISplatin, fluorouracil</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14722">
						<sec_title>Advanced ovarian cancer/metastatic melanoma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14730">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x14730">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis> over 1 hr q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14737">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml, 20 mg/0.5 ml, 20 mg/ml, 80 mg/2 ml, 80 mg/4 ml; 20, 80 mg powder for injection</para>
					</section>
					<section type="none" id="sidelem4x14742">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x14750">
							<label>•</label>
							<sec_title>
								<route>PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x14750">
									<item>
										<label>•</label>
										<para>Premedicate with dexamethasone 8 mg  bid × 3 days starting 1 day before treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x14755">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product and prn</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14763">
							<label>•</label>
							<sec_title>
								<route>Confirmation that dexamethasone was given 12 hr and 6 hr before infusion begins</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14766">
								<item>
									<label>•</label>
									<para>Store prepared sol up to 27 hr in refrigerator</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14771">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x14775">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures</para>
									</item>
									<item>
										<label>•</label>
										<para>Use non-PVC bag and use non-DEHP tubing</para>
									</item>
									<item>
										<label>•</label>
										<para>Allow vials to warm to room temperature; withdraw all diluent, inject in vial of DOCEtaxel; rotate gently to mix; allow to stand to decrease foaming, then withdraw the required amount (10 mg/ml), inject in 250 ml of 0.9% NaCl, D<emphasis style="inf">5</emphasis>W; mix gently; give over 1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, dexrazoxane, diazepam, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOPamine, doripenem, doxacurium, DOXOrubicin HCL, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, meperidine, meropenem, mesna, methotrexate, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, nafcillin, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreoide, ofloxacin, ondansetron, oxaliplatin, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, riTUXimab, rocuronium, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14799">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14802">
					<section type="none" id="sidelem4x14803">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14810">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension, fluid retention, peripheral edema,</emphasis> flushing, <emphasis style="bold">MI, sinus tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14820">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> stomatitis, colitis</para>
					</section>
					<section type="none" id="sidelem4x14830">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, thrombocytopenia, anemia,</emphasis> bleeding, infections, <emphasis style="bold">myelosuppression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14840">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> nail pain, rash, skin eruptions</para>
					</section>
					<section type="none" id="sidelem4x14848">
						<sec_title>MISC:</sec_title>
						<para> Amenorrhea, fever of unknown origin, <emphasis style="bold">secondary malignancy, Stevens-Johnson syndrome,</emphasis> epiphora</para>
					</section>
					<section type="none" id="sidelem4x14856">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Arthralgia, myalgia</emphasis>, back pain, weakness</para>
					</section>
					<section type="none" id="sidelem4x14864">
						<sec_title>NEURO:</sec_title>
						<para> <emphasis style="italic">Peripheral neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14871">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="bold">pulmonary edema, fibrosis, embolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14878">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">
								<emphasis style="italic">Hypersensitivity reactions</emphasis>
							</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14886">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in feces, terminal half-life 11.1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x14891">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CYP3A inhibition: anastrozole (high doses), aprepitant, fosaprepitant, clarithromycin, conivaptan, delavirdine, efavirenz (induces or inhibits), erythromycin, fluconazole, FLUoxetine, fluvoxaMINE, imatinib, itraconazole, ketoconazole, nefazodone, voriconazole, and others</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CYP3A induction: barbiturates, bosentan, carBAMazepine, nevirapine, phenytoin, fosphenytoin, rifabutin, rifampin, rifapentine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> immune response—live virus vaccines</para>
			</section>
			<section type="considerations" id="sidelem4x14910">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14913">
					<section type="none" id="sidelem4x14914">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>CBC, differential, platelet count before treatment and weekly; withhold product if WBC is &lt;1500/mm3 or platelet count is &lt;100,000/mm3; notify prescriber</bbw>
						</para>
						<para>
							<bbw>DOCEtaxel, polysorbate 80 hypersensitivity: contraindicated</bbw>
						</para>
						<para>
							<bbw>Edema: oral corticosteroids should be given as premedication, assess for fluid retention</bbw>
						</para>
						<para>
							<bbw>Lung cancer: increased mortality in those with increased LFTs and a history of platinum-based products</bbw>
						</para>
						<para>
							<list id="lidelem4x14963">
								<item>
									<label>•</label>
									<para>Monitor temperature; fever may indicate beginning of infection</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hepatic disease:</emphasis> hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) prn or monthly; check for jaundiced skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</bbw>
						</para>
						<section type="none" id="sidelem4x14985">
							<label>•</label>
							<sec_title>CNS changes</sec_title>
							<para>
								<list id="lidelem4x14985">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS changes:</emphasis> confusion, paresthesias, peripheral neuropathy, dysesthesia, pain, weakness; if severe, product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x14989">
								<item>
									<label>•</label>
									<para>VS during 1st hr of infusion, check IV site for signs of infiltration</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hypersensitive reactions, anaphylaxis,</emphasis> including hypotension, dyspnea, angioedema, generalized urticaria; discontinue infusion immediately</bbw>
						</para>
						<section type="none" id="sidelem4x15010">
							<label>•</label>
							<sec_title>Bone marrow depression/bleeding<route> hematuria, guaiac, bruising or petechiae, mucosa or orifices q8hr; obtain prescription for viscous lidocaine (Xylocaine); avoid invasive procedures</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15013">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15018">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15022">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15029">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x15037">
							<label>•</label>
							<sec_title>To report signs of infection<route> fever, sore throat, flulike symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15043">
							<label>•</label>
							<sec_title>To report signs of anemia<route> fatigue, headache, faintness, SOB, irritability</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15049">
							<label>•</label>
							<sec_title>
								<route>To report bleeding; to avoid use of razors, commercial mouthwash</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15052">
								<item>
									<label>•</label>
									<para>To avoid use of aspirin, ibuprofen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15057">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color and texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15062">
								<item>
									<label>•</label>
									<para>That pain in muscles and joints 2-5 days after infusion is common</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15070">
							<label>•</label>
							<sec_title>
								<route>To use barrier contraception during and for several mo after treatment, pregnancy (D); to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15073">
								<item>
									<label>•</label>
									<para>To avoid receiving vaccinations while taking product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>docosanol topical</mono_name>
			<section type="none" id="sidelem4x15081">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>docusate calcium (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(dok′yoo-sate cal′see-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x150931">Kaopectate Stool Softener</tradename>
					<tradename id="tnidelem4x150930">Kao-Tin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="11" status="active">
			<mono_name>docusate sodium (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x1510111">Colace</tradename>
					<tradename id="tnidelem4x1510110">Correctol</tradename>
					<tradename id="tnidelem4x151019">Diocto</tradename>
					<tradename id="tnidelem4x151018">Docu DOK</tradename>
					<tradename id="tnidelem4x151017">Doculace</tradename>
					<tradename id="tnidelem4x151016">Enemeez</tradename>
					<tradename id="tnidelem4x151015">Fleet Pedialax</tradename>
					<tradename id="tnidelem4x151014">Fleet Sof-Lax</tradename>
					<tradename id="tnidelem4x151013">Phillips Liquid-Gels</tradename>
					<tradename id="tnidelem4x151012">
						<country code="CAN">Selex </country>
					</tradename>
					<tradename id="tnidelem4x151011">Silace</tradename>
					<tradename id="tnidelem4x151010">
						<country code="CAN">Soflax </country>
					</tradename>
				</tradenames>
				<class type="func"> Laxative, emollient; stool softener</class>
				<class type="chem"> Anionic surfactant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15116">
				<sec_title>Action:</sec_title>
				<para>Increases water, fat penetration in intestine; allows for easier passage of stool</para>
			</section>
			<section type="uses" id="sidelem4x15121">
				<sec_title>Uses:</sec_title>
				<para>Prevention of dry, hard stools</para>
			</section>
			<section type="contra" id="sidelem4x15126">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, obstruction, fecal impaction, nausea/vomiting</para>
				<section type="none" id="sidelem4x15131">
					<section type="none" id="sidelem4x15132">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15137">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15145">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15145">
							<item>
								<label>•</label>
								<para> 50-300 mg/day (sodium) or 240 mg (calcium);  4 ml</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15155">
					<label>•</label>
					<sec_title>Child &gt;12 yr<route> ENEMA</route></sec_title>
					<para>
						<list id="lidelem4x15155">
							<item>
								<label>•</label>
								<para> 2 ml</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15162">
					<label>•</label>
					<sec_title>Child 6-12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15162">
							<item>
								<label>•</label>
								<para> 40-150 mg/day (sodium) in divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15169">
					<label>•</label>
					<sec_title>Child 3-6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15169">
							<item>
								<label>•</label>
								<para> 20-60 mg/day (sodium) in divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15176">
					<label>•</label>
					<sec_title>Child &lt;3 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15176">
							<item>
								<label>•</label>
								<para> 10-40 mg/day (sodium) in divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15180">
					<section type="none" id="sidelem4x15181">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Calcium:</emphasis> 240 mg; <emphasis style="italic">sodium:</emphasis> caps 50, 100, 250 mg; tabs 100 mg; syr 20 mg/5 ml; liquid 50 mg/5 ml, enema 283 mg</para>
					</section>
					<section type="none" id="sidelem4x15192">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15196">
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Oral sol: diluted in milk, fruit juice to decrease bitter taste</para>
								</item>
								<item>
									<label>•</label>
									<para>In morning or evening (oral dose)</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15217">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15220">
					<section type="none" id="sidelem4x15221">
						<sec_title>EENT:</sec_title>
						<para> Bitter taste, throat irritation</para>
					</section>
					<section type="none" id="sidelem4x15226">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, cramps, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x15231">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15236">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 12-72 hr</para>
			</section>
			<section type="interactions" id="sidelem4x15241">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x15249">
					<label>•</label>
					<sec_title>Toxicity</sec_title>
					<para>
						<list id="lidelem4x15249">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Toxicity:</emphasis> mineral oil</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15253">
					<section type="none" id="sidelem4x15254">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> laxative action—flax, senna</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15261">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15264">
					<section type="none" id="sidelem4x15265">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15273">
							<label>•</label>
							<sec_title>
								<route>Cause of constipation;</route>
							</sec_title>
							<para>
								<list id="lidelem4x15273">
									<item>
										<label>•</label>
										<para> identify whether fluids, bulk, or exercise missing from lifestyle; constipating products</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15277">
								<item>
									<label>•</label>
									<para>Cramping, rectal bleeding, nausea, vomiting; if these occur, product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15282">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15286">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15292">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15296">
								<item>
									<label>•</label>
									<para>That normal bowel movements do not always occur daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use in presence of abdominal pain, nausea, vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if constipation unrelieved or if symptoms of electrolyte imbalance occur: muscle cramps, pain, weakness, dizziness, excessive thirst</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may take up to 3 days to soften stools</para>
								</item>
								<item>
									<label>•</label>
									<para>To take oral preparations with a full glass of water (unless on fluid restrictions) and to increase fluid intake</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name> dofetilide (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x153280">Tikosyn</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic (Class III)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15334">
				<sec_title>Action:</sec_title>
				<para>Blocks cardiac ion channel carrying the rapid component of delayed potassium current; no effect on sodium channels</para>
			</section>
			<section type="uses" id="sidelem4x15339">
				<sec_title>Uses:</sec_title>
				<para>Atrial fibrillation, flutter, maintenance of normal sinus rhythm</para>
			</section>
			<section type="contra" id="sidelem4x15344">
				<sec_title>Contraindications:</sec_title>
				<para>Children, hypersensitivity, digoxin toxicity, aortic stenosis, pulmonary hypertension, severe renal disease</para>
				<para>
					<bbw>QT prolongation, torsades de pointes, renal failure</bbw>
				</para>
				<section type="none" id="sidelem4x15359">
					<section type="none" id="sidelem4x15360">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, AV block, bradycardia, electrolyte imbalance</para>
						<para>
							<bbw>Renal disease, arrhythmias, ventricular arrhythmias/tachycardia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15375">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15378">
					<section type="none" id="sidelem4x15379">
						<sec_title>Conversion of atrial fibrillation/atrial flutter to normal sinus rhythm; maintenance therapy with highly symptomatic atrial fibrillation/atrial flutter of ≥1 wk duration</sec_title>
						<section type="none" id="sidelem4x15387">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15387">
									<item>
										<label>•</label>
										<para> Individualize dosage based on renal function and QTc in a monitored facility; refer to the step-by-step procedure for determining the initial dosage of dofetilide</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15391">
						<sec_title>Maintenance therapy of atrial fibrillation/atrial flutter after hospital discharge</sec_title>
						<section type="none" id="sidelem4x15399">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15399">
									<item>
										<label>•</label>
										<para> Continue dosage at discharge as from initial dosage titration; individualize dosage based on renal function and QTc, which should be re-evaluated every 3 mo or as medically warranted; if the QTc &gt;500 msec (550 msec in patients with ventricular conduction abnormalities) at any time, discontinue; carefully monitor until QTc returns to baseline; if renal function deteriorates, adjust the dosage as described in the dosage guidelines for patients with renal impairment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15403">
						<sec_title>Discontinuation of dofetilide before use of interacting drugs</sec_title>
						<section type="none" id="sidelem4x15411">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15411">
									<item>
										<label>•</label>
										<para> Discontinue dofetilide for ≥2 days before starting a potentially interacting drug</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15415">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x15423">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &gt;60 ml/min, 500 mcg bid; CCr 40-60 ml/min, 250 mcg bid; CCr 20-39 ml/min, 125 mcg bid; CCr &lt;20 ml/min, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15426">
						<sec_title>Available forms:</sec_title>
						<para> Caps 125, 250, 500 mcg</para>
					</section>
					<section type="none" id="sidelem4x15431">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15435">
								<item>
									<label>•</label>
									<para>Physician and pharmacy must be registered to use product</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 1: Assess cardiac conduction:</emphasis> Before first dose, the QTc interval must be determined using an average of 5-10 beats; if the QTc interval is &gt;440 msec (or &gt;500 msec in ventricular conduction abnormalities), do not use; if baseline heart rate is &lt;60 bpm, then the QT interval should be used</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 2: Assess renal function:</emphasis> Before first dose, determine renal function using the Cockroft-Gault equation, use actual body weight to calculate creatinine clearance</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 3: Adjust starting dose according to renal function:</emphasis> Refer to the renal dose section above to determine the appropriate initial dosage</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 4: ECG monitoring:</emphasis> Begin continuous ECG monitoring starting with the first dose</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 5: Dosage adjustments:</emphasis> Approximately 2-3 hr after the first dose, determine the QTc interval; if the QTc interval has increased by &gt;15% (compared to baseline), or if the QTc interval is &gt;500 msec (&gt;550 msec in patients with ventricular conduction abnormalities), the initial dosage should be reduced by half as follows:•Decrease an initial dose of 500 mcg bid to 250 mcg bid•Decrease an initial dose of 250 mcg bid to 125 mcg bid•Decrease an initial dose of 125 mcg bid to 125 mcg/day</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 6: Reassess QTc interval:</emphasis> Reassess the QTc interval 2-3 hr after each subsequent dose; if the QTc interval lengthens to &gt;500 msec (or &gt;550 msec in patients with ventricular conduction abnormalities), discontinue</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Step 7: ECG monitoring:</emphasis> Monitor continuous ECG for a minimum of 3 days or for 12 hr after conversion to normal sinus rhythm, whichever is greater</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15544">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15547">
					<section type="none" id="sidelem4x15548">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Syncope, dizziness,</emphasis> headache, <emphasis style="bold">stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15558">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension, postural hypotension, bradycardia,</emphasis> angina, PVCs, substernal pressure, transient hypertension, precipitation of angina, <emphasis style="bold">QT prolongation, torsades de pointes, ventricular dysrhythmias,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x15569">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> severe diarrhea, anorexia</para>
					</section>
					<section type="none" id="sidelem4x15577">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15584">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, respiratory infections</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15589">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, max plasma concentrations 2-3 hr, steady state 2-3 days, half-life 10 hr, metabolized by liver, excreted by kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x15594">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x15602">
					<label>•</label>
					<sec_title>
						<route>Do not use with cimetidine, ketoconazole, verapamil, prochlorperazine, trimethoprim-sulfamethoxazole, megestrol, hydrochlorothiazide</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation, torsades de pointes—class IA/III antidysrhythmics, arsenic trioxide, chloroquine, clarithromycin, droperidol, erythromycin, halofantrine, haloperidol, methadone, pentamidine, some phenothiazines, ziprasidone, ciprofloxacin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—potassium-depleting diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—aMILoride metFORMIN, entecavir, lamiVUDine, memantine, triamterene, procainamide, trospium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dofetilide levels—antiretroviral protease inhibitors</para>
				<section type="none" id="sidelem4x15620">
					<section type="none" id="sidelem4x15621">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x15625">
								<item>
									<label>•</label>
									<para>Do not use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15632">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15635">
					<section type="none" id="sidelem4x15636">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15644">
							<label>•</label>
							<sec_title>
								<route>AF patients should receive anticoagulation prior to cardioversion</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15647">
								<item>
									<label>•</label>
									<para>Cardiac status: rate, rhythm, character, continuously; B/P</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Severe renal impairment CCr &lt;20 ml/min:</emphasis> do not use for mild to moderate renal disease; monitor BUN/creatinine; adjust dose based on creatinine clearance</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x15664">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15668">
								<item>
									<label>•</label>
									<para>Therapeutic response: control of atrial fibrillation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15674">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15679">
								<item>
									<label>•</label>
									<para>To make position changes slowly; orthostatic hypotension may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15687">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if fast heartbeats with fainting or dizziness occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15690">
								<item>
									<label>•</label>
									<para>To notify all prescribers of all medications, supplements taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15695">
								<item>
									<label>•</label>
									<para>That if dose is missed, not to double; to take next dose at usual time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15700">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>dolasetron (Rx)</mono_name>
			<info>
				<pronunciation>(do-la′se-tron)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x157100">Anzemet</tradename>
				</tradenames>
				<class type="func"> Antiemetic</class>
				<class type="chem"> 5-HT3 receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x15720">
				<sec_title>Action:</sec_title>
				<para>Prevents nausea, vomiting by blocking serotonin peripherally, centrally, and in the small intestine</para>
			</section>
			<section type="uses" id="sidelem4x15725">
				<sec_title>Uses:</sec_title>
				<para>Prevention of postoperative nausea, vomiting</para>
				<section type="none" id="sidelem4x15730">
					<section type="none" id="sidelem4x15731">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Radiotherapy-induced nausea/vomiting</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15736">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x15741">
					<section type="none" id="sidelem4x15742">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, hypokalemia, electrolyte imbalances; granisetron/ondansetron/palonosetron hypersensitivity, QT prolongation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15747">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15750">
					<section type="none" id="sidelem4x15751">
						<sec_title>Prevention of postoperative nausea and vomiting</sec_title>
						<section type="none" id="sidelem4x15759">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15759">
									<item>
										<label>•</label>
										<para> 12.5 mg as single dose 15 min before cessation of anesthesia;  100 mg 2 hr before surgery (prevention only)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15769">
							<label>•</label>
							<sec_title>Child 2-16 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15769">
									<item>
										<label>•</label>
										<para> 0.35 mg/kg as single dose 15 min before cessation of anesthesia;  1.2 mg/kg 2 hr before surgery (prevention only)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15776">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50, 100 mg; inj 20 mg/ml, 12.5 mg/0.625 ml</para>
					</section>
					<section type="none" id="sidelem4x15781">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x15784">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x15788">
									<item>
										<label>•</label>
										<para>Do not mix product for oral administration in apple or apple-grape juice until immediately before administration; diluted product can be kept for 2 hr at room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature 48 hr after dilution</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15799">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x15803">
									<item>
										<label>•</label>
										<para>By inj 100 mg/30 sec or more or diluted in 50 ml compatible sol; give over 15 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15814">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15817">
					<section type="none" id="sidelem4x15818">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, fatigue, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x15826">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias,</emphasis> ECG changes, hypo/hypertension, tachycardia, bradycardia; <emphasis style="bold">ventricular tachycardia/fibrillation, QT prolongation, torsades de pointes, cardiac arrest (IV)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15836">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> constipation, increased AST/ALT, abdominal pain, anorexia</para>
					</section>
					<section type="none" id="sidelem4x15844">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, oliguria</para>
					</section>
					<section type="none" id="sidelem4x15849">
						<sec_title>MISC:</sec_title>
						<para> Rash, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15856">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, metabolized to active metabolite, half-life of active metabolite 8 hr, max concentrations after 1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x15862">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x15870">
					<label>•</label>
					<sec_title>QT Prolongation<route> QRS, PR prolongation; do not use in those with congenital long QT syndrome, hypokalemia, hypomagnesemia, complete heart block (unless a pacemaker is in place), correct electrolytes before use, monitor ECG in elderly patients, renal cardiac disease</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—antidysrhythmics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dolasetron levels—cimetidine</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—thiazide/loop diuretics, antidysrhythmics—class IA, III, arsenic trioxide, chloroquine, clarithromycin, droperidol, erythromycin, halofantrine, haloperidol, methadone, pentamidine, some phenothiazines, ziprasidone; occurs at higher dose of dolasetron</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dolasetron levels—rifampin</para>
			</section>
			<section type="considerations" id="sidelem4x15888">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15891">
					<section type="none" id="sidelem4x15892">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15900">
							<label>•</label>
							<sec_title>Hypersensitivity reaction<route> rash, bronchospasm</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15906">
							<label>•</label>
							<sec_title>
								<route>Cardiac conduction conditions, electrolyte imbalances, dysrhythmias, heart rate</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15909">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15913">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting during cancer chemotherapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15919">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15923">
								<item>
									<label>•</label>
									<para>To report diarrhea, constipation, nausea, vomiting, rash, or changes in respirations</para>
								</item>
								<item>
									<label>•</label>
									<para>May cause headache; use analgesic</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>dolutegravir</mono_name>
			<info>
				<pronunciation>(dole-oo-teg′ra-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x159390">Tivicay</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15949">
				<sec_title>Action:</sec_title>
				<para>Inhibits catalytic activity of HIV integrase, which is an HIV-encoded enzyme needed for replication</para>
			</section>
			<section type="uses" id="sidelem4x15954">
				<sec_title>Uses:</sec_title>
				<para>HIV in combination with other retrovirals</para>
			</section>
			<section type="contra" id="sidelem4x15959">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x15964">
					<section type="none" id="sidelem4x15965">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, hepatic disease, immune reconstitution syndrome, hepatitis, antimicrobial resistance, lactase deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15970">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15978">
					<label>•</label>
					<sec_title>Adult and child ≥12 yr and ≥40 kg (treatment naïve or treatment experienced but integrase strand transfer inhibitor naïve)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15978">
							<item>
								<label>•</label>
								<para> 50 mg daily; if given with efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, or rifampin, give 50 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15982">
					<section type="none" id="sidelem4x15983">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg</para>
					</section>
					<section type="none" id="sidelem4x15988">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15992">
								<item>
									<label>•</label>
									<para>May give without regard to meals, with 8 oz of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>Give 2 hr before or 6 hr after cation-containing antacids or laxatives, sucralfate, oral iron, oral calcium, or buffered products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16008">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16011">
					<section type="none" id="sidelem4x16012">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, fever, dizziness, headache, asthenia, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16019">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16026">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, abdominal pain, asthenia, gastritis, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16033">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria</para>
					</section>
					<section type="none" id="sidelem4x16038">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x16043">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Immune reconstitution syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16050">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-3 hr, steady state 5 days, terminal half-life 14 hr, 98% protein binding, metabolized in the liver, excreted in feces 53%, urine 31%</para>
			</section>
			<section type="interactions" id="sidelem4x16055">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decreased:</emphasis> effect of dolutegravir—antacids, laxatives/ sucralfate, oral iron, oral calcium, buffered products</para>
				<para>
					<emphasis style="bold">Decreased:</emphasis> levels—rifampin efavirenz, tenofovir, tipranavir/ritonavir</para>
				<section type="none" id="sidelem4x16066">
					<section type="none" id="sidelem4x16067">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x16071">
								<item>
									<label>•</label>
									<para>Avoid concurrent use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16078">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16081">
					<section type="none" id="sidelem4x16082">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16087">
								<item>
									<label>•</label>
									<para>HIV infection: CD4, T-cell count, plasma HIV RNA, viral load; resistance testing before treatment, at treatment failure</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16092">
								<item>
									<label>•</label>
									<para>Drug resistance testing before use in treatment naïve patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16100">
							<label>•</label>
							<sec_title>
								<route>Immune reconstitution syndrome, usually during initial phase of treatment; may need antiinfective before starting</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x16103">
								<item>
									<label>•</label>
									<para>Monitor total HDL/LDL cholesterol baseline and periodically; all may be elevated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16108">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16112">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in cell counts, T-cell counts</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16118">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16122">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose missed to take as soon as remembered up to 1 hr before next dose; not to double dose; not to share with others</para>
								</item>
								<item>
									<label>•</label>
									<para>That sexual partners need to be told that patient has HIV; that product does not cure infection, just controls symptoms, does not prevent infecting others</para>
								</item>
								<item>
									<label>•</label>
									<para>To report sore throat, fever, fatigue (may indicate superinfection)</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; to avoid breastfeeding and to continue follow-up exams and work</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>donepezil (Rx)</mono_name>
			<info>
				<pronunciation>(don-ep-ee′zill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x161481">Aricept</tradename>
					<tradename id="tnidelem4x161480">Aricept ODT</tradename>
				</tradenames>
				<class type="func"> Anti-Alzheimer’s agent</class>
				<class type="chem"> Reversible cholinesterase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x16158">
				<sec_title>Action:</sec_title>
				<para>Elevates acetylcholine concentrations (cerebral cortex) by slowing degradation of acetylcholine released in cholinergic neurons; does not alter underlying dementia</para>
			</section>
			<section type="uses" id="sidelem4x16163">
				<sec_title>Uses:</sec_title>
				<para>Mild to severe dementia with Alzheimer’s disease</para>
				<section type="none" id="sidelem4x16168">
					<section type="none" id="sidelem4x16169">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Subcortical, vascular dementia; dementia with Lewy bodies</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16174">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or piperidine derivatives</para>
				<section type="none" id="sidelem4x16179">
					<section type="none" id="sidelem4x16180">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, sick sinus syndrome, history of ulcers, GI bleeding, hepatic disease, bladder obstruction, asthma, seizures, COPD, abrupt discontinuation, AV block, GI obstruction, Parkinson’s disease, surgery</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16185">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16193">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x16193">
							<item>
								<label>•</label>
								<para> 5 mg/day at bedtime; may increase to 10 mg/day after 4-6 wk, may increase to 23 mg/day after 3 mo of 10 mg/day (moderate to severe)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16197">
					<section type="none" id="sidelem4x16198">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 23 mg; orally disintegrating tabs (Aricept ODT) 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x16203">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16208">
								<item>
									<label>•</label>
									<para>Daily in the evening before bedtime; swallow whole; do not cut, break, chew, or crush tab</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16213">
								<item>
									<label>•</label>
									<para>Dosage adjusted to response no more than q4-6wk; oral dosage forms are interchangeable</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16221">
							<label>•</label>
							<sec_title>Orally disintegrating tabs</sec_title>
							<para>
								<list id="lidelem4x16221">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tabs:</emphasis> allow to dissolve on tongue before swallowing; may be given with/without water</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16225">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16228">
					<section type="none" id="sidelem4x16229">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, <emphasis style="italic">insomnia,</emphasis> somnolence, <emphasis style="italic">headache,</emphasis> fatigue, abnormal dreams, syncope, <emphasis style="bold">seizures,</emphasis> drowsiness, agitation, depression, confusion, fever, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x16243">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Atrial fibrillation,</emphasis> hypo/hypertension, <emphasis style="bold">sinus bradycardia, AV block</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16253">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, <emphasis style="italic">diarrhea,</emphasis> abdominal pain, <emphasis style="bold">GI bleeding,</emphasis> weight loss</para>
					</section>
					<section type="none" id="sidelem4x16267">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, UTI, incontinence</para>
					</section>
					<section type="none" id="sidelem4x16272">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, diaphoresis, bruising</para>
					</section>
					<section type="none" id="sidelem4x16277">
						<sec_title>META:</sec_title>
						<para> Hyperlipidemia</para>
					</section>
					<section type="none" id="sidelem4x16282">
						<sec_title>MS:</sec_title>
						<para> Cramps, arthritis, arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x16288">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis, URI, cough, pharyngitis, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16293">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed PO; metabolized by CYP2D6, CYP3A4; elimination half-life 10 hr single dose, 70 hr multiple doses; protein binding 96%</para>
			</section>
			<section type="interactions" id="sidelem4x16298">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> donepezil effects—CYP2D6, CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> synergistic effect—succinylcholine, cholinesterase inhibitors, cholinergic agonists</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI intolerance—NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> donepezil effects—CYP2D6, CYP3A4 inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of anticholinergics</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—dofetilide, dronedarone, grepafloxacin, mesoridazine, pimozide, probucol, sparfloxacin, ziprasidone, do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> donepezil effect—carBAMazepine, dexamethasone, phenytoin, PHENobarbital, rifampin</para>
				<section type="none" id="sidelem4x16328">
					<section type="none" id="sidelem4x16329">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> donepezil—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16336">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16339">
					<section type="none" id="sidelem4x16340">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16344">
								<item>
									<label>•</label>
									<para>B/P: hypo/hypertension, heart rate</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression, complete suicide assessment; neurologic status</para>
								</item>
								<item>
									<label>•</label>
									<para>GI status: nausea, vomiting, anorexia, diarrhea; monitor weight</para>
								</item>
								<item>
									<label>•</label>
									<para>GU status: urinary frequency, incontinence, I&amp;O</para>
								</item>
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy; dizziness, ataxia may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16370">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16374">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in confusion, improved mood</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16380">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16385">
								<item>
									<label>•</label>
									<para>To report side effects: twitching, nausea, vomiting, sweating, dizziness; indicates cholinergic crisis or overdose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16390">
								<item>
									<label>•</label>
									<para>To use product exactly as prescribed, not to use with other products, unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16395">
								<item>
									<label>•</label>
									<para>To notify prescriber of nausea, vomiting, diarrhea (dose increase or beginning treatment), or rash</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16403">
							<label>•</label>
							<sec_title>
								<route>Not to increase or abruptly decrease dose; serious consequences may result</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x16406">
								<item>
									<label>•</label>
									<para>That product is not a cure, relieves symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active" ha="yes">
			<mono_name> DOPamine (Rx)</mono_name>
			<info>
				<pronunciation>(doe′pa-meen)</pronunciation>
				<class type="func"> Adrenergic</class>
				<class type="chem"> Catecholamine </class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x16426">
				<para>
					<confusion>
						<tradename id="tnidelem4x164260">DOPamine</tradename>
						<drug type="generic" refid="idelem4x164260">DOBUTamine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x16430">
				<sec_title>Action:</sec_title>
				<para>Causes increased cardiac output; acts on β<emphasis style="inf">1</emphasis>- and α-receptors, causing vasoconstriction in blood vessels; low dose causes renal and mesenteric vasodilation; β<emphasis style="inf">1</emphasis> stimulation produces inotropic effects with increased cardiac output</para>
			</section>
			<section type="uses" id="sidelem4x16441">
				<sec_title>Uses:</sec_title>
				<para>Shock, increased perfusion, hypotension, cardiogenic/septic shock</para>
				<section type="none" id="sidelem4x16446">
					<section type="none" id="sidelem4x16447">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bradycardia, cardiac arrest, CPR, acute renal failure, cirrhosis, barbiturate intoxication</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16452">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, ventricular fibrillation, tachydysrhythmias, pheochromocytoma, hypovolemia</para>
				<section type="none" id="sidelem4x16457">
					<section type="none" id="sidelem4x16458">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, arterial embolism, peripheral vascular disease, sulfite hypersensitivity, acute MI</para>
						<para>
							<bbw>Extravasation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16473">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16481">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x16481">
							<item>
								<label>•</label>
								<para> 2-5 mcg/kg/min, titrate upward in 5-10 mcg/kg/min increments, max 50 mcg/kg/min; titrate to patient’s response</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16488">
					<label>•</label>
					<sec_title>Child<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x16488">
							<item>
								<label>•</label>
								<para> 1-5 mcg/kg/min initially; usual dosage range, 2-20 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16493">
					<section type="none" id="sidelem4x16494">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x16502">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16502">
									<item>
										<label>•</label>
										<para> 3-10 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16506">
						<sec_title>Bradycardia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16514">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x16514">
									<item>
										<label>•</label>
										<para> 2-10 mcg/kg/min, titrate as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16518">
						<sec_title>Available forms:</sec_title>
						<para> Inj 40 mg, 80 mg, 160 mg/ml; concentrations for IV infusion 0.8, 1.6, 3.2 mg/ml in 250, 500 ml D<emphasis style="inf">5</emphasis>W</para>
					</section>
					<section type="none" id="sidelem4x16526">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16530">
								<item>
									<label>•</label>
									<para>Store reconstituted sol for up to 24 hr if refrigerated</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use discolored sol; protect from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16541">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x16546">
									<item>
										<label>•</label>
										<para>IV after diluting 200-400 mg/250-500 ml of D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis> 0.45% NaCl, D<emphasis style="inf">5</emphasis> 0.9% NaCl, D<emphasis style="inf">5</emphasis>LR, LR; use large vein</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x16566">
								<para>
									<list id="lidelem4x16566">
										<item>
											<label>•</label>
											<para>After reconstituting, use infusion pump; give at rate of 0.5-5 mcg/kg/min, increase by 1-4 mcg/kg/min at 10-30 min intervals until desired response
<bbw>
													<emphasis alert="lifethreat">Extravasation:</emphasis> if extravasation occurs, stop infusion, may inject area with phentolamine 10 mg/15 ml of NS</bbw>
</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, alprostadil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clarithromycin, clindamycin, cloNIDine, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, foscarnet, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, meperidine, methicillin, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micanfungin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, temocillin, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, warfarin, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16584">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16587">
					<section type="none" id="sidelem4x16588">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> anxiety</para>
					</section>
					<section type="none" id="sidelem4x16596">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations,</emphasis><emphasis style="bold">tachycardia,</emphasis><emphasis style="italic">hypertension, ectopic beats, angina,</emphasis><emphasis style="bold">wide QRS complex,</emphasis> peripheral vasoconstriction, hypotension</para>
					</section>
					<section type="none" id="sidelem4x16610">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16617">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Necrosis, tissue sloughing with extravasation, gangrene</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16624">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16629">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x16632">
					<section type="none" id="sidelem4x16633">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min; duration &lt;10 min; metabolized in liver, kidney, plasma; excreted in urine (metabolites); half-life 2 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x16638">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x16646">
					<label>•</label>
					<sec_title>
						<route>Do not use within 2 wk of MAOIs; hypertensive crisis may result</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia, hypotension—phenytoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—general anesthetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypertension—ergots</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—oxytocics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pressor effect—tricyclics, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> DOPamine action—β-/α-blockers</para>
				<section type="none" id="sidelem4x16673">
					<section type="none" id="sidelem4x16674">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> urinary catecholamine, serum glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16681">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16684">
					<section type="none" id="sidelem4x16685">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x16690">
								<item>
									<label>•</label>
									<para>Hypovolemia; if present, correct first</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16698">
							<label>•</label>
							<sec_title>Oxygenation/perfusion deficit<route> check B/P, chest pain, dizziness, loss of consciousness</route></sec_title>
						</section>
						<section type="none" id="sidelem4x16704">
							<label>•</label>
							<sec_title>Heart failure<route> S</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x16712">
								<item>
									<label>•</label>
									<para>I&amp;O ratio: if urine output decreases without decrease in B/P, product may need to be reduced</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16720">
							<label>•</label>
							<sec_title>
								<route>ECG during administration continuously; if B/P increases, product should be decreased; PCWP, CVP during infusion</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x16723">
								<item>
									<label>•</label>
									<para>B/P, pulse q5min</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16728">
								<item>
									<label>•</label>
									<para>Paresthesias and coldness of extremities; peripheral blood flow may decrease</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16736">
							<label>•</label>
							<sec_title>Inj site<route> tissue sloughing; if this occurs, administer phentolamine mixed with NS</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16739">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16743">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased B/P with stabilization; increased urine output</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16749">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16753">
								<item>
									<label>•</label>
									<para>About the reason for product administration</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>doripenem (Rx)</mono_name>
			<info>
				<pronunciation>(dore-i-pen′em)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x167690">Doribax</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Carbapenem</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x16779">
				<sec_title>Action:</sec_title>
				<para>Bactericidal; interferes with cell-wall replication of susceptible organisms; osmotically unstable cell-wall swells, bursts from osmotic pressure</para>
			</section>
			<section type="uses" id="sidelem4x16784">
				<sec_title>Uses:</sec_title>
				<para>Serious infections caused by <emphasis style="italic">Acinetobacter baumannii, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Escherichia coli, Klebsiella pneumoniae, Peptostreptococcus micros, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus constellatus, Streptococcus intermedius</emphasis>; complicated urinary tract infections, pyelonephritis, complicated intraabdominal infections</para>
			</section>
			<section type="contra" id="sidelem4x16792">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to carbapenems (meropenem, doripenem, imipenem), penicillin, β-lactam; viral infection</para>
				<section type="none" id="sidelem4x16797">
					<section type="none" id="sidelem4x16798">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, renal disease, seizure disorder, pseudomembranous colitis, nebulizer or inhalation use, hypersensitivity to cephalosporins, children/adolescents</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16804">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16812">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x16812">
							<item>
								<label>•</label>
								<para> 500 mg q8hr × 5-14 days; if improvement occurs after 3 days, switch to appropriate oral product</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x16816">
					<section type="none" id="sidelem4x16817">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x16825">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 30-50 ml/min, 250 mg over 1 hr, q8hr; CCr &gt;10 to &lt;30 ml/min, 250 mg over 1 hr q12hr; CCr ≤10 ml/min, no data</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x16828">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 250, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x16833">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x16836">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x16841">
									<item>
										<label>•</label>
										<para>Visually inspect parenteral products for particulate matter and discoloration before use, diluted range in color from clear, colorless solutions to solutions that are clear and slightly yellow</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x16849">
								<label>•</label>
								<sec_title>Reconstitution</sec_title>
								<para>
									<list id="lidelem4x16849">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reconstitution:</emphasis> no bacteriostatic preservative is present; observe aseptic technique while preparing the infusion</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x16856">
								<label>•</label>
								<sec_title>
									<route>500-mg dose using the 500-mg vial</route>
								</sec_title>
								<para>
									<list id="lidelem4x16856">
										<item>
											<label>•</label>
											<para>: reconstitute the vial with 10 ml of sterile water for injection or sodium chloride 0.9% (normal saline); gently shake (50 mg/ml); <emphasis style="italic">the reconstituted suspension is not for direct injection; further dilution is required;</emphasis> using a syringe with a 21-G needle, withdraw the suspension and add it to an infusion bag containing 100 ml of NS or D<emphasis style="inf">5</emphasis>W; gently shake until clear: final concentrations: 4.5 mg/ml</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x16869">
								<label>•</label>
								<sec_title>
									<route>250-mg dose using the 500-mg vial</route>
								</sec_title>
								<para>
									<list id="lidelem4x16869">
										<item>
											<label>•</label>
											<para>: reconstitute the vial with 10 ml of sterile water for injection or sodium chloride 0.9% (normal saline); gently shake (50 mg/ml); <emphasis style="italic">the reconstituted suspension is not for direct injection; further dilution is required;</emphasis> using a syringe with a 21-G needle, withdraw 5 ml (250 mg) and add it to an infusion bag containing 100 ml of normal saline or D<emphasis style="inf">5</emphasis>W; gently shake until clear; remove 55 ml of this solution and discard; the remaining infusion sol contains 250 mg (4.5 mg/ml)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x16882">
								<label>•</label>
								<sec_title>
									<route>250-mg dose using the 250-mg vial</route>
								</sec_title>
								<para>
									<list id="lidelem4x16882">
										<item>
											<label>•</label>
											<para>: reconstitute the vial with 10 ml of sterile water for injection or sodium chloride 0.9% (normal saline); gently shake (25 mg/ml); <emphasis style="italic">the reconstituted suspension is not for direct injection; further dilution is required;</emphasis> using a syringe with a 21-G needle, withdraw the contents of the vial and add it to an infusion bag containing 50 or 100 ml of normal saline or D<emphasis style="inf">5</emphasis>W; gently shake until clear; final concentrations 4.2 mg/ml (50 ml infusion bag) or 2.3 mg/ml (100 ml infusion bag)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x16895">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x16895">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> reconstituted suspensions may be held in vial for up to 1 hr before transfer and dilution in the infusion bag; including storage and infusion time, diluted infusion sols are stable for up to 12 hr (NS) or 4 hr (D<emphasis style="inf">5</emphasis>W) at controlled room temperature; diluted infusion sols are stable for up to 72 hr (NS) or 24 hr (D<emphasis style="inf">5</emphasis>W) refrigerated; do not freeze reconstituted solutions</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x16905">
									<item>
										<label>•</label>
										<para>If Baxter Minibag Plus infusion bags are to be used, consult the instructions provided by the infusion bag manufacturer</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16910">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x16914">
									<item>
										<label>•</label>
										<para>After C&amp;S is taken</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not mix with or physically add to solutions containing other drugs; infuse over 1 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amikacin, aminophylline, amiodarone, anidulafungin, atropine, azithromycin, bumetanide, calcium gluconate, CARBOplatin, caspofungin, ceftaroline, ceftobiprole, cimetidine, ciprofloxacin, CISplatin, cyclophosphamide, cycloSPORINE, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin, enalaprilat, esmolol, esomeprazole, etoposide, famotidine, fentaNYL, fluconazole, fluorouracil, foscarnet, furosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, insulin (regular), labetalol, levofloxacin, linezolid, LORazepam, magnesium sulfate, mannitol, meperidine, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, micafungin, midazolam, milrinone, morphine, moxifloxacin, norepinephrine, ondansetron, PACLitaxel, pantoprazole, PHENobarbital, phenylephrine, potassium chloride, ranitidine, sodium bicarbonate/phosphates, tacrolimus, telavancin, tigecycline, tobramycin, vancomycin, voriconazole, zidovudine</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, sterile water for inj</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16938">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16941">
					<section type="none" id="sidelem4x16942">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> headache</para>
					</section>
					<section type="none" id="sidelem4x16950">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea,</emphasis> vomiting, <emphasis style="bold">pseudomembranous colitis, hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16960">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal impairments/failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16967">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16974">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, phlebitis, erythema at inj site, <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis,</emphasis> pruritus</para>
					</section>
					<section type="none" id="sidelem4x16985">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pneumonitis (inhalation)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16992">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16999">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x17002">
					<section type="none" id="sidelem4x17003">
						<sec_title>IV:</sec_title>
						<para> Distributed to most body fluids/tissue, excreted mainly unchanged in urine, 70% recovered in 48 hr, half-life 1 hr, half-life extended in renal disease</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x17008">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> doripenem plasma levels—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of valproic acid, divalproex sodium</para>
				<section type="none" id="sidelem4x17019">
					<section type="none" id="sidelem4x17020">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, LDH, BUN, alk phos, bilirubin, creatinine</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> direct Coombs’ test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17031">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17034">
					<section type="none" id="sidelem4x17035">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17043">
							<label>•</label>
							<sec_title>
								<route>Sensitivity to carbapenem antibiotics, penicillins, cephalosporins, other beta lactams</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17046">
								<item>
									<label>•</label>
									<para>Renal disease: lower dose may be required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17051">
								<item>
									<label>•</label>
									<para>Bowel pattern daily; if severe diarrhea occurs, product should be discontinued; may indicate pseudomembranous colitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17056">
								<item>
									<label>•</label>
									<para>For infection: temperature; sputum; characteristics of wound before, during, and after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17062">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis: rash, urticaria, pruritus; may occur few days after therapy begins</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17070">
							<label>•</label>
							<sec_title>Overgrowth of infection<route> perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17073">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17077">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S; absence of symptoms and signs of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17083">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x17091">
							<label>•</label>
							<sec_title>
								<route>To report severe diarrhea; may indicate pseudomembranous colitis</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x17097">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, bruising, bleeding, joint pain; may indicate blood dyscrasias (rare)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x17103">
							<label>•</label>
							<sec_title>To report overgrowth of infection<route> black, furry tongue; vaginal itching; foul-smelling stools</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x17106">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding; product is excreted in breast milk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active">
			<mono_name>dorzolamide (ophthalmic)</mono_name>
			<info>
				<pronunciation>(dor-zole′ah-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x171210">Trusopt</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma</class>
				<class type="chem"> Carbonic anhydrase inhibitor</class>
			</info>
			<section type="actions" id="sidelem4x17131">
				<sec_title>Action:</sec_title>
				<para>Decreases aqueous humor secretion by decreasing bicarbonate, thus decreasing IOP</para>
			</section>
			<section type="uses" id="sidelem4x17136">
				<sec_title>Uses:</sec_title>
				<para>For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma</para>
			</section>
			<section type="contra" id="sidelem4x17141">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x17147">
					<section type="none" id="sidelem4x17148">
						<sec_title>Precautions:</sec_title>
						<para> Hypersensitivity to sulfonamides, hepatic/renal disease, angle-closure glaucoma, electrolyte disturbances</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17153">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17156">
					<section type="none" id="sidelem4x17157">
						<sec_title>Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma</sec_title>
						<section type="none" id="sidelem4x17165">
							<label>•</label>
							<sec_title>Adult/adolescent/child/infant/neonate ≥1 wk<route> Ophthalmic</route></sec_title>
							<para>
								<list id="lidelem4x17165">
									<item>
										<label>•</label>
										<para> Instill 1 drop of a 2% solution into the affected eye(s) tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17169">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 2%</para>
					</section>
					<section type="none" id="sidelem4x17174">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17178">
								<item>
									<label>•</label>
									<para>Wash hands before and after use, tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch, squeeze the prescribed number of drops into the pouch and gently close eyes for 1-2 min; do not blink</para>
								</item>
								<item>
									<label>•</label>
									<para>Care should be taken to avoid contamination; do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
								</item>
								<item>
									<label>•</label>
									<para>The sol may be used concomitantly with other topical ophthalmic drug products to lower IOP; if more than one topical ophthalmic drug is being used, administer ≥10 min apart</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17194">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17197">
					<section type="none" id="sidelem4x17198">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x17203">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, tearing, allergy, burning/stinging, photophobia</para>
					</section>
					<section type="none" id="sidelem4x17208">
						<sec_title>GI:</sec_title>
						<para> Bitter taste</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17213">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 1-2 hr, peak 3 hr, duration 8 hr, half-life 4 mo</para>
			</section>
			<section type="interactions" id="sidelem4x17218">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—carbonic anhydrase inhibitors (PO)</para>
			</section>
			<section type="considerations" id="sidelem4x17225">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17228">
					<section type="none" id="sidelem4x17229">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17233">
								<item>
									<label>•</label>
									<para>Hypersensitivity</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor IOP during treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17244">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17248">
								<item>
									<label>•</label>
									<para>Decreasing IOP</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17254">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17259">
								<item>
									<label>•</label>
									<para>How to use product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17264">
								<item>
									<label>•</label>
									<para>Not to share with others or use for other conditions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17272">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately if vision changes or if condition worsens</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17275">
								<item>
									<label>•</label>
									<para>To take as prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>doxazosin (Rx)</mono_name>
			<info>
				<pronunciation>(dox-ay′zoe-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x172851">Cardura</tradename>
					<tradename id="tnidelem4x172850">Cardura XL</tradename>
				</tradenames>
				<class type="func"> Peripheral α-adrenergic receptor blocker</class>
				<class type="chem"> Quinazoline</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x17298">
				<para>
					<confusion>
						<tradename id="tnidelem4x172980">Cardura</tradename>
						<drug type="generic" refid="idelem4x172980">Coumadin/Cardene/Ridaura</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x17302">
				<sec_title>Action:</sec_title>
				<para>Dilates peripheral blood vessels, lowers peripheral resistance; reduction in B/P results from peripheral α<emphasis style="inf">1</emphasis>-adrenergic receptors being blocked</para>
			</section>
			<section type="uses" id="sidelem4x17310">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, urinary outflow obstruction, symptoms of benign prostatic hyperplasia</para>
			</section>
			<section type="contra" id="sidelem4x17315">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to quinazolines</para>
				<section type="none" id="sidelem4x17320">
					<section type="none" id="sidelem4x17321">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hepatic disease, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17326">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17329">
					<section type="none" id="sidelem4x17330">
						<sec_title>BPH</sec_title>
						<section type="none" id="sidelem4x17338">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17338">
									<item>
										<label>•</label>
										<para> 1 mg/day at bedtime; increase in stepwise manner to 2, 4, 8 mg/day as needed at 1-2 wk intervals, max 8 mg; ext rel tab (Cardura XL) 4 mg daily with breakfast, adjust dose q3-4wk, up to 8 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17342">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x17350">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17350">
									<item>
										<label>•</label>
										<para> 1 mg/day at bedtime; increasing up to 16 mg/day if required; usual range 4-16 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17357">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17357">
									<item>
										<label>•</label>
										<para> 0.5 mg nightly, gradually increase</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17361">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 4, 8 mg; ext rel tabs 4, 8 mg</para>
					</section>
					<section type="none" id="sidelem4x17367">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17372">
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17380">
							<label>•</label>
							<sec_title>
								<route>Tabs</route>
							</sec_title>
							<para>
								<list id="lidelem4x17380">
									<item>
										<label>•</label>
										<para> broken, crushed, or chewed; if chewed, will be bitter; do not break, crush, chew XL tabs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17387">
							<label>•</label>
							<sec_title>Immediate release tab</sec_title>
							<para>
								<list id="lidelem4x17387">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Immediate release tab:</emphasis> without regard to meals; <emphasis style="bold">ext rel tabs:</emphasis> give with breakfast; when switching from immediate release to ext rel, the final evening dose of immediate release should not be taken</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17394">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17397">
					<section type="none" id="sidelem4x17398">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> drowsiness, anxiety, depression, <emphasis style="italic">vertigo,</emphasis> weakness, fatigue, asthenia, syncope</para>
					</section>
					<section type="none" id="sidelem4x17409">
						<sec_title>CV:</sec_title>
						<para> Palpitations, <emphasis style="italic">orthostatic hypotension</emphasis>, tachycardia, <emphasis style="italic">edema,</emphasis><emphasis style="bold">dysrhythmias,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x17422">
						<sec_title>EENT:</sec_title>
						<para> Epistaxis, tinnitus, dry mouth, red sclera, pharyngitis, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x17427">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, constipation, abdominal pain, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17437">
						<sec_title>GU:</sec_title>
						<para> Incontinence, polyuria, priapism, impotence</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17442">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x17445">
					<section type="none" id="sidelem4x17446">
						<sec_title>PO:</sec_title>
						<para> Onset 2 hr, peak 2-3 hr, duration up to 24 hr, half-life 22 hr, metabolized in liver, excreted via bile/feces (&lt;63%) and in urine (9%), extensively protein bound (98%) ​</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x17451">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effects—alcohol, other antihypertensives, nitrates, PDE-5 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effects of cloNIDine</para>
			</section>
			<section type="considerations" id="sidelem4x17462">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17465">
					<section type="none" id="sidelem4x17466">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17474">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x17474">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P (lying, standing), pulse 2-6 hr after each dose, with each increase; postural effects may occur, crackles, dyspnea, orthopnea with B/P; pulse; jugular venous distention during beginning treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17481">
							<label>•</label>
							<sec_title>BPH</sec_title>
							<para>
								<list id="lidelem4x17481">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">BPH:</emphasis> urinary pattern changes (hesitancy, dribbling, incomplete bladder emptying, dysuria, urgency, nocturia, urgency incontinence, intermittency) before and during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17485">
								<item>
									<label>•</label>
									<para>I&amp;O, weight daily; edema in feet, legs daily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17490">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17494">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P; decreased symptoms of BPH</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17500">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x17508">
							<label>•</label>
							<sec_title>
								<route>That fainting occasionally occurs after 1st dose; not to drive, operate machinery for 4 hr after 1st dose, after dosage increase; to take 1st dose at bedtime; may take 1-2 wk to respond with BPH</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17511">
								<item>
									<label>•</label>
									<para>Rise slowly from sitting position</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>doxepin (Rx)</mono_name>
			<info>
				<pronunciation>(dox′e-pin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x175262">Prudoxin Cream</tradename>
					<tradename id="tnidelem4x175261">Silenor</tradename>
					<tradename id="tnidelem4x175260">Zonalon Topical Cream</tradename>
				</tradenames>
				<class type="func"> Antidepressant, tricyclic, antihistamine (topical)</class>
				<class type="chem"> Dibenzoxepin, tertiary amine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17536">
				<sec_title>Action:</sec_title>
				<para>Blocks reuptake of norepinephrine, serotonin into nerve endings, increasing action of norepinephrine, serotonin in nerve cells</para>
			</section>
			<section type="uses" id="sidelem4x17541">
				<sec_title>Uses:</sec_title>
				<para>Major depression, anxiety; <emphasis style="italic">topical:</emphasis> lichen simplex, atopic dermatitis, eczema, insomnia, migraine prophylaxis</para>
				<section type="none" id="sidelem4x17549">
					<section type="none" id="sidelem4x17550">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Topical pruritus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17555">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to tricyclics, urinary retention, closed-angle glaucoma, prostatic hypertrophy, acute recovery from MI</para>
				<section type="none" id="sidelem4x17560">
					<section type="none" id="sidelem4x17561">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (PO) (B) (topical), breastfeeding, geriatric patients, seizures</para>
						<para>
							<bbw>Children, suicidal patients</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17577">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17580">
					<section type="none" id="sidelem4x17581">
						<sec_title>Depression/anxiety</sec_title>
						<section type="none" id="sidelem4x17589">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17589">
									<item>
										<label>•</label>
										<para> 50-75 mg/day, may increase to 300 mg/day for severely ill; give in divided doses if &gt;150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17596">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17596">
									<item>
										<label>•</label>
										<para> 25-50 mg at bedtime, increase weekly by 25-50 mg to desired dose, max 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17600">
						<sec_title>Pruritus</sec_title>
						<section type="none" id="sidelem4x17608">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17608">
									<item>
										<label>•</label>
										<para> 10 mg at bedtime, may increase to 25 mg at bedtime;  apply thin film qid at least 3 hr apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17615">
						<sec_title>Insomnia (Silenor)</sec_title>
						<section type="none" id="sidelem4x17623">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17623">
									<item>
										<label>•</label>
										<para> 6 mg 30 min before bedtime, 3 mg may be sufficient, max 6 mg/night</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17627">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10, 25, 50, 75, 100, 150 mg; oral concentrations 10 mg/ml; cream 5%; tabs (Silenor) 3, 6 mg</para>
					</section>
					<section type="none" id="sidelem4x17632">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17640">
							<label>•</label>
							<sec_title>Oral concentrations</sec_title>
							<para>
								<list id="lidelem4x17640">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral concentrations:</emphasis> should be diluted with 120 ml water, milk or orange, grapefruit, tomato, prune, or pineapple juice; do not mix with grape juice</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17644">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17649">
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms; do not give with carbonated beverages</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17654">
								<item>
									<label>•</label>
									<para>Dosage at bedtime to avoid oversedation during day; may take entire dose at bedtime; geriatric patients may not tolerate daily dosing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17659">
								<item>
									<label>•</label>
									<para>Gum, hard candy, or frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17664">
								<item>
									<label>•</label>
									<para>Store in tight container protected from direct sunlight</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17672">
							<label>•</label>
							<sec_title>Topical</sec_title>
							<para>
								<list id="lidelem4x17672">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Topical:</emphasis> by applying to affected area, rub slightly; do not use occlusive dressings</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17676">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17679">
					<section type="none" id="sidelem4x17680">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, EPS (geriatric patients), increased psychiatric symptoms, paresthesia, <emphasis style="bold">suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17690">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension, ECG changes, tachycardia,</emphasis><emphasis style="bold">hypertension,</emphasis> palpitations, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17702">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis, ophthalmoplegia, glossitis</para>
					</section>
					<section type="none" id="sidelem4x17710">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dry mouth,</emphasis> nausea, vomiting, <emphasis style="bold">paralytic ileus,</emphasis> increased appetite, cramps, epigastric distress, jaundice, <emphasis style="bold">hepatitis,</emphasis> stomatitis, constipation</para>
					</section>
					<section type="none" id="sidelem4x17724">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary retention,</emphasis><emphasis style="bold">acute renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17733">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia,</emphasis> pancytopenia, purpuric disorder</para>
					</section>
					<section type="none" id="sidelem4x17741">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17746">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x17749">
					<section type="none" id="sidelem4x17750">
						<sec_title>PO:</sec_title>
						<para> Peak 2 hr, metabolized by liver, excreted by kidneys, crosses placenta, excreted in breast milk, half-life 8-24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x17755">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: hyperpyretic crisis, seizures, hypertensive episode—MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypertensive action—EPINEPHrine, norepinephrine</para>
				<para>
					<emphasis alert="lifethreat">Increase: hypertensive crisis—cloNIDine; do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> doxepin effect—cimetidine, FLUoxetine, fluvoxaMINE, PARoxetine, sertraline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—barbiturates, benzodiazepines, sedative/hypnotics, alcohol, other CNS depressants</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT interval: class IC/III antiarrhythmics (propafenone, flecainide), quinolones</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serotonin syndrome, toxicity—SSRIs, SNRIs, serotonin-receptor agonists</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—anticholinergics</para>
				<section type="none" id="sidelem4x17787">
					<section type="none" id="sidelem4x17788">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x17792">
								<item>
									<label>•</label>
									<para>Serotonin syndrome: St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17798">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos, LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17805">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17808">
					<section type="none" id="sidelem4x17809">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17814">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17821">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, leukocytes, differential, cardiac enzymes if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17826">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17831">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17839">
							<label>•</label>
							<sec_title>
								<route>ECG for flattening of</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x17850">
							<label>•</label>
							<sec_title>
								<route>EPS</route>
							</sec_title>
							<para>
								<list id="lidelem4x17850">
									<item>
										<label>•</label>
										<para> primarily in geriatric patients: rigidity, dystonia, akathisia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17857">
							<label>•</label>
							<sec_title>Depression<route> mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x17863">
							<label>•</label>
							<sec_title>Chronic pain</sec_title>
							<para>
								<list id="lidelem4x17863">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Chronic pain:</emphasis> location, severity, type before and during treatment, alleviating/aggravating factors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17867">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation most likely in children, geriatric patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17875">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x17875">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not usual unless product is discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17879">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol is consumed, hold dose until morning</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17884">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy because drowsiness/dizziness occurs; safety measures primarily for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17889">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17893">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17899">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17904">
								<item>
									<label>•</label>
									<para>That therapeutic effect (depression) may take 2-3 wk, antianxiety effects sooner</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17909">
								<item>
									<label>•</label>
									<para>To use caution when driving, during other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17914">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants; may potentiate effects</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17919">
								<item>
									<label>•</label>
									<para>Not to discontinue medication abruptly after long-term use; may cause nausea, headache, malaise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17924">
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat; photosensitivity occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17932">
							<label>•</label>
							<sec_title>
								<route>That clinical worsening and suicide may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17935">
								<item>
									<label>•</label>
									<para>To immediately report urinary retention</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active" ha="yes">
			<mono_name> DOXOrubicin</mono_name>
			<info>
				<pronunciation>(dox-oh-roo′bi-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x179520">Adriamycin</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="chem"> Anthracycline glycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x17962">
				<para>
					<confusion>
						<tradename id="tnidelem4x179620">DOXOrubicin</tradename>
						<drug type="generic" refid="idelem4x179620">DOXOrubicin liposomal/DAUNOrubicin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x17966">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA synthesis primarily; replication is decreased by binding to DNA, which causes strand splitting; active throughout entire cell cycle; a vesicant</para>
			</section>
			<section type="uses" id="sidelem4x17971">
				<sec_title>Uses:</sec_title>
				<para>Wilms’ tumor; bladder, breast, lung, ovarian, stomach, thyroid cancer; Hodgkin’s/non-Hodgkin’s disease; acute lymphoblastic leukemia; myeloblastic leukemia; neuroblastomas; soft tissue/bone sarcomas</para>
			</section>
			<section type="contra" id="sidelem4x17976">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 1st trimester, breastfeeding, hypersensitivity, systemic infections, cardiac disorders, severe myelosuppression, lifetime dose of 550 mg/m<emphasis style="sup">2</emphasis></para>
				<para>
					<bbw>Hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x17993">
					<section type="none" id="sidelem4x17994">
						<sec_title>Precautions:</sec_title>
						<para> Accidental exposure, cardiac disease, dental work, electrolyte imbalance, infection, hyperuricemia</para>
						<para>
							<bbw>Bone marrow suppression, extravasation, heart failure, secondary malignancy; requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18010">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18018">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x18018">
							<item>
								<label>•</label>
								<para> 60-75 mg/m<emphasis style="sup">2</emphasis> every 3 wk, or may be used in combination with other antineoplastics with 40-75 mg/m<emphasis style="sup">2</emphasis> every 21-28 days, max cumulative dose 550 mg/m<emphasis style="sup">2</emphasis> or 450 mg/m<emphasis style="sup">2</emphasis> if prior DAUNOrubicin, cyclophosphamide, mediastinal XRT</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x18034">
					<section type="none" id="sidelem4x18035">
						<sec_title>Hepatic dose</sec_title>
						<para>
							<emphasis alert="nurse">Adult: IV Bilirubin 1.2-3 mg/dl, give 50% of dose; bilirubin 3.1-5 mg/dl, give 25% of dose</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x18043">
						<sec_title>Renal dose</sec_title>
						<para>
							<emphasis alert="nurse">Adult: IV CCr &lt; 10 ml/min give 75% of dose</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x18051">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 10, 20, 50 mg; inj 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x18056">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18059">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x18064">
									<item>
										<label>•</label>
										<para>Give antiemetic 30-60 min before product to prevent vomiting</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18069">
									<item>
										<label>•</label>
										<para>Give allopurinol or sodium bicarbonate to maintain uric acid levels, alkalization of urine</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18077">
								<label>•</label>
								<sec_title>Use cytotoxic handling procedures<route> inspect for particulate and discoloration before use</route></sec_title>
							</section>
							<para>
								<list id="lidelem4x18098">
									<item>
										<label>•</label>
										<para>Aluminum needles may be used during administration; avoid aluminum during storage</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18103">
									<item>
										<label>•</label>
										<para>Rapid injection can cause facial flushing or erythema along the vein</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18108">
							<sec_title>Reconstitution:</sec_title>
							<para>
								<list id="lidelem4x18113">
									<item>
										<label>•</label>
										<para>To avoid risks with reconstitution, the commercially available injection may be used; there are still risks involved in handling the injection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18118">
									<item>
										<label>•</label>
										<para>Do not use diluents containing preservatives to reconstitute powder for injection</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18123">
									<item>
										<label>•</label>
										<para>Reconstitute 10, 20, 50, 100 mg of DOXOrubicin with 5, 10, 25, 50 ml, respectively, of nonbacteriostatic NS injection (2 mg/ ml), shake until completely dissolved; use reconstituted solution within 24 hr; do not expose to sunlight</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x18131">
								<label>•</label>
								<sec_title>
									<route>IV injection</route>
								</sec_title>
								<para>
									<list id="lidelem4x18131">
										<item>
											<label>•</label>
											<para> Inject reconstituted solution over &gt;3-5 min via <emphasis style="sans-serif">Y</emphasis>-site or 3-way stopcock into a free-flowing IV infusion of NS or D<emphasis style="inf">5</emphasis>W; a butterfly needle inserted into a large vein is preferred
<bbw>Care should be taken to avoid extravasation because the drug is extremely irritating to extravascular tissue</bbw>
</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x18150">
									<item>
										<label>•</label>
										<para>Increased fluid intake to 2-3 L/day to prevent urate, calculi formation</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18155">
									<item>
										<label>•</label>
										<para>Store at room temperature for 24 hr after reconstituting</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amifostine, amikacin, anidulafungin, argatroban, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceftizoxime, chlorproMAZINE, cimetidine, ciprofloxacin, CISplatin, cladribine, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, gemcitabine, gentamicin, granisetron, haloperidol, hydrocortisone, HYDROmorphone, ifosfamide, imipenem cilastatin, inamrinone, isoproterenol, ketorolac, labetalol, leucovorin, levorphanol, lidocaine, linezolid, LORazepam, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoMYcin, morphine, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pancuronium, phenylephrine, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, sargramostim, sodium acetate, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18166">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18169">
					<section type="none" id="sidelem4x18170">
						<sec_title>CV:</sec_title>
						<para> Increased B/P, sinus tachycardia, PVCs, chest pain, bradycardia, extrasystoles, <emphasis style="bold">irreversible cardiomyopathy, acute left ventricular failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18177">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, <emphasis style="italic">mucositis,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18189">
						<sec_title>GU:</sec_title>
						<para> Impotence, sterility, amenorrhea, gynecomastia, hyperuricemia, urine discoloration</para>
					</section>
					<section type="none" id="sidelem4x18194">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18201">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">necrosis at inj site,</emphasis> dermatitis, reversible <emphasis style="italic">alopecia,</emphasis> cellulitis, thrombophlebitis at inj site, <emphasis style="bold">radiation recall</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18216">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18223">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 30 min, terminal 16.5 hr; metabolized by liver; crosses placenta; excreted in urine, bile, breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x18228">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: life-threatening dysrhythmias—posaconazole, fluconazole, do not use together</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—other drugs that increase QT prolongation</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: neutropenia, thrombocytopenia—progesterone</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: cardiomyopathy—calcium-channel blockers</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—other antineoplastics, cycloSPORINE, radiation, mercaptopurine</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: hemorrhagic cystitis risk, cardiac toxicity—cyclophosphamide</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of phenytoin, fosphenytoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> DOXOrubicin effect—streptozocin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> DOXOrubicin effect—PHENobarbital</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antineoplastic effect—hematopoietic progenitor cell; do not use 24 hr before or after treatment</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of DOXOrubicin—PACLitaxel</para>
				<section type="none" id="sidelem4x18273">
					<section type="none" id="sidelem4x18274">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18281">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18284">
					<section type="none" id="sidelem4x18285">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> CBC, differential, platelet count weekly; withhold or reduce dose of product if WBC is &lt;1500/mm3 or platelet count is &lt;50,000/mm3; notify prescriber of these results</bbw>
						</para>
						<para>
							<emphasis style="bold">Renal studies:</emphasis> BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
						<para>
							<emphasis style="bold">I&amp;O ratio:</emphasis> Report fall in urine output to &lt;30 ml/hr</para>
						<para>
							<emphasis style="bold">Monitor temperature:</emphasis> Fever might indicate beginning infection</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> hepatic studies before, during therapy: bilirubin, AST, ALT, alk phos as needed or monthly; check for jaundice of skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Dysrhythmias:</emphasis> ECG; watch for ST-T wave changes, low QRS and T, possible dysrhythmias (sinus tachycardia, heart block, PVCs), ejection fraction before treatment, signs of irreversible cardiomyopathy, can occur up to 6 mo after treatment begins</bbw>
						</para>
						<para>
							<list id="lidelem4x18343">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae of mucosa or orifices every 8 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes; almost total alopecia is expected</para>
								</item>
								<item>
									<label>•</label>
									<para>Buccal cavity every 8 hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
								<item>
									<label>•</label>
									<para>Alkalosis if severe vomiting is present</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Extravasation:</emphasis> local irritation, pain, burning at inj site; a vesicant; if extravasation occurs, stop drug, restart at another site, apply ice, elevate extremity to reduce swelling; if resolution does not occur, surgical debridement may be required</bbw>
						</para>
						<para>
							<list id="lidelem4x18376">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18387">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18391">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18397">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18402">
								<item>
									<label>•</label>
									<para>To add 2-3 L of fluids unless contraindicated before and for 24-48 hr after to decrease possible hemorrhagic cystitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18407">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to nurse or prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18412">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece might make patient feel better; that new hair might be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18417">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18422">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18427">
								<item>
									<label>•</label>
									<para>That urine, other body fluids may be red-orange for 48 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18432">
								<item>
									<label>•</label>
									<para>To avoid crowds and persons with infections when granulocyte count is low</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18440">
							<label>•</label>
							<sec_title>
								<route>That barrier contraceptive measures are recommended during therapy and for 4 mo after (pregnancy [D]); to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18443">
								<item>
									<label>•</label>
									<para>To avoid vaccinations</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active" ha="yes">
			<mono_name> DOXOrubicin liposomal</mono_name>
			<info>
				<pronunciation>(dox-oh-roo′bi-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x184551">Doxil</tradename>
					<tradename id="tnidelem4x184550">Lipodex</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="chem"> Anthracycline glycoside</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x18465">
				<para>
					<confusion>
						<tradename id="tnidelem4x184650">DOXOrubicin</tradename>
						<drug type="generic" refid="idelem4x184650">DOXOrubicin liposomal/DAUNOrubicin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x18469">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA synthesis primarily; replication is decreased by binding to DNA, which causes strand splitting; active throughout entire cell cycle; a vesicant</para>
			</section>
			<section type="uses" id="sidelem4x18474">
				<sec_title>Uses:</sec_title>
				<para>AIDS-related Kaposi’s sarcoma, multiple myeloma, metastatic ovarian carcinoma</para>
			</section>
			<section type="contra" id="sidelem4x18479">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, systemic infections, cardiac disorders</para>
				<para>
					<bbw>Cardiotoxicity, infusion reactions, myelosuppression, hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x18494">
					<section type="none" id="sidelem4x18495">
						<sec_title>Precautions:</sec_title>
						<para> Children, infection, leukopenia, stomatitis, thrombocytopenia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18500">
				<sec_title>Dosage and routes</sec_title>
				<para>Max lifetime cumulative dose 550 mg/m<emphasis style="sup">2</emphasis>; 400 mg/m<emphasis style="sup">2</emphasis> for those who have received other cardiotoxics or mediastinal radiation</para>
				<section type="none" id="sidelem4x18511">
					<section type="none" id="sidelem4x18512">
						<sec_title>Kaposi’s sarcoma</sec_title>
						<section type="none" id="sidelem4x18520">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x18520">
									<item>
										<label>•</label>
										<para> 20 mg/m<emphasis style="sup">2</emphasis> every 3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18528">
						<sec_title>Multiple myeloma</sec_title>
						<section type="none" id="sidelem4x18536">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x18536">
									<item>
										<label>•</label>
										<para> 30 mg/m<emphasis style="sup">2</emphasis> IV infusion on day 4 every 3 wk plus bortezomib 1.3 mg/m<emphasis style="sup">2</emphasis>/dose IV bolus on days 1, 4, 8, 11 of each cycle; give DOXOrubicin liposomal after bortezomib receipt on day 4; administer up to 8 treatment cycles or until disease progression or unacceptable toxicity occurs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18546">
						<sec_title>Breast cancer, metastatic (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18554">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x18554">
									<item>
										<label>•</label>
										<para> 50 mg/m<emphasis style="sup">2</emphasis> day 1, q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18561">
						<sec_title>Available forms:</sec_title>
						<para> Liposomal dispersion for inj: 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x18566">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18571">
								<item>
									<label>•</label>
									<para>Prepared liposomal DOXOrubicin is a translucent, red liposomal dispersion; visually inspect for particulate matter and discoloration before use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18579">
							<label>•</label>
							<sec_title>
								<route>Pegylated liposomal DOXOrubicin (Doxil) is for IV INFUSION use only and should not be given IM/subcut, give under the supervision of a physician who is experienced in cancer chemotherapy</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18591">
								<item>
									<label>•</label>
									<para>Premedication with antiemetics is recommended</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18596">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x18604">
								<label>•</label>
								<sec_title>Reconstitution (Doxil)</sec_title>
								<para>
									<list id="lidelem4x18604">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Reconstitution (Doxil):</emphasis> dilute the appropriate dose, not to exceed 90 mg/250 ml D<emphasis style="inf">5</emphasis>W; do not mix with any other diluent, drugs, or bacteriostatic agent, use aseptic technique; product contains no preservative or bacteriostatic agent; diluted solution must be refrigerated and used within 24 hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18614">
								<label>•</label>
								<sec_title>IV INFUSION (Doxil)</sec_title>
								<para>
									<list id="lidelem4x18614">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">IV INFUSION (Doxil):</emphasis> do not administer as a bolus injection or an undiluted solution; rapid injection can increase the risk of an infusion-related reaction
<bbw>Care should be taken to avoid extravasation because the drug is irritating to extravascular tissue</bbw>
</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18630">
								<label>•</label>
								<sec_title>
									<route>An acute infusion reaction can occur during the first infusion and is usually resolved by slowing the rate of infusion; most patients can tolerate subsequent infusion</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x18636">
								<label>•</label>
								<sec_title>Rate</sec_title>
								<para>
									<list id="lidelem4x18636">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Rate:</emphasis> infuse at an initial rate of 1 mg/min; if no infusion-related action, the rate can be increased to complete the infusion over 1 hr; do not filter</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x18643">
								<label>•</label>
								<sec_title>For hematologic toxicity in patients with ovarian cancer or HIV-related Kaposi’s sarcoma<route> Grade 1 (ANC of 1500-1900/mm</route></sec_title>
							</section>
							<para>
								<list id="lidelem4x18726">
									<item>
										<label>•</label>
										<para>Give antiemetic 30-60 min before product to prevent vomiting</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18731">
									<item>
										<label>•</label>
										<para>Use allopurinol or sodium bicarbonate to maintain uric acid levels, alkalinization of urine</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18736">
									<item>
										<label>•</label>
										<para>Avoid mixing with other products</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18741">
									<item>
										<label>•</label>
										<para>Increase fluid intake to 2-3 L/day to prevent urate, calculi formation</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x18746">
									<item>
										<label>•</label>
										<para>Store refrigerated for 24 hr after reconstituting</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18751">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18754">
					<section type="none" id="sidelem4x18755">
						<sec_title>CNS:</sec_title>
						<para> Paresthesias, headache, depression, insomnia, fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x18760">
						<sec_title>CV:</sec_title>
						<para> Chest pain, decreased B/P, <emphasis style="bold">cardiomyopathy, heart failure, dysrhythmias, tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18767">
						<sec_title>EENT:</sec_title>
						<para> Optic neuritis, rhinitis, pharyngitis, stomatitis</para>
					</section>
					<section type="none" id="sidelem4x18772">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, <emphasis style="italic">mucositis,</emphasis><emphasis style="bold">hepatotoxicity, constipation, oral candidiasis, abdominal pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18785">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18792">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">necrosis at inj site,</emphasis> dermatitis, reversible <emphasis style="italic">alopecia,</emphasis><emphasis style="bold">exfoliative dermatitis, palmar-plantar erythrodysesthesia,</emphasis> thrombophlebitis at inj site</para>
					</section>
					<section type="none" id="sidelem4x18807">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough, respiratory infections</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18812">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 55 hr; metabolized by liver; crosses placenta; excreted in urine, bile, breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x18817">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: life-threatening dysrhythmias—posaconazole, fluconazole, do not use together</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—other drugs that increase QT prolongation</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: neutropenia, thrombocytopenia—progesterone</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: cardiomyopathy—calcium-channel blockers</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—other antineoplastics, cycloSPORINE, radiation, mercaptopurine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hemorrhagic cystitis risk, cardiac toxicity—cyclophosphamide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—phenytoin, fosphenytoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> DOXOrubicin effect—streptozocin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> DOXOrubicin effect—PHENobarbital</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antineoplastic effect—hematopoietic progenitor cell; do not use 24 hr before or after treatment</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of DOXOrubicin—PACLitaxel</para>
				<section type="none" id="sidelem4x18864">
					<section type="none" id="sidelem4x18865">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18872">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18875">
					<section type="none" id="sidelem4x18876">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> CBC, differential, platelet count weekly; withhold product if WBC is &lt;4000/mm3 or platelet count is &lt;75,000/mm3; notify prescriber of these results</bbw>
						</para>
						<para>
							<list id="lidelem4x18897">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>I&amp;O ratio: report fall in urine output to &lt;30 ml/hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Monitor temperature; fever can indicate beginning infection</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> Hepatic studies before, during therapy: bilirubin, AST, ALT, alk phos as needed or monthly; check for jaundice of skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Dysrhythmias:</emphasis> ECG: watch for ST-T wave changes, low QRS and T, possible dysrhythmias (sinus tachycardia, heart block, PVCs), ejection fraction before treatment, signs of irreversible cardiomyopathy, can occur up to 6 mo after treatment begins</bbw>
						</para>
						<para>
							<list id="lidelem4x18937">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, petechiae of mucosa or orifices every 8 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes; almost total alopecia is expected</para>
								</item>
								<item>
									<label>•</label>
									<para>Inflammation of mucosa, breaks in skin</para>
								</item>
								<item>
									<label>•</label>
									<para>Buccal cavity every 8 hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
								<item>
									<label>•</label>
									<para>Alkalosis if severe vomiting is present</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Extravasation:</emphasis> Local irritation, pain, burning at inj site; a vesicant; if extravasation occurs, stop drug, restart at another site, apply ice, elevate extremity to reduce swelling; if resolution does not occur, surgical debridement may be required</bbw>
						</para>
						<para>
							<list id="lidelem4x18975">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18987">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18991">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18997">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x19005">
							<label>•</label>
							<sec_title>
								<route>hemorrhagic cystitis</route>
							</sec_title>
							<para>
								<list id="lidelem4x19005">
									<item>
										<label>•</label>
										<para>To add 2-3 L of fluids unless contraindicated before and for 24-48 hr after to decrease possible </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19009">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to nurse or prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19014">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece might make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19019">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19024">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19029">
								<item>
									<label>•</label>
									<para>That urine, other body fluids may be red-orange for 48 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19034">
								<item>
									<label>•</label>
									<para>To avoid crowds and persons with infections when granulocyte count is low</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19042">
							<label>•</label>
							<sec_title>
								<route>That barrier contraceptive measures are recommended during therapy and for 4 mo after (pregnancy [D]); to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19045">
								<item>
									<label>•</label>
									<para>To avoid vaccinations because reactions can occur; to avoid alcohol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>doxycycline (Rx)</mono_name>
			<info>
				<pronunciation>(dox-i-sye′kleen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x190550">Oracea</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="24" status="active">
			<mono_name>doxycycline calcium</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x190600">Vibramycin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="25" status="active">
			<mono_name>doxycycline hyclate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x190658">Adoxa</tradename>
					<tradename id="tnidelem4x190657">
						<country code="CAN">Apo-Doxy </country>
					</tradename>
					<tradename id="tnidelem4x190656">Doryx</tradename>
					<tradename id="tnidelem4x190655">Doxy</tradename>
					<tradename id="tnidelem4x190654">Doxycaps</tradename>
					<tradename id="tnidelem4x190653">
						<country code="CAN">Doxycin </country>
					</tradename>
					<tradename id="tnidelem4x190652">Periostat</tradename>
					<tradename id="tnidelem4x190651">Vibramycin</tradename>
					<tradename id="tnidelem4x190650">Vibra-Tabs</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="26" status="active">
			<mono_name>doxycycline monohydrate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x190762">Adoxa</tradename>
					<tradename id="tnidelem4x190761">Monodox</tradename>
					<tradename id="tnidelem4x190760">Vibramycin</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Tetracycline</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x19086">
				<para>
					<confusion>
						<tradename id="tnidelem4x190860">doxycycline</tradename>
						<drug type="generic" refid="idelem4x190860">doxepin/dicyclomine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x19090">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis, phosphorylation in microorganisms by binding to 30S ribosomal subunits, reversibly binding to 30S ribosomal subunits; bacteriostatic</para>
			</section>
			<section type="uses" id="sidelem4x19095">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">Acinetobacter</emphasis> sp., <emphasis style="italic">Actinomyces israelii, Bacillus anthracis, Bacteroides</emphasis> sp., <emphasis style="italic">Balantidium coli, Bartonella bacilliformis, Borrelia recurrentis, Brucella</emphasis> sp., <emphasis style="italic">Campylobacter fetus, Chlamydia psittaci, Chlamydia trachomatis, Clostridium</emphasis> sp., <emphasis style="italic">Entamoeba histolytica, Enterobacter aerogenes, Enterococcus</emphasis> sp., <emphasis style="italic">Escherichia coli, Francisella tularensis, Fusobacterium fusiforme, Haemophilus ducreyi, Haemophilus influenzae</emphasis> (beta-lactamase negative), <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase positive), <emphasis style="italic">Klebsiella granulomatis, Klebsiella</emphasis> sp., <emphasis style="italic">Leptospira</emphasis> sp., <emphasis style="italic">Listeria monocytogenes, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Orientia tsutsugamushi, Plasmodium falciparum, Propionibacterium acnes, Rickettsia akari, Rickettsia prowazekii, Rickettsia rickettsii, Shigella</emphasis> sp., <emphasis style="italic">Staphylococcus aureus</emphasis> (MSSA), <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes</emphasis> (group A beta-hemolytic streptococci), <emphasis style="italic">Streptococcus</emphasis> sp., <emphasis style="italic">Treponema pallidum, Treponema pertenue, Ureaplasma urealyticum, Vibrio cholerae, Viridans streptococci, Yersinia pestis;</emphasis> syphilis, gonorrhea, lymphogranuloma venereum, uncommon gram-negative/gram-positive organisms, malaria prophylaxis</para>
				<section type="none" id="sidelem4x19141">
					<section type="none" id="sidelem4x19142">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Enterocolitis, biliary tract, intraabdominal infections; epididymitis <emphasis style="italic">(Chlamydia trachomatis);</emphasis> chronic prostatitis <emphasis style="italic">(Ureaplasma urealyticum);</emphasis> traveler’s diarrhea (enterotoxigenic <emphasis style="italic">Escherichia coli</emphasis>); Legionnaire’s disease <emphasis style="italic">(Legionella pneumophila);</emphasis> Lyme disease <emphasis style="italic">(Borrelia burgdorferi),</emphasis> Lyme disease (erythema migrans); Lyme arthritis; Lyme carditis; pleural effusion; malaria (chloroquine-resistant <emphasis style="italic">Plasmodium falciparum</emphasis>); pelvic inflammatory disease (PID), tubo-ovarian abscess in combination; acute dental infection, dentoalveolar infection, endodontic infection; aggressive juvenile periodontitis, plaque prophylaxis <emphasis style="italic">(Yersinia pestis);</emphasis> tularemia prophylaxis <emphasis style="italic">(Francisella tularensis);</emphasis> Bancroft’s filariasis (elephantiasis) <emphasis style="italic">(Wuchereria bancrofti):</emphasis> melioidosis due to <emphasis style="italic">Burkholderia pseudomallei; Burkholderia pseudomallei</emphasis> bacteremia melioidosis; leptospirosis (<emphasis style="italic">Leptospira</emphasis> sp); infection prophylaxis for gynecologic procedures/surgical infection prophylaxis hysterosalpingogram or chromotubation/induced abortion/dilation and evacuation; methicillin-resistant <emphasis style="italic">Staphylococcus aureus</emphasis> (MRSA)-associated bone and joint infections</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x19185">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), children &lt;8 yr, hypersensitivity to tetracyclines, esophageal ulceration</para>
				<section type="none" id="sidelem4x19190">
					<section type="none" id="sidelem4x19191">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, hepatic disease, pseudomembranous colitis, ulcerative colitis, sulfite hypersensitivity, excessive sunlight</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19196">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19199">
					<section type="none" id="sidelem4x19200">
						<sec_title>Most infections</sec_title>
						<section type="none" id="sidelem4x19208">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x19208">
									<item>
										<label>•</label>
										<para> 100 mg q12hr on day 1, then 100 mg/day;  200 mg in 1-2 infusion on day 1, then 100-200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19218">
							<label>•</label>
							<sec_title>Child &gt;8 yr, ≥45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19218">
									<item>
										<label>•</label>
										<para> 100 mg q12hr on day 1, then 100 mg daily; severe infections 100 mg q12hr;  200 mg on day 1, then 100-200 mg daily, give 200 mg dose as 1 or 2 infusion</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19228">
							<label>•</label>
							<sec_title>Child ≥8 yr, &lt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19228">
									<item>
										<label>•</label>
										<para> 2.2 mg/kg q12hr on day 1, then 2.2 mg/kg daily, severe infections 2.2 mg/kg q12hr;  4.4 mg/kg divided on day 1, then 2.2-4.4 mg/kg daily in 1 to 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19235">
						<sec_title>Gonorrhea (uncomplicated) in patients allergic to penicillin</sec_title>
						<section type="none" id="sidelem4x19243">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19243">
									<item>
										<label>•</label>
										<para> 100 mg q12hr × 7 days or 300 mg followed 1 hr later by another 300 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19247">
						<sec_title>Malaria prophylaxis</sec_title>
						<section type="none" id="sidelem4x19255">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19255">
									<item>
										<label>•</label>
										<para> 100 mg/day 1-2 days before travel, daily during travel, and for 4 wk after return</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19262">
							<label>•</label>
							<sec_title>Adolescent/child ≥8 yr, &lt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19262">
									<item>
										<label>•</label>
										<para> 2 mg/kg/day (up to 100 mg/day) begin 1-2 days before travel, continue for 4 wk after return</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19266">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">C. trachomatis</emphasis>
							</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x19276">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19276">
									<item>
										<label>•</label>
										<para> 100 mg bid × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19280">
						<sec_title>Syphilis</sec_title>
						<section type="none" id="sidelem4x19288">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19288">
									<item>
										<label>•</label>
										<para> 100 mg bid × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19292">
						<sec_title>Anthrax</sec_title>
						<section type="none" id="sidelem4x19300">
							<label>•</label>
							<sec_title>Adult and child &gt;8 yr and ≥45 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x19300">
									<item>
										<label>•</label>
										<para> 100 mg q12hr; change to  when able × 60 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19310">
							<label>•</label>
							<sec_title>Adolescent/child ≥8 yr and &lt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19310">
									<item>
										<label>•</label>
										<para> 2.2 mg/kg q12hr × 60 days;  100 mg q12hr, change to  when able × 60 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19320">
						<sec_title>Lyme disease</sec_title>
						<section type="none" id="sidelem4x19328">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19328">
									<item>
										<label>•</label>
										<para> 100 mg bid × 10-21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19332">
						<sec_title>Periodontitis</sec_title>
						<section type="none" id="sidelem4x19340">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x19340">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 20 mg bid after scaling and root planing for ≤9 mo; give close to meal time <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19349">
						<sec_title>Pleural effusion (unlabeled)</sec_title>
						<section type="none" id="sidelem4x19357">
							<label>•</label>
							<sec_title>Adult<route> INTRACAVITARY</route></sec_title>
							<para>
								<list id="lidelem4x19357">
									<item>
										<label>•</label>
										<para> 500 mg diluted with 250 ml 0.9% NaCl given by chest tube lavage and drainage</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19361">
						<sec_title>Available forms:</sec_title>
						<para> Doxycycline: cap 40 mg; doxycycline calcium: susp 50 mg/5 ml; doxycycline hyclate: cap 20, 50, 100 mg; del rel tabs 75, 100, 150 mg; del rel cap 75, 100 mg; inj 42.5, 100, 200 mg; tabs 20, 100 mg; doxycycline monohydrate: caps 50, 100, 150 mg; tabs 50, 75, 100 mg; oral susp 25 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x19366">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19369">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19374">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew caps; may crush tabs and mix with food</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x19379">
									<item>
										<label>•</label>
										<para>On empty stomach or with full glass of water 2 hr before or after meals; avoid dairy products, antacids, laxatives, iron-containing products; if these must be taken, give 2 hr before or after product; avoid giving oral products within 1 hr of bedtime, esophageal uleration may occur</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x19387">
								<label>•</label>
								<sec_title>Delayed release cap</sec_title>
								<para>
									<list id="lidelem4x19387">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Delayed release cap:</emphasis> Swallow whole or open and sprinkle on applesauce</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x19394">
								<label>•</label>
								<sec_title>Susp</sec_title>
								<para>
									<list id="lidelem4x19394">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Susp:</emphasis> Shake well, use calibrated device, may give with food/milk for GI irritation, store at room temperature, discard after 14 days</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x19399">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x19403">
									<item>
										<label>•</label>
										<para>After diluting 100 mg or less/10 ml or 200 mg/20 ml of sterile water or NS for inj, each 100 mg must be further diluted with 100-1000 ml of NaCl, D<emphasis style="inf">5</emphasis>W, Ringer’s, LR D<emphasis style="inf">5</emphasis>LR, Normosol-M, Normosol-R in D<emphasis style="inf">5</emphasis>W; run 100 mg or less over 1-4 hr; infusion must be completed in 6 hr when diluted in LR sol or 12 hr with other sol; protect from light, heat</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoid rapid use, extravasation</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container at room temperature; IV stable for 12 hr at room temperature, 72 hr refrigerated; discard if precipitate forms</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, amifostine, amikacin, aminophylline, amiodarone, anidulafungin, ascorbic acid, atracurium, atropine, aztreonam, bivalirudin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefonicid, cefotaxime, cefTRIAXone, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, IDArubicin, ifosfamide, imipenem/cilastatin, insulin, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, mitoXANtrone, morphine, multivitamins, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, pancuronium, pantoprazole, papaverine, pentamidine, pentazocine, perphenazine, phentolamine, phenylephrine, phytonadione, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, remifentanil, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, telavancin, teniposide, theophylline, thiamine, thiotepa, tirofiban, tobramycin, tolazoline, TPN (2 in 1), trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19432">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19435">
					<section type="none" id="sidelem4x19436">
						<sec_title>CNS:</sec_title>
						<para> Fever, headache</para>
					</section>
					<section type="none" id="sidelem4x19441">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Pericarditis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19448">
						<sec_title>EENT:</sec_title>
						<para> Dysphagia, glossitis, decreased calcification of deciduous teeth, oral candidiasis, tooth discoloration</para>
					</section>
					<section type="none" id="sidelem4x19453">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, abdominal pain, vomiting, diarrhea,</emphasis> anorexia, enterocolitis, <emphasis style="bold">hepatotoxicity,</emphasis> flatulence, abdominal cramps, gastric burning, stomatitis</para>
					</section>
					<section type="none" id="sidelem4x19464">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Increased BUN</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19471">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19478">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria, photosensitivity, increased pigmentation,</emphasis><emphasis style="bold">exfoliative dermatitis,</emphasis> pruritus, phlebitis, injection site reaction</para>
					</section>
					<section type="none" id="sidelem4x19488">
						<sec_title>MS:</sec_title>
						<para> Bone growth retardation (&lt;8 yr old), muscle, joint pain</para>
					</section>
					<section type="none" id="sidelem4x19493">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
					<section type="none" id="sidelem4x19498">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, angioedema, anaphylaxis, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19505">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x19508">
					<section type="none" id="sidelem4x19509">
						<sec_title>PO:</sec_title>
						<para> Well absorbed widely distributed; peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr; half-life 1 day; excreted in urine, feces, bile; 90% protein bound; crosses placenta; enters breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x19520">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—anticoagulants, digoxin, methotrexate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> doxycycline effect—antacids, NaHCO<emphasis style="inf">3</emphasis>, dairy products, alkali products, iron, kaolin/pectin, barbiturates, carBAMazepine, phenytoin, cimetidine sucralfate, cholestyramine, colestipol, rifampin, bismuth; iron, magnesium, zinc, calcium, aluminum salts, Sevelamer</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects—penicillins, oral contraceptives, digoxin</para>
				<section type="none" id="sidelem4x19539">
					<section type="none" id="sidelem4x19540">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, alk phos, bilirubin, amylase, ALT, AST, eosinophils, WBC</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19555">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19558">
					<section type="none" id="sidelem4x19559">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19564">
								<item>
									<label>•</label>
									<para>I&amp;O ratio</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19569">
								<item>
									<label>•</label>
									<para>Blood studies: PT, CBC, AST, ALT, BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19574">
								<item>
									<label>•</label>
									<para>Signs of infection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19582">
							<label>•</label>
							<sec_title>Allergic reactions<route> rash, itching, pruritus, angioedema</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19585">
								<item>
									<label>•</label>
									<para>Nausea, vomiting, diarrhea; administer antiemetic, antacids as ordered</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19593">
							<label>•</label>
							<sec_title>Overgrowth of infection<route> fever, malaise, redness, pain, swelling, drainage, perineal itching, diarrhea, changes in cough or sputum</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x19596">
								<item>
									<label>•</label>
									<para>IV site for phlebitis/thrombosis; product is highly irritating</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19601">
								<item>
									<label>•</label>
									<para>After C&amp;S is obtained, do not wait for results</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19606">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19610">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased temperature, absence of lesions, negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19616">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19621">
								<item>
									<label>•</label>
									<para>To avoid sun because burns may occur; that sunscreen does not seem to decrease photosensitivity</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19629">
							<label>•</label>
							<sec_title>
								<route>That all prescribed medication must be taken to prevent superinfection; not to use outdated products because Fanconi syndrome may occur (reversible nephrotoxicity)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19635">
							<label>•</label>
							<sec_title>
								<route>That if children ≤8 yr old are undergoing tooth development, teeth will be permanently discolored</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19638">
								<item>
									<label>•</label>
									<para>Not to use with antacids, iron products, H2 blockers, Sevelamer</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19643">
								<item>
									<label>•</label>
									<para>To take with full glass of water; if nausea occurs take with food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active" ru="yes">
			<mono_name> doxylamine/pyridoxine</mono_name>
			<info>
				<pronunciation>(docks-ill’ah-meen/peer-reh-dock’seen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x196550"/>
				</tradenames>
				<class type="func"> Antiemetic</class>
			</info>
			<section type="uses" id="sidelem4x19663">
				<sec_title>Uses:</sec_title>
				<para>Nausea and vomiting of pregnancy in women who do not respond to other treatment</para>
			</section>
			<section type="contra" id="sidelem4x19668">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x19673">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis style="bold">Adult pregnant females: PO</emphasis> 2 tabs (on an empty stomach) at bedtime, on day 1; if dose controls symptoms the next day, continue regimen. If symptoms persist on the afternoon of day 2, continue 2 tabs at bedtime, then take 3 tabs starting on day 3 (1 tab in <emphasis style="smallcaps">am</emphasis> and 2 tabs at bedtime); if symptoms are controlled, continue regimen. If symptoms persist, on day 4, take 4 tabs (1 tab in <emphasis style="smallcaps">am</emphasis>, 1 tab midafternoon, and 2 tabs at bedtime); max 4 tabs/day. Use only as needed</para>
				<section type="none" id="sidelem4x19686">
					<section type="none" id="sidelem4x19687">
						<sec_title>Available forms: </sec_title>
						<para>tab 10 mg/10 mg</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active" ha="yes">
			<mono_name> dronedarone (Rx)</mono_name>
			<info>
				<pronunciation>(drone′da′rone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x196990">Multaq</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic (class III)</class>
				<class type="chem"> Iodinated benzofuran derivative</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x19709">
				<sec_title>Action:</sec_title>
				<para>Prolongs duration of action potential and effective refractory period, noncompetitive α- and β-adrenergic inhibition; increases RR and QT intervals, decreases sinus rate, decreases peripheral vascular resistance</para>
			</section>
			<section type="uses" id="sidelem4x19716">
				<sec_title>Uses:</sec_title>
				<para>Atrial fibrillation, atrial flutter</para>
			</section>
			<section type="contra" id="sidelem4x19721">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding; 2nd-, 3rd-degree AV block; bradycardia, severe sinus node dysfunction, hypersensitivity, heart failure, hepatic disease, QT prolongation, aminodarone-induced lung/liver toxicity</para>
				<para>
					<bbw>NYHA Class IV heart failure or Class II-III with recent decompensation requiring hospitalization, permanent atrial fibrillation (cannot restore sinus rhythm)</bbw>
				</para>
				<section type="none" id="sidelem4x19736">
					<section type="none" id="sidelem4x19737">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, Asian patients, females, electrolyte imbalances, atrial fibrillation/flutter</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19742">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19750">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19750">
							<item>
								<label>•</label>
								<para> 400 mg bid; </para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19756">
					<section type="none" id="sidelem4x19757">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 400 mg</para>
					</section>
					<section type="none" id="sidelem4x19762">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19765">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19769">
									<item>
										<label>•</label>
										<para>Give bid with morning, evening meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Give MedGuide; should be dispensed with each prescription, refill</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19780">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19783">
					<section type="none" id="sidelem4x19784">
						<sec_title>CNS:</sec_title>
						<para> Weakness</para>
					</section>
					<section type="none" id="sidelem4x19789">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Bradycardia,</emphasis><emphasis style="bold">heart failure, QT prolongation, torsades de pointes,</emphasis> atrial flutter</para>
					</section>
					<section type="none" id="sidelem4x19799">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperthyroidism</para>
					</section>
					<section type="none" id="sidelem4x19804">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, abdominal pain, <emphasis style="bold">severe hepatic injury, hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19811">
						<sec_title>INTEG:</sec_title>
						<para> Rash, photosensitivity, <emphasis style="bold">anaphylaxis, angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19818">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Interstitial pneumonitis, pulmonary fibrosis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19825">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-6 hr, half-life 13-19 hr, metabolized by liver, excreted in feces (84%), via kidneys (6%), protein binding &gt;98%</para>
			</section>
			<section type="interactions" id="sidelem4x19830">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> dronedarone levels: CYP3A inhibitors/2D6 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dronedarone levels: 3A/2D6 inducers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia—β-blockers, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of cycloSPORINE, dextromethorphan, digoxin, disopyramide, flecainide, methotrexate, phenytoin, procainamide, quiNIDine, theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effects—dabigatran, warfarin</para>
				<section type="none" id="sidelem4x19853">
					<section type="none" id="sidelem4x19854">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> anticoagulant effect—yohimbine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> dronedarone effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x19865">
						<sec_title>Drug/Food:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> dronedarone effect, grapefruit; avoid use</para>
					</section>
					<section type="none" id="sidelem4x19872">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> T<emphasis style="inf">4</emphasis>, creatinine, LFTs, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19886">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19889">
					<section type="none" id="sidelem4x19890">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>NYHA Class IV heart failure or symptomatic heart failure with recent decomposition requiring hospitalization doubles risk of death</bbw>
						</para>
						<section type="none" id="sidelem4x19907">
							<label>•</label>
							<sec_title>
								<route>ECG to determine product effectiveness; measure PR, QRS, QT intervals; check for PVCs, other dysrhythmias, B/P continuously for hypo/hypertension; report dysrhythmias, slowing heart rate</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19910">
								<item>
									<label>•</label>
									<para>Serum creatinine, potassium, magnesium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19915">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; electrolytes (potassium, creatinine, magnesium)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19920">
								<item>
									<label>•</label>
									<para>Dehydration or hypovolemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19925">
								<item>
									<label>•</label>
									<para>Rebound hypertension after 1-2 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19933">
							<label>•</label>
							<sec_title>Hypothyroidism</sec_title>
							<para>
								<list id="lidelem4x19933">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypothyroidism:</emphasis> lethargy, dizziness, constipation, enlarged thyroid gland, edema of extremities; cool, pale skin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19940">
							<label>•</label>
							<sec_title>Hyperthyroidism</sec_title>
							<para>
								<list id="lidelem4x19940">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperthyroidism:</emphasis> restlessness, tachycardia, eyelid puffiness, weight loss, frequent urination, menstrual irregularities, dyspnea; warm, moist skin</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19946">
								<item>
									<label>•</label>
									<para>Cardiac rate, respiration: rate, rhythm, character, chest pain; start with patient hospitalized and monitored up to 1 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19951">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19955">
								<item>
									<label>•</label>
									<para>Therapeutic response: atrial fibrillation, flutter</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19961">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19966">
								<item>
									<label>•</label>
									<para>To take this product as directed; to avoid missed doses; not to use with grapefruit juice, to avoid all other products without approval of provider</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19974">
							<label>•</label>
							<sec_title>
								<route>To immediately report weight gain, edema, difficulty breathing</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19980">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception during treatment (pregnancy [X]) not to breastfeed</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>droxidopa</mono_name>
			<info>
				<pronunciation>(drox′-i-doe′-pa)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x199960">Northera</tradename>
				</tradenames>
				<class type="func"> Cardiovascular agent-vasopressor</class>
			</info>
			<section type="actions" id="sidelem4x20002">
				<sec_title>Action:</sec_title>
				<para> A synthetic amino acid precursor of norepinephrine. It is used to increase blood pressure with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (e.g., Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine β-hydroxylase deficiency, or nondiabetic autonomic neuropathy</para>
			</section>
			<section type="uses" id="sidelem4x20007">
				<sec_title>Uses:</sec_title>
				<para> To increase blood pressure</para>
			</section>
			<section type="contra" id="sidelem4x20012">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<section type="none" id="sidelem4x20017">
					<section type="none" id="sidelem4x20018">
						<sec_title>Precautions:</sec_title>
						<para> Angina, breastfeeding, cardiac arrhythmias, cardiac disease, children, coronary artery disease, heart disease, hyperthermia, infants, mental status changes, myocardial infarction, neonates, pregnancy, salicylate/tartrazine dye hypersensitivity</para>
						<para>
							<bbw>Hypertension</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20033">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20041">
					<label>•</label>
					<sec_title>Adults<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x20041">
							<item>
								<label>•</label>
								<para> 100 mg tid: upon arising in the morning, at midday, and in the late afternoon at least 3 hr before bedtime; titrate to response, by 100 mg tid q24-48hr up to a dose of 600 mg PO tid, max 1800 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x20045">
					<section type="none" id="sidelem4x20046">
						<sec_title>Available forms:</sec_title>
						<para> Caps 100, 200, 300 mg</para>
					</section>
					<section type="none" id="sidelem4x20051">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20055">
								<item>
									<label>•</label>
									<para>Give tid at the following times: upon arising in the morning, at midday, and in the late afternoon at least 3 hr before bedtime (to reduce the potential for supine hypertension during sleep)</para>
								</item>
								<item>
									<label>•</label>
									<para>Use without regard to food, but should be taken consistently in regard to food to ensure consistent absorption</para>
								</item>
								<item>
									<label>•</label>
									<para>Swallow capsules whole</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20071">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20074">
					<section type="none" id="sidelem4x20075">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x20080">
						<sec_title>CV:</sec_title>
						<para> Supine hypertension, arrhythmia exacerbation, chest pain</para>
					</section>
					<section type="none" id="sidelem4x20085">
						<sec_title>MISC:</sec_title>
						<para> Urinary tract infection, <emphasis style="bold">neuroleptic malignant syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20092">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x20097">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x20100">
					<section type="none" id="sidelem4x20101">
						<sec_title>Increase:</sec_title>
						<para> droxidopa effects—carbidopa, serotonin receptor agonists, sympathomimetics</para>
					</section>
					<section type="none" id="sidelem4x20106">
						<sec_title>Increase:</sec_title>
						<para> hypertensive crisis—MAOIs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20111">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20114">
					<section type="none" id="sidelem4x20115">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x20120">
								<item>
									<label>•</label>
									<para>Monitor supine B/P before and at every dosage increase, assess response periodically. Advise to elevate the head of the bed when resting or sleeping to lessen the risk for supine hypertension. B/P should be monitored, in supine position and the recommended head-elevated sleeping position. Reduce or discontinue if supine hypertension persists</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20130">
							<label>•</label>
							<sec_title>Neuroleptic malignant syndrome<route> Hyperthermia, severe extrapyramidal dysfunction, alterations in consciousness, mental status changes, and autonomic instability (tachycardia, blood pressure fluctuations, diaphoresis). In those with Parkinson’s disease, this condition may occur with abrupt reduction of products with dopaminergic properties</route></sec_title>
						</section>
						<section type="none" id="sidelem4x20136">
							<label>•</label>
							<sec_title>Arrhythmia exacerbation<route> exacerbation of existing ischemic cardiac disease (coronary artery disease, angina, myocardial infarction, CHF); consider the potential risk before initiating therapy; if chest pain occurs during use, assess cardiac status</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x20139">
						<sec_title>Evaluate:</sec_title>
						<section type="none" id="sidelem4x20147">
							<label>•</label>
							<sec_title>Therapeutic response</sec_title>
							<para>
								<list id="lidelem4x20147">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Therapeutic response:</emphasis> Increased B/P</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20151">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20155">
								<item>
									<label>•</label>
									<para>Instruct patients to rest and sleep in an upper-body elevated position and to monitor blood pressure (to reduce the potential for supine hypertension)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>DULoxetine (Rx)</mono_name>
			<info>
				<pronunciation>(du-lox′uh-teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x201660">Cymbalta</tradename>
				</tradenames>
				<class type="func"> Antidepressant</class>
				<class type="chem"> Serotonin-norepinephrine reuptake inhibitor (SNRI)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x20176">
				<sec_title>Action:</sec_title>
				<para>May potentiate serotonergic, noradrenergic activity in the CNS; in studies, DULoxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake</para>
			</section>
			<section type="uses" id="sidelem4x20181">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder (MDD), neuropathic pain associated with diabetic neuropathy, generalized anxiety disorder, fibromyalgia, chronic low back pain, osteoarthritis pain</para>
				<section type="none" id="sidelem4x20186">
					<section type="none" id="sidelem4x20187">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Stress, urinary incontinence</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x20192">
				<sec_title>Contraindications:</sec_title>
				<para>Alcohol intoxication, alcoholism, closed-angle glaucoma, hepatic disease, hepatitis, jaundice, hypersensitivity</para>
				<section type="none" id="sidelem4x20197">
					<section type="none" id="sidelem4x20198">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, mania, hypertension, renal/cardiac disease, seizures, increased intraocular pressure, anorexia nervosa, bleeding, dehydration, diabetes, hyponatremia, hypotension, hypovolemia, orthostatic hypotension, abrupt product withdrawal</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20213">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20216">
					<section type="none" id="sidelem4x20217">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x20225">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20225">
									<item>
										<label>•</label>
										<para> 40-60 mg/day as single dose or 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20229">
						<sec_title>Diabetic neuropathy</sec_title>
						<section type="none" id="sidelem4x20237">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20237">
									<item>
										<label>•</label>
										<para> 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20241">
						<sec_title>Generalized anxiety disorder</sec_title>
						<section type="none" id="sidelem4x20249">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20249">
									<item>
										<label>•</label>
										<para> 60 mg/day, may start with 30 mg/day × 1 wk, then increase to 60 mg/day; maintenance 60-120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20253">
						<sec_title>Fibromyalgia</sec_title>
						<section type="none" id="sidelem4x20261">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20261">
									<item>
										<label>•</label>
										<para> 30 mg/day × 1 wk, then 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20265">
						<sec_title>Musculoskeletal pain</sec_title>
						<section type="none" id="sidelem4x20273">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20273">
									<item>
										<label>•</label>
										<para> 60 mg/day or 30 mg/day × 1 wk, then 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20277">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x20285">
							<label>•</label>
							<sec_title>Adult<route> PO Start with 20 mg, gradually increase; avoid use in severe renal disease</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x20288">
						<sec_title>Available forms:</sec_title>
						<para> Caps 20, 30, 60 mg</para>
					</section>
					<section type="none" id="sidelem4x20293">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20297">
								<item>
									<label>•</label>
									<para>Swallow cap whole; do not break, crush, or chew; do not sprinkle on food or mix with liquid</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20313">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20316">
					<section type="none" id="sidelem4x20317">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, anxiety, dizziness, tremor, somnolence, fatigue, decreased appetite, decreased weight, agitation, diaphoresis, hallucinations, <emphasis style="bold">neuroleptic malignant–like syndrome reaction,</emphasis> aggression, <emphasis style="bold">seizures,</emphasis><emphasis style="italic">headache,</emphasis> abnormal dreams, flushing, hot flashes, chills</para>
					</section>
					<section type="none" id="sidelem4x20332">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Thrombophlebitis,</emphasis> peripheral edema, hypertension, palpitations, <emphasis style="bold">supraventricular dysrhythmia,</emphasis> orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x20343">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Abnormal vision</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20350">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperglycemia, SIADH</para>
					</section>
					<section type="none" id="sidelem4x20355">
						<sec_title>GI:</sec_title>
						<para> Constipation, diarrhea, dysphagia, <emphasis style="italic">nausea,</emphasis> vomiting, anorexia, dry mouth, colitis, gastritis, abdominal pain, <emphasis style="bold">hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20365">
						<sec_title>GU:</sec_title>
						<para> Abnormal ejaculation, urinary hesitation/retention/frequency, ejaculation delayed, erectile dysfunction, gynecologic bleeding</para>
					</section>
					<section type="none" id="sidelem4x20370">
						<sec_title>INTEG:</sec_title>
						<para> Photosensitivity, bruising, sweating, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20377">
						<sec_title>MS:</sec_title>
						<para> Gait disturbance, muscle spasm, restless leg syndrome, myalgia</para>
					</section>
					<section type="none" id="sidelem4x20382">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema, serotonin syndrome, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20389">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed; extensively metabolized (CYP2D6, CYP1A2) in the liver to an active metabolite; 70% of product recovered in urine, 20% in feces; 90% protein binding; elimination half-life 9.2-19.1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x20394">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x20402">
					<label>•</label>
					<sec_title>
						<route>Do not use with linezolid or methylene blue IV</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x20408">
					<label>•</label>
					<sec_title>Narrow therapeutic index<route> CYP2D6 extensively metabolized products (flecainide, phenothiazines, propafenone, tricyclics, thioridazine)</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x20412">
						<item>
							<para>
								<emphasis alert="nurse">Hyperthermia, rigidity, rapid fluctuations of vital signs, mental status changes, neuroleptic malignant syndrome—MAOIs, coadministration contraindicated within 14 days of MAOI use</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—opioids, antihistamines, sedative/hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serotonin syndrome, neuroleptic malignant syndrome—SSRIs, serotonin-receptor agonists</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, antiplatelets, salicylates, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of DULoxetine—CYP1A2 inhibitors (fluvoxamine, quinolone antiinfectives); CYP2D6 inhibitors (FLUoxetine, quiNIDine, PARoxetine)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ALT, bilirubin—alcohol</para>
				<section type="none" id="sidelem4x20437">
					<section type="none" id="sidelem4x20438">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x20442">
								<item>
									<label>•</label>
									<para>Serotonin syndrome: St. John’s wort</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x20452">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> blood glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20459">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20462">
					<section type="none" id="sidelem4x20463">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Depression:</emphasis> mood, sensorium, affect, <emphasis alert="lifethreat">suicidal tendencies,</emphasis> increase in psychiatric symptoms; depression, panic, monitor children weekly face to face during first 4 wk, or dosage change, then every other wk for next 4 wk, then at 12 wk</bbw>
						</para>
						<para>
							<list id="lidelem4x20482">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20487">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20492">
								<item>
									<label>•</label>
									<para>Weight weekly; weight loss or gain; appetite may increase; peripheral edema may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20497">
								<item>
									<label>•</label>
									<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20505">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x20505">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not common unless product is discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20510">
								<item>
									<para>
										<emphasis alert="nurse">Malignant neuroleptic-like syndrome reaction</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20516">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome: nausea/vomiting, dizziness, facial flush, shivering, sweating</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20524">
							<label>•</label>
							<sec_title>Sexual dysfunction</sec_title>
							<para>
								<list id="lidelem4x20524">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sexual dysfunction:</emphasis> ejaculation dysfunction, erectile dysfunction, decreased libido, orgasm dysfunction</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20528">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy; drowsiness, dizziness occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20534">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20538">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20544">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20548">
								<item>
									<label>•</label>
									<para>To report urinary retention; about signs and symptoms of bleeding (GI bleeding, nosebleed, ecchymoses, bruising)</para>
								</item>
								<item>
									<label>•</label>
									<para>To use with caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, MAOIs, other CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use; may cause nausea, headache, malaise; taper
<bbw>That clinical worsening and suicide risk may occur</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat; photosensitivity may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned or suspected, or if breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>Improvement may occur in 4-8 wk or in up to 12 wk (geriatric patients)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>dutasteride (Rx)</mono_name>
			<info>
				<pronunciation>(doo-tass′ter-ide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x205980">Avodart</tradename>
				</tradenames>
				<class type="func"> Androgen inhibitor</class>
				<class type="chem"> Synthetic 5α-reductase inhibitor, 4-azasteroid compound</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x20608">
				<sec_title>Action:</sec_title>
				<para>Inhibits both type 1 and type 2 forms of a steroid enzyme that converts testosterone to 5α-dihydrotestosterone (DHT), which is responsible for the initial growth of prostatic tissue</para>
			</section>
			<section type="uses" id="sidelem4x20613">
				<sec_title>Uses:</sec_title>
				<para>Treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland; may be used in combination with tamsulosin</para>
				<section type="none" id="sidelem4x20618">
					<section type="none" id="sidelem4x20619">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Alopecia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x20624">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, women, children, hypersensitivity</para>
				<section type="none" id="sidelem4x20629">
					<section type="none" id="sidelem4x20630">
						<sec_title>Precautions:</sec_title>
						<para> Hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20635">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20638">
					<section type="none" id="sidelem4x20639">
						<sec_title>Benign prostatic hyperplasia (BPH)</sec_title>
						<section type="none" id="sidelem4x20647">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20647">
									<item>
										<label>•</label>
										<para> 0.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20651">
						<sec_title>Alopecia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20659">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20659">
									<item>
										<label>•</label>
										<para> 0.5-2.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20663">
						<sec_title>Available form:</sec_title>
						<para> Caps 0.5 mg</para>
					</section>
					<section type="none" id="sidelem4x20668">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x20672">
								<item>
									<label>•</label>
									<para>Swallow caps whole; do not break, crush, chew</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20683">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20686">
					<section type="none" id="sidelem4x20687">
						<sec_title>GU:</sec_title>
						<para> Decreased libido, impotence, gynecomastia, ejaculation disorders (rare), mastalgia, <emphasis style="bold">teratogenesis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20694">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Serious skin infections</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20701">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-3 hr, protein binding 99%, metabolized in liver by CYP3A4, excreted in feces, half-life 5 wk at steady state</para>
			</section>
			<section type="interactions" id="sidelem4x20706">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> dutasteride concentrations—ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, ciprofloxacin, antiretroviral protease inhibitors, or other products metabolized by CYP3A4</para>
				<section type="none" id="sidelem4x20713">
					<section type="none" id="sidelem4x20714">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> PSA</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x20721">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20724">
					<section type="none" id="sidelem4x20725">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x20733">
							<label>•</label>
							<sec_title>For decreasing symptoms of BPH</sec_title>
							<para>
								<list id="lidelem4x20733">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For decreasing symptoms of BPH:</emphasis> decreasing urinary retention, frequency, urgency, nocturia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20737">
								<item>
									<label>•</label>
									<para>PSA levels; digital rectal, urinary obstruction; determine the absence of urinary cancer before starting treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20742">
								<item>
									<label>•</label>
									<para>Blood studies: ALT, AST, bilirubin, CBC with differential, serum creatinine, serum electrolytes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20748">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20752">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing symptoms of BPH; decreased urinary retention, frequency, urgency, nocturia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20758">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20763">
								<item>
									<label>•</label>
									<para>To read patient information leaflet before starting therapy; to reread it upon prescription renewal</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20768">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases, if edema occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20773">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20778">
								<item>
									<label>•</label>
									<para>About changes in sex characteristics</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20786">
							<label>•</label>
							<sec_title>
								<route>That men taking dutasteride should not donate blood for at least 6 mo after last dose to prevent blood administration to pregnant female</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x20792">
							<label>•</label>
							<sec_title>
								<route>That caps should not be handled by a woman who is pregnant or who may become pregnant because product can be absorbed through skin</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x20795">
								<item>
									<label>•</label>
									<para>That ejaculate volume may decrease during treatment; that product rarely interferes with sexual function</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20803">
							<label>•</label>
							<sec_title>
								<route>Should not be used or handled by breastfeeding women</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x20806">
								<item>
									<label>•</label>
									<para>Swallow whole; do not crush, chew, or open</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20815">
							<label>•</label>
							<sec_title>
								<route>May increase risk for developing high-grade prostate cancer</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>